

11/28/00



11-30-00

A

Please type a plus sign (+) inside this box → ☐PTO/SB/05 (12/97) (modified)
Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	300622003111	Total Pages	2
First Named Inventor or Application Identifier			
JULIEN, Bryan			
Express Mail Label No.	EL749340471US		

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL749340471US

Date of Deposit: November 28, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Julie BroylesJC825 U.S. PTO
09/22/00
11/28/00**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 143]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) [Total Sheets 9]
4. ☒ Oath or Declaration [Total Pages 3]
 - a. ☐ Newly executed (original or copy)
 - b. ☒ Copy from a prior application (37 CFR 1.63(d)
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)
5. ☒ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☒ Small Entity ☒ Statement filed in prior application, Status still proper and desired
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No: 09/443,501**18. CORRESPONDENCE ADDRESS**Carolyn A. Favorito
Registration No. (39,183)Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5195
Facsimile: (858) 720-5125

- ☒ If a paper is untimely filed in the above-referenced application by applicant or his/her representative, the Assistant Commissioner is hereby petitioned under 37 C.F.R. § 1.136(a) for the minimum extension of time required to make said paper timely. In the event a petition for extension of time is made under the provisions of this paragraph, the Assistant Commissioner is hereby requested to charge any fee required under 37 C.F.R. § 1.17(a)-(d) to **Deposit Account No. 03-1952** referencing docket number 300622003111. However, the Assistant Commissioner is **NOT** authorized to charge the cost of the issue fee to the Deposit Account.

The filing fee has been calculated as follows:

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	6 - 20 =	0	x \$18.00	\$-0-
INDEPENDENT CLAIMS	3 - 3 =	0	x \$80.00	\$-0-
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$-0-
			BASIC FEE	\$710.00
			TOTAL OF ABOVE CALCULATIONS =	\$710.00
Reduction by 1/2 for filing by small entity (Note 37 C.F.R. §§ 1.9, 1.27, 1.28). If applicable, verified statement must be attached.				\$355.00
Assignment Recording Fee (if enclosed)				\$-0-
			TOTAL =	\$355.00


- ☒ A check in the amount of \$355.00 is attached.
- ☐ Charge \$_____ to **Deposit Account No. 03-1952** referencing docket no. 300622003111.

Applicant(s) hereby petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees or to credit any overpayment to **Deposit Account No. 03-1952** referencing docket no. 300622003111. A duplicate copy of this transmittal is enclosed, for that purpose.

Dated: November 28, 2000

Respectfully submitted,


By:


Carolyn A. Favorito
Registration No. (39,183)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5195
Facsimile: (858) 720-5125

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail #EL749340471US in an envelope addressed to: Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231, on November 28, 2000.


Julie Broyles

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

JULIEN, Bryan, et al.

Serial No.: Divisional of 09/443,501

Filing Date: November 19, 1999

For: RECOMBINANT METHODS AND
MATERIALS FOR PRODUCING
EPOTHILONE AND EPOTHILONE
DERIVATIVES

Examiner: K. Kerr

Group Art Unit: 1652

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Dear Sir:

Prior to examination on the merits, Applicants respectfully request entry of the amendments and consideration of the remarks presented herein.

I. AMENDMENTS

In the Specification

On page 1, line 5, after "This application", please insert --is a divisional of U.S. Application Serial No. 09/443,501, filed 19 Nov. 1999, which in turn--.

On page 114, line 2, change "number ____" to --number PTA-926--.

On page 114, line 13, change "number ____" to --number PTA-927--.

In the Claims

Cancel claims 1-14, 18, 20-23, and 26-28 in their entirety, without prejudice.

II. REMARKS

Amendments to the Specification

The subject application filed herewith is being filed pursuant to 37 C.F.R. § 1.53(b), and claims priority back to the parent application, U.S. Application Serial No. 09/443,501, filed November 19, 1999. After entry of the amendments herein, the claims in the subject application will correspond to claims in the parent application, as more fully explained below. By the present amendment, the specification has been amended with respect to deposits of biological material under the Budapest Treaty. Copies of the "International Form" under the Budapest Treaty showing that deposit PTA-926 and deposit PTA-927 have been accepted by the ATCC in its capacity as an International Depository under the treaty have been filed in the parent application. Accordingly, this application is a divisional application of the parent application.

Amendments to the Claims

Applicants submit herewith for prosecution on the merits claims 15-17, 19, and 24-25, which correspond to the claims of Group III in the parent application, U.S. Application Serial No. 09/443,501, filed November 19, 1999. No new matter is introduced in this amendment.

III. SUMMARY

Applicants believe that the claims presented herein are in condition for allowance. If a telephone call would further prosecution of this application, the Examiner is invited to call the undersigned attorney at (858) 720-5195.

In the event the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief, including extensions of time, and authorize the Commissioner to charge the cost of such petitions and/or any other fees deemed due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket number 300622003111. However, the Commissioner is not authorized to charge the cost of the issue fee to the deposit account.

Dated: November 28, 2000

Respectfully submitted,

By: 

Carolyn A. Favorito
Registration No. (39,183)

Morrison & Foerster LLP
3811 Valley Center Dr.,
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5195
Facsimile: (858) 720-5125

- 1 -

RECOMBINANT METHODS AND MATERIALS FOR PRODUCING EPOTHILONE AND EPOTHILONE DERIVATIVES

Cross-Reference to Related Applications

5 This application claims priority to U.S. provisional application Serial Nos. 60/130,560, filed 22 Apr. 1999; 60/122,620, filed 8 Mar. 1999; 60/119,386, filed 10 Feb. 1999; and 60/109,401, filed 20 Nov. 1998, each of which is incorporated herein by reference.

10 Reference to Government Funding

 This invention was supported in part by SBIR grant 1R43-CA79228-01. The U.S. government has certain rights in this invention.

Field of the Invention

15 The present invention provides recombinant methods and materials for producing epothilone and epothilone derivatives. The invention relates to the fields of agriculture, chemistry, medicinal chemistry, medicine, molecular biology, and pharmacology.

Background of the Invention


20 The epothilones were first identified by Gerhard Hofle and colleagues at the National Biotechnology Research Institute as an antifungal activity extracted from the myxobacterium *Sorangium cellulosum* (see K. Gerth *et al.*, 1996, J. Antibiotics 49: 560-563 and Germany Patent No. DE 41 38 042). The epothilones were later found to have activity in a tubulin polymerization assay (see D. Bollag *et al.*, 1995, Cancer Res.

25 55:2325-2333) to identify antitumor agents and have since been extensively studied as potential antitumor agents for the treatment of cancer.


 The chemical structure of the epothilones produced by *Sorangium cellulosum* strain So ce 90 was described in Hofle *et al.*, 1996, Epothilone A and B - novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and
30 conformation in solution, Angew. Chem. Int. Ed. Engl. 35(13/14): 1567-1569,

- 2 -

incorporated herein by reference. The strain was found to produce two epothilone compounds, designated A ($R = H$) and B ($R = CH_3$), as shown below, which showed broad cytotoxic activity against eukaryotic cells and noticeable activity and selectivity against breast and colon tumor cell lines.



The desoxy counterparts of epothilones A and B, also known as epothilones C ($R = H$) and D ($R = CH_3$), are known to be less cytotoxic, and the structures of these epothilones are shown below.



Two other naturally occurring epothilones have been described. These are epothilones E and F, in which the methyl side chain of the thiazole moiety of epothilones A and B has been hydroxylated to yield epothilones E and F, respectively.

Because of the potential for use of the epothilones as anticancer agents, and because of the low levels of epothilone produced by the native *So ce 90* strain, a number of research teams undertook the effort to synthesize the epothilones. This effort has been successful (see Balog *et al.*, 1996, Total synthesis of (-)-epothilone A, *Angew. Chem. Int. Ed. Engl.* 35(23/24): 2801-2803; Su *et al.*, 1997, Total synthesis of (-)-epothilone B: an extension of the Suzuki coupling method and insights into structure-activity relationships of the epothilones, *Angew. Chem. Int. Ed. Engl.* 36(7): 757-759; Meng *et al.*, 1997, Total syntheses of epothilones A and B, *JACS* 119(42): 10073-10092; and Balog *et al.*, 1998, A novel aldol condensation with 2-methyl-4-pentenal and its application to an improved total synthesis of epothilone B, *Angew. Chem. Int. Ed. Engl.* 37(19): 2675-2678, each of

- 3 -

which is incorporated herein by reference). Despite the success of these efforts, the chemical synthesis of the epothilones is tedious, time-consuming, and expensive. Indeed, the methods have been characterized as impractical for the full-scale pharmaceutical development of an epothilone.

5 A number of epothilone derivatives, as well as epothilones A - D, have been studied *in vitro* and *in vivo* (see Su *et al.*, 1997, Structure-activity relationships of the epothilones and the first *in vivo* comparison with paclitaxel, Angew. Chem. Int. Ed. Engl. 36(19): 2093-2096; and Chou *et al.*, Aug. 1998, Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising *in vivo* profile relative to
10 epothilone B, Proc. Natl. Acad. Sci. USA 95: 9642-9647, each of which is incorporated herein by reference). Additional epothilone derivatives and methods for synthesizing epothilones and epothilone derivatives are described in PCT patent publication Nos. 99/54330, 99/54319, 99/54318, 99/43653, 99/43320, 99/42602, 99/40047, 99/27890, 99/07692, 99/02514, 99/01124, 98/25929, 98/22461, 98/08849, and 97/19086; U.S. Patent
15 No. 5,969,145; and Germany patent publication No. DE 41 38 042, each of which is incorporated herein by reference.

 There remains a need for economical means to produce not only the naturally occurring epothilones but also the derivatives or precursors thereof, as well as new epothilone derivatives with improved properties. There remains a need for a host cell that
20 produces epothilones or epothilone derivatives that is easier to manipulate and ferment than the natural producer *Sorangium cellulosum*. The present invention meets these and other needs.

Summary of the Invention

25 In one embodiment, the present invention provides recombinant DNA compounds that encode the proteins required to produce epothilones A, B, C, and D. The present invention also provides recombinant DNA compounds that encode portions of these proteins. The present invention also provides recombinant DNA compounds that encode a hybrid protein, which hybrid protein includes all or a portion of a protein involved in
30 epothilone biosynthesis and all or a portion of a protein involved in the biosynthesis of

- 4 -

another polyketide or non-ribosomal-derived peptide. In a preferred embodiment, the recombinant DNA compounds of the invention are recombinant DNA cloning vectors that facilitate manipulation of the coding sequences or recombinant DNA expression vectors that code for the expression of one or more of the proteins of the invention in
5 recombinant host cells.

In another embodiment, the present invention provides recombinant host cells that produce a desired epothilone or epothilone derivative. In one embodiment, the invention provides host cells that produce one or more of the epothilones or epothilone derivatives at higher levels than produced in the naturally occurring organisms that produce
10 epothilones. In another embodiment, the invention provides host cells that produce mixtures of epothilones that are less complex than the mixtures produced by naturally occurring host cells. In another embodiment, the present invention provides non-*Sorangium* recombinant host cells that produce an epothilone or epothilone derivative.

In a preferred embodiment, the host cells of the invention produce less complex
15 mixtures of epothilones than do naturally occurring cells that produce epothilones. Naturally occurring cells that produce epothilones typically produce a mixture of epothilones A, B, C, D, E, and F. The table below summarizes the epothilones produced in different illustrative host cells of the invention.

<u>Cell Type</u>	<u>Epothilones Produced</u>	<u>Epothilones Not Produced</u>
1	A, B, C, D, E, F	----
2	A, C, E	B, D, F
3	B, D, F	A, C, E
4	A, B, C, D	E, F
5	A, C	B, D, E, F
6	C	A, B, D, E, F
7	B, D	A, C, E, F
8	D	A, B, C, E, F

20 In addition, cell types may be constructed which produce only the newly discovered epothilones G and H, further discussed below, and one or the other of G and

- 5 -

H or both in combination with the downstream epothilones. Thus, it is understood, based on the present invention, that the biosynthetic pathway which relates the naturally occurring epothilones is, respectively, $G \rightarrow C \rightarrow A \rightarrow E$ and $H \rightarrow D \rightarrow B \rightarrow F$.

Appropriate enzymes may also convert members of each pathway to the corresponding member of the other.

Thus, the recombinant host cells of the invention also include host cells that produce only one desired epothilone or epothilone derivative.

In another embodiment, the invention provides *Sorangium* host cells that have been modified genetically to produce epothilones either at levels greater than those observed in naturally occurring host cells or as less complex mixtures of epothilones than produced by naturally occurring host cells, or produce an epothilone derivative that is not produced in nature. In a preferred embodiment, the host cell produces the epothilones at equal to or greater than 20 mg/L.

In another embodiment, the recombinant host cells of the invention are host cells other than *Sorangium cellulosum* that have been modified genetically to produce an epothilone or an epothilone derivative. In a preferred embodiment, the host cell produces the epothilones at equal to or greater than 20 mg/L. In a more preferred embodiment, the recombinant host cells are *Myxococcus*, *Pseudomonas*, or *Streptomyces* host cells that produce the epothilones or an epothilone derivative at equal to or greater than 20 mg/L.

In another embodiment, the present invention provides novel compounds useful in agriculture, veterinary practice, and medicine. In one embodiment, the compounds are useful as fungicides. In another embodiment, the compounds are useful in cancer chemotherapy. In a preferred embodiment, the compound is an epothilone derivative that is at least as potent against tumor cells as epothilone B or D. In another embodiment, the compounds are useful as immunosuppressants. In another embodiment, the compounds are useful in the manufacture of another compound. In a preferred embodiment, the compounds are formulated in a mixture or solution for administration to a human or animal.

These and other embodiments of the invention are described in more detail in the following description, the examples, and claims set forth below.

Brief Description of the Figures

Figure 1 shows a restriction site map of the insert *Sorangium cellulosum* genomic DNA in four overlapping cosmid clones (designated 8A3, 1A2, 4, and 85 and
5 corresponding to pKOS35-70.8A3, pKOS35-70.1A2, pKOS35-70.4, and pKOS35-79.85, respectively) spanning the epothilone gene cluster. A functional map of the epothilone gene cluster is also shown. The loading domain (Loading, *epoA*), the non-ribosomal peptide synthase (NRPS, Module 1, *epoB*) module, and each module (Modules 2 through 9, *epoC*, *epoD*, *epoE*, and *epoF*) of the remaining eight modules of the epothilone
10 synthase gene are shown, as is the location of the *epoK* gene that encodes a cytochrome P450-like epoxidation enzyme.

Figure 2 shows a number of precursor compounds to N-acylcysteamine thioester derivatives that can be supplied to an epothilone PKS of the invention in which the NRPS-like module 1 or module 2 KS domain has been inactivated to produce a novel
15 epothilone derivative. A general synthetic procedure for making such compounds is also shown.

Figure 3 shows restriction site and function maps of plasmids pKOS35-82.1 and pKOS35-82.2.

Figure 4 shows restriction site and function maps of plasmids pKOS35-154 and
20 pKOS90-22.

Figure 5 shows a schematic of a protocol for introducing the epothilone PKS and modification enzyme genes into the chromosome of a *Myxococcus xanthus* host cell as described in Example 3.

Figure 6 shows restriction site and function maps of plasmids pKOS039-124 and
25 pKOS039-124R.

Figure 7 shows a restriction site and function map of plasmid pKOS039-126R.

Figure 8 shows a restriction site and function map of plasmid pKOS039-141.

Figure 9 shows a restriction site and function map of plasmid pKOS045-12.

- 7 -

Detailed Description of the Invention

The present invention provides the genes and proteins that synthesize the epothilones in *Sorangium cellulosum* in recombinant and isolated form. As used herein, the term recombinant refers to a compound or composition produced by human
5 intervention, typically by specific and directed manipulation of a gene or portion thereof. The term isolated refers to a compound or composition in a preparation that is substantially free of contaminating or undesired materials or, with respect to a compound or composition found in nature, substantially free of the materials with which that compound or composition is associated in its natural state. The epothilones (epothilone
10 A, B, C, D, E, and F) and compounds structurally related thereto (epothilone derivatives) are potent cytotoxic agents specific for eukaryotic cells. These compounds have application as anti-fungals, cancer chemotherapeutics, and immunosuppressants. The epothilones are produced at very low levels in the naturally occurring *Sorangium cellulosum* cells in which they have been identified. Moreover, *S. cellulosum* is very slow
15 growing, and fermentation of *S. cellulosum* strains is difficult and time-consuming. One important benefit conferred by the present invention is the ability simply to produce an epothilone or epothilone derivative in a non-*S. cellulosum* host cell. Another advantage of the present invention is the ability to produce the epothilones at higher levels and in greater amounts in the recombinant host cells provided by the invention than possible in
20 the naturally occurring epothilone producer cells. Yet another advantage is the ability to produce an epothilone derivative in a recombinant host cell.

The isolation of recombinant DNA encoding the epothilone biosynthetic genes resulted from the probing of a genomic library of *Sorangium cellulosum* SMP44 DNA. As described more fully in Example 1 below, the library was prepared by partially
25 digesting *S. cellulosum* genomic DNA with restriction enzyme *SauIIIA1* and inserting the DNA fragments generated into *Bam*HI-digested Supercos™ cosmid DNA (Stratagene). Cosmid clones containing epothilone gene sequences were identified by probing with DNA probes specific for sequences from PKS genes and reprobings with secondary probes comprising nucleotide sequences identified with the primary probes.

Four overlapping cosmid clones were identified by this effort. These four cosmids were deposited with the American Type Culture Collection (ATCC), Manassas, VA, USA, under the terms of the Budapest Treaty, and assigned ATCC accession numbers. The clones (and accession numbers) were designated as cosmids pKOS35-70.1A2 (ATCC 203782), pKOS35-70.4 (ATCC 203781), pKOS35-70.8A3 (ATCC 203783), and pKOS35-79.85 (ATCC 203780). The cosmids contain insert DNA that completely spans the epothilone gene cluster. A restriction site map of these cosmids is shown in Figure 1. Figure 1 also provides a function map of the epothilone gene cluster, showing the location of the six epothilone PKS genes and the *epoK* P450 epoxidase gene.

The epothilone PKS genes, like other PKS genes, are composed of coding sequences organized to encode a loading domain, a number of modules, and a thioesterase domain. As described more fully below, each of these domains and modules corresponds to a polypeptide with one or more specific functions. Generally, the loading domain is responsible for binding the first building block used to synthesize the polyketide and transferring it to the first module. The building blocks used to form complex polyketides are typically acylthioesters, most commonly acetyl, propionyl, malonyl, methylmalonyl, and ethylmalonyl CoA. Other building blocks include amino acid-like acylthioesters. PKSs catalyze the biosynthesis of polyketides through repeated, decarboxylative Claisen condensations between the acylthioester building blocks. Each module is responsible for binding a building block, performing one or more functions on that building block, and transferring the resulting compound to the next module. The next module, in turn, is responsible for attaching the next building block and transferring the growing compound to the next module until synthesis is complete. At that point, an enzymatic thioesterase (TE) activity cleaves the polyketide from the PKS.

Such modular organization is characteristic of the class of PKS enzymes that synthesize complex polyketides and is well known in the art. Recombinant methods for manipulating modular PKS genes are described in U.S. Patent Nos. 5,672,491; 5,712,146; 5,830,750; and 5,843,718; and in PCT patent publication Nos. 98/49315 and 97/02358, each of which is incorporated herein by reference. The polyketide known as 6-deoxyerythronolide B (6-dEB) is synthesized by a PKS that is a prototypical modular

PKS enzyme. The genes, known as *eryAI*, *eryAII*, and *eryAIII*, that code for the multi-subunit protein known as deoxyerythronolide B synthase or DEBS (each subunit is known as DEBS1, DEBS2, or DEBS3) that synthesizes 6-dEB are described in U.S. Patent Nos. 5,712,146 and 5,824,513, incorporated herein by reference.

5 The loading domain of the DEBS PKS consists of an acyltransferase (AT) and an acyl carrier protein (ACP). The AT of the DEBS loading domain recognizes propionyl CoA (other loading domain ATs can recognize other acyl-CoAs, such as acetyl, malonyl, methylmalonyl, or butyryl CoA) and transfers it as a thioester to the ACP of the loading domain. Concurrently, the AT on each of the six extender modules recognizes a
10 methylmalonyl CoA (other extender module ATs can recognize other CoAs, such as malonyl or alpha-substituted malonyl CoAs, i.e., malonyl, ethylmalonyl, and 2-hydroxymalonyl CoA) and transfers it to the ACP of that module to form a thioester. Once DEBS is primed with acyl- and methylmalonyl-ACPs, the acyl group of the loading domain migrates to form a thioester (trans-esterification) at the KS of the first module; at
15 this stage, module one possesses an acyl-KS adjacent to a methylmalonyl ACP. The acyl group derived from the DEBS loading domain is then covalently attached to the alpha-carbon of the extender group to form a carbon-carbon bond, driven by concomitant decarboxylation, and generating a new acyl-ACP that has a backbone two carbons longer than the loading unit (elongation or extension). The growing polyketide chain is
20 transferred from the ACP to the KS of the next module of DEBS, and the process continues.

 The polyketide chain, growing by two carbons for each module of DEBS, is sequentially passed as a covalently bound thioester from module to module, in an assembly line-like process. The carbon chain produced by this process alone would
25 possess a ketone at every other carbon atom, producing a polyketone, from which the name polyketide arises. Commonly, however, additional enzymatic activities modify the beta keto group of each two carbon unit just after it has been added to the growing polyketide chain but before it is transferred to the next module. Thus, in addition to the minimal module containing KS, AT, and ACP necessary to form the carbon-carbon bond,
30 modules may contain a ketoreductase (KR) that reduces the keto group to an alcohol.

- 10 -

Modules may also contain a KR plus a dehydratase (DH) that dehydrates the alcohol to a double bond. Modules may also contain a KR, a DH, and an enoylreductase (ER) that converts the double bond to a saturated single bond using the beta carbon as a methylene function. The DEBS modules include those with only a KR domain, only an inactive KR domain, and with all three KR, DH, and ER domains.

Once a polyketide chain traverses the final module of a PKS, it encounters the releasing domain or thioesterase found at the carboxyl end of most PKSs. Here, the polyketide is cleaved from the enzyme and, for most but not all polyketides, cyclized. The polyketide can be modified further by tailoring or modification enzymes; these enzymes add carbohydrate groups or methyl groups, or make other modifications, i.e., oxidation or reduction, on the polyketide core molecule. For example, 6-dEB is hydroxylated, methylated, and glycosylated (glycosidated) to yield the well known antibiotic erythromycin A in the *Saccharopolyspora erythraea* cells in which it is produced naturally.

While the above description applies generally to modular PKS enzymes and specifically to DEBS, there are a number of variations that exist in nature. For example, many PKS enzymes comprise loading domains that, unlike the loading domain of DEBS, comprise an "inactive" KS domain that functions as a decarboxylase. This inactive KS is in most instances called KS^Q, where the superscript is the single-letter abbreviation for the amino acid (glutamine) that is present instead of the active site cysteine required for ketosynthase activity. The epothilone PKS loading domain contains a KS^T domain not present in other PKS enzymes for which amino acid sequence is currently available in which the amino acid tyrosine has replaced the cysteine. The present invention provides recombinant DNA coding sequences for this novel KS domain.

Another important variation in PKS enzymes relates to the type of building block incorporated. Some polyketides, including epothilone, incorporate an amino acid derived building block. PKS enzymes that make such polyketides require specialized modules for incorporation. Such modules are called non-ribosomal peptide synthetase (NRPS) modules. The epothilone PKS, for example, contains an NRPS module. Another example of a variation relates to additional activities in a module. For example, one module of the

- 11 -

epothilone PKS contains a methyltransferase (MT) domain, a heretofore unknown domain of PKS enzymes that make modular polyketides.

The complete nucleotide sequence of the coding sequence of the open reading frames (ORFs) of the epothilone PKS genes and epothilone tailoring (modification) enzyme genes is provided in Example 1, below. This sequence information together with the information provided below regarding the locations of the open reading frames of the genes within that sequence provides the amino acid sequence of the encoded proteins. Those of skill in the art will recognize that, due to the degenerate nature of the genetic code, a variety of DNA compounds differing in their nucleotide sequences can be used to encode a given amino acid sequence of the invention. The native DNA sequence encoding the epothilone PKS and epothilone modification enzymes of *Sorangium cellulosum* is shown herein merely to illustrate a preferred embodiment of the invention. The present invention includes DNA compounds of any sequence that encode the amino acid sequences of the polypeptides and proteins of the invention. In similar fashion, a polypeptide can typically tolerate one or more amino acid substitutions, deletions, and insertions in its amino acid sequence without loss or significant loss of a desired activity and, in some instances, even an improvement of a desired activity. The present invention includes such polypeptides with alternate amino acid sequences, and the amino acid sequences shown merely illustrate preferred embodiments of the invention.

The present invention provides recombinant genes for the production of epothilones. The invention is exemplified by the cloning, characterization, and manipulation of the epothilone PKS and modification enzymes of *Sorangium cellulosum* SMP44. The description of the invention and the recombinant vectors deposited in connection with that description enable the identification, cloning, and manipulation of epothilone PKS and modification enzymes from any naturally occurring host cell that produces an epothilone. Such host cells include other *S. cellulosum* strains, such as So ce 90, other *Sorangium* species, and non-*Sorangium* cells. Such identification, cloning, and characterization can be conducted by those of ordinary skill in accordance with the present invention using standard methodology for identifying homologous DNA sequences and for identifying genes that encode a protein of function similar to a known

- 12 -

protein. Moreover, the present invention provides recombinant epothilone PKS and modification enzyme genes that are synthesized de novo or are assembled from non-epothilone PKS genes to provide an ordered array of domains and modules in one or more proteins that assemble to form a PKS that produces epothilone or an epothilone derivative.

The recombinant nucleic acids, proteins, and peptides of the invention are many and diverse. To facilitate an understanding of the invention and the diverse compounds and methods provided thereby, the following discussion describes various regions of the epothilone PKS and corresponding coding sequences. This discussion begins with a general discussion of the genes that encode the PKS, the location of the various domains and modules in those genes, and the location of the various domains in those modules. Then, a more detailed discussion follows, focusing first on the loading domain, followed by the NRPS module, and then the remaining eight modules of the epothilone PKS.

There are six epothilone PKS genes. The *epoA* gene encodes the 149 kDa loading domain (which can also be referred to as a loading module). The *epoB* gene encodes module 1, the 158 kDa NRPS module. The *epoC* gene encodes the 193 kDa module 2. The *epoD* gene encodes a 765 kDa protein that comprises modules 3 through 6, inclusive. The *epoE* gene encodes a 405 kDa protein that comprises modules 7 and 8. The *epoF* gene encodes a 257 kDa protein that comprises module 9 and the thioesterase domain. Immediately downstream of the *epoF* gene is *epoK*, the P450 epoxidase gene which encodes a 47 kDa protein, followed immediately by the *epoL* gene, which may encode a 24 kDa dehydratase. The *epoL* gene is followed by a number of ORFs that include genes believed to encode proteins involved in transport and regulation.

The sequences of these genes are shown in Example 1 in one contiguous sequence or contig of 71,989 nucleotides. This contig also contains two genes that appear to originate from a transposon and are identified below as ORF A and ORF B. These two genes are believed not to be involved in epothilone biosynthesis but could possibly contain sequences that function as a promoter or enhancer. The contig also contains more than 12 additional ORFs, only 12 of which, designated ORF2 through ORF12 and ORF2 complement, are identified below. As noted, ORF2 actually is two ORFs, because the

complement of the strand shown also comprises an ORF. The function of the corresponding gene product, if any, of these ORFs has not yet been established. The Table below provides the location of various open reading frames, module-coding sequences, and domain encoding sequences within the contig sequence shown in

- 5 Example 1. Those of skill in the art will recognize, upon consideration of the sequence shown in Example 1, that the actual start locations of several of the genes could differ from the start locations shown in the table, because of the presence in frame codons for methionine or valine in close proximity to the codon indicated as the start codon. The actual start codon can be confirmed by amino acid sequencing of the proteins expressed
- 10 from the genes.

<u>Start</u>	<u>Stop</u>	<u>Comment</u>
3	992	transposase gene ORF A, not part of the PKS
989	1501	transposase gene ORF B, not part of the PKS
1998	6263	<i>epoA</i> gene, encodes the loading domain
2031	3548	KS ^Y of the loading domain
3621	4661	AT of the loading domain
4917	5810	ER of the loading domain, potentially involved in formation of the thiazole moiety
5856	6155	ACP of the loading domain
6260	10493	<i>epoB</i> gene, encodes module 1, the NRPS module
6620	6649	condensation domain C2 of the NRPS module
6861	6887	heterocyclization signature sequence
6962	6982	condensation domain C4 of the NRPS module
7358	7366	condensation domain C7 (partial) of the NRPS module
7898	7921	adenylation domain A1 of the NRPS module
8261	8308	adenylation domain A3 of the NRPS module
8411	8422	adenylation domain A4 of the NRPS module
8861	8905	adenylation domain A6 of the NRPS module
8966	8983	adenylation domain A7 of the NRPS module
9090	9179	adenylation domain A8 of the NRPS module
9183	9992	oxidation region for forming thiazole
10121	10138	Adenylation domain A10 of the NRPS module

- 14 -

<u>Start</u>	<u>Stop</u>	<u>Comment</u>
10261	10306	Thiolation domain (PCP) of the NRPS module
10639	16137	<i>epoC</i> gene, encodes module 2
10654	12033	KS2, the KS domain of module 2
12250	13287	AT2, the AT domain of module 2
13327	13899	DH2, the DH domain of module 2
14962	15756	KR2, the KR domain of module 2
15763	16008	ACP2, the ACP domain of module 2
16134	37907	<i>epoD</i> gene, encodes modules 3-6
16425	17606	KS3
17817	18857	AT3
19581	20396	KR3
20424	20642	ACP3
20706	22082	KS4
22296	23336	AT4
24069	24647	KR4
24867	25151	ACP4
25203	26576	KS5
26793	27833	AT5
27966	28574	DH5
29433	30287	ER5
30321	30869	KR5
31077	31373	ACP5
31440	32807	KS6
33018	34067	AT6
34107	34676	DH6
35760	36641	ER6
36705	37256	KR6
37470	37769	ACP6
37912	49308	<i>epoE</i> gene, encodes modules 7 and 8
38014	39375	KS7
39589	40626	AT7
41341	41922	KR7
42181	42423	ACP7

- 15 -

<u>Start</u>	<u>Stop</u>	<u>Comment</u>
42478	43851	KS8
44065	45102	AT8
45262	45810	DH (inactive)
46072	47172	MT8, the methyltransferase domain of module 8
48103	48636	KR8, this domain is inactive
48850	49149	ACP8
49323	56642	<i>epoF</i> gene, encodes module 9 and the TE domain
49416	50774	KS9
50985	52025	AT9
52173	53414	DH (inactive)
54747	55313	KR9
55593	55805	ACP9
55878	56600	TE9, the thioesterase domain
56757	58016	<i>epoK</i> gene, encodes the P450 epoxidase
58194	58733	<i>epoL</i> gene (putative dehydratase)
59405	59974	ORF2 complement, complement of strand shown
59460	60249	ORF2
60271	60738	ORF3, complement of strand shown
61730	62647	ORF4 (putative transporter)
63725	64333	ORF5
64372	65643	ORF6
66237	67472	ORF7 (putative oxidoreductase)
67572	68837	ORF8 (putative oxidoreductase membrane/subunit)
68837	69373	ORF9
69993	71174	ORF10 (putative transporter)
71171	71542	ORF11
71557	71989	ORF12

With this overview of the organization and sequence of the epothilone gene cluster, one can better appreciate the many different recombinant DNA compounds provided by the present invention.

- 16 -

The epothilone PKS is multiprotein complex composed of the gene products of the *epoA*, *epoB*, *epoC*, *epoD*, *epoE*, and *epoF* genes. To confer the ability to produce epothilones to a host cell, one provides the host cell with the recombinant *epoA*, *epoB*, *epoC*, *epoD*, *epoE*, and *epoF* genes of the present invention, and optionally other genes, capable of expression in that host cell. Those of skill in the art will appreciate that, while the epothilone and other PKS enzymes may be referred to as a single entity herein, these enzymes are typically multisubunit proteins. Thus, one can make a derivative PKS (a PKS that differs from a naturally occurring PKS by deletion or mutation) or hybrid PKS (a PKS that is composed of portions of two different PKS enzymes) by altering one or more genes that encode one or more of the multiple proteins that constitute the PKS.

The post-PKS modification or tailoring of epothilone includes multiple steps mediated by multiple enzymes. These enzymes are referred to herein as tailoring or modification enzymes. Surprisingly, the products of the domains of the epothilone PKS predicted to be functional by analysis of the genes that encode them are compounds that have not been previously reported. These compounds are referred to herein as epothilones G and H. Epothilones G and H lack the C-12-C-13 π -bond of epothilones C and D and the C-12-C-13 epoxide of epothilones A and B, having instead a hydrogen and hydroxyl group at C-13, a single bond between C-12 and C-13, and a hydrogen and methyl group at C-12. These compounds are predicted to result from the epothilone PKS, because the DNA and corresponding amino acid sequence for module 4 of the epothilone PKS does not appear to include a DH domain.

As described below, however, expression of the epothilone PKS genes *epoA*, *epoB*, *epoC*, *epoD*, *epoE*, and *epoF* in certain heterologous host cells that do not express *epoK* or *epoL* leads to the production of epothilones C and D, which lack the C-13 hydroxyl and have a double bond between C-12 and C-13. The dehydration reaction that mediates the formation of this double bond may be due to the action of an as yet unrecognized domain of the epothilone PKS (for example, dehydration could occur in the next module, which possesses an active DH domain and could generate a conjugated diene precursor prior to its dehydrogenation by an ER domain) or an endogenous enzyme in the heterologous host cells (*Streptomyces coelicolor*) in which it was observed. In the

- 17 -

latter event, epothilones G and H may be produced in *Sorangium cellulosum* or other host cells and, to be converted to epothilones C and D, by the action of a dehydratase, which may be encoded by the *epoL* gene. In any event, epothilones C and D are converted to epothilones A and B by an epoxidase encoded by the *epoK* gene. Epothilones A and B are converted to epothilones E and F by a hydroxylase gene, which may be encoded by one of the ORFs identified above or by another gene endogenous to *Sorangium cellulosum*. Thus, one can produce an epothilone or epothilone derivative modified as desired in a host cell by providing that host cell with one or more of the recombinant modification enzyme genes provided by the invention or by utilizing a host cell that naturally expresses (or does not express) the modification enzyme. Thus, in general, by utilizing the appropriate host and by appropriate inactivation, if desired, of modification enzymes, one may interrupt the progression of $G \rightarrow C \rightarrow A \rightarrow E$ or the corresponding downstream processing of epothilone H at any desired point; by controlling methylation, one or both of the pathways can be selected.

Thus, the present invention provides a wide variety of recombinant DNA compounds and host cells for expressing the naturally occurring epothilones A, B, C, and D and derivatives thereof. The invention also provides recombinant host cells, particularly *Sorangium cellulosum* host cells that produce epothilone derivatives modified in a manner similar to epothilones E and F. Moreover, the invention provides host cells that can produce the heretofore unknown epothilones G and H, either by expression of the epothilone PKS genes in host cells that do not express the dehydratase that converts epothilones G and H to C and D or by mutating or altering the PKS to abolish the dehydratase function, if it is present in the epothilone PKS.

The macrolide compounds that are products of the PKS cluster can thus be modified in various ways. In addition to the modifications described above, the PKS products can be glycosylated, hydroxylated, dehydroxylated, oxidized, methylated and demethylated using appropriate enzymes. Thus, in addition to modifying the product of the PKS cluster by altering the number, functionality, or specificity of the modules contained in the PKS, additional compounds within the scope of the invention can be produced by additional enzyme-catalyzed activity either provided by a host cell in which

- 18 -

the polyketide synthases are produced or by modifying these cells to contain additional enzymes or by additional *in vitro* modification using purified enzymes or crude extracts or, indeed, by chemical modification.

The present invention also provides a wide variety of recombinant DNA
5 compounds and host cells that make epothilone derivatives. As used herein, the phrase
“epothilone derivative” refers to a compound that is produced by a recombinant
epothilone PKS in which at least one domain has been either rendered inactive, mutated
to alter its catalytic function, or replaced by a domain with a different function or in
which a domain has been inserted. In any event, the “epothilone derivative PKS”
10 functions to produce a compound that differs in structure from a naturally occurring
epothilone but retains its ring backbone structure and so is called an “epothilone
derivative.” To facilitate a better understanding of the recombinant DNA compounds and
host cells provided by the invention, a detailed discussion of the loading domain and each
of the modules of the epothilone PKS, as well as novel recombinant derivatives thereof,
15 is provided below.

The loading domain of the epothilone PKS includes an inactive KS domain, KS^Y,
an AT domain specific for malonyl CoA (which is believed to be decarboxylated by the
KS^Y domain to yield an acetyl group), and an ACP domain. The present invention
provides recombinant DNA compounds that encode the epothilone loading domain. The
20 loading domain coding sequence is contained within an ~8.3 kb EcoRI restriction
fragment of cosmid pKOS35-70.8A3. The KS domain is referred to as inactive, because
the active site region “TAYSSSL” of the KS domain of the loading domain has a Y
residue in place of the cysteine required for ketosynthase activity; this domain does have
decarboxylase activity. See Witkowski *et al.*, 7 Sep. 1999, Biochem. 38(36): 11643-
25 11650, incorporated herein by reference.

The presence of the Y residue in place of a Q residue (which occurs typically in
an inactive loading domain KS) may make the KS domain less efficient at
decarboxylation. The present invention provides a recombinant epothilone PKS loading
domain and corresponding DNA sequences that encode an epothilone PKS loading
30 domain in which the Y residue has been changed to a Q residue by changing the codon

- 19 -

therefor in the coding sequence of the loading domain. The present invention also provides recombinant PKS enzymes comprising such loading domains and host cells for producing such enzymes and the polyketides produced thereby. These recombinant loading domains include those in which just the Y residue has been changed, those in which amino acids surrounding and including the Y domain have been changed, and those in which the complete KS^Y domain has been replaced by a complete KS^Q domain. The latter embodiment includes but is not limited to a recombinant epothilone loading domain in which the KS^Y domain has been replaced by the KS^Q domain of the oleandolide PKS or the narbonolide PKS (see the references cited below in connection with the oleandomycin, narbomycin, and picromycin PKS and modification enzymes).

The epothilone loading domain also contains an AT domain believed to bind malonyl CoA. The sequence "QTAFTQPALFTFEYALAALW. . . GHSIG" in the AT domain is consistent with malonyl CoA specificity. As noted above, the malonyl CoA is believed to be decarboxylated by the KS^Y domain to yield acetyl CoA. The present invention provides recombinant epothilone derivative loading domains or their encoding DNA sequences in which the malonyl specific AT domain or its encoding sequence has been changed to another specificity, such as methylmalonyl CoA, ethylmalonyl CoA, and 2-hydroxymalonyl CoA. When expressed with the other proteins of the epothilone PKS, such loading domains lead to the production of epothilones in which the methyl substituent of the thiazole ring of epothilone is replaced with, respectively, ethyl, propyl, and hydroxymethyl. The present invention provides recombinant PKS enzymes comprising such loading domains and host cells for producing such enzymes and the polyketides produced thereby.

Those of skill in the art will recognize that an AT domain that is specific for 2-hydroxymalonyl CoA will result in a polyketide with a hydroxyl group at the corresponding location in the polyketide produced, and that the hydroxyl group can be methylated to yield a methoxy group by polyketide modification enzymes. See, e.g., the patent applications cited in connection with the FK-520 PKS in the table below. Consequently, reference to a PKS that has a 2-hydroxymalonyl specific AT domain

- 20 -

herein similarly refers to polyketides produced by that PKS that have either a hydroxyl or methoxyl group at the corresponding location in the polyketide.

The loading domain of the epothilone PKS also comprises an ER domain. While, this ER domain may be involved in forming one of the double bonds in the thiazole moiety in epothilone (in the reverse of its normal reaction), or it may be non-functional. In either event, the invention provides recombinant DNA compounds that encode the epothilone PKS loading domain with and without the ER region, as well as hybrid loading domains that contain an ER domain from another PKS (either active or inactive, with or without accompanying KR and DH domains) in place of the ER domain of the epothilone loading domain. The present invention also provides recombinant PKS enzymes comprising such loading domains and host cells for producing such enzymes and the polyketides produced thereby.

The recombinant nucleic acid compounds of the invention that encode the loading domain of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the epothilone loading domain is coexpressed with the proteins of a heterologous PKS. As used herein, reference to a heterologous modular PKS (or to the coding sequence therefor) refers to all or part of a PKS, including each of the multiple proteins constituting the PKS, that synthesizes a polyketide other than an epothilone or epothilone derivative (or to the coding sequences therefor). This coexpression can be in one of two forms. The epothilone loading domain can be coexpressed as a discrete protein with the other proteins of the heterologous PKS or as a fusion protein in which the loading domain is fused to one or more modules of the heterologous PKS. In either event, the hybrid PKS formed, in which the loading domain of the heterologous PKS is replaced by the epothilone loading domain, provides a novel PKS. Examples of a heterologous PKS that can be used to prepare such hybrid PKS enzymes of the invention include but are not limited to DEBS and the picromycin (narbonolide), oleandolide, rapamycin, FK-506, FK-520, rifamycin, and avermectin PKS enzymes and their corresponding coding sequences.

- 21 -

In another embodiment, a nucleic acid compound comprising a sequence that encodes the epothilone loading domain is coexpressed with the proteins that constitute the remainder of the epothilone PKS (i.e., the *epoB*, *epoC*, *epoD*, *epoE*, and *epoF* gene products) or a recombinant epothilone PKS that produces an epothilone derivative due to an alteration or mutation in one or more of the *epoB*, *epoC*, *epoD*, *epoE*, and *epoF* genes. As used herein, reference to an epothilone or a PKS that produces an epothilone derivative (or to the coding sequence therefor) refers to all or any one of the proteins that comprise the PKS (or to the coding sequences therefor).

In another embodiment, the invention provides recombinant nucleic acid compounds that encode a loading domain composed of part of the epothilone loading domain and part of a heterologous PKS. In this embodiment, the invention provides, for example, either replacing the malonyl CoA specific AT with a methylmalonyl CoA, ethylmalonyl CoA, or 2-hydroxymalonyl CoA specific AT. This replacement, like the others described herein, is typically mediated by replacing the coding sequences therefor to provide a recombinant DNA compound of the invention; the recombinant DNA is used to prepare the corresponding protein. Such changes (including not only replacements but also deletions and insertions) may be referred to herein either at the DNA or protein level.

The compounds of the invention also include those in which both the KS^Y and AT domains of the epothilone loading domain have been replaced but the ACP and/or linker regions of the epothilone loading domain are left intact. Linker regions are those segments of amino acids between domains in the loading domain and modules of a PKS that help form the tertiary structure of the protein and are involved in correct alignment and positioning of the domains of a PKS. These compounds include, for example, a recombinant loading domain coding sequence in which the KS^Y and AT domain coding sequences of the epothilone PKS have been replaced by the coding sequences for the KS^Q and AT domains of, for example, the oleandolide PKS or the narbonolide PKS. There are also PKS enzymes that do not employ a KS^Q domain but instead merely utilize an AT domain that binds acetyl CoA, propionyl CoA, or butyryl CoA (the DEBS loading domain) or isobutyryl CoA (the avermectin loading domain). Thus, the compounds of the invention also include, for example, a recombinant loading domain coding sequence in

- 22 -

which the KS^Y and AT domain coding sequences of the epothilone PKS have been replaced by an AT domain of the DEBS or avermectin PKS. The present invention also provides recombinant DNA compounds encoding loading domains in which the ACP domain or any of the linker regions of the epothilone loading domain has been replaced
5 by another ACP or linker region.

Any of the above loading domain coding sequences is coexpressed with the other proteins that constitute a PKS that synthesizes epothilone, an epothilone derivative, or another polyketide to provide a PKS of the invention. If the product desired is epothilone or an epothilone derivative, then the loading domain coding sequence is typically
10 expressed as a discrete protein, as is the loading domain in the naturally occurring epothilone PKS. If the product desired is produced by the loading domain of the invention and proteins from one or more non-epothilone PKS enzymes, then the loading domain is expressed either as a discrete protein or as a fusion protein with one or more modules of the heterologous PKS.

15 The present invention also provides hybrid PKS enzymes in which the epothilone loading domain has been replaced in its entirety by a loading domain from a heterologous PKS with the remainder of the PKS proteins provided by modified or unmodified epothilone PKS proteins. The present invention also provides recombinant expression vectors and host cells for producing such enzymes and the polyketides produced thereby.
20 In one embodiment, the heterologous loading domain is expressed as a discrete protein in a host cell that expresses the *epoB*, *epoC*, *epoD*, *epoE*, and *epoF* gene products. In another embodiment, the heterologous loading domain is expressed as a fusion protein with the *epoB* gene product in a host cell that expresses the *epoC*, *epoD*, *epoE*, and *epoF* gene products. In a related embodiment, the present invention provides recombinant
25 epothilone PKS enzymes in which the loading domain has been deleted and replaced by an NRPS module and corresponding recombinant DNA compounds and expression vectors. In this embodiment, the recombinant PKS enzymes thus produce an epothilone derivative that comprises a dipeptide moiety, as in the compound leinamycin. The invention provides such enzymes in which the remainder of the epothilone PKS is

- 23 -

identical in function to the native epothilone PKS as well as those in which the remainder is a recombinant PKS that produces an epothilone derivative of the invention.

The present invention also provides reagents and methods useful in deleting the loading domain coding sequence or any portion thereof from the chromosome of a host
5 cell, such as *Sorangium cellulosum*, or replacing those sequences or any portion thereof with sequences encoding a recombinant loading domain. Using a recombinant vector that comprises DNA complementary to the DNA including and/or flanking the loading domain coding sequence in the *Sorangium* chromosome, one can employ the vector and homologous recombination to replace the native loading domain coding sequence with a
10 recombinant loading domain coding sequence or to delete the sequence altogether.

Moreover, while the above discussion focuses on deleting or replacing the epothilone loading domain coding sequences, those of skill in the art will recognize that the present invention provides recombinant DNA compounds, vectors, and methods useful in deleting or replacing all or any portion of an epothilone PKS gene or an
15 epothilone modification enzyme gene. Such methods and materials are useful for a variety of purposes. One purpose is to construct a host cell that does not make a naturally occurring epothilone or epothilone derivative. For example, a host cell that has been modified to not produce a naturally occurring epothilone may be particularly preferred for making epothilone derivatives or other polyketides free of any naturally occurring
20 epothilone. Another purpose is to replace the deleted gene with a gene that has been altered so as to provide a different product or to produce more of one product than another.

If the epothilone loading domain coding sequence has been deleted or otherwise rendered non-functional in a *Sorangium cellulosum* host cell, then the resulting host cell
25 will produce a non-functional epothilone PKS. This PKS could still bind and process extender units, but the thiazole moiety of epothilone would not form, leading to the production of a novel epothilone derivative. Because this derivative would predictably contain a free amino group, it would be produced at most in low quantities. As noted above, however, provision of a heterologous or other recombinant loading domain to the

- 24 -


host cell would result in the production of an epothilone derivative with a structure determined by the loading domain provided.

The loading domain of the epothilone PKS is followed by the first module of the PKS, which is an NRPS module specific for cysteine. This NRPS module is naturally
5 expressed as a discrete protein, the product of the *epoB* gene. The present invention provides the *epoB* gene in recombinant form. The recombinant nucleic acid compounds of the invention that encode the NRPS module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a nucleic acid compound comprising a sequence that encodes the
10 epothilone NRPS module is coexpressed with genes encoding one or more proteins of a heterologous PKS. The NRPS module can be expressed as a discrete protein or as a fusion protein with one of the proteins of the heterologous PKS. The resulting PKS, in which at least a module of the heterologous PKS is replaced by the epothilone NRPS module or the NRPS module is in effect added as a module to the heterologous PKS,
15 provides a novel PKS. In another embodiment, a DNA compound comprising a sequence that encodes the epothilone NRPS module is coexpressed with the other epothilone PKS proteins or modified versions thereof to provide a recombinant epothilone PKS that produces an epothilone or an epothilone derivative.


Two hybrid PKS enzymes provided by the invention illustrate this aspect. Both
20 hybrid PKS enzymes are hybrids of DEBS and the epothilone NRPS module. The first hybrid PKS is composed of four proteins: (i) DEBS1; (ii) a fusion protein composed of the KS domain of module 3 of DEBS and all but the KS domain of the loading domain of the epothilone PKS; (iii) the epothilone NRPS module; and (iv) a fusion protein composed of the KS domain of module 2 of the epothilone PKS fused to the AT domain
25 of module 5 of DEBS and the rest of DEBS3. This hybrid PKS produces a novel polyketide with a thiazole moiety incorporated into the macrolactone ring and a molecular weight of 413.53 when expressed in *Streptomyces coelicolor*. Glycosylated, hydroxylated, and methylated derivatives can be produced by expression of the hybrid PKS in *Saccharopolyspora erythraea*.

- 25 -

Diagrammatically, the construct is represented:



The structure of the product is:




5

The second hybrid PKS illustrating this aspect of the invention is composed of five proteins: (i) DEBS1; (ii) a fusion protein composed of the KS domain of module 3 of DEBS and all but the KS domain of the loading domain of the epothilone PKS; (iii) the epothilone NRPS module; and (iv) a fusion protein composed of the KS domain of module 2 of the epothilone PKS fused to the AT domain of module 4 of DEBS and the rest of DEBS2; and (v) DEBS3. This hybrid PKS produces a novel polyketide with a thiazole moiety incorporated into the macrolactone ring and a molecular weight of 455.61 when expressed in *Streptomyces coelicolor*. Glycosylated, hydroxylated, and methylated derivatives can be produced by expression of the hybrid PKS in *Saccharopolyspora erythraea*.


15

Diagrammatically, the construct is represented:



- 26 -

The structure of the product is:



In another embodiment, a portion of the NRPS module coding sequence is utilized in conjunction with a heterologous coding sequence. In this embodiment, the invention provides, for example, changing the specificity of the NRPS module of the epothilone PKS from a cysteine to another amino acid. This change is accomplished by constructing a coding sequence in which all or a portion of the epothilone PKS NRPS module coding sequences have been replaced by those coding for an NRPS module of a different specificity. In one illustrative embodiment, the specificity of the epothilone NRPS module is changed from cysteine to serine or threonine. When the thus modified NRPS module is expressed with the other proteins of the epothilone PKS, the recombinant PKS produces an epothilone derivative in which the thiazole moiety of epothilone (or an epothilone derivative) is changed to an oxazole or 5-methyloxazole moiety, respectively. Alternatively, the present invention provides recombinant PKS enzymes composed of the products of the *epoA*, *epoC*, *epoD*, *epoE*, and *epoF* genes (or modified versions thereof) without an NRPS module or with an NRPS module from a heterologous PKS. The heterologous NRPS module can be expressed as a discrete protein or as a fusion protein with either the *epoA* or *epoC* genes.

The invention also provides methods and reagents useful in changing the specificity of a heterologous NRPS module from another amino acid to cysteine. This change is accomplished by constructing a coding sequence in which the sequences that determine the specificity of the heterologous NRPS module have been replaced by those that specify cysteine from the epothilone NRPS module coding sequence. The resulting heterologous NRPS module is typically coexpressed in conjunction with the proteins

- 27 -

constituting a heterologous PKS that synthesizes a polyketide other than epothilone or an epothilone derivative, although the heterologous NRPS module can also be used to produce epothilone or an epothilone derivative.

In another embodiment, the invention provides recombinant epothilone PKS enzymes and corresponding recombinant nucleic acid compounds and vectors in which the NRPS module has been inactivated or deleted. Such enzymes, compounds, and vectors are constructed generally in accordance with the teaching for deleting or inactivating the epothilone PKS or modification enzyme genes above. Inactive NRPS module proteins and the coding sequences therefore provided by the invention include those in which the peptidyl carrier protein (PCP) domain has been wholly or partially deleted or otherwise rendered inactive by changing the active site serine (the site for phosphopantetheinylation) to another amino acid, such as alanine, or the adenylation domains have been deleted or otherwise rendered inactive. In one embodiment, both the loading domain and the NRPS have been deleted or rendered inactive. In any event, the resulting epothilone PKS can then function only if provided a substrate that binds to the KS domain of module 2 (or a subsequent module) of the epothilone PKS or a PKS for an epothilone derivative. In a method provided by the invention, the thus modified cells are then fed activated acylthioesters that are bound by preferably the second, but potentially any subsequent, module and processed into novel epothilone derivatives.

Thus, in one embodiment, the invention provides *Sorangium* and non-*Sorangium* host cells that express an epothilone PKS (or a PKS that produces an epothilone derivative) with an inactive NRPS. The host cell is fed activated acylthioesters to produce novel epothilone derivatives of the invention. The host cells expressing, or cell free extracts containing, the PKS can be fed or supplied with N-acylcysteamine thioesters (NACS) of novel precursor molecules to prepare epothilone derivatives. See U.S. patent application Serial No. 60/117,384, filed 27 Jan. 1999, and PCT patent publication No. US99/03986, both of which are incorporated herein by reference, and Example 6, below.

The second (first non-NRPS) module of the epothilone PKS includes a KS, an AT specific for methylmalonyl CoA, a DH, a KR, and an ACP. This module is encoded by a

- 28 -

sequence within an ~13.1 kb EcoRI-NsiI restriction fragment of cosmid pKOS35-70.8A3.

The recombinant nucleic acid compounds of the invention that encode the second module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. The second module of the epothilone PKS is produced as a discrete protein by the *epoC* gene. The present invention provides the *epoC* gene in recombinant form. In one embodiment, a DNA compound comprising a sequence that encodes the epothilone second module is coexpressed with the proteins constituting a heterologous PKS either as a discrete protein or as a fusion protein with one or more modules of the heterologous PKS. The resulting PKS, in which a module of the heterologous PKS is either replaced by the second module of the epothilone PKS or the latter is merely added to the modules of the heterologous PKS, provides a novel PKS. In another embodiment, a DNA compound comprising a sequence that encodes the second module of the epothilone PKS is coexpressed with the other proteins constituting the epothilone PKS or a recombinant epothilone PKS that produces an epothilone derivative.

In another embodiment, all or only a portion of the second module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, either replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or 2-hydroxymalonyl CoA specific AT; deleting either the DH or KR or both; replacing the DH or KR or both with a DH or KR or both that specify a different stereochemistry; and/or inserting an ER. Generally, any reference herein to inserting or replacing a PKS KR, DH, and/or ER domain includes the replacement of the associated KR, DH, or ER domains in that module, typically with corresponding domains from the module from which the inserted or replacing domain is obtained. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the epothilone PKS, from a gene for a PKS that produces a polyketide other than epothilone, or from chemical synthesis. The resulting heterologous second module coding sequence can be coexpressed with the other proteins

- 29 -

that constitute a PKS that synthesizes epothilone, an epothilone derivative, or another polyketide. Alternatively, one can delete or replace the second module of the epothilone PKS with a module from a heterologous PKS, which can be expressed as a discrete protein or as a fusion protein fused to either the *epoB* or *epoD* gene product.

5 Illustrative recombinant PKS genes of the invention include those in which the AT domain encoding sequences for the second module of the epothilone PKS have been altered or replaced to change the AT domain encoded thereby from a methylmalonyl specific AT to a malonyl specific AT. Such malonyl specific AT domain encoding nucleic acids can be isolated, for example and without limitation, from the PKS genes
10 encoding the narbonolide PKS, the rapamycin PKS (i.e., modules 2 and 12), and the FK-520 PKS (i.e., modules 3, 7, and 8). When such a hybrid second module is coexpressed with the other proteins constituting the epothilone PKS, the resulting epothilone derivative produced is a 16-desmethyl epothilone derivative.

In addition, the invention provides DNA compounds and vectors encoding
15 recombinant epothilone PKS enzymes and the corresponding recombinant proteins in which the KS domain of the second (or subsequent) module has been inactivated or deleted. In a preferred embodiment, this inactivation is accomplished by changing the codon for the active site cysteine to an alanine codon. As with the corresponding variants described above for the NRPS module, the resulting recombinant epothilone PKS
20 enzymes are unable to produce an epothilone or epothilone derivative unless supplied a precursor that can be bound and extended by the remaining domains and modules of the recombinant PKS enzyme. Illustrative diketides are described in Example 6, below.

The third module of the epothilone PKS includes a KS, an AT specific for malonyl CoA, a KR, and an ACP. This module is encoded by a sequence within an ~8 kb
25 BglII-NsiI restriction fragment of cosmid pKOS35-70.8A3.

The recombinant DNA compounds of the invention that encode the third module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. The third module of the epothilone PKS is expressed in a protein, the product of the *epoD* gene, which also contains modules 4, 5, and 6. The
30 present invention provides the *epoD* gene in recombinant form. The present invention

- 30 -

also provides recombinant DNA compounds that encode each of the epothilone PKS modules 3, 4, 5, and 6, as discrete coding sequences without coding sequences for the other epothilone modules. In one embodiment, a DNA compound comprising a sequence that encodes the epothilone third module is coexpressed with proteins constituting a
5 heterologous PKS. The third module of the epothilone PKS can be expressed either as a discrete protein or as a fusion protein fused to one or more modules of the heterologous PKS. The resulting PKS, in which a module of the heterologous PKS is either replaced by that for the third module of the epothilone PKS or the latter is merely added to the modules of the heterologous PKS, provides a novel PKS. In another embodiment, a DNA
10 compound comprising a sequence that encodes the third module of the epothilone PKS is coexpressed with proteins comprising the remainder of the epothilone PKS or a recombinant epothilone PKS that produces an epothilone derivative, typically as a protein comprising not only the third but also the fourth, fifth, and sixth modules.

In another embodiment, all or a portion of the third module coding sequence is
15 utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, either replacing the malonyl CoA specific AT with a methylmalonyl CoA, ethylmalonyl CoA, or 2-hydroxymalonyl CoA specific AT; deleting the KR; replacing the KR with a KR that specifies a different stereochemistry; and/or inserting a DH or a DH and an ER. As above, the reference to
20 inserting a DH or a DH and an ER includes the replacement of the KR with a DH and KR or an ER, DH, and KR. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the epothilone PKS, from a coding sequence for a PKS that produces a
25 polyketide other than epothilone, or from chemical synthesis. The resulting heterologous third module coding sequence can be utilized in conjunction with a coding sequence for a PKS that synthesizes epothilone, an epothilone derivative, or another polyketide.

Illustrative recombinant PKS genes of the invention include those in which the AT domain encoding sequences for the third module of the epothilone PKS have been
30 altered or replaced to change the AT domain encoded thereby from a malonyl specific

- 31 -

AT to a methylmalonyl specific AT. Such methylmalonyl specific AT domain encoding nucleic acids can be isolated, for example and without limitation, from the PKS genes encoding DEBS, the narbonolide PKS, the rapamycin PKS, and the FK-520 PKS. When coexpressed with the remaining modules and proteins of the epothilone PKS or an epothilone PKS derivative, the recombinant PKS produces the 14-methyl epothilone derivatives of the invention.

Those of skill in the art will recognize that the KR domain of the third module of the PKS is responsible for forming the hydroxyl group involved in cyclization of epothilone. Consequently, abolishing the KR domain of the third module or adding a DH or DH and ER domains will interfere with the cyclization, leading either to a linear molecule or to a molecule cyclized at a different location than is epothilone.

The fourth module of the epothilone PKS includes a KS, an AT that can bind either malonyl CoA or methylmalonyl CoA, a KR, and an ACP. This module is encoded by a sequence within an ~10 kb NsiI-HindIII restriction fragment of cosmid pKOS35-70.1A2.

The recombinant DNA compounds of the invention that encode the fourth module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the epothilone fourth module is inserted into a DNA compound that comprises the coding sequence for one or more modules of a heterologous PKS. The resulting construct encodes a protein in which a module of the heterologous PKS is either replaced by that for the fourth module of the epothilone PKS or the latter is merely added to the modules of the heterologous PKS. Together with other proteins that constitute the heterologous PKS, this protein provides a novel PKS. In another embodiment, a DNA compound comprising a sequence that encodes the fourth module of the epothilone PKS is expressed in a host cell that also expresses the remaining modules and proteins of the epothilone PKS or a recombinant epothilone PKS that produces an epothilone derivative. For making epothilone or epothilone derivatives, the recombinant fourth module is usually expressed in a protein that also contains the epothilone third, fifth, and sixth modules or modified versions thereof.

- 32 -

In another embodiment, all or a portion of the fourth module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, either replacing the malonyl CoA and methylmalonyl specific AT with a malonyl CoA, methylmalonyl CoA, ethylmalonyl CoA, or 2-hydroxymalonyl CoA specific AT; deleting the KR; and/or replacing the KR, including, optionally, to specify a different stereochemistry; and/or inserting a DH or a DH and ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the epothilone PKS, from a gene for a PKS that produces a polyketide other than epothilone, or from chemical synthesis. The resulting heterologous fourth module coding sequence is incorporated into a protein subunit of a recombinant PKS that synthesizes epothilone, an epothilone derivative, or another polyketide. If the desired polyketide is an epothilone or epothilone derivative, the recombinant fourth module is typically expressed as a protein that also contains the third, fifth, and sixth modules of the epothilone PKS or modified versions thereof. Alternatively, the invention provides recombinant PKS enzymes for epothilones and epothilone derivatives in which the entire fourth module has been deleted or replaced by a module from a heterologous PKS.

In a preferred embodiment, the invention provides recombinant DNA compounds comprising the coding sequence for the fourth module of the epothilone PKS modified to encode an AT that binds methylmalonyl CoA and not malonyl CoA. These recombinant molecules are used to express a protein that is a recombinant derivative of the *epoD* protein that comprises the modified fourth module as well as modules 3, 5, and 6, any one or more of which can optionally be in derivative form, of the epothilone PKS. In another preferred embodiment, the invention provides recombinant DNA compounds comprising the coding sequence for the fourth module of the epothilone PKS modified to encode an AT that binds malonyl CoA and not methylmalonyl CoA. These recombinant molecules are used to express a protein that is a recombinant derivative of the *epoD* protein that comprises the modified fourth module as well as modules 3, 5, and 6, any one or more of which can optionally be in derivative form, of the epothilone PKS.

- 33 -

Prior to the present invention, it was known that *Sorangium cellulosum* produced epothilones A, B, C, D, E, and F and that epothilones A, C, and E had a hydrogen at C-12, while epothilones B, D, and F had a methyl group at this position. Unappreciated prior to the present invention was the order in which these compounds were synthesized in *S. cellulosum*, and the mechanism by which some of the compounds had a hydrogen at C-12 where others had a methyl group at this position. The present disclosure reveals that epothilones A and B are derived from epothilones C and D by action of the *epoK* gene product and that the presence of a hydrogen or methyl moiety at C-12 is due to the AT domain of module 4 of the epothilone PKS. This domain can bind either malonyl or methylmalonyl CoA and, consistent with its having greater similarity to malonyl specific AT domains than to methylmalonyl specific AT domains, binds malonyl CoA more often than methylmalonyl CoA.

Thus, the invention provides recombinant DNA compounds and expression vectors and the corresponding recombinant PKS in which the hybrid fourth module with a methylmalonyl specific AT has been incorporated. The methylmalonyl specific AT coding sequence can originate, for example and without limitation, from coding sequences for the oleandolide PKS, DEBS, the narbonolide PKS, the rapamycin PKS, or any other PKS that comprises a methylmalonyl specific AT domain. In accordance with the invention, the hybrid fourth module expressed from this coding sequence is incorporated into the epothilone PKS (or the PKS for an epothilone derivative), typically as a derivative *epoD* gene product. The resulting recombinant epothilone PKS produces epothilones with a methyl moiety at C-12, i.e., epothilone H (or an epothilone H derivative) if there is no dehydratase activity to form the C-12-C-13 alkene; epothilone D (or an epothilone D derivative), if the dehydratase activity but not the epoxidase activity is present; epothilone B (or an epothilone B derivative), if both the dehydratase and epoxidase activity but not the hydroxylase activity are present; and epothilone F (or an epothilone F derivative), if all three dehydratase, epoxidase, and hydroxylase activities are present. As indicated parenthetically above, the cell will produce the corresponding epothilone derivative if there have been other changes to the epothilone PKS.

If the recombinant PKS comprising the hybrid methylmalonyl specific fourth module is expressed in, for example, *Sorangium cellulosum*, the appropriate modifying enzymes are present (unless they have been rendered inactive in accordance with the methods herein), and epothilones D, B, and/or F are produced. Such production is typically carried out in a recombinant *S. cellulosum* provided by the present invention in which the native epothilone PKS is unable to function at all or unable to function except in conjunction with the recombinant fourth module provided. In an illustrative example, one can use the methods and reagents of the invention to render inactive the *epoD* gene in the native host. Then, one can transform that host with a vector comprising the recombinant *epoD* gene containing the hybrid fourth module coding sequence. The recombinant vector can exist as an extrachromosomal element or as a segment of DNA integrated into the host cell chromosome. In the latter embodiment, the invention provides that one can simply integrate the recombinant methylmalonyl specific module 4 coding sequence into wild-type *S. cellulosum* by homologous recombination with the native *epoD* gene to ensure that only the desired epothilone is produced. The invention provides that the *S. cellulosum* host can either express or not express (by mutation or homologous recombination of the native genes therefor) the dehydratase, epoxidase, and/or oxidase gene products and thus form or not form the corresponding epothilone D, B, and F compounds, as the practitioner elects.

Sorangium cellulosum modified as described above is only one of the recombinant host cells provided by the invention. In a preferred embodiment, the recombinant methylmalonyl specific epothilone fourth module coding sequences are used in accordance with the methods of invention to produce epothilone D, B, and F (or their corresponding derivatives) in heterologous host cells. Thus, the invention provides reagents and methods for introducing the epothilone or epothilone derivative PKS and epothilone dehydratase, epoxidase, and hydroxylase genes and combinations thereof into heterologous host cells.

The recombinant methylmalonyl specific epothilone fourth module coding sequences provided by the invention afford important alternative methods for producing desired epothilone compounds in host cells. Thus, the invention provides a hybrid fourth

module coding sequence in which, in addition to the replacement of the endogenous AT coding sequence with a coding sequence for an AT specific for methylmalonyl Co A, coding sequences for a DH and KR for, for example and without limitation, module 10 of the rapamycin PKS or modules 1 or 5 of the FK-520 PKS have replaced the endogenous
5 KR coding sequences. When the gene product comprising the hybrid fourth module and epothilone PKS modules 3, 5, and 6 (or derivatives thereof) encoded by this coding sequence is incorporated into a PKS comprising the other epothilone PKS proteins (or derivatives thereof) produced in a host cell, the cell makes either epothilone D or its trans stereoisomer (or derivatives thereof), depending on the stereochemical specificity of the
10 inserted DH and KR domains.

Similarly, and as noted above, the invention provides recombinant DNA compounds comprising the coding sequence for the fourth module of the epothilone PKS modified to encode an AT that binds malonyl CoA and not methylmalonyl CoA. The invention provides recombinant DNA compounds and vectors and the corresponding
15 recombinant PKS in which this hybrid fourth module has been incorporated into a derivative *epoD* gene product. When incorporated into the epothilone PKS (or the PKS for an epothilone derivative), the resulting recombinant epothilone PKS produces epothilones C, A, and E, depending, again, on whether epothilone modification enzymes are present. As noted above, depending on the host, whether the fourth module includes a
20 KR and DH domain, and on whether and which of the dehydratase, epoxidase, and oxidase activities are present, the practitioner of the invention can produce one or more of the epothilone G, C, A, and E compounds and derivatives thereof using the compounds, host cells, and methods of the invention.

The fifth module of the epothilone PKS includes a KS, an AT that binds malonyl
25 CoA, a DH, an ER, a KR, and an ACP. This module is encoded by a sequence within an ~12.4 kb NsiI-NotI restriction fragment of cosmid pKOS35-70.1A2.

The recombinant DNA compounds of the invention that encode the fifth module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence
30 that encodes the epothilone fifth module is inserted into a DNA compound that comprises

the coding sequence for one or more modules of a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the fifth module of the epothilone PKS or the latter is merely added to coding sequences for the modules of the heterologous PKS, can be incorporated into an expression vector and used to produce the recombinant protein encoded thereby.

When the recombinant protein is combined with the other proteins of the heterologous PKS, a novel PKS is produced. In another embodiment, a DNA compound comprising a sequence that encodes the fifth module of the epothilone PKS is inserted into a DNA compound that comprises coding sequences for the epothilone PKS or a recombinant epothilone PKS that produces an epothilone derivative. In the latter constructs, the epothilone fifth module is typically expressed as a protein comprising the third, fourth, and sixth modules of the epothilone PKS or derivatives thereof.

In another embodiment, a portion of the fifth module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module coding sequence and the hybrid module encoded thereby. In this embodiment, the invention provides, for example, either replacing the malonyl CoA specific AT with a methylmalonyl CoA, ethylmalonyl CoA, or 2-hydroxymalonyl CoA specific AT; deleting any one, two, or all three of the ER, DH, and KR; and/or replacing any one, two, or all three of the ER, DH, and KR with either a KR, a DH and KR, or a KR, DH, and ER, including, optionally, to specify a different stereochemistry. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the epothilone PKS, from a coding sequence for a PKS that produces a polyketide other than epothilone, or from chemical synthesis. The resulting hybrid fifth module coding sequence can be utilized in conjunction with a coding sequence for a PKS that synthesizes epothilone, an epothilone derivative, or another polyketide. Alternatively, the fifth module of the epothilone PKS can be deleted or replaced in its entirety by a module of a heterologous PKS to produce a protein that in combination with the other proteins of the epothilone PKS or derivatives thereof constitutes a PKS that produces an epothilone derivative.

Illustrative recombinant PKS genes of the invention include recombinant *epoD* gene derivatives in which the AT domain encoding sequences for the fifth module of the epothilone PKS have been altered or replaced to change the AT domain encoded thereby from a malonyl specific AT to a methylmalonyl specific AT. Such methylmalonyl specific AT domain encoding nucleic acids can be isolated, for example and without limitation, from the PKS genes encoding DEBS, the narbonolide PKS, the rapamycin PKS, and the FK-520 PKS. When such recombinant *epoD* gene derivatives are coexpressed with the *epoA*, *epoB*, *epoC*, *epoE*, and *epoF* genes (or derivatives thereof), the PKS composed thereof produces the 10-methyl epothilones or derivatives thereof.

Another recombinant *epoD* gene derivative provided by the invention includes not only this altered module 5 coding sequence but also module 4 coding sequences that encode an AT domain that binds only methylmalonyl CoA. When incorporated into a PKS with the *epoA*, *epoB*, *epoC*, *epoE*, and *epoF* genes, the recombinant *epoD* gene derivative product leads to the production of 10-methyl epothilone B and/or D derivatives.

Other illustrative recombinant *epoD* gene derivatives of the invention include those in which the ER, DH, and KR domain encoding sequences for the fifth module of the epothilone PKS have been replaced with those encoding (i) a KR and DH domain; (ii) a KR domain; and (iii) an inactive KR domain. These recombinant *epoD* gene derivatives of the invention are coexpressed with the *epoA*, *epoB*, *epoC*, *epoE*, and *epoF* genes to produce a recombinant PKS that makes the corresponding (i) C-11 alkene, (ii) C-11 hydroxy, and (iii) C-11 keto epothilone derivatives. These recombinant *epoD* gene derivatives can also be coexpressed with recombinant *epo* genes containing other alterations or can themselves be further altered to produce a PKS that makes the corresponding C-11 epothilone derivatives. For example, one recombinant *epoD* gene derivative provided by the invention also includes module 4 coding sequences that encode an AT domain that binds only methylmalonyl CoA. When incorporated into a PKS with the *epoA*, *epoB*, *epoC*, *epoE*, and *epoF* genes, the recombinant *epoD* gene derivative product leads to the production of the corresponding C-11 epothilone B and/or D derivatives.

Functionally similar *epoD* genes for producing the epothilone C-11 derivatives can also be made by inactivation of one, two, or all three of the ER, DH, and KR domains of the epothilone fifth module. However, the preferred mode for altering such domains in any module is by replacement with the complete set of desired domains taken from
5 another module of the same or a heterologous PKS coding sequence. In this manner, the natural architecture of the PKS is conserved. Also, when present, KR and DH or KR, DH, and ER domains that function together in a native PKS are preferably used in the recombinant PKS. Illustrative replacement domains for the substitutions described above include, for example and without limitation, the inactive KR domain from the rapamycin
10 PKS module 3 to form the ketone, the KR domain from the rapamycin PKS module 5 to form the alcohol, and the KR and DH domains from the rapamycin PKS module 4 to form the alkene. Other such inactive KR, active KR, and active KR and DH domain encoding nucleic acids can be isolated from, for example and without limitation, the PKS genes encoding DEBS, the narbonolide PKS, and the FK-520 PKS. Each of the resulting
15 PKS enzymes produces a polyketide compound that comprises a functional group at the C-11 position that can be further derivatized *in vitro* by standard chemical methodology to yield semi-synthetic epothilone derivatives of the invention.

The sixth module of the epothilone PKS includes a KS, an AT that binds methylmalonyl CoA, a DH, an ER, a KR, and an ACP. This module is encoded by a
20 sequence within an ~14.5 kb *Hind*III-*Nsi*I restriction fragment of cosmid pKOS35-70.1A2.

The recombinant DNA compounds of the invention that encode the sixth module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence
25 that encodes the epothilone sixth module is inserted into a DNA compound that comprises the coding sequence for one or more modules of a heterologous PKS. The resulting protein encoded by the construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the sixth module of the epothilone PKS or the latter is merely added to coding sequences for the modules of the
30 heterologous PKS, provides a novel PKS when coexpressed with the other proteins

- 39 -

comprising the PKS. In another embodiment, a DNA compound comprising a sequence that encodes the sixth module of the epothilone PKS is inserted into a DNA compound that comprises the coding sequence for modules 3, 4, and 5 of the epothilone PKS or a recombinant epothilone PKS that produces an epothilone derivative and coexpressed with the other proteins of the epothilone or epothilone derivative PKS to produce a PKS that makes epothilone or an epothilone derivative in a host cell.

In another embodiment, a portion of the sixth module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, either replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or 2-hydroxymalonyl CoA specific AT; deleting any one, two, or all three of the ER, DH, and KR; and/or replacing any one, two, or all three of the ER, DH, and KR with either a KR, a DH and KR, or a KR, DH, and ER, including, optionally, to specify a different stereochemistry. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the epothilone PKS, from a coding sequence for a PKS that produces a polyketide other than epothilone, or from chemical synthesis. The resulting heterologous sixth module coding sequence can be utilized in conjunction with a coding sequence for a protein subunit of a PKS that makes epothilone, an epothilone derivative, or another polyketide. If the PKS makes epothilone or an epothilone derivative, the hybrid sixth module is typically expressed as a protein comprising modules 3, 4, and 5 of the epothilone PKS or derivatives thereof. Alternatively, the sixth module of the epothilone PKS can be deleted or replaced in its entirety by a module from a heterologous PKS to produce a PKS for an epothilone derivative.

Illustrative recombinant PKS genes of the invention include those in which the AT domain encoding sequences for the sixth module of the epothilone PKS have been altered or replaced to change the AT domain encoded thereby from a methylmalonyl specific AT to a malonyl specific AT. Such malonyl specific AT domain encoding nucleic acids can be isolated from, for example and without limitation, the PKS genes

encoding the narbonolide PKS, the rapamycin PKS, and the FK-520 PKS. When a recombinant *epoD* gene of the invention encoding such a hybrid module 6 is coexpressed with the other epothilone PKS genes, the recombinant PKS makes the 8-desmethyl epothilone derivatives. This recombinant *epoD* gene derivative can also be coexpressed with recombinant *epo* gene derivatives containing other alterations or can itself be further altered to produce a PKS that makes the corresponding 8-desmethyl epothilone derivatives. For example, one recombinant *epoD* gene provided by the invention also includes module 4 coding sequences that encode an AT domain that binds only methylmalonyl CoA. When incorporated into a PKS with the *epoA*, *epoB*, *epoC*, *epoE*, and *epoF* genes, the recombinant *epoD* gene product leads to the production of the 8-desmethyl derivatives of epothilones B and D.

Other illustrative recombinant *epoD* gene derivatives of the invention include those in which the ER, DH, and KR domain encoding sequences for the sixth module of the epothilone PKS have been replaced with those that encode (i) a KR and DH domain; (ii) a KR domain; and (iii) an inactive KR domain. These recombinant *epoD* gene derivatives of the invention, when coexpressed with the other epothilone PKS genes make the corresponding (i) C-9 alkene, (ii) C-9 hydroxy, and (iii) C-9 keto epothilone derivatives. These recombinant *epoD* gene derivatives can also be coexpressed with other recombinant *epo* gene derivatives containing other alterations or can themselves be further altered to produce a PKS that makes the corresponding C-9 epothilone derivatives. For example, one recombinant *epoD* gene derivative provided by the invention also includes module 4 coding sequences that encode an AT domain that binds only methylmalonyl CoA. When incorporated into a PKS with the *epoA*, *epoB*, *epoC*, *epoE*, and *epoF* genes, the recombinant *epoD* gene product leads to the production of the C-9 derivatives of epothilones B and D.

Functionally equivalent sixth modules can also be made by inactivation of one, two, or all three of the ER, DH, and KR domains of the epothilone sixth module. The preferred mode for altering such domains in any module is by replacement with the complete set of desired domains taken from another module of the same or a heterologous PKS coding sequence. Illustrative replacement domains for the substitutions

described above include but are not limited to the inactive KR domain from the rapamycin PKS module 3 to form the ketone, the KR domain from the rapamycin PKS module 5 to form the alcohol, and the KR and DH domains from the rapamycin PKS module 4 to form the alkene. Other such inactive KR, active KR, and active KR and DH domain encoding nucleic acids can be isolated from for example and without limitation the PKS genes encoding DEBS, the narbonolide PKS, and the FK-520 PKS. Each of the resulting PKSs produces a polyketide compound that comprises a functional group at the C-9 position that can be further derivatized *in vitro* by standard chemical methodology to yield semi-synthetic epothilone derivatives of the invention.

The seventh module of the epothilone PKS includes a KS, an AT specific for methylmalonyl CoA, a KR, and an ACP. This module is encoded by a sequence within an ~8.7 kb BglII restriction fragment from cosmid pKOS35-70.4.

The recombinant DNA compounds of the invention that encode the seventh module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. The seventh module of the epothilone PKS is contained in the gene product of the *epoE* gene, which also contains the eighth module. The present invention provides the *epoE* gene in recombinant form, but also provides DNA compounds that encode the seventh module without coding sequences for the eighth module as well as DNA compounds that encode the eighth module without coding sequences for the seventh module. In one embodiment, a DNA compound comprising a sequence that encodes the epothilone seventh module is inserted into a DNA compound that comprises the coding sequence for one or more modules of a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the seventh module of the epothilone PKS or the latter is merely added to coding sequences for the modules of the heterologous PKS, provides a novel PKS coding sequence that can be expressed in a host cell. Alternatively, the epothilone seventh module can be expressed as a discrete protein. In another embodiment, a DNA compound comprising a sequence that encodes the seventh module of the epothilone PKS is expressed to form a protein that, together with other proteins, constitutes the epothilone PKS or a PKS that produces an epothilone derivative. In these

embodiments, the seventh module is typically expressed as a protein comprising the eighth module of the epothilone PKS or a derivative thereof and coexpressed with the *epoA*, *epoB*, *epoC*, *epoD*, and *epoF* genes or derivatives thereof to constitute the PKS.

In another embodiment, a portion or all of the seventh module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, either replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or 2-hydroxymalonyl CoA specific AT; deleting the KR; replacing the KR with a KR that specifies a different stereochemistry; and/or inserting a DH or a DH and an ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the epothilone PKS, from a coding sequence for a PKS that produces a polyketide other than epothilone, or from chemical synthesis. The resulting heterologous seventh module coding sequence is utilized, optionally in conjunction with other coding sequences, to express a protein that together with other proteins constitutes a PKS that synthesizes epothilone, an epothilone derivative, or another polyketide. When used to prepare epothilone or an epothilone derivative, the seventh module is typically expressed as a protein comprising the eighth module or derivative thereof and coexpressed with the *epoA*, *epoB*, *epoC*, *epoD*, and *epoF* genes or derivatives thereof to constitute the PKS. Alternatively, the coding sequences for the seventh module in the *epoE* gene can be deleted or replaced by those for a heterologous module to prepare a recombinant *epoE* gene derivative that, together with the *epoA*, *epoB*, *epoC*, *epoD*, and *epoF* genes, can be expressed to make a PKS for an epothilone derivative.

Illustrative recombinant *epoE* gene derivatives of the invention include those in which the AT domain encoding sequences for the seventh module of the epothilone PKS have been altered or replaced to change the AT domain encoded thereby from a methylmalonyl specific AT to a malonyl specific AT. Such malonyl specific AT domain encoding nucleic acids can be isolated from for example and without limitation the PKS genes encoding the narbonolide PKS, the rapamycin PKS, and the FK-520 PKS. When

coexpressed with the other epothilone PKS genes, *epoA*, *epoB*, *epoC*, *epoD*, and *epoF*, or derivatives thereof, a PKS for an epothilone derivative with a C-6 hydrogen, instead of a C-6 methyl, is produced. Thus, if the genes contain no other alterations, the compounds produced are the 6-desmethyl epothilones.

5 The eighth module of the epothilone PKS includes a KS, an AT specific for methylmalonyl CoA, inactive KR and DH domains, a methyltransferase (MT) domain, and an ACP. This module is encoded by a sequence within an ~10 kb NotI restriction fragment of cosmid pKOS35-79.85.

10 The recombinant DNA compounds of the invention that encode the eighth module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the epothilone eighth module is inserted into a DNA compound that comprises the coding sequence for one or more modules of a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS
15 is either replaced by that for the eighth module of the epothilone PKS or the latter is merely added to coding sequences for modules of the heterologous PKS, provides a novel PKS coding sequence that is expressed with the other proteins constituting the PKS to provide a novel PKS. Alternatively, the eighth module can be expressed as a discrete protein that can associate with other PKS proteins to constitute a novel PKS. In another
20 embodiment, a DNA compound comprising a sequence that encodes the eighth module of the epothilone PKS is coexpressed with the other proteins constituting the epothilone PKS or a PKS that produces an epothilone derivative. In these embodiments, the eighth module is typically expressed as a protein that also comprises the seventh module or a derivative thereof.

25 In another embodiment, a portion or all of the eighth module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, either replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or 2-hydroxymalonyl CoA specific AT; deleting the inactive KR and/or the inactive DH; replacing the inactive KR
30 and/or DH with an active KR and/or DH; and/or inserting an ER. In addition, the KS

and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the epothilone PKS, from a coding sequence for a PKS that produces a polyketide other than epothilone, or from chemical synthesis. The resulting heterologous eighth module coding sequence is expressed as a protein that is utilized in conjunction with the other proteins that constitute a PKS that synthesizes epothilone, an epothilone derivative, or another polyketide. When used to prepare epothilone or an epothilone derivative, the heterologous or hybrid eighth module is typically expressed as a recombinant *epoE* gene product that also contains the seventh module. Alternatively, the coding sequences for the eighth module in the *epoE* gene can be deleted or replaced by those for a heterologous module to prepare a recombinant *epoE* gene that, together with the *epoA*, *epoB*, *epoC*, *epoD*, and *epoF* genes, can be expressed to make a PKS for an epothilone derivative.

The eighth module of the epothilone PKS also comprises a methylation or methyltransferase (MT) domain with an activity that methylates the epothilone precursor. This function can be deleted to produce a recombinant *epoD* gene derivative of the invention, which can be expressed with the other epothilone PKS genes or derivatives thereof that makes an epothilone derivative that lacks one or both methyl groups, depending on whether the AT domain of the eighth module has been changed to a malonyl specific AT domain, at the corresponding C-4 position of the epothilone molecule. In another important embodiment, the present invention provides recombinant DNA compounds that encode a polypeptide with this methylation domain and activity and a variety of recombinant PKS coding sequences that encode recombinant PKS enzymes that incorporate this polypeptide. The availability of this MT domain and the coding sequences therefor provides a significant number of new polyketides that differ from known polyketides by the presence of at least an additional methyl group. The MT domain of the invention can in effect be added to any PKS module to direct the methylation at the corresponding location in the polyketide produced by the PKS. As but one illustrative example, the present invention provides the recombinant nucleic acid compounds resulting from inserting the coding sequence for this MT activity into a

coding sequence for any one or more of the six modules of the DEBS enzyme to produce a recombinant DEBS that synthesizes a 6-deoxyerythronolide B derivative that comprises one or more additional methyl groups at the C-2, C-4, C-6, C-8, C-10, and/or C-12 positions. In such constructs, the MT domain can be inserted adjacent to the AT or the ACP.

The ninth module of the epothilone PKS includes a KS, an AT specific for malonyl CoA, a KR, an inactive DH, and an ACP. This module is encoded by a sequence within an ~14.7 HindIII-BglII kb restriction fragment of cosmid pKOS35-79.85.

The recombinant DNA compounds of the invention that encode the ninth module of the epothilone PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. The ninth module of the epothilone PKS is expressed as a protein, the product of the *epoF* gene, that also contains the TE domain of the epothilone PKS. The present invention provides the *epoF* gene in recombinant form, as well as DNA compounds that encode the ninth module without the coding sequences for the TE domain and DNA compounds that encode the TE domain without the coding sequences for the ninth module. In one embodiment, a DNA compound comprising a sequence that encodes the epothilone ninth module is inserted into a DNA compound that comprises the coding sequence for one or more modules of a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the ninth module of the epothilone PKS or the latter is merely added to coding sequences for the modules of the heterologous PKS, provides a novel PKS protein coding sequence that when coexpressed with the other proteins constituting a PKS provides a novel PKS. The ninth module coding sequence can also be expressed as a discrete protein with or without an attached TE domain. In another embodiment, a DNA compound comprising a sequence that encodes the ninth module of the epothilone PKS is expressed as a protein together with other proteins to constitute an epothilone PKS or a PKS that produces an epothilone derivative. In these embodiments, the ninth module is typically expressed as a protein that also contains the TE domain of either the epothilone PKS or a heterologous PKS.

In another embodiment, a portion or all of the ninth module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, either replacing the malonyl CoA specific AT with a methylmalonyl CoA, ethylmalonyl CoA, or 2-hydroxy malonyl CoA specific AT; deleting the KR; replacing the KR with a KR that specifies a different stereochemistry; and/or inserting a DH or a DH and an ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the epothilone PKS, from a coding sequence for a PKS that produces a polyketide other than epothilone, or from chemical synthesis. The resulting heterologous ninth module coding sequence is coexpressed with the other proteins constituting a PKS that synthesizes epothilone, an epothilone derivative, or another polyketide. Alternatively, the present invention provides a PKS for an epothilone or epothilone derivative in which the ninth module has been replaced by a module from a heterologous PKS or has been deleted in its entirety. In the latter embodiment, the TE domain is expressed as a discrete protein or fused to the eighth module.

The ninth module of the epothilone PKS is followed by a thioesterase domain. This domain is encoded in the ~14.7 kb HindIII-BglII restriction comprising the ninth module coding sequence. The present invention provides recombinant DNA compounds that encode hybrid PKS enzymes in which the ninth module of the epothilone PKS is fused to a heterologous thioesterase or one or more modules of a heterologous PKS are fused to the epothilone PKS thioesterase. Thus, for example, a thioesterase domain coding sequence from another PKS can be inserted at the end of the ninth module ACP coding sequence in recombinant DNA compounds of the invention. Recombinant DNA compounds encoding this thioesterase domain are therefore useful in constructing DNA compounds that encode a protein of the epothilone PKS, a PKS that produces an epothilone derivative, and a PKS that produces a polyketide other than epothilone or an epothilone derivative.

In one important embodiment, the present invention thus provides a hybrid PKS and the corresponding recombinant DNA compounds that encode the proteins constituting those hybrid PKS enzymes. For purposes of the present invention a hybrid PKS is a recombinant PKS that comprises all or part of one or more modules, loading domain, and thioesterase/cyclase domain of a first PKS and all or part of one or more modules, loading domain, and thioesterase/cyclase domain of a second PKS. In one preferred embodiment, the first PKS is most but not all of the epothilone PKS, and the second PKS is only a portion or all of a non-epothilone PKS. An illustrative example of such a hybrid PKS includes an epothilone PKS in which the natural loading domain has been replaced with a loading domain of another PKS. Another example of such a hybrid PKS is an epothilone PKS in which the AT domain of module four is replaced with an AT domain from a heterologous PKS that binds only methylmalonyl CoA. In another preferred embodiment, the first PKS is most but not all of a non-epothilone PKS, and the second PKS is only a portion or all of the epothilone PKS. An illustrative example of such a hybrid PKS includes an erythromycin PKS in which an AT specific for methylmalonyl CoA is replaced with an AT from the epothilone PKS specific for malonyl CoA. Another example is an erythromycin PKS that includes the MT domain of the epothilone PKS.

Those of skill in the art will recognize that all or part of either the first or second PKS in a hybrid PKS of the invention need not be isolated from a naturally occurring source. For example, only a small portion of an AT domain determines its specificity. See U.S. patent application Serial No. 09/346,860 and PCT patent application No. WO US99/15047, each of which is incorporated herein by reference. The state of the art in DNA synthesis allows the artisan to construct de novo DNA compounds of size sufficient to construct a useful portion of a PKS module or domain. For purposes of the present invention, such synthetic DNA compounds are deemed to be a portion of a PKS.

The following Table lists references describing illustrative PKS genes and corresponding enzymes that can be utilized in the construction of the recombinant PKSs and the corresponding DNA compounds that encode them of the invention. Also presented are various references describing polyketide tailoring and modification

enzymes and corresponding genes that can be employed to make the recombinant DNA compounds of the present invention.

Avermectin

5 U.S. Pat. No. 5,252,474 to Merck.

MacNeil *et al.*, 1993, Industrial Microorganisms: Basic and Applied Molecular Genetics, Baltz, Hegeman, & Skatrud, eds. (ASM), pp. 245-256, A Comparison of the Genes Encoding the Polyketide Synthases for Avermectin, Erythromycin, and Nemadectin.

10 MacNeil *et al.*, 1992, Gene 115: 119-125, Complex Organization of the *Streptomyces avermitilis* genes encoding the avermectin polyketide synthase.

Ikeda and Omura, 1997, Chem. Res. 97: 2599-2609, Avermectin biosynthesis.

Candicidin (FR008)

Hu *et al.*, 1994, Mol. Microbiol. 14: 163-172.

15 Erythromycin

PCT Pub. No. 93/13663 to Abbott.

US Pat. No. 5,824,513 to Abbott.

Donadio *et al.*, 1991, Science 252:675-9.

20 Cortes *et al.*, 8 Nov. 1990, Nature 348:176-8, An unusually large multifunctional polypeptide in the erythromycin producing polyketide synthase of *Saccharopolyspora erythraea*.

Glycosylation Enzymes

PCT Pat. App. Pub. No. 97/23630 to Abbott.

FK-506

25 Motamedi *et al.*, 1998, The biosynthetic gene cluster for the macrolactone ring of the immunosuppressant FK-506, Eur. J. Biochem. 256: 528-534.

Motamedi *et al.*, 1997, Structural organization of a multifunctional polyketide synthase involved in the biosynthesis of the macrolide immunosuppressant FK-506, Eur. J. Biochem. 244: 74-80.

Methyltransferase

US 5,264,355, issued 23 Nov. 1993, Methylating enzyme from *Streptomyces* MA6858. 31-O-desmethyl-FK-506 methyltransferase.

Motamedi *et al.*, 1996, Characterization of methyltransferase and hydroxylase genes involved in the biosynthesis of the immunosuppressants FK-506 and FK-520, J. Bacteriol. 178: 5243-5248.

FK-520

U.S. patent application Serial No. 09/154,083, filed 16 Sep. 1998.

U.S. patent application Serial No. 09/410,551, filed 1 Oct. 1999.

10 Nielsen *et al.*, 1991, Biochem. 30:5789-96.

Lovastatin

U.S. Pat. No. 5,744,350 to Merck.

Narbomycin

U.S. patent application Serial No. 60/107,093, filed 5 Nov. 1998.

15 **Nemadectin**

MacNeil *et al.*, 1993, *supra*.

Niddamycin

Kakavas *et al.*, 1997, Identification and characterization of the niddamycin polyketide synthase genes from *Streptomyces caelestis*, J. Bacteriol. 179: 7515-7522.

20 **Oleandomycin**

Swan *et al.*, 1994, Characterisation of a *Streptomyces antibioticus* gene encoding a type I polyketide synthase which has an unusual coding sequence, Mol. Gen. Genet. 242: 358-362.

U.S. patent application Serial No. 60/120,254, filed 16 Feb. 1999, Serial No. 09/_____, filed 28 Oct. 1999, claiming priority thereto by inventors S. Shah, M. Betlach, R. McDaniel, and L. Tang, attorney docket No. 30063-20029.00.

Olano *et al.*, 1998, Analysis of a *Streptomyces antibioticus* chromosomal region involved in oleandomycin biosynthesis, which encodes two glycosyltransferases responsible for glycosylation of the macrolactone ring, Mol. Gen. Genet. 259(3): 299-308.

Picromycin

PCT patent application No. WO US99/11814, filed 28 May 1999.

U.S. patent application Serial No. 09/320,878, filed 27 May 1999.

U.S. patent application Serial No. 09/141,908, filed 28 Aug. 1998.

- 5 Xue *et al.*, 1998, Hydroxylation of macrolactones YC-17 and narbomycin is mediated by the pikC-encoded cytochrome P450 in *Streptomyces venezuelae*, Chemistry & Biology 5(11): 661-667.

- Xue *et al.*, Oct. 1998, A gene cluster for macrolide antibiotic biosynthesis in *Streptomyces venezuelae*: Architecture of metabolic diversity, Proc. Natl. Acad. Sci.
10 USA 95: 12111 12116.

Platenolide

EP Pat. App. Pub. No. 791,656 to Lilly.

Pradimicin

PCT Pat. Pub. No. WO 98/11230 to Bristol-Myers Squibb.

15 **Rapamycin**

Schwecke *et al.*, Aug. 1995, The biosynthetic gene cluster for the polyketide rapamycin, Proc. Natl. Acad. Sci. USA 92:7839-7843.

- Aparicio *et al.*, 1996, Organization of the biosynthetic gene cluster for rapamycin in *Streptomyces hygroscopicus*: analysis of the enzymatic domains in the modular
20 polyketide synthase, Gene 169: 9-16.

Rifamycin

PCT Pat. Pub. No. WO 98/07868 to Novartis.

- August *et al.*, 13 Feb. 1998, Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the *rif* biosynthetic gene cluster of
25 Amycolatopsis mediterranei S669, Chemistry & Biology, 5(2): 69-79.

Sorangium PKS

U.S. patent application Serial No. 09/144,085, filed 31 Aug. 1998.

Soraphen

U.S. Pat. No. 5,716,849 to Novartis.

Schupp *et al.*, 1995, J. Bacteriology 177: 3673-3679. A *Sorangium cellulosum* (Myxobacterium) Gene Cluster for the Biosynthesis of the Macrolide Antibiotic Soraphen A: Cloning, Characterization, and Homology to Polyketide Synthase Genes from Actinomycetes.

5 **Spiramycin**

U.S. Pat. No. 5,098,837 to Lilly.

Activator Gene

U.S. Pat. No. 5,514,544 to Lilly.

Tylosin

10 U.S. Pat. No. 5,876,991 to Lilly.

EP Pub. No. 791,655 to Lilly.

Kuhstoss *et al.*, 1996, Gene 183:231-6., Production of a novel polyketide through the construction of a hybrid polyketide synthase.

Tailoring enzymes

15 Merson-Davies and Cundliffe, 1994, Mol. Microbiol. 13: 349-355. Analysis of five tylosin biosynthetic genes from the tylBA region of the *Streptomyces fradiae* genome.

As the above Table illustrates, there are a wide variety of PKS genes that serve as readily available sources of DNA and sequence information for use in constructing the
20 hybrid PKS-encoding DNA compounds of the invention. Methods for constructing hybrid PKS-encoding DNA compounds are described without reference to the epothilone PKS in U.S. Patent Nos. 5,672,491 and 5,712,146 and U.S. patent application Serial Nos. 09/073,538, filed 6 May 1998, and 09/141,908, filed 28 Aug 1998, each of which is incorporated herein by reference. Preferred PKS enzymes and coding sequences for the
25 proteins which constitute them for purposes of isolating heterologous PKS domain coding sequences for constructing hybrid PKS enzymes of the invention are the soraphen PKS and the PKS described as a *Sorangium* PKS in the above table.

To summarize the functions of the genes cloned and sequenced in Example 1:

- 52 -

<u>Gene</u>	<u>Protein</u>	<u>Modules</u>	<u>Domains Present</u>
<i>epoA</i>	EpoA	Load	Ks ^y mAT ER ACP
<i>epoB</i>	EpoB	1	NRPS, condensation, heterocyclization, adenylation, thiolation, PCP
<i>epoC</i>	EpoC	2	KS mmAT DH KR ACP
<i>epoD</i>	EpoD	3	KS mAT KR ACP
		4	KS mAT KR ACP
		5	KS mAT DH ER KR ACP
		6	KS mmAT DH ER KR ACP
<i>epoE</i>	EpoE	7	KS mmAT KR ACP
		8	KS mmAT MT DH* KR* ACP
<i>epoF</i>	EpoF	9	KS mAT KR DH* ACP TE

NRPS – non-ribosomal peptide synthetase; KS – ketosynthase; mAT – malonyl CoA specifying acyltransferase; mmAT – methylmalonyl CoA specifying acyltransferase; DH – dehydratase; ER – enoylreductase; KR – ketoreductase; MT – methyltransferase; TE thioesterase; * – inactive domain.

The hybrid PKS-encoding DNA compounds of the invention can be and often are hybrids of more than two PKS genes. Even where only two genes are used, there are often two or more modules in the hybrid gene in which all or part of the module is derived from a second (or third) PKS gene. Illustrative examples of recombinant epothilone derivative PKS genes of the invention, which are identified by listing the specificities of the hybrid modules (the other modules having the same specificity as the epothilone PKS), include:

(a) module 4 with methylmalonyl specific AT (mm AT) and a KR and module 2 with a malonyl specific AT (m AT) and a KR;

(b) module 4 with mM AT and a KR and module 3 with mM AT and a KR;

(c) module 4 with mM AT and a KR and module 5 with mM AT and a ER, DH, and KR;

- 53 -

(d) module 4 with mM AT and a KR and module 5 with mM AT and a DH and KR;

(e) module 4 with mM AT and a KR and module 5 with mM AT and a KR;

5 (f) module 4 with mM AT and a KR and module 5 with mM AT and an inactive KR;

(g) module 4 with mM AT and a KR and module 6 with m AT and a ER, DH, and KR;

(h) module 4 with mM AT and a KR and module 6 with m AT and a DH and KR;

(i) module 4 with mM AT and a KR and module 6 with m AT and a KR;

10 (j) module 4 with mM AT and a KR and module 6 with m AT and an inactive KR;

(k) module 4 with mM AT and a KR and module 7 with m AT;

(l) hybrids (c) through (f), except that module 5 has a m AT;

(m) hybrids (g) through (j) except that module 6 has a mM AT; and

15 (n) hybrids (a) through (m) except that module 4 has a m AT.

The above list is illustrative only and should not be construed as limiting the invention, which includes other recombinant epothilone PKS genes and enzymes with not only two hybrid modules other than those shown but also with three or more hybrid modules.

Those of skill in the art will appreciate that a hybrid PKS of the invention
20 includes but is not limited to a PKS of any of the following types: (i) an epothilone or epothilone derivative PKS that contains a module in which at least one of the domains is from a heterologous module; (ii) an epothilone or epothilone derivative PKS that contains a module from a heterologous PKS; (iii) an epothilone or epothilone derivative PKS that contains a protein from a heterologous PKS; and (iv) combinations of the foregoing.

25 While an important embodiment of the present invention relates to hybrid PKS genes, the present invention also provides recombinant epothilone PKS genes in which there is no second PKS gene sequence present but which differ from the epothilone PKS gene by one or more deletions. The deletions can encompass one or more modules and/or can be limited to a partial deletion within one or more modules. When a deletion
30 encompasses an entire module other than the NRPS module, the resulting epothilone

derivative is at least two carbons shorter than the compound produced from the PKS from which the deleted version was derived. The deletion can also encompass the NRPS module and/or the loading domain, as noted above. When a deletion is within a module, the deletion typically encompasses a KR, DH, or ER domain, or both DH and ER

5 domains, or both KR and DH domains, or all three KR, DH, and ER domains.

The catalytic properties of the domains and modules of the epothilone PKS and of epothilone modification enzymes can also be altered by random or site specific mutagenesis of the corresponding genes. A wide variety of mutagenizing agents and methods are known in the art and are suitable for this purpose. The technique known as

10 DNA shuffling can also be employed. See, e.g., U.S. Patent Nos. 5,830,721; 5,811,238; and 5,605,793; and references cited therein, each of which is incorporated herein by reference.

Recombinant Manipulations

15 To construct a hybrid PKS or epothilone derivative PKS gene of the invention, or simply to express unmodified epothilone biosynthetic genes, one can employ a technique, described in PCT Pub. No. 98/27203 and U.S. patent application Serial Nos. 08/989,332, filed 11 Dec. 1997, and 60/129,731, filed 16 April 1999, each of which is incorporated herein by reference, in which the various genes of the PKS are divided into two or more,

20 often three, segments, and each segment is placed on a separate expression vector. In this manner, the full complement of genes can be assembled and manipulated more readily for heterologous expression, and each of the segments of the gene can be altered, and various altered segments can be combined in a single host cell to provide a recombinant PKS of the invention. This technique makes more efficient the construction of large

25 libraries of recombinant PKS genes, vectors for expressing those genes, and host cells comprising those vectors. In this and other contexts, the genes encoding the desired PKS are not only present on two or more vectors, but also can be ordered or arranged differently than in the native producer organism from which the genes were derived. Various examples of this technique as applied to the epothilone PKS are described in the

30 Examples below. In one embodiment, the *epoA*, *epoB*, *epoC*, and *epoD* genes are present

on a first plasmid, and the *epoE* and *epoF* and optionally either the *epoK* or the *epoK* and *epoL* genes are present on a second (or third) plasmid.

Thus, in one important embodiment, the recombinant nucleic acid compounds of the invention are expression vectors. As used herein, the term "expression vector" refers to any nucleic acid that can be introduced into a host cell or cell-free transcription and translation medium. An expression vector can be maintained stably or transiently in a cell, whether as part of the chromosomal or other DNA in the cell or in any cellular compartment, such as a replicating vector in the cytoplasm. An expression vector also comprises a gene that serves to produce RNA that is translated into a polypeptide in the cell or cell extract. Thus, the vector typically includes a promoter to enhance gene expression but alternatively may serve to incorporate the relevant coding sequence under the control of an endogenous promoter. Furthermore, expression vectors may typically contain additional functional elements, such as resistance-conferring genes to act as selectable markers and regulatory genes to enhance promoter activity.

The various components of an expression vector can vary widely, depending on the intended use of the vector. In particular, the components depend on the host cell(s) in which the vector will be used or is intended to function. Vector components for expression and maintenance of vectors in *E. coli* are widely known and commercially available, as are vector components for other commonly used organisms, such as yeast cells and *Streptomyces* cells.

In one embodiment, the vectors of the invention are used to transform *Sorangium* host cells to provide the recombinant *Sorangium* host cells of the invention. U.S. Pat. No. 5,686,295, incorporated herein by reference, describes a method for transforming *Sorangium* host cells, although other methods may also be employed. *Sorangium* is a convenient host for expressing epothilone derivatives of the invention in which the recombinant PKS that produces such derivatives is expressed from a recombinant vector in which the epothilone PKS gene promoter is positioned to drive expression of the recombinant coding sequence. The epothilone PKS gene promoter is provided in recombinant form by the present invention and is an important embodiment thereof. The promoter is contained within an ~500 nucleotide sequence between the end of the

transposon sequences and the start site of the open reading frame of the *epoA* gene. Optionally, one can include sequences from further upstream of this 500 bp region in the promoter. Those of skill in the art will recognize that, if a *Sorangium* host that produces epothilone is used as the host cell, the recombinant vector need drive expression of only a portion of the PKS containing the altered sequences. Thus, such a vector may comprise only a single altered epothilone PKS gene, with the remainder of the epothilone PKS polypeptides provided by the genes in the host cell chromosomal DNA. If the host cell naturally produces an epothilone, the epothilone derivative will thus be produced in a mixture containing the naturally occurring epothilone(s).

Those of skill will also recognize that the recombinant DNA compounds of the invention can be used to construct *Sorangium* host cells in which one or more genes involved in epothilone biosynthesis have been rendered inactive. Thus, the invention provides such *Sorangium* host cells, which may be preferred host cells for expressing epothilone derivatives of the invention so that complex mixtures of epothilones are avoided. Particularly preferred host cells of this type include those in which one or more of any of the epothilone PKS gene ORFs has been disrupted, and/or those in which any or more of the epothilone modification enzyme genes have been disrupted. Such host cells are typically constructed by a process involving homologous recombination using a vector that contains DNA homologous to the regions flanking the gene segment to be altered and positioned so that the desired homologous double crossover recombination event desired will occur.

Homologous recombination can thus be used to delete, disrupt, or alter a gene. In a preferred illustrative embodiment, the present invention provides a recombinant epothilone producing *Sorangium cellulosum* host cell in which the *epoK* gene has been deleted or disrupted by homologous recombination using a recombinant DNA vector of the invention. This host cell, unable to make the *epoK* epoxidase gene product is unable to make epothilones A and B and so is a preferred source of epothilones C and D.

Homologous recombination can also be used to alter the specificity of a PKS module by replacing coding sequences for the module or domain of a module to be altered with those specifying a module or domain of the desired specificity. In another

- 57 -

preferred illustrative embodiment, the present invention provides a recombinant
epothilone producing *Sorangium cellulosum* host cell in which the coding sequence for
the AT domain of module 4 encoded by the *epoD* gene has been altered by homologous
recombination using a recombinant DNA vector of the invention to encode an AT
5 domain that binds only methylmalonyl CoA. This host cell, unable to make epothilones
A, C, and E is a preferred source of epothilones B, D, and F. The invention also provides
recombinant *Sorangium* host cells in which both alterations and deletions of epothilone
biosynthetic genes have been made. For example, the invention provides recombinant
Sorangium cellulosum host cells in which both of the foregoing alteration and deletion
10 have been made, producing a host cell that makes only epothilone D.

In similar fashion, those of skill in the art will appreciate the present invention
provides a wide variety of recombinant *Sorangium cellulosum* host cells that make less
complex mixtures of the epothilones than do the wild type producing cells as well as
those that make one or more epothilone derivatives. Such host cells include those that
15 make only epothilones A, C, and E; those that make only epothilones B, D, and F, those
that make only epothilone D; and those that make only epothilone C.

In another preferred embodiment, the present invention provides expression
vectors and recombinant *Myxococcus*, preferably *M. xanthus*, host cells containing those
expression vectors that express a recombinant epothilone PKS or a PKS for an epothilone
20 derivative. Presently, vectors that replicate extrachromosomally in *M. xanthus* are not
known. There are, however, a number of phage known to integrate into *M. xanthus*
chromosomal DNA, including Mx8, Mx9, Mx81, and Mx82. The integration and
attachment function of these phages can be placed on plasmids to create phage-based
expression vectors that integrate into the *M. xanthus* chromosomal DNA. Of these, phage
25 Mx9 and Mx8 are preferred for purposes of the present invention. Plasmid pPLH343,
described in Salmi *et al.*, Feb. 1998, Genetic determinants of immunity and integration of
temperate *Myxococcus xanthus* phage Mx8, J. Bact. 180(3): 614-621, is a plasmid that
replicates in *E. coli* and comprises the phage Mx8 genes that encode the attachment and
integration functions.

The promoter of the epothilone PKS gene functions in *Myxococcus xanthus* host cells. Thus, in one embodiment, the present invention provides a recombinant promoter for use in recombinant host cells derived from the promoter of the *Sorangium cellulosum* epothilone PKS gene. The promoter can be used to drive expression of one or more
5 epothilone PKS genes or another useful gene product in recombinant host cells. The invention also provides an epothilone PKS expression vector in which one or more of the epothilone PKS or epothilone modification enzyme genes are under the control of their own promoter. Another preferred promoter for use in *Myxococcus xanthus* host cells for purposes of expressing a recombinant PKS of the invention is the promoter of the pilA
10 gene of *M. xanthus*. This promoter, as well as two *M. xanthus* strains that express high levels of gene products from genes controlled by the pilA promoter, a pilA deletion strain and a pilS deletion strain, are described in Wu and Kaiser, Dec. 1997, Regulation of expression of the pilA gene in *Myxococcus xanthus*, J. Bact. 179(24):7748-7758, incorporated herein by reference. Optionally, the invention provides recombinant
15 *Myxococcus* host cells comprising both the pilA and pilS deletions. Another preferred promoter is the starvation dependent promoter of the sdcK gene.

Selectable markers for use in *Myxococcus xanthus* include kanamycin, tetracycline, chloramphenicol, zeocin, spectinomycin, and streptomycin resistance conferring genes. The recombinant DNA expression vectors of the invention for use in
20 *Myxococcus* typically include such a selectable marker and may further comprise the promoter derived from an epothilone PKS or epothilone modification enzyme gene.

The present invention provides preferred expression vectors for use in preparing the recombinant *Myxococcus xanthus* expression vectors and host cells of the invention. These vectors, designated plasmids pKOS35-82.1 and pKOS35-82.2 (Figure 3), are able
25 to replicate in *E. coli* host cells as well as integrate into the chromosomal DNA of *M. xanthus*. The vectors comprise the Mx8 attachment and integration genes as well as the pilA promoter with restriction enzyme recognition sites placed conveniently downstream. The two vectors differ from one another merely in the orientation of the pilA promoter on the vector and can be readily modified to include the epothilone PKS

- 59 -

and modification enzyme genes of the invention. The construction of the vectors is described in Example 2.

Especially preferred *Myxococcus* host cells of the invention are those that produce an epothilone or epothilone derivative or mixtures of epothilones or epothilone derivatives at equal to or greater than 20 mg/L, more preferably at equal to or greater than 200 mg/L, and most preferably at equal to or greater than 1 g/L. Especially preferred are *M. xanthus* host cells that produce at these levels. *M. xanthus* host cells that can be employed for purposes of the invention include the DZ1 (Campos *et al.*, 1978, J. Mol. Biol. 119: 167-178, incorporated herein by reference), the TA-producing cell line ATCC 31046, DK1219 (Hodgkin and Kaiser, 1979, Mol. Gen. Genet. 171: 177-191, incorporated herein by reference), and the DK1622 cell lines (Kaiser, 1979, Proc. Natl. Acad. Sci. USA 76: 5952-5956, incorporated herein by reference).

In another preferred embodiment, the present invention provides expression vectors and recombinant *Pseudomonas fluorescens* host cells that contain those expression vectors and express a recombinant PKS of the invention. A plasmid for use in constructing the *P. fluorescens* expression vectors and host cells of the invention is plasmid pRSF1010, which replicates in *E. coli* and *P. fluorescens* host cells (see Scholz *et al.*, 1989, Gene 75:271-8, incorporated herein by reference). Low copy number replicons and vectors can also be used. As noted above, the invention also provides the promoter of the *Sorangium cellulosum* epothilone PKS and epothilone modification enzyme genes in recombinant form. The promoter can be used to drive expression of an epothilone PKS gene or other gene in *P. fluorescens* host cells. Also, the promoter of the soraphen PKS genes can be used in any host cell in which a *Sorangium* promoter functions. Thus, in one embodiment, the present invention provides an epothilone PKS expression vector for use in *P. fluorescens* host cells.

In another preferred embodiment, the expression vectors of the invention are used to construct recombinant *Streptomyces* host cells that express a recombinant PKS of the invention. *Streptomyces* host cells useful in accordance with the invention include *S. coelicolor*, *S. lividans*, *S. venezuelae*, *S. ambofaciens*, *S. fradiae*, and the like. Preferred *Streptomyces* host cell/vector combinations of the invention include *S. coelicolor* CH999

and *S. lividans* K4-114 and K4-155 host cells, which do not produce actinorhodin, and expression vectors derived from the pRM1 and pRM5 vectors, as described in U.S. Patent No. 5,830,750 and U.S. patent application Serial Nos. 08/828,898, filed 31 Mar. 1997, and 09/181,833, filed 28 Oct. 1998. Especially preferred *Streptomyces* host cells of the invention are those that produce an epothilone or epothilone derivative or mixtures of epothilones or epothilone derivatives at equal to or greater than 20 mg/L, more preferably at equal to or greater than 200 mg/L, and most preferably at equal to or greater than 1 g/L. Especially preferred are *S. coelicolor* and *S. lividans* host cells that produce at these levels. Also, species of the closely related genus *Saccharopolyspora* can be used to produce epothilones, including but not limited to *S. erythraea*.

The present invention provides a wide variety of expression vectors for use in *Streptomyces*. For replicating vectors, the origin of replication can be, for example and without limitation, a low copy number replicon and vectors comprising the same, such as SCP2* (see Hopwood *et al.*, Genetic Manipulation of *Streptomyces*: A Laboratory manual (The John Innes Foundation, Norwich, U.K., 1985); Lydiate *et al.*, 1985, Gene 35: 223-235; and Kieser and Melton, 1988, Gene 65: 83-91, each of which is incorporated herein by reference), SLP1.2 (Thompson *et al.*, 1982, Gene 20: 51-62, incorporated herein by reference), and pSG5(ts) (Muth *et al.*, 1989, Mol. Gen. Genet. 219: 341-348, and Bierman *et al.*, 1992, Gene 116: 43-49, each of which is incorporated herein by reference), or a high copy number replicon and vectors comprising the same, such as pIJ101 and pJV1 (see Katz *et al.*, 1983, J. Gen. Microbiol. 129: 2703-2714; Vara *et al.*, 1989, J. Bacteriol. 171: 5782-5781; and Servin-Gonzalez, 1993, Plasmid 30: 131-140, each of which is incorporated herein by reference). High copy number vectors are generally, however, not preferred for expression of large genes or multiple genes. For non-replicating and integrating vectors and generally for any vector, it is useful to include at least an *E. coli* origin of replication, such as from pUC, p1P, p1I, and pBR. For phage based vectors, the phage phiC31 and its derivative KC515 can be employed (see Hopwood *et al.*, *supra*). Also, plasmid pSET152, plasmid pSAM, plasmids pSE101 and pSE211, all of which integrate site-specifically in the chromosomal DNA of *S. lividans*, can be employed.

- 61 -

Typically, the expression vector will comprise one or more marker genes by which host cells containing the vector can be identified and/or selected. Useful antibiotic resistance conferring genes for use in *Streptomyces* host cells include the ermE (confers resistance to erythromycin and lincomycin), tsr (confers resistance to thiostrepton), aadA (confers resistance to spectinomycin and streptomycin), aacC4 (confers resistance to apramycin, kanamycin, gentamicin, geneticin (G418), and neomycin), hyg (confers resistance to hygromycin), and vph (confers resistance to viomycin) resistance conferring genes.

The recombinant PKS gene on the vector will be under the control of a promoter, typically with an attendant ribosome binding site sequence. A preferred promoter is the actI promoter and its attendant activator gene actII-ORF4, which is provided in the pRM1 and pRM5 expression vectors, *supra*. This promoter is activated in the stationary phase of growth when secondary metabolites are normally synthesized. Other useful *Streptomyces* promoters include without limitation those from the ermE gene and the melC1 gene, which act constitutively, and the tipA gene and the merA gene, which can be induced at any growth stage. In addition, the T7 RNA polymerase system has been transferred to *Streptomyces* and can be employed in the vectors and host cells of the invention. In this system, the coding sequence for the T7 RNA polymerase is inserted into a neutral site of the chromosome or in a vector under the control of the inducible merA promoter, and the gene of interest is placed under the control of the T7 promoter. As noted above, one or more activator genes can also be employed to enhance the activity of a promoter. Activator genes in addition to the actII-ORF4 gene discussed above include dnrf, redD, and ptpA genes (see U.S. patent application Serial No. 09/181,833, *supra*), which can be employed with their cognate promoters to drive expression of a recombinant gene of the invention.

The present invention also provides recombinant expression vectors that drive expression of the epothilone PKS and PKS enzymes that produce epothilone or epothilone derivatives in plant cells. Such vectors are constructed in accordance with the teachings in U.S. patent application Serial No. 09/114,083, filed 10 July 1998, and PCT patent publication No. 99/02669, each of which is incorporated herein by reference.

Plants and plant cells expressing epothilone are disease resistant and able to resist fungal infection. For improved production of an epothilone or epothilone derivative in any heterologous host cells, including plant, *Myxococcus*, *Pseudomonas*, and *Streptomyces* host cells, one can also transform the cell to express a heterologous phosphopantetheinyl transferase. See U.S. patent application Serial No. 08/728,742, filed 11 Oct. 1996, and PCT patent publication No. 97/13845, both of which are incorporated herein by reference.

In addition to providing recombinant expression vectors that encode the epothilone or an epothilone derivative PKS, the present invention also provides, as discussed above, DNA compounds that encode epothilone modification enzyme genes. As discussed above, these gene products convert epothilones C and D to epothilones A and B, and convert epothilones A and B to epothilones E and F. The present invention also provides recombinant expression vectors and host cells transformed with those vectors that express any one or more of those genes and so produce the corresponding epothilone or epothilone derivative. In one aspect, the present invention provides the *epoK* gene in recombinant form and host cells that express the gene product thereof, which converts epothilones C and D to epothilones A and B, respectively.

In another important embodiment, and as noted above, the present invention provides vectors for disrupting the function of any one or more of the *epoL*, *epoK*, and any of the ORFs associated with the epothilone PKS gene cluster in *Sorangium* cells. The invention also provides recombinant *Sorangium* host cells lacking (or containing inactivated forms of) any one or more of these genes. These cells can be used to produce the corresponding epothilones and epothilone derivatives that result from the absence of any one or more of these genes.

The invention also provides non-*Sorangium* host cells that contain a recombinant epothilone PKS or a PKS for an epothilone derivative but do not contain (or contain non-functional forms of) any epothilone modification enzyme genes. These host cells of the invention are expected produce epothilones G and H in the absence of a dehydratase activity capable of forming the C-12-C-13 alkene of epothilones C and D. This dehydration reaction is believed to take place in the absence of the *epoL* gene product in

Streptomyces host cells. The host cells produce epothilones C and D (or the corresponding epothilone C and D derivative) when the dehydratase activity is present and the P450 epoxidase and hydroxylase (that converts epothilones A and B to epothilones E and F, respectively) genes are absent. The host cells also produce epothilones A and B (or the corresponding epothilone A and B derivatives) when the hydroxylase gene only is absent. Preferred for expression in these host cells is the recombinant epothilone PKS enzymes of the invention that contain the hybrid module 4 with an AT specific for methylmalonyl CoA only, optionally in combination with one or more additional hybrid modules. Also preferred for expression in these host cells is the recombinant epothilone PKS enzymes of the invention that contain the hybrid module 4 with an AT specific for malonyl CoA only, optionally in combination with one or more additional hybrid modules.

The recombinant host cells of the invention can also include other genes and corresponding gene products that enhance production of a desired epothilone or epothilone derivative. As but one non-limiting example, the epothilone PKS proteins require phosphopantetheinylation of the ACP domains of the loading domain and modules 2 through 9 as well as of the PCP domain of the NRPS. Phosphopantetheinylation is mediated by enzymes that are called phosphopantetheinyl transferases (PPTases). To produce functional PKS enzyme in host cells that do not naturally express a PPTase able to act on the desired PKS enzyme or to increase amounts of functional PKS enzyme in host cells in which the PPTase is rate-limiting, one can introduce a heterologous PPTase, including but not limited to Sfp, as described in PCT Pat. Pub. Nos. 97/13845 and 98/27203, and U.S. patent application Serial Nos. 08/728,742, filed 11 Oct. 1996, and 08/989,332, each of which is incorporated herein by reference.

The host cells of the invention can be grown and fermented under conditions known in the art for other purposes to produce the compounds of the invention. The compounds of the invention can be isolated from the fermentation broths of these cultured cells and purified by standard procedures. Fermentation conditions for producing the compounds of the invention from *Sorangium* host cells can be based on the protocols described in PCT patent publication Nos. 93/10121, 97/19086, 98/22461, and 99/42602,

each of which is incorporated herein by reference. The novel epothilone analogs of the present invention, as well as the epothilones produced by the host cells of the invention, can be derivatized and formulated as described in PCT patent publication Nos. 93/10121, 97/19086, 98/08849, 98/22461, 98/25929, 99/01124, 99/02514, 99/07692, 99/27890, 5 99/39694, 99/40047, 99/42602, 99/43653, 99/43320, 99/54319, 99/54319, and 99/54330, and U.S. Patent No. 5,969,145, each of which is incorporated herein by reference.


Invention Compounds

Preferred compounds of the invention include the 14-methyl epothilone

- 10 derivatives (made by utilization of the hybrid module 3 of the invention that has an AT that binds methylmalonyl CoA instead of malonyl CoA); the 8,9-dehydro epothilone derivatives (made by utilization of the hybrid module 6 of the invention that has a DH and KR instead of an ER, DH, and KR); the 10-methyl epothilone derivatives (made by utilization of the hybrid module 5 of the invention that has an AT that binds
- 15 methylmalonyl CoA instead of malonyl CoA); the 9-hydroxy epothilone derivatives (made by utilization of the hybrid module 6 of the invention that has a KR instead of an ER, DH, and KR); the 8-desmethyl-14-methyl epothilone derivatives (made by utilization of the hybrid module 3 of the invention that has an AT that binds methylmalonyl CoA instead of malonyl CoA and a hybrid module 6 that binds malonyl CoA instead of
- 20 methylmalonyl CoA); and the 8-desmethyl-8,9-dehydro epothilone derivatives (made by utilization of the hybrid module 6 of the invention that has a DH and KR instead of an ER, DH, and KR and an AT that specifies malonyl CoA instead of methylmalonyl CoA).

More generally, preferred epothilone derivative compounds of the invention are those that can be produced by altering the epothilone PKS genes as described herein and 25 optionally by action of epothilone modification enzymes and/or by chemically modifying the resulting epothilones produced when those genes are expressed. Thus, the present invention provides compounds of the formula:

- 65 -



(1)

including the glycosylated forms thereof and stereoisomeric forms where the stereochemistry is not shown,

- 5 wherein A is a substituted or unsubstituted straight, branched chain or cyclic alkyl, alkenyl or alkynyl residue optionally containing 1-3 heteroatoms selected from O, S and N; or wherein A comprises a substituted or unsubstituted aromatic residue;
 R² represents H, H, or H, lower alkyl, or lower alkyl, lower alkyl;
 X⁵ represents =O or a derivative thereof, or H, OH or H, NR₂ wherein R is H, or alkyl, or acyl or H, OCOR or H, OCONR₂ wherein R is H, or alkyl, or is H, H;
 10 R⁶ represents H or lower alkyl, and the remaining substituent on the corresponding carbon is H;
 X⁷ represents OR, NR₂, wherein R is H, or alkyl or acyl or is OCOR, or OCONR₂ wherein R is H or alkyl or X⁷ taken together with X⁹ forms a carbonate or carbamate
 15 cycle, and wherein the remaining substituent on the corresponding carbon is H;
 R⁸ represents H or lower alkyl and the remaining substituent on the carbon is H;
 X⁹ represents =O or a derivative thereof, or is H, OR or H, NR₂, wherein R is H, or alkyl or acyl or is H, OCOR or H, OCONR₂ wherein R is H or alkyl, or represents H, H or
 wherein X⁹ together with X⁷ or with X¹¹ can form a cyclic carbonate or carbamate;
 20 R¹⁰ is H, H or H, lower alkyl, or lower alkyl, lower alkyl;
 X¹¹ is =O or a derivative thereof, or is H, OR, or H, NR₂ wherein R is H, or alkyl or acyl or is H, OCOR or H, OCONR₂ wherein R is H or alkyl, or is H, H or wherein X¹¹ in combination with X⁹ may form a cyclic carbonate or carbamate;
 R¹² is H, H, or H, lower alkyl, or lower alkyl, lower alkyl;

- 66 -


X^{13} is =O or a derivative thereof, or H, OR or H, NR₂ wherein R is H, alkyl or acyl or is H, OCOR or H, OCONR₂ wherein R is H or alkyl;

R^{14} is H, H, or H, lower alkyl, or lower alkyl, lower alkyl;


R^{16} is H or lower alkyl; and

- 5 wherein optionally H or another substituent may be removed from positions 12 and 13 and/or 8 and 9 to form a double bond, wherein said double bond may optionally be converted to an epoxide.

Particularly preferred are compounds of the formulas




1(a),



1(b)


and

- 67 -




wherein the noted substituents are as defined above.

Especially preferred are compounds of the formulas



1(d)

and



1(e)

- 10 wherein both Z are O or one Z is N and the other Z is O, and the remaining substituents are as defined above.

As used herein, a substituent which "comprises an aromatic moiety" contains at least one aromatic ring, such as phenyl, pyridyl, pyrimidyl, thiophenyl, or thiazolyl. The substituent may also include fused aromatic residues such as naphthyl, indolyl, benzothiazolyl, and the like. The aromatic moiety may also be fused to a nonaromatic ring and/or may be coupled to the remainder of the compound in which it is a substituent through a nonaromatic, for example, alkylene residue. The aromatic moiety may be substituted or unsubstituted as may the remainder of the substituent.

Preferred embodiments of A include the "R" groups shown in Figure 2.

As used herein, the term alkyl refers to a C₁-C₈ saturated, straight or branched chain hydrocarbon radical derived from a hydrocarbon moiety by removal of a single hydrogen atom. Alkenyl and alkynyl refer to the corresponding unsaturated forms. Examples of alkyl include but are not limited to methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, i-hexyl, n-heptyl, n-octyl. Lower alkyl (or alkenyl or alkynyl) refers to a 1-4C radical. Methyl is preferred. Acyl refers to alkylCO, alkenylCO or alkynylCO.

The terms halo and halogen as used herein refer to an atom selected from fluorine, chlorine, bromine, and iodine. The term haloalkyl as used herein denotes an alkyl group to which one, two, or three halogen atoms are attached to any one carbon and includes without limitation chloromethyl, bromoethyl, trifluoromethyl, and the like.

The term heteroaryl as used herein refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from S, O, and N; zero, one, or two ring atoms are additional heteroatoms independently selected from S, O, and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.

The term heterocycle includes but is not limited to pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.

The term "substituted" as used herein refers to a group substituted by independent replacement of any of the hydrogen atoms thereon with, for example, Cl, Br, F, I, OH,

CN, alkyl, alkoxy, alkoxy substituted with aryl, haloalkyl, alkylthio, amino, alkylamino, dialkylamino, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, or carboxamide. Any one substituent may be an aryl, heteroaryl, or heterocycloalkyl group.

It will be apparent that the nature of the substituents at positions 2, 4, 6, 8, 10, 12, 14 and 16 in formula (1) is determined at least initially by the specificity of the AT catalytic domain of modules 9, 8, 7, 6, 5, 4, 3 and 2, respectively. Because AT domains that accept malonyl CoA, methylmalonyl CoA, ethylmalonyl CoA (and in general, lower alkyl malonyl CoA), as well as hydroxymalonyl CoA, are available, one of the substituents at these positions may be H, and the other may be H, lower alkyl, especially methyl and ethyl, or OH. Further reaction at these positions, e.g., a methyl transferase reaction such as that catalyzed by module 8 of the epothilone PKS, may be used to replace H at these positions as well. Further, an H,OH embodiment may be oxidized to =O or, with the adjacent ring C, be dehydrated to form a π -bond. Both OH and =O are readily derivatized as further described below.

Thus, a wide variety of embodiments of R^2 , R^6 , R^8 , R^{10} , R^{12} , R^{14} and R^{16} is synthetically available. The restrictions set forth with regard to embodiments of these substituents set forth in the definitions with respect to Formula (1) above reflect the information described in the SAR description in Example 8 below.

Similarly, β -carbonyl modifications (or absence of modification) can readily be controlled by modifying the epothilone PKS gene cluster to include the appropriate sequences in the corresponding positions of the epothilone gene cluster which will or will not contain active KR, DH and/or ER domains. Thus, the embodiments of X^5 , X^7 , X^9 , X^{11} and X^{13} synthetically available are numerous, including the formation of π -bonds with the adjacent ring positions.

Positions occupied by OH are readily converted to ethers or esters by means well known in the art; protection of OH at positions not to be derivatized may be required. Further, a hydroxyl may be converted to a leaving group, such as a tosylate, and replaced by an amino or halo substituent. A wide variety of "hydroxyl derivatives" such as those discussed above is known in the art.

Similarly, ring positions which contain oxo groups may be converted to "carbonyl derivatives" such as oximes, ketals, and the like. Initial reaction products with the oxo moieties may be further reacted to obtain more complex derivatives. As described in Example 8, such derivatives may ultimately result in a cyclic substituent linking two ring positions.

The enzymes useful in modification of the polyketide initially synthesized, such as transmethylnases, dehydratases, oxidases, glycosylation enzymes and the like, can be supplied endogenously by a host cell when the polyketide is synthesized intracellularly, by modifying a host to contain the recombinant materials for the production of these modifying enzymes, or can be supplied in a cell-free system, either in purified forms or as relatively crude extracts. Thus, for example, the epoxidation of the π -bond at position 12-13 may be effected using the protein product of the *epoK* gene directly *in vitro*.

The nature of A is most conveniently controlled by employing an epothilone PKS which comprises an inactivated module 1 NRPS (using a module 2 substrate) or a KS2 knockout (using a module 3 substrate) as described in Example 6, hereinbelow. Limited variation can be obtained by altering the AT catalytic specificity of the loading module; further variation is accomplished by replacing the NRPS of module 1 with an NRPS of different specificity or with a conventional PKS module. However, at present, variants are more readily prepared by feeding the synthetic module 2 substrate precursors and module 3 substrate precursors to the appropriately altered epothilone PKS as described in Example 6.

Pharmaceutical Compositions

The compounds can be readily formulated to provide the pharmaceutical compositions of the invention. The pharmaceutical compositions of the invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid, or liquid form. This preparation will contain one or more of the compounds of the invention as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral application. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers

for tablets, pellets, capsules, suppositories, pessaries, solutions, emulsions, suspensions, and any other form suitable for use.

The carriers which can be used include water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, and other carriers suitable for use in manufacturing preparations, in solid, semi-solid, or liquified form. In addition, auxiliary stabilizing, thickening, and coloring agents and perfumes may be used. For example, the compounds of the invention may be utilized with hydroxypropyl methylcellulose essentially as described in U.S. Patent No. 4,916,138, incorporated herein by reference, or with a surfactant essentially as described in EPO patent publication No. 428,169, incorporated herein by reference.

Oral dosage forms may be prepared essentially as described by Hondo *et al.*, 1987, Transplantation Proceedings XIX, Supp. 6: 17-22, incorporated herein by reference. Dosage forms for external application may be prepared essentially as described in EPO patent publication No. 423,714, incorporated herein by reference. The active compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the disease process or condition.

For the treatment of conditions and diseases caused by infection, immune system disorder (or to suppress immune function), or cancer, a compound of the invention may be administered orally, topically, parenterally, by inhalation spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvant, and vehicles. The term parenteral, as used herein, includes subcutaneous injections, and intravenous, intrathecal, intramuscular, and intrasternal injection or infusion techniques.

Dosage levels of the compounds of the present invention are of the order from about 0.01 mg to about 100 mg per kilogram of body weight per day, preferably from about 0.1 mg to about 50 mg per kilogram of body weight per day. The dosage levels are useful in the treatment of the above-indicated conditions (from about 0.7 mg to about 3.5 mg per patient per day, assuming a 70 kg patient). In addition, the compounds of the

present invention may be administered on an intermittent basis, i.e., at semi-weekly, weekly, semi-monthly, or monthly intervals.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for oral administration to humans may contain from 0.5 mg to 5 gm of active agent compounded with an appropriate and convenient amount of carrier material, which may vary from about 5 percent to about 95 percent of the total composition. Dosage unit forms will generally contain from about 0.5 mg to about 500 mg of active ingredient. For external administration, the compounds of the invention may be formulated within the range of, for example, 0.00001% to 60% by weight, preferably from 0.001% to 10% by weight, and most preferably from about 0.005% to 0.8% by weight.

It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors. These factors include the activity of the specific compound employed; the age, body weight, general health, sex, and diet of the subject; the time and route of administration and the rate of excretion of the drug; whether a drug combination is employed in the treatment; and the severity of the particular disease or condition for which therapy is sought.

A detailed description of the invention having been provided above, the following examples are given for the purpose of illustrating the present invention and shall not be construed as being a limitation on the scope of the invention or claims.

Example 1

DNA Sequencing of Cosmid Clones and Subclones Thereof

The epothilone producing strain, *Sorangium cellulosum* SMP44, was grown on a cellulose-containing medium, see Bollag *et al.*, 1995, Cancer Research 55: 2325-2333, incorporated herein by reference, and epothilone production was confirmed by LC/MS analysis of the culture supernatant. Total DNA was prepared from this strain using the procedure described by Jaoua *et al.*, 1992, Plasmid 28: 157-165, incorporated herein by reference. To prepare a cosmid library, *S. cellulosum* genomic DNA was partially

digested with Sau3AI and ligated with BamHI-digested pSupercos (Stratagene). The DNA was packaged in lambda phage as recommended by the manufacturer and the mixture then used to infect *E. coli* XL1-Blue MR cells. This procedure yielded approximately 3,000 isolated colonies on LB-ampicillin plates. Because the size of the
5 *S. celluloseum* genome is estimated to be circa 10^7 nucleotides, the DNA inserts present among 3000 colonies would correspond to circa 10 *S. celluloseum* genomes.

To screen the library, two segments of KS domains were used to design oligonucleotide primers for a PCR with *Sorangium celluloseum* genomic DNA as template. The fragment generated was then used as a probe to screen the library. This
10 approach was chosen, because it was found, from the examination of over a dozen PKS genes, that KS domains are the most highly conserved (at the amino acid level) of all the PKS domains examined. Therefore, it was expected that the probes produced would detect not only the epothilone PKS genes but also other PKS gene clusters represented in the library. The two degenerate oligonucleotides synthesized using conserved regions
15 within the ketosynthase (KS) domains compiled from the DEBS and soraphen PKS gene sequences were (standard nomenclature for degenerate positions is used):
CTSGTSKCSSTBCACCTSGCSTGC and TGAYRTGSGCGTTSGTSCCGSWGGA. A single band of ~750 bp, corresponding to the predicted size, was seen in an agarose gel after PCR employing the oligos as primers and *S. celluloseum* SMP44 genomic DNA as
20 template. The fragment was removed from the gel and cloned in the HincII site of pUC118 (which is a derivative of pUC18 with an insert sequence for making single stranded DNA). After transformation of *E. coli*, plasmid DNA from ten independent clones was isolated and sequenced. The analysis revealed nine unique sequences that each corresponded to a common segment of KS domains in PKS genes. Of the nine,
25 three were identical to a polyketide synthase gene cluster previously isolated from this organism and determined not to belong to the epothilone gene cluster from the analysis of the modules. The remaining six KS fragments were excised from the vector, pooled, end-labeled with ^{32}P and used as probe in hybridizations with the colonies containing the cosmid library under high stringency conditions.

The screen identified 15 cosmids that hybridized to the pooled KS probes. DNA was prepared from each cosmid, digested with NotI, separated on an agarose gel, and transferred to a nitrocellulose membrane for Southern hybridization using the pooled KS fragments as probe. The results revealed that two of the cosmids did not contain KS-hybridizing inserts, leaving 13 cosmids to analyze further. The blot was stripped of the label and re-probed, under less stringent conditions, with labeled DNA containing the sequence corresponding to the enoylreductase domain from module four of the DEBS gene cluster. Because it was anticipated that the epothilone PKS gene cluster would encode two consecutive modules that contain an ER domain, and because not all PKS gene clusters have ER domain-containing modules, hybridization with the ER probe was predicted to identify cosmids containing insert DNA from the epothilone PKS gene cluster. Two cosmids were found to hybridize strongly to the ER probe, one hybridized moderately, and a final cosmid hybridized weakly. Analysis of the restriction pattern of the NotI fragments indicated that the two cosmids that hybridized strongly with the ER probe overlapped one another. The nucleotide sequence was also obtained from the ends of each of the 13 cosmids using the T7 and T3 primer binding sites. All contained sequences that showed homology to PKS genes. Sequence from one of the cosmids that hybridized strongly to the ER probe showed homology to NRPSs and, in particular, to the adenylation domain of an NRPS. Because it was anticipated that the thiazole moiety of epothilone might be derived from the formation of an amide bond between an acetate and cysteine molecule (with a subsequent cyclization step), the presence of an NRPS domain in a cosmid that also contained ER domain(s) supported the prediction that this cosmid might contain all or part of the epothilone PKS gene cluster.

Preliminary restriction analysis of the 12 remaining cosmids suggested that three might overlap with the cosmid of interest. To verify this, oligonucleotides were synthesized for each end of the four cosmids (determined from the end sequencing described above) and used as primer sets in PCRs with each of the four cosmid DNAs. Overlap would be indicated by the appearance of a band from a non-cognate primer-template reaction. The results of this experiment verified that two of the cosmids overlapped with the cosmid containing the NRPS. Restriction mapping of the three

cosmids revealed that the cosmids did, in fact, overlap. Furthermore, because PKS sequences extended to the end of the insert in the last overlapping fragment, based on the assumption that the NRPS would map to the 5'-end of the cluster, the results also indicated that the 3' end of the gene cluster had not been isolated among the clones identified.

To isolate the remaining segment of the epothilone biosynthesis genes, a PCR fragment was generated from the cosmid containing the most 3'-terminal region of the putative gene cluster. This fragment was used as a probe to screen a newly prepared cosmid library of *Sorangium cellulosum* genomic DNA of again approximately 3000 colonies. Several hybridizing clones were identified; DNA was made from six of them. Analysis of NotI-digested fragments indicated that all contained overlapping regions. The cosmid containing the largest insert DNA that also had the shortest overlap with the cosmid used to make the probe was selected for further analysis.

Restriction maps were created for the four cosmids, as shown in Figure 1. Sequence obtained from one of the ends of cosmid pKOS35-70.8A3 showed no homology to PKS sequences or any associated modifying enzymes. Similarly, sequence from one end of cosmid pKOS35-79.85 also did not contain sequences corresponding to a PKS region. These findings supported the observation that the epothilone cluster was contained within the ~70 kb region encompassed by the four cosmid inserts.


To sequence the inserts in the cosmids, each of the NotI restriction fragments from the four cosmids was cloned into the NotI site of the commercially available pBluescript plasmid. Initial sequencing was performed on the ends of each of the clones. Analysis of the sequences allowed the prediction, before having the complete sequence, that there would be 10 modules in this PKS gene cluster, a loading domain plus 9 modules.

Sequence was obtained for the complete PKS as follows. Each of the 13 non-overlapping NotI fragments was isolated and subjected to partial HinPI digestion. Fragments of ~2 to 4 kb in length were removed from an agarose gel and cloned in the AccI site of pUC118. Sufficient clones from each library of the NotI fragments were

sequenced to provide at least 4 -fold coverage of each. To sequence across each of the NotI sites, a set of oligos, one 5' and the other 3' to each NotI site, was made and used as primers in PCR amplification of a fragment that contained each NotI site. Each fragment produced in this manner was cloned and sequenced.

5 The nucleotide sequence was determined for a linear segment corresponding to ~72 kb. Analysis revealed a PKS gene cluster with a loading domain and nine modules. Downstream of the PKS sequence is an ORF, designated *epoK*, that shows strong homology to cytochrome P450 oxidase genes and encodes the epothilone epoxidase. The nucleotide sequence of 15 kb downstream of *epoK* has also been determined: a number of
10 additional ORFs have been identified but an ORF that shows homology to any known dehydratase has not been identified. The *epoL* gene may encode a dehydratase activity, but this activity may instead be resident within the epothilone PKS or encoded by another gene.

The PKS genes are organized in 6 open reading frames. At the polypeptide level,
15 the loading domain and modules 1, 2, and 9 appear on individual polypeptides; their corresponding genes are designated *epoA*, *epoB*, *epoC* and *epoF* respectively. Modules 3, 4, 5, and 6 are contained on a single polypeptide whose gene is designated *epoD*, and modules 7 and 8 are on another polypeptide whose gene is designated *epoE*. It is clear from the spacing between ORFs that *epoC*, *epoD*, *epoE* and *epoF* constitute an operon.
20 The *epoA*, *epoB*, and *epoK* genes may be also part of the large operon, but there are spaces of approximately 100 bp between *epoB* and *epoC* and 115 bp between *epoF* and *epoK* which could contain a promoter. The present invention provides the intergenic sequences in recombinant form. At least one, but potentially more than one, promoter is used to express all of the epothilone genes. The epothilone PKS gene cluster is shown
25 schematically below.



A detailed examination of the modules shows an organization and composition that is consistent with one able to be used for the biosynthesis of epothilone. The description that follows is at the polypeptide level. The sequence of the AT domain in the loading module and in modules 3, 4, 5, and 9 shows similarity to the consensus sequence for malonyl loading domains, consistent with the presence of an H side chain at C-14, C-12 (epothilones A and C), C-10, and C-2, respectively, as well as the loading region. The AT domains in modules 2, 6, 7, and 8 resemble the consensus sequence for methylmalonyl specifying AT domains, again consistent with the presence of methyl side chains at C-16, C-8, C-6, and C-4 respectively.

10 The loading module contains a KS domain in which the cysteine residue usually present at the active site is instead a tyrosine. This domain is designated as KS^y and serves as a decarboxylase, which is part of its normal function, but cannot function as a condensing enzyme. Thus, the loading domain is expected to load malonyl CoA, move it to the ACP, and decarboxylate it to yield the acetyl residue required for condensation
15 with cysteine.

Module 1 is the non-ribosomal peptide synthetase that activates cysteine and catalyzes the condensation with acetate on the loading module. The sequence contains segments highly similar to ATP-binding and ATPase domains, required for activation of amino acids, a phosphopantotheinylation site, and an elongation domain. In database
20 searches, module 1 shows very high similarity to a number of previously identified peptide synthetases.


Module 2 determines the structure of epothilone at C-15 – C-17. The presence of the DH domain in module 2 yields the C-16-17 dehydro moiety in the molecule. The domains in module 3 are consistent with the structure of epothilone at C-14 and C-15; the
25 OH that comes from the action of the KR is employed in the lactonization of the molecule.

Module 4 controls the structure at C-12 and C-13 where a double bond is found in epothilones C and D, consistent with the presence of a DH domain. Although the sequence of the AT domain appears to resemble those that specify malonate loading, it

can also load methylmalonate, thereby accounting in part for the mixture of epothilones found in the fermentation broths of the naturally producing organisms.

A significant departure from the expected array of functions was found in module 4. This module was expected to contain a DH domain, thereby directing the synthesis of epothilones C and D as the products of the PKS. Rigorous analysis revealed that the space between the AT and KR domains of module 4 was not large enough to accommodate a functional DH domain. Thus, the extent of reduction at module 4 does not proceed beyond the ketoreduction of the beta-keto formed after the condensation directed by module 4. Because the C-12,13 unsaturation has been demonstrated (epothilones C and D), there must be an additional dehydratase function that introduces the double bond, and this function is believed to be in the PKS itself or resident in an ORF in the epothilone biosynthetic gene cluster.

Thus, the action of the dehydratase could occur either during the synthesis of the polyketide or after cyclization has taken place. In the former case, the compounds produced at the end of acyl chain growth would be epothilones C and D. If the C-12,13 dehydration were a post-polyketide event, the completed acyl chain would have a hydroxyl group at C-13, as shown below. The names epothilones G and H have been assigned to the 13-hydroxy compounds produced in the absence of or prior to the action of the dehydratase.



Epothilones G (R=H) and H (R=CH₃).

Modules 5 and 6 each have the full set of reduction domains (KR, DH and ER) to yield the methylene functions at C-11 and C-9. Modules 7 and 9 have KR domains to

yield the hydroxyls at C-7 and C-3, and module 8 does not have a functional KR domain, consistent with the presence of the keto group at C-5. Module 8 also contains a methyltransferase (MT) domain that results in the presence of the geminal dimethyl function at C-4. Module 9 has a thioesterase domain that terminates polyketide synthesis and catalyzes ring closure. The genes, proteins, modules, and domains of the epothilone PKS are summarized in the Table hereinabove.

Inspection of the sequence has revealed translational coupling between *epoA* and *epoB* (loading domain and module 1) and between *epoC* and *epoD*. Very small gaps are seen between *epoD* and *epoE* and *epoE* and *epoF* but gaps exceeding 100 bp are found between *epoB* and *epoC* and *epoF* and *epoK*. These intergenic regions may contain promoters. Sequencing efforts have not revealed the presence of regulatory genes, and it is possible that epothilone synthesis is not regulated by operon specific regulation in *Sorangium cellulosum*.

The sequence of the epothilone PKS and flanking regions has been compiled into a single contig, as shown below.

```

1  TCGTGCGCGG GCACGTCGAG GCGTTTGCCG ACTTCGGCGG CGTCCCGCGC GTGCTGCTCT
61 ACGACAACCT CAAGAACGCC GTCGTCGAGC GCCACGGCGA CGCGATCCGG TTCCACCCCA
121 CGCTGCTGGC TCTGTGCGCG GATTACCGCT TCGAGCCGCG CCGCGTCGCC GTCGCCCCGCG
181 GCAACGAGAA GGGCCGCGTC GAGCGCGCCA TCCGCTACGT CCGCGAGGGC TTCTTCGAGG
201 241 CCGGGGCTTA CGCCGACCTC GGAGACCTCA ACCGCCAAGC GACCGAGTGG ACCAGCTCCG
301 CGGCGCTCGA TCGCTCCTGG GTCGAGGACC GCGCCCGCAC CGTGGCTCAG GCCTTCGACG
361 ACGAGCGCAG CGTGCTGCTG CGACACCCTG ACACACCGTT TCCGGACCAC GAGCGCGTCG
421 AGGTCGAGGT CGGAAAGACC CCTACGCGC GCTTCGATCT CAACGACTAC TCGGTCCCCC
481 ACGACCGGAC GCGCCGACAG CTGGTCGTCC TCGCCGACCT CAGTCAGGTA CGCATCGCCG
25 541 ACGGCAACCA GATCGTCGCG ACCACGTCC GTTCGTGGGA CCGCGGCCAG CAGATCGAGC
601 AGCCCGAGCA CCTCCAGCGC CTGGTCGACG AGAAGCGCCG CGCCCGCGAG CACCGCGGCC
661 TTGATCGCCT CGCGCGCGCC GCCCGCAGCA GCCAGGCATT CCTGCGCATC GTCGCCGAGC
721 GCGGCGATAA CGTCGGCAGC GCGATCGCCC GGCTTCTGCA ACTGCTCGAC GCCGTGGGCG
781 CCGCCGAGCT CGAAGAGGCC CTGGTCGAGG TGCTTGAGCG CGACACCATC CACATCGGTG
30 841 CCGTCCGCCA GGTGATCGAC CGCCGCGCT CCGAGCGCCA CCTGCCGCTT CCAGTCTCAA
901 TCCCGGTCAC CCGCGGCGAG CACGCGGCC TCGTCGTCAC GCCGCATTCC CTCACCACCT
961 ACGACGCCCT GAAGAAGGAC CCGACGCCAT GACCGACCTG ACGCCACCG AGACCAAAGA
1021 CCGGCTCAAG AGCCTCGGCC TCTTCGGCCT GCTCGCCTGC TGGGAGCAGC TCGCCGACAA
1081 GCCCTGGCTT CGCGAGGTGC TCGCCATCGA GGAGCGCGAG CGCCACAAGC GCAGCCTCGA
35 1141 ACGCCGCTG AAGAACTCCC GCGTCGCCGC CTTCAAGCCC ATGACCGACT TCGACTCGTC
1201 CTGGCCCAAG AAGATCGACC GCGAGGCCGT CGACGACCTC TACGATAGCC GCTACGCGGA
1261 CCTGCTCTTC GAGGTGCTCA CCCGTCGCTA CGACGCGCAG AAGCCGCTCT TGCTCAGCAC
1321 GAACAAGGCA TTCGCCGACT GGGGCCAGGT CTTCCCGCAC GCGCGGTGCG TCGTCACGCT
1381 CGTCGACCGG CTCGTGCACC GCGCCGAGGT GATCGAGATC GAGGCCGAGA GCTACCGGCT
40 1441 GAAGGAAGCC AAGGAGCTCA ACGCCACCCG CACCAAGCAG CGCCGACCA AGAAGCACTG
1501 AGCGGCATTT TCACCGGTGA ACTTCACCGA AATCCCGCGT GTTGCCGAGA TCATCTACAG

```


- 80 -

1561	GCGGATCGAG	ACCGTGCTCA	CGGCGTGGAC	GACATGGCGC	GGAAACGTCG	TCGTAAC TGC
1621	CCAGCAATGT	CATGGGAATG	GCCCCCTTGAG	GGGCTGGCCG	GGGTCGACGA	TATCGCGCGA
1681	TCTCCCCGTC	AATTCCCGAG	CGTAAAAGAA	AAATTTGTCA	TAGATCGTAA	GCTGTGCTAG
1741	TGATCTGCCT	TACGTTACGT	CTTCCGCACC	TCGAGCGAAT	TCTCTCGGAT	AAC TTTCAAG
1801	TTTTCTGAGG	GGGCTTGGTC	TCTGGTTCCT	CAGGAAGCCT	GATCGGGACG	AGCTAATTCC
1861	CATCCATTTT	TTTGAGACTC	TGCTCAAAGG	GATTAGACCG	AGTGAGACAG	TTCTTTTGCA
1921	GTGAGCGAAG	AACCTGGGGC	TCGACCGGAG	GACGATCGAC	GTCCGCGAGC	GGGTCAGCCG
1981	CTGAGGATGT	GCCCCGTCGT	GCGGATCGTC	CCATCGAGCG	CGCAGCCGAA	GATCCGATTG
2041	CGATCGTCGG	AGCGGGCTGC	CGTCTGCCCC	GTGGCGTGAT	CGATCTGAGC	GGGTTCTGGA
2101	CGCTCCTCGA	GGGCTCGCGC	GACACCGTCG	GGCAAGTCCC	CGCCGAACGC	TGGGATGCAG
2161	CAGCGTGGTT	TGATCCCGAC	CTCGATGCCC	CGGGGAAGAC	GCCCCGTTACG	CGCGCATCTT
2221	TCCTGAGCGA	CGTAGCCTGC	TTGCAAGCCT	CCTTCTTCGG	CATCTCGCCT	CGCGAAGCGC
2281	TGCGGATGGA	CCCTGCACAT	CGACTCTTGC	TGGAGGTGTG	CTGGGAGGCG	CTGGAGAACG
2341	CCGCGATCGC	TCCATCGGCG	CTCGTGGGTA	CGGAAACGGG	AGTGTTTCATC	GGGATCGGCC
2401	CGTCCGAATA	TGAGGCCGCG	CTGCCGCGAG	CGACGGCGTC	CGCAGAGATC	GACGCTCATG
2461	GCGGGCTGGG	GACGATGCCC	AGCGTCGGAG	CGGGCCGAAT	CTCGTATGTC	CTCGGGCTGC
2521	GAGGGCCGTG	TGTCGCGGTG	GATACGGCCT	ATTCGTCTTC	GCTCGTGGCC	GTTTCATCTGG
2581	CCTGTGAGAG	CTTGCGCTCC	GGGGAATGCT	CCACGGCCCT	GGCTGGTGGG	GTATCGCTGA
2641	TGTTGTGCGC	GAGCACCTCT	GTGTGGCTCT	CGAAGACCCG	CGCGCTGGGC	ACGGACGGTC
2701	GCTGCAAGGC	GTTTTTCGGC	GAGGCCGATG	GGTTCGGACG	AGGCGAAGGG	TGCGCCGTGC
2761	TGGTCCTCAA	GCGGCTCAGT	GGAGCCGCGC	CGGACGGCGA	CCGGATATTG	CGGCTGATTG
2821	GAGGATCCGC	GATCAATCAC	GACGGAGCGA	GCAGCGGTCT	GACCGTGCCG	AACGGGAGCT
2881	CCCAAGAAAT	CGTGCTGAAA	CGGGCCCTGG	CGGACGCAGG	CTGCGCCGCG	TCTTCGGTGG
2941	GTTATGTGCA	GGCACACGGC	ACGGGCACGA	CGCTTGGTGA	CCCCATCGAA	ATCCAAGCTC
3001	TGAATGCGGT	ATACGGCCTC	GGGCGAGACG	TCGCCACGCC	GCTGCTGATC	GGGTCGGTGA
3061	AGACCAACCT	TGGCCATCCT	GAGTATGCGT	CGGGGATCAC	TGGGCTGCTG	AAGGTCGTCT
3121	TGTCCCTTCA	GCACGGGCAG	ATTCTGCGC	ACCTCCACGC	GCAGGCGCTG	AACCCCGGA
3181	TCTCATGGGG	TGATCTTCGG	CTGACCGTCA	CGCGCGCCCG	GACACCGTGG	CCGGACTGGA
3241	ATACGCCGCG	ACGGGCGGGG	GTGAGCTCGT	TCGGCATGAG	CGGGACCAAC	GCGCACGTGG
3301	TGCTGGAAGA	GGCGCCGGCG	GCGACGTGCA	CACCGCCGGC	GCCGGAGCGG	CCGGCAGAGC
3361	TGCTGGTGCT	GTCGGCAAGG	ACCGCGGCAG	CCTTGGATGC	ACACGCGGCG	CGGCTGCGCG
3421	ACCATCTGGA	GACCTACCCT	TCGCAGTGTC	TGGGCGATGT	GGCGTTCAGT	CTGGCGACGA
3481	CGCGCAGCGC	GATGGAGCAC	CGGCTCGCGG	TGGCGGCGAC	GTGAGCGGAG	GGGCTGCGGG
3541	CAGCCCTGGA	CGCTGCGGCG	CAGGGACAGA	CGCCGCCCGG	TGTGGTGCGC	GGTATCGCCG
3601	ATTCCTCACG	CGGCAAGCTC	GCCTTTCTCT	TCACCGGACA	GGGGGCGCAG	ACGCTGGGCA
3661	TGGGCCGTGG	GCTGTATGAT	GTATGGCCCG	CGTTCGCGCA	GGCGTTCGAC	CTGTGCGTGA
3721	GGCTGTTCAA	CCAGGAGCTC	GACCGGCCCG	TCCGCGAGGT	GATGTGGGCG	GAACCGGCCA
3781	GCGTCGACGC	CGCGCTGCTC	GACCAGACAG	CCTTTACCCA	GCCGGCGCTG	TTCACCTTCG
3841	AGTATGCGCT	CGCCGCGCTG	TGGCGGTCTG	GGGGCGTAGA	GCCGGAGTTG	GTGCTGGGCC
3901	ATAGCATCGG	TGAGCTGGTG	GCTGCCTGCG	TGGCGGGCGT	GTTCTCGCTT	GAGGACGCGG
3961	TGTTCTTGGT	GGCTGCGCGC	GGGCGCCTGA	TGCAGGCGCT	GCCGGCCGGC	GGGGCGATGG
4021	TGTCGATCGC	GGCGCCGGAG	GCCGATGTGG	CTGCTGCGGT	GGCGCCGCAC	GCAGCGTCGG
4081	TGTCGATCGC	CGCGGTCAAC	GGTCCGGACC	AGGTGGTCAT	CGCGGGCGCC	GGGCAACCCG
4141	TGCATGCGAT	CGCGGCGGCG	ATGGCCGCGC	GCGGGGCGCG	AACCAAGGCG	CTCCACGTCT
4201	CGCATGCGTT	CCACTCACCG	CTCATGGCCC	CGATGCTGGA	GGCGTTCGGG	CGTGTGGCCG
4261	AGTCGGTGAG	CTACCGGCGG	CCGTCGATCG	TCCTGGTCAG	CAATCTGAGC	GGGAAGGCTG
4321	GCACAGACGA	GGTGAGCTCG	CCGGGCTATT	GGGTGCGCCA	CGCGCGAGAG	GTGGTGCGCT
4381	TCGCGGATGG	AGTGAAGGCG	CTGCACGCGG	CCGGTGCGGG	CACCTTCGTC	GAGGTGCGTC
4441	CGAAATCGAC	GCTGCTCGGC	CTGGTGCCCTG	CCTGCCTGCC	GGACGCCCGG	CCGGCGCTGC
4501	TCGCATCGTC	GCGCGCTGGG	CGTGACGAGC	CAGCGACCGT	GCTCGAGGCG	CTCGGCGGGC
4561	TCTGGGCCGT	CGGTGGCCCTG	GTCTCCTGGG	CCGGCCCTCT	CCCCTCAGGG	GGGCGGCGGG
4621	TGCCGCTGCC	CACGTACCCT	TGGCAGCGCG	AGCGCTACTG	GATCGACACG	AAAGCCGACG
4681	ACGCGGCGCG	TGGCGACCGC	CGTGCTCCGG	GAGCGGGTCA	CGACGAGGTC	GAGAAGGGGG
4741	GCGCGGTGCG	CGGCGGCGAC	CGGCGCAGCG	CTCGGCTCGA	CCATCCGCCG	CCCAGAGAGC

- 81 -

5	4801	GACGCCGGGA	GAAGGTCGAG	GCCGCCGGCG	ACCGTCCGTT	CCGGCTCGAG	ATCGATGAGC
	4861	CAGGCGTGCT	CGATCGCCTG	GTGCTTCGGG	TCACGGAGCG	GCGCGCCCCT	GCTCTTGGCG
	4921	AGGTCGAGAT	CGCCGTCGAC	GCGGCGGGGC	TCAGCTTCAA	TGATGTCCAG	CTCGCGCTGG
	4981	GCATGGTGCC	CGACGACCTG	CCGGGAAAGC	CCAACCCCTC	GCTGCTGCTC	GGAGGCGAGT
	5041	GCGCCGGGCG	CATCGTCGCC	GTGGGCGAGG	GCGTGAACGG	CCTTGTGTGT	GGCCAACCGG
	5101	TCATCGCCCT	TTCGGCGGGA	GCGTTTGCTA	CCCACGTCAC	CACGTCGGCT	GCGCTGGTGC
	5161	TGCCTCGGCC	TCAGGCGCTC	TCGGCGACCG	AGGCGGCCGC	CATGCCCGTC	GCGTACCTGA
	5221	CGGCATGGTA	CGCGCTCGAC	GGAATAGCCC	GCCTTCAGCC	GGGGGAGCGG	GTGCTGATCC
10	5281	ACGCGGCGAC	CGGCGGGGTC	GGTCTCGCCG	CGGTGCAGTG	GGCGCAGCAC	GTGGGAGCCG
	5341	AGGTCCATGC	GACGGCCGGC	ACGCCCAGAG	AGCGCGCCTA	CCTGGAGTCG	CTGGGCGTGC
	5401	GGTATGTGAG	CGATTCCC GC	TCGGACCGGT	TCGTCGCCGA	CGTGC GCGCG	TGGACGGGCG
	5461	GCGAGGGAGT	AGACGTCGTG	CTCAACTCGC	TTTCGGGCGA	GCTGATCGAC	AAGAGTTTCA
	5521	ATCTCCTGCG	ATCGCACGGC	CGGTTTGTTG	AGCTCGGCAA	GCGCGACTGT	TACGCGGATA
	5581	ACCAGCTCGG	GCTGCGGCCG	TTCTGCGCA	ATCTCTCCTT	CTCGCTGGTG	GATCTCCGGG
15	5641	GGATGATGCT	CGAGCGGCCG	GCGCGGGTCC	GTGCGCTCTT	CGAGGAGCTC	CTCGGCCCTGA
	5701	TCGCGGCAGG	CGTGTTCACC	CCTCCCCCCA	TCGCGACGCT	CCCGATCGCT	CGTGTGCGCCG
	5761	ATGCGTTCCG	GAGCATGGCG	CAGGCGCAGC	ATCTTGGGAA	GCTCGTACTC	ACGCTGGGTG
	5821	ACCCGGAGGT	CCAGATCCGT	ATTCCGACCC	ACG CAGGCGC	CGGCCCGTCC	ACCGGGGATC
	5881	GGGATCTGCT	CGACAGGCTC	GCGTCAGCTG	CGCCGGCCGC	GCGCGCGGCG	GCGCTGGAGG
20	5941	CGTTCCTCCG	TACGCAGGTC	TCGCAGGTGC	TGCGCACGCC	CGAAATCAAG	GTGCGCGCGG
	6001	AGGCGCTGTT	CACCCGCCTC	GGCATGGACT	CGCTCATGGC	CGTGGAGCTG	CGCAATCGTA
	6061	TCGAGGCGAG	CCTCAAGCTG	AAGCTGTGCA	CGACGTTCTT	GTCCACGTC	CCCAATATCG
	6121	CCTTGTTGAC	CCAAAACCTG	TTGGATGCTC	TCGCCACAGC	TCTCTCCTTG	GACGAGGTGG
	6181	CGGCGGAGAA	CCTACGGGCA	GGCGTGCAAA	GCGACTTCGT	CTCATCGGGC	GCAGATCAAG
25	6241	ACTGGGAAAT	CATTGCCCTA	TGACGATCAA	TCAGCTTCTG	AACGAGCTCG	AGCACCAGGG
	6301	TGTCAAGCTG	GCGGCCGATG	GGGAGCGCCT	CCAGATACAG	GCCCCAAGA	ACGCCCTGAA
	6361	CCCGAACCTG	CTCGCTCGAA	TCTCCGAGCA	CAAAAGCACG	ATCCTGACGA	TGCTCCGTCA
	6421	GAGACTCCCC	GCAGAGTCCA	TCGTGCCCCG	CCCAGCCGAG	CGGCACGTTT	CGTTTCTCTT
	6481	CACAGACATC	CAAGGATCCT	ACTGGCTGGG	TCGGACAGGA	GCGTTTACGG	TCCCCAGCGG
30	6541	GATCCACGCC	TATCGCGAAT	ACGACTGTAC	GGATCTCGAC	GTGGCGAGGC	TGAGCCGCGC
	6601	CTTTCGGAAA	GTCGTCGCGC	GGCAGACAT	GCTTCGGGCC	CACACGCTGC	CCGACATGAT
	6661	GCAGGTGATC	GAGCCTAAAG	TCGACGCCGA	CATCGAGATC	ATCGATCTGC	GCGGGCTCGA
	6721	CCGGAGCACA	CGGGAAGCGA	GGCTCGTATC	GTTGCGAGAT	GCGATGTGCG	ACCGCATCTA
	6781	TGACACCGAG	CGCCCTCCGC	TCTATCACGT	CGTCGCCGTT	CGGCTGGACG	AGCAGCAAAC
35	6841	CCGTCTCGTG	CTCAGTATCG	ATCTCATTAA	CGTTGACCTA	GGCAGCCTGT	CCATCATCTT
	6901	CAAGGATTGG	CTCAGCTTCT	ACGAAGATCC	CGAGACCTCT	CTCCCTGTCC	TGGAGCTCTC
	6961	GTACCCGCGAC	TATGTGCTCG	CGCTGGAGTC	TCGCAAGAAG	TCTGAGGCGG	ATCAACGATC
	7021	GATGGATTAC	TGGAAGCGGC	GCGTCGCCGA	GCTCCACCT	CCGCCGATGC	TTCCGATGAA
	7081	GGCCGATCCA	TCTACCCTGA	GGGAGATCCG	CTTCCGGCAC	ACGGAGCAAT	GGCTGCCGTC
40	7141	GGACTCCTGG	AGTCGATTGA	AGCAGCGTGT	CGGGGAGCGC	GGGCTGACCC	CGACGGGCGT
	7201	CATTCTGGCT	GCATTTTCCG	AGGTGATCGG	GCGCTGGAGC	GCGAGCCCCC	GGTTTACGCT
	7261	CAACATAACG	CTCTTCAACC	GGCTCCCCGT	CCATCCGCGC	GTGAACGATA	TCACCGGGGA
	7321	CTTCACGTCG	ATGGTCCTCC	TGGACATCGA	CACCACTCGC	GACAAGAGCT	TCGAACAGCG
	7381	CGCTAAGCGT	ATTCAAGAGC	AGCTGTGGGA	AGCGATGGAT	CACTGCGACG	TAAGCGGTAT
45	7441	CGAGGTCCAG	CGAGAGGCCG	CCCGGGTCCT	GGGGATCCAA	CGAGGCGCAT	TGTTCCCCGT
	7501	GGTGCTCACG	AGCGCGCTCA	ACCAGCAAGT	CGTTGGTGTC	ACCTCGCTGC	AGAGGCTCGG
	7561	CACTCCGGTG	TACACCAGCA	CGCAGACTCC	TCAGCTGCTG	CTGGATCATC	AGCTCTACGA
	7621	GCACGATGGG	GACCTCGTCC	TCGCGTGCGA	CATCGTCGAC	GGAGTGTTCC	CGCCCCACCT
	7681	TCTGGACGAC	ATGCTCGAAG	CGTACGTCGC	TTTTCTCCGG	CGGCTCACTG	AGGAACCATG
50	7741	GAGTGAACAG	ATGCGCTGTT	CGCTTCCGCC	TGCCCAGCTA	GAAGCGCGGG	CGAGCGCAAA
	7801	CGAGACCAAC	TCGCTGCTGA	GCGAGCATAC	GCTGCACGGC	CTGTTGCGCG	CGCGGGTCGA
	7861	GCAGCTGCCT	ATGCAGCTCG	CCGTGGTGTC	GGCGCGCAAG	ACGCTCACGT	ACGAAGAGCT
	7921	TTGCGGCCGT	TCGCGGCGAC	TTGGCGCGCG	GCTGCGCGAG	CAGGGGGCAC	GCCCCAACAC
	7981	ATTGGTTCGCG	GTGGTGATGG	AGAAAGGCTG	GGAGCAGGTT	GTCGCGGTTT	TCGCGGTGCT

5 8041 CGAGTCAGGC GCGGCCTACG TGCCGATCGA TGCCGACCTA CCGGCGGAGC GSTATCCACTA
8101 CCTCCTCGAT CATGGTGAGG TAAAGCTCGT GCTGACGCAG CCATGGCTGG ATGGCAAACCT
8161 GTCATGGCCG CCGGGGATCC AGCGGCTGCT CGTGAGCGAT GCCGGCGTCC AAGGCGACGG
8221 CGACCAGCTT CCGATGATGC CCATTGAGAC ACCTTCGGAT CTCGCGTATG TCATCTACAC
8281 CTCGGGATCC ACAGGGTTGC CCAAGGGGGT GATGATCGAT CATCGGGGTG CCGTCAACAC
8341 CATCCTGGAC ATCAACGAGC GCTTCGAAAT AGGGCCCGGA GACAGAGTGC TGGCGCTCTC
8401 CTCGCTGAGC TTCGATCTCT CGGTCTACGA TGTGTTCCGG ATCCTGGCGG CGGGCGGTAC
8461 GATCGTGGTG CCGGACGCGT CCAAGCTGCG CGATCCGGCG CATTGGGCAG CGTTGATCGA
10 8521 ACGAGAGAAG GTGACGGTGT GGAACCTCGT GCCGGCGCTG ATGCGGATGC TCGTCGAGCA
8581 TTCCGAGGGT CGCCCCGATT CGCTCGCTAG GTCTCTGCGG CTTTTCGCTG TGAGCGGCGA
8641 CTGGATCCCG GTGGGCCTGC CTGGCGAGCT CCAGGCCATC AGGCCCGGCG TGTCGGTGAT
8701 CAGCCTGGGC GGGGCCACCG AAGCGTCGAT CTGGTCCATC GGGTACCCCG TGAGGAACGT
8761 CGATCCATCG TGGGCGAGCA TCCCTTACGG CCGTCCGCTG CGCAACCAGA CGTTCCACGT
8821 GCTCGATGAG GCGCTCGAAC CGCGCCGGT CTGGGTTCGG GGGCAACTCT ACATTGGCGG
15 8881 GGTCCGACTG GCACTGGGCT ACTGGCGCGA TGAAGAGAAG ACGCGCAACA GCTTCCTCGT
8941 GCACCCCGAG ACCGGGGAGC GCCTCTACAA GACCGGCGAT CTGGGCCGCT ACCTGCCCGA
9001 TGGAAACATC GAGTTCATGG GCGGGGAGGA CAACCAAATC AAGCTTCGCG GATACCGCGT
9061 TGAGCTCGGG GAAATCGAGG AAACGCTCAA GTCGCATCCG AACGTACGCG ACGCGGTGAT
9121 TGTGCCCCGTC GGAACGACG CGGCGAACAA GCTCCTTCTA GCCTATGTGG TCCCGGAAGG
20 9181 CACACGGAGA CGCGCTGCCG AGCAGGACGC GAGCCTCAAG ACCGAGCGGG TCGACGCGAG
9241 AGCACACGCC GCCAAAGCGG ACGGATTGAG CGACGGCGAG AGGGTGCAGT TCAAGCTCGC
9301 TCGACACGGA CTCCGGAGGG ATCTGGACGG AAAGCCCGTC GTCGATCTGA CCGGGCTGGT
9361 TCCGCGGGAG CGGGGGCTGG ACGTCTACGC GCGTCGCCGT AGCGTCCGAA CGTTCCTCGA
9421 GGCCCCGATT CCATTTGTTG AATTCGGCCG ATTCTGAGC TGCCTGAGC GCGTGGAGCC
25 9481 CGACGGCGCG GCCCTTCCCA AATTCCGTTA TCCATCGGCT GGCAGCACGT ACCCGGTGCA
9541 AACCTACGCG TACGCCAAAT CCGGCCGCAT CGAGGGCGTG GACGAGGGCT TCTATTATTA
9601 CCACCCGTTT GAGCACCGTT TGCTGAAGGT CTCCGATCAC GGGATCGAGC GCGGAGCGCA
9661 CGTTCGCGAA AACTTCGACG TGTTCGATGA AGCGGCGTTC GGCCTCCTGT TCGTGGGCAG
9721 GATCGATGCC ATCGAGTCGC TGTATGGATC GTTGTACGA GAATTCTGCC TGCTGGAGGC
30 9781 CGGATATATG GCGCAGCTCC TGATGGAGCA GGCGCCTTCC TGCAACATCG GCGTCTGTCC
9841 GGTGGGTCAA TTCGATTTTG AACAGGTTCC GCCGGTTCTC GACCTGCGGC ATTCGGACGT
9901 TTACGTGCAC GGCATGCTGG GCGGGCGGGT AGACCCGCGG CAGTTCCAGG TCTGTACGCT
9961 CGGTCAGGAT TCCTCACCAG GCGCGGCCAC GACGCGCGGC GCCCTCCCG GCCGCGATCA
35 10021 GCACTTCGCC GATATCCTTC GCGACTTCTT GAGGACCAA CTACCCGAGT ACATGGTGCC
10081 TACAGTCTTC GTGGAGCTCG ATGCGTTGCC GCTGACGTCC AACGGCAAGG TCGATCGTAA
10141 GGCCCTGCGC GAGCGGAAGG ATACCTCGTC GCCGCGGCAT TCGGGGCA CA CGGCGCCACG
10201 GGACGCCTTG GAGGAGATCC TCGTTGCGGT CGTACGGGAG GTGCTCGGCG TGGAGGTGGT
10261 TGGGCTCCAG CAGAGCTTCG TCGATCTTGG TCGACATCG ATTCACATCG TTCGCATGAG
40 10321 GAGTCTGTTG CAGAAGAGGC TGGATAGGGA GATCGCCATC ACCGAGTTGT TCCAGTACCC
10381 GAACCTCGGC TCGCTGGCGT CCGGTTTGCG CCGAGACTCG AAAGATCTAG AGCAGCGGCC
10441 GAACATGCAG GACCGAGTGG AGGCTCGGCG CAAGGGCAGG AGACGTAGCT AAGAGCGCCG
10501 AACAAAACCA GGCCGAGCGG GCCAATGAAC CGCAAGCCCG CCTGCGTCAC CCTGGGACTC
10561 ATCTGATCTG ATCGCGGGTA CGCGTCCGCG GTGTGCGCGT TGAGCCGTGT TGCTCGAACG
45 10621 CTGAGGAACG GTGAGCTCAT GGAAGAACAA GAGTCCTCCG CTATCGCAGT CATCGGCATG
10681 TCGGGCCGTT TTCCGGGGGC GCGGGATCTG GACGAATTCT GGAGGAACCT TCGAGACGGC
10741 ACGGAGGCCG TGCAGCGCTT CTCCGAGCAG GAGCTCGCGG CGTCCGGAGT CGACCCAGCG
10801 CTGGTGCTGG ACCCGAATA CGTCCGGGCG GGCAGCGTGC TGGAAGATGT CGACCGGTTT
10861 GACGCTGCTT TCTTCGGCAT CAGCCCGCGC GAGGCAGAGC TCATGGATCC GCAGACCCG
50 10921 ATCTTCATGG AATGCGCCTG GGAGGCGCTG GAGAACGCCG GATACGACCC GACAGCCTAC
10981 GAGGGCTCTA TCGGCGTGTA CGCCGGCGCC AACATGAGCT CGTACTTGAC GTCGAACCTC
11041 CACGAGCACC CAGCGATGAT GCGGTGGCCC GGCTGGTTTC AGACGTTGAT CGGCAACGAC
11101 AAGGATTACC TCGCGACCCA CGTCTCCTAC AGGCTGAATC TGAGAGGGCC GAGCATCTCC
11161 GTTCAAACCTG CCTGCTCTAC CTCGCTCGTG GCGGTTCACT TGGCGTGCAT GAGCCTCCTG
11221 GACCGCGAGT GCGACATGGC GCTGGCCGGC GGGATTACCG TCCGATCCC CCATCGAGCC

- 83 -

5 11281 GGCTATGTAT ATGCTGAGGG GGGCATCTTC TCTCCCGACG GCCATTGCCG GGCCTTCGAC
11341 GCCAAGGCGA ACGGCACGAT CATGGGCAAC GGCTGCGGGG TTGTCTTCCT CAGCCGCTG
11401 GACCGGGGCG TCTCCGATGG TGATCCCGTC CGCGCGGTCA TCCTTGGGTC GCCACAAAC
11461 AACGACGGAG CGAGGAAGAT CGGGTTCACT GCGCCAGTG AGGTGGGCCA GCGCAAGCG
11521 ATCATGGAGG CGCTGGCGCT GGCAGGGGTC GAGGCCCCGT CCATCCAATA CATCGAGACC
11581 CACGGGACCG GCACGCTGCT CGGAGACGCC ATCGAGACGG CGGCGTTGCG GCGGGTGTTT
11641 GATCGCGACG CTTGACCCG GAGGTCTTGC GCGATCGGCT CCGTGAAGAC CGGCATCGGA
11701 CACCTCGAAT CGGCGGCTGG CATCGCCGGT TTGATCAAGA CCGTCTTGGC GCTGGAGCAC
10 11761 CGGCAGCTGC CGCCAGCCT GAACTTCGAG TCTCCTAACC CATCGATCGA TTTCGCGAGC
11821 AGCCCGTTCT ACGTCAATAC CTCTCTTAAG GATTGGAATA CCGGCTCGAC TCCGCGCGG
11881 GCCGGCGTCA GCTCGTTCGG GATCGGGGGC CCAACGCC ATGTCGTGCT GGAGGAAGCA
11941 CCCGCGGCGA AGCTTCCAGC CGCGGCGCGG GCGCGCTCTG CCGAGCTCTT CGTCGTCTCG
12001 GCCAAGAGCG CAGCGGCGCT GGATGCCGCG GCGGCACGGC TACGAGATCA TCTGCAGGCG
12061 CACCAGGGGC TTTCGTTGGG CGACGTCGCC TTCAGCCTGG CGACGACGCG CAGTCCCATG
15 12121 GAGCACCAGG TCGCGATGGC GGCACCGTCG CGCGAGGCGT TCGAGAGGG GCTCGACGCA
12181 GCGGCGCGAG GCCAGACCCC GCCGGGCGCC GTGCGTGGCC GCTGCTCCCC AGGCAACGTG
12241 CCGAAGGTGG TCTTCGTCTT TCCCGGCCAG GGCTCTCAGT GGGTCGGTAT GGGCCGTCAG
12301 CTCCTGGCTG AGGAACCCGT CTTCCACGCG GCGCTTTCGG CGTGCGACCG GGCCATCCAG
12361 GCCGAAGCTG GTTGGTCGCT GCTCGCCGAG CTCGCCGCGG ACGAAGGGT GTCCAGATC
20 12421 GAGCGCATCG ACGTGGTGCA GCCGGTGCTG TTCGCGCTCG CCGTGGCATT TCGGCGCTG
12481 TGGCGGTGCT GGGGTGTCGG GCCCGACGTC GTGATCGGCC ACAGCATGG CGAGGTAGCC
12541 GCCGCGCATG TGGCCGGGGC GCTGTGCTC GAGGATGCGG TGGCGATCAT GTGCCGGCGC
12601 AGCCGGCTGC TCCGGCGCAT CAGCGGTGAG GCGGAGATGG CCGTGACCGA CTTGTCGCTG
12661 GCCGAGGCCG AGGCAGCGCT CCGAGGCTAC GAGGATCGGG TGAGCGTGGC CGTGAGCAAC
25 12721 AGCCCGCGCT CGACGGTGCT CTCGGGCGAG CCGGCAGCGA TCGGCGAGGT GCTGTGCTCC
12781 CTGAACGCGA AGGGGGTGTT CTGCGTGGT GTGAAGGTGG ATGTCGCCAG CCACAGCCCC
12841 CAGGTCGACC CGCTGCGCGA GGACCTCTTG GCAGCGCTGG GCGGGCTCCG GCCGCTGCG
12901 GCTGCGGTGC CGATGCGCTC GACGGTGACG GGCGCCATGG TAGCGGGCCC GGAGCTCGGA
12961 GCGAATTACT GGATGAACAA TCTCAGGCAG CCTGTGCGCT TCGCCGAGGT AGTCCAGGCG
30 13021 CAGCTCCAAG GCGGCCACGG TCTGTTCGTG GAGATGAGCC CGCATCCGAT CCTAACGACT
13081 TCGGTCGAGG AGATGCGGCG CGCGGCCAG CCGGCGGGCG CAGCGGTGGG CTGCTGCGG
13141 CGAGGGCAGG ACGAGCGCCC GCGATGCTG GAGGCGCTGG GCGCGCTGTG GCGCAGGGC
13201 TACCCTGTAC CCTGGGGGCG GCTGTTTCCC GCGGGGGGGC GCGGGGTACC GTCGCCGACC
13261 TATCCCTGGC AGCGCGAGCG GTACTGGATC GAAGCGCCG CCAAGAGCGC CGCGGGCGAT
35 13321 CGCCGCGGCG TGCGTGCGGG CGGTACCCG CTCCTCGGTG AAATGCAGAC CCTATCAACC
13381 CAGACGAGCA CGCGGCTGTG GGAGACGAC CTGGATCTCA AGCGGCTGCC GTGGCTCGGC
13441 GACCACCGGG TGCAGGGAGC GGTGCTGTTT CCGGGCGCGG CGTACCTGGA GATGGCGATT
13501 TCGTCGGGGG CCGAGGCTTT GGGCGATGGC CCATTGCAGA TAACCGACG GGTGCTCGCC
13561 GAGGCGCTGG CTTTCGCGGG CGACGCGGCG GTGTTGGTCC AGGTGGTGAC GACGGAGCAG
40 13621 CCGTCGGGAG GGCTGCAGTT CCAGATCGCG AGCCGGGCGC CGGGCGCTGG CCACGCGTCC
13681 TTCCGGGTCC ACGCTCGCGG CGCGTTGCTC CGAGTGGAGC GCACCGAGGT CCCGGCTGGG
13741 CTTACGCTTT CCGCCGTGCG CGCACGGCTC CAGGCCAGCA TGCCCGCCGC GGCCACCTAC
13801 GCGGAGCTGA CCGAGATGGG GCTGCAGTAC GGCCCTGCCT TCCAGGGGAT TGCTGAGCTA
13861 TGGCGCGGTG AGGGCGAGGC GCTGGGACGG GTACGCTGC CCGACGCGGC CGGCTCGGCA
45 13921 GCGGAGTATC GGTTGCATCC TGCGCTGCTG GACGCGTGCT TCCAGGTGCT CGGCAGCCTC
13981 TTCGCCGGCG GTGGCGAGGC GACGCCGTGG GTGCCGTGG AAGTGGGCTC GCTGCGGCTC
14041 TTGCAGCGGC CTTGCGGGGA GCTGTGGTGC CATGCGCGCG TCGTGAACCA CGGGCGCCAA
14101 ACCCCCGATC GGCAGGGCGC CGACTTTTGG GTGGTCGACA GCTCGGGTGC AGTGGTCGCC
14161 GAAGTCAGCG GGCTCGTGCC GCAGCGGCTT CCGGGAGGGG TGCGCCGGCG CGAAGAAGAC
50 14221 GATTGGTTCC TGGAGCTCGA GTGGGAACCC GCAGCGGTG GCACAGCCAA GGTCAACGCG
14281 GGCGGTTGGC TGCTCCTCGG CGGCGGCGGT GGGCTCGGCG CCGCGTTGCG CTCGATGCTG
14341 GAGGCCGGCG GCCATGCCGT CGTCCATGCG GCAGAGAGCA ACACGAGCGC TGCCGGCGTA
14401 CGCGCGCTCC TGGCAAAGGC CTTTGACGGC CAGGCTCCGA CCGCGGTGGT GCACCTCGGC
14461 AGCCTCGATG GGGGTGGCGA GCTCGACCCA GGGCTCGGGG CGCAAGGCGC ATTGGACGCG

14521 CCCCGGAGCG CCGACGTCAG TCCCGATGCC CTCGATCCGG CGCTGGTACG TGGCTGTGAC
14581 AGCGTGCTCT GGACCGTGCA GGCCCTGGCC GGCATGGGCT TTCGAGACGC CCCGCGATTG
14641 TGGCTTCTGA CCCGCGGCGC ACAGGCCGTC GCGCGCGGCG ACGTCTCCGT GACACAGGCA
14701 CCGCTGCTGG GGCTGGGCGG CGTCATCGCC ATGGAGCACG CGGATCTGCG CTGCGCTCGG
5 14761 GTCGACCTCG ATCCGACCCG GCCCGATGGG GAGCTCGGTG CCCTGCTGGC CGAGCTGCTG
14821 GCGGACGACG CCGAAGCGGA AGTCGCGTTG CGCGGTGGCG AGCGATGCGT CGCTCGGATC
14881 GTCCGCCGCG AGCCCGAGAC CCGGCCCGG GGGAGGATCG AGAGCTGCGT TCCGACCGAC
14941 GTCACCATCC GCGCGGACAG CACCTACCTT GTGACCGGCG GTCTGGGTGG GCTCGGTCTG
10 15001 AGCGTGGCCG GATGGCTGGC CGAGCGCGGC GCTGGTCACC TGGTGTGGT GGGCCGCTCC
15061 GGCGCGGCGA GCGTGGAGCA ACGGGCAGCC GTCGCGGCGC TCGAGGCCCG CGGCGCGCGC
15121 GTCACCGTGG CGAAGGCAGA TGTCGCGCAT CGGGCGCAGC TCGAGCGGAT CCTCCGCGAG
15181 GTTACCACGT CGGGGATGCC GCTGCGGGGC GTCGTCCATG CGGCCGGCAT CTTGGACGAC
15241 GGGCTGCTGA TGCAGCAGAC TCCCGCGCGG TTTCGTAAGG TGATGGCGCC CAAGGTCCAG
15301 GGGGCCTTGC ACCTGCACGC GTTGACGCGC GAAGCGCCGC TTTCCTTCTT CGTGCTGTAC
15 15361 GCTTCGGGAG TAGGGCTCTT GGGCTCGCCG GGCCAGGGCA ACTACGCCGC GGCCAACACG
15421 TTCCTCGACG CTCTGGCGCA CCACCGGAGG GCGCAGGGGC TGCCAGCGTT GAGCGTCGAC
15481 TGGGGCCTGT TCGCGGAGGT GGGCATGGCG GCCGCGCAGG AAGATCGCGG CGCGCGGCTG
15541 GTCTCCCGCG GAATGCGGAG CCTACCCCC GACGAGGGGC TGTCCGCTCT GGCACGGCTG
15601 CTCGAAAGCG GCCGCGTGCA GGTGGGGGTG ATGCCGGTGA ACCCGCGGCT GTGGGTGGAG
20 15661 CTCTACCCCG CGGCGGCGTC TTCGCGAATG TTGTCGCGCC TGGTGACGCG GCATCGCGCG
15721 AGCGCCGCGG GCGCAGCCGG GGACGGGGAC CTGCTCCGCC GCCTCGCTGC TCCCGAGCCG
15781 AGCGCGCGGA GCGGGCTCCT GGAGCCGCTC CTCCGCGCGC AGATCTCGCA GGTGCTGCGC
15841 CTCCCGAGG GCAAGATCGA GGTGGACGCC CCGCTCACGA GCCTGGGCAT GAACTCGCTG
15901 ATGGGGCTCG AGCTGCGCAA CCGCATCGAG GCCATGCTGG GCATCACCGT ACCGGCAACG
25 15961 CTGTTGTGGA CCTATCCCAC GGTGGCGGCG CTGAGCGGGC ATCTGGCGCG GGAGGCATGC
16021 GAAGCCGCTC CTGTGGAGTC ACCGCACACC ACCGCCGATT CTGCTGTGCA GATCGAGGAG
16081 ATGTCGAGG ACGATCTGAC GCAGTTGATC GCAGCAAAAT TCAAGGCGCT TACATGACTA
16141 CTCGCGGTCC TACGGCACAG CAGAATCCGC TGAACAAGC GGCCATCATC ATTCAGCGGC
16201 TGGAGGAGCG GCTCGCTGGG CTCGCACAGG CGGAGCTGGA ACGGACCGAG CCGATCGCCA
30 16261 TCGTCGGTAT CGGCTGCCGC TTCCCTGGCG GTGCGGACGC TCCGGAAGCG TTTTGGGAGC
16321 TGCTCGACGC GGAGCGCGAC GCGGTCCAGC CGCTCGACAG GCGCTGGGCG CTGGTAGGTG
16381 TCGTCCCGT CGAGGCCGTG CCGCACTGGG CGGGGCTGCT CACCGAGCCG ATAGATTGCT
16441 TCGATGCTGC GTTCTTCGGC ATCTCGCCTC GGGAGGCGCG ATCGCTCGAC CCGCAGCATC
16501 GTCTGTTGCT GGAGGTCGCT TGGGAGGGGC TCGAGGACGC CGGTATCCCG CCCCGGTCCA
35 16561 TCGACGGGAG CCGCACCGGT GTGTTCGTG CCGCTTTCAC GGCGGACTAC GCGCGCACGG
16621 TCGCTCGGTT GCCGCGCGAG GAGCGAGAC CGTACAGCGC CACCGGCAAC ATGCTCAGCA
16681 TCGCCGCCGG ACGGCTGTG TACACGCTGG GGCTGCAGG ACCTTGCCCTG ACCGTCGACA
16741 CGGCGTGCTC GTCATCGCTG GTGGCGATTG ACCTCGCCTG CCGCAGCCTG CGCGCAGGAG
16801 AGAGCGATCT CGCGTTGGCG GGAGGGGTCA GCACGCTCCT CTCCCCGAC ATGATGGAAG
40 16861 CCGCGGCGCG CACGCAAGCG CTGTGCGCCG ATGGTCGTTG CCGGACCTTC GATGCTTCGG
16921 CCAACGGGTT CGTCCGTGGC GAGGGCTGTG GCCTGGTCGT CCTCAAACGG CTCTCCGACG
16981 CGCAACGGGA TGGCGACCGC ATCTGGGCGC TGATCCGGGG CTCGGCCATC AACCATGATG
17041 GCCGGTCGAC CGGGTTGACC GCGCCCAACG TGCTGGCTCA GGAGACGGTC TTGCGCGAGG
45 17101 CGCTGCGGAG CGCCACGTC GAAGCTGGGG CCGTCGATTA CGTCGAGACC CACGGAACAG
17161 GGACCTCGCT GGGCGATCCC ATCGAGGTCG AGGCGCTGCG GGCGACGGTG GGGCCGGCGC
17221 GCTCCGACGG CACACGCTGC GTGCTGGGCG CCGTGAAGAC CAACATCGGC CATCTCGAGG
17281 CCGCGGCAGG CGTAGCGGGC CTGATCAAGG CAGCGCTTTC GCTGACGCAC GAGCGCATCC
17341 CGAGAAACCT CAACTTCCGC ACGCTCAATC CGCGGATCCG GCTCGAGGGC AGCGCGCTCG
17401 CGTTGGCGAC CGAGCCGGTG CCGTGGCCGC GCACGGACCG TCCGCGCTTC GCGGGGGTGA
50 17461 GCTCGTTCGG GATGAGCGGA ACGAACGCGC ATGTGGTGCT GGAAGAGGCG CCGGCGGTGG
17521 AGCTGTGGCC TGCCGCGCCG GAGCGCTCGG CGGAGCTTTT GGTGCTGTG GGCAAGAGCG
17581 AGGGGGCGCT CGACGCGCAG GCGGCGCGGC TGCGCGAGCA CCTGGACATG CACCCGGAGC
17641 TCGGGCTCGG GGACGTGGCG TTCAGCTGG CGACGACCG CAGCGCGATG ACCCAGCGGC
17701 TCGCGGTGGC GGTGACGTCG CGCGAGGGGC TGCTGGCGGC GCTTTCGGCC GTGGCGCAGG

- 85 -

17761 GGCAGACGCC GCGGGGGGCG GCGCGCTGCA TCGCGAGCTC CTCGCGCGGC AAGCTGGCGT
17821 TGCTGTTTAC CGGACAGGGC GCGCAGACGC CGGGCATGGG CCGGGGGCTC TGGCGGGCGT
17881 GGCCAGCGTT CCGGGAGGCG TTCGACCGGT GCGTGACGCT GTTCGACCGG GAGCTGGACC
17941 GCGCGCTGCG CGAGGTGATG TGGGCGGAGG CCGGGAGCGC CGAGTCGTTG TTGCTGGACC
5 18001 AGACGGCGTT CACCCAGCCC GCGCTCTTCG CCGTGGAGTA CCGCTGACG GCGCTGTGGC
18061 GGTCGTGGGG CGTAGAGCCG GAGCTCCTGG TTGGGCATAG CATCGGGGAG CTGGTGGCGG
18121 CGTGCCTGGC GGGGGTGTTT TCGCTGGAAG ATGGGGTGAG GCTCGTGGCG GCGCGCGGGC
18181 GGCTGATGCA GGGGCTCTCG GCGGGCGGCG CGATGGTGTC GCTCGGAGCG CCGGAGGCGG
18241 AGGTGGCCGC GCGGCTGGCG CCGCACGCGG CGTGGGTGTC GATCGCGGCG GTCAATGGGC
10 18301 CGGAGCAGGT GGTGATCGCG GCGGTGGAGC AAGCGGTGCA GCGGATCGCG GCGGGGTTTCG
18361 CGGCGCGCGG CGTGCGCACC AAGCGGTGTC ATGTCTCGCA CCGGTTCCAC TCGCCGCTGA
18421 TGGAACCGAT GCTGGAGGAG TTCGGGCGGG TGGCGGCGTC GGTGACGTAC CGGCGGCCAA
18481 GCGTTTCGCT GGTGAGCAAC CTGAGCGGGA AGGTGGTCAC GGACGAGCTG AGCGCGCCGG
18541 GCTACTGGGT GCGGCACGTG CCGGAGGCGG TCGCTTCGCG GGACGGGGTG AAGGCGCTGC
15 18601 ACGAAGCCCG GCGGGGCACG TTCCTCGAAG TGGGCCCCGA GCGGACGCTG CTCGGCCTGT
18661 TGCCAGCTTG CCTGCCGGAG GCGGAGCCGA CGTTGCTGGC GTCGTTGCGC GCGGGGCGCG
18721 AGGAGGCTGC GGGGGTGCTC GAGGCGCTGG GCAGGCTGTG GGCCGCTGGC GGCTCGGTCA
18781 GCTGGCCGGG CGTCTTCCCC ACGGCTGGGC GCGGGGTGCC GCTGCCGACC TATCCGTGGC
18841 AGCGGCAGCG GTACTGGATC GAGGCGCCCG CCGAAGGGCT CCGAGCCACG GCGGCCGATG
20 18901 CGCTGGCGCA GTGGTTCTAC CCGGTGGACT GGCCCGAGAT GCCTCGCTCA TCCGTGGATT
18961 CGCGGCGAGC CCGGTCCGCG GGGTGGCTGT TGCTGGCCGA CCGGGGTGGA GTCGGGGAGG
19021 CGGCCGCGCG GCGGCTTTCG TCGCAGGGAT GTTCGTGCGC CGTGCTCCAT GCGCCCCCGG
19081 AGGCTCCGCG GGTGCGCCGAG CAGGTGACCC AGGCCCTCGG TGGCCGCAAC GACTGGCAGG
19141 GGGTGCTGTA CCTGTGGGGT CTGGACGCCG TCGTGGAGGC GGGGGCATCG GCCGAAGAGG
25 19201 TCGGCAAAGT CACCCATCTT GCCACGGCGC CCGTGTCTCG GCTGATTAG GCGGTGGGCA
19261 CCGGGCCGCG CTCACCCCGG CTCTGGATCG TGACCCGAGG GGCTGACG GTGGGCGGCG
19321 AGCCTGACGC TGCCCCCTGT CAGGCGGCGC TGTGGGTAT GGGCCGGGTC GCGGCGCTGG
19381 AGCATCCCGG CTCCTGGGGC GGGCTCGTGG ACCTGGATCC GGAGGAGAGC CCGACGGAGG
19441 TCGAGGCCCT GGTGGCCGAG CTGCTTTCG CCGACCCGA GGATCAGCTG GCATTCCGCC
30 19501 AGGGGCGCCG GCGCGCAGCG CGGCTCGTGG CCGCCCCACC GGAGGGAAAC GCAGCGCCGG
19561 TGTCGCTGTC TGCGGAGGGG AGTTACTTGG TGACGGGTGG GCTGGGCGCC CTTGGCCTCC
19621 TCGTTGCGCG GTGGTTGGTG GAGCGCGGGG CCGGGCACCT TGTGCTGATC AGCCGGCACG
19681 GATTGCCCGA CCGCGAGGAA TGGGGCCGAG ATCAGCCGCC AGAGGTGCGC GCGCGATTG
19741 CGGCGATCGA GCGGCTGGAG GCGCAGGGCG CCGGGGTAC CGTGGCGGCG GTCGACGTGG
35 19801 CCGATGCCGA AGGCATGGCG GCGCTCTTGG CCGCCGTCGA GCCGCCGCTG CCGGGGGTCCG
19861 TGCACGCCCG GGGTCTGCTC GACGACGGGC TGCTGGCCCA CCAGGACGCC GGTGCGCTCG
19921 CCGGGGTGTT GCGCCCCAAG GTGGAGGGGG CATGGGTGCT GCACACCTTT ACCCGCGAGC
19981 AGCCGCTGGA CCTCTTCGTA CTGTTTTCCT CCGCGTCGGG CGTCTTCGCG TCGATCGGCC
20041 AGGGCAGCTA CGCGGCAGGC AATGCCTTTT TGACGCGGCT GCGGACCTC CGTGAACGC
40 20101 AGGGGCTCGC CGCCTGAGC ATCGCCTGGG GCGTGTGGG GGAGGGGGGG ATGGGCTCGC
20161 AGGCGCAGCG CCGGGAACAT GAGGCATCGG GAATCTGGGC GATGCCGACG AGTCGTGCCC
20221 TGGCGGCGAT GGAATGGGTG CTCGGTACGC GCGCGACGCA GCGCGTGGTC ATCCAGATGG
20281 ATTGGGCCCA TGCGGGAGCG GCTCCGCGCG ACGCGAGCCG AGGCCGCTTC TGGGATCGGC
20341 TGGTAACTGT CACGAAAGCG GCCTCCTCCT CCGCCGTGCC AGCTGTAGAG CGCTGGCGCA
45 20401 ACGCGTCTGT TGTGGAGACC CGCTCGGCGC TCTACGAGCT TGTGCGCGG GTGGTCGCCG
20461 GGGTGATGGG CTTTACCGAC CAAGGCACGC TCGACGTGCG ACGAGGCTTC GCCGAGCAGG
20521 GCCTCGACTC CCTGATGGCT GTGGAGATCC GCAAACGGCT TCAGGGTGAG CTGGGTATGC
20581 CGCTGTCGGC GACGCTGGCG TTCGACCATC CGACCGTGGG GCGGCTGGTG GAATACTTGC
20641 TGAGCCAGGC GCTGGAGCTG CAGGACCGCA CCGACGTGCG AAGCGTTTCG TTGCCGGCGA
50 20701 CAGAGGACCC GATCGCCATC GTGGGTGCCG CCTGCCGCTT CCGGGGCGGG GTCGAGGACC
20761 TGGAGTCCTA CTGGCAGCTG TTGACCGAGG GCGTGGTGGT CAGCACCGAG GTGCCGGCCG
20821 ACCGGTGGA TGGGGCAGAC GGGCGCGGCC CCGGCTCGGG AGAGGCTCCG AGACAGACCT
20881 ACGTGCCAG GGGTGGCTTT CTGCGCGAGG TGGAGACGTT CGATGCGGCG TTCTTCCACA
20941 TCTCGCCTCG GGAGGCGATG AGCCTGGACC CGCAACAGCG GCTGCTGCTG GAAGTGAGCT

	21001	GGGAGGCGAT	CGAGCGCGCG	GGCCAGGACC	CGTCGGCGCT	GCGCGAGAGC	CCCACGGGCG
	21061	TGTTCTGTGG	CGCGGGCCCC	AACGAATATG	CCGAGCGGGT	GCAGGACCTC	GGCGATGAGG
	21121	CGGCGGGGCT	CTACAGCGGC	ACCGGCAACA	TGCTCAGCGT	TGCGGCGGGA	CGGCTGTCTAT
	21181	TTTTCTGTGG	CCTGCACGGG	CCGACCCTGG	CTGTGGATAC	GGCGTGCTCC	TCGTCTGCTCG
5	21241	TGGCGGTGCA	CCTCGGCTGC	CAGAGCTTGC	GACGGGGCGA	GTGCGACCAA	GCCCTGGTTG
	21301	GCGGGGTCAA	CATGCTGCTC	TCGCCGAAGA	CCTTCGCGCT	GCTCTACGG	ATGCACGCGC
	21361	TTTCGCCCCG	CGGGCGGTGC	AAGACGTTCT	CGGCCGACGC	GGACGGCTAC	GCGCGGGCCG
	21421	AGGGCTGCGC	CGTGGTGGTG	CTCAAGCGGC	TCTCCGACGC	GCAGCGCGAC	CGCGACCCCA
	21481	TCCTGGCGGT	GATCCGGGGT	ACGGCGATCA	ATCATGATGG	CCCGAGCAGC	GGGCTGACAG
10	21541	TGCCCAGCGG	CCCTGCCCAG	GAGGCGCTGT	TACGCCAGGC	GCTGGCGCAC	GCAGGGGTGG
	21601	TTCCGGCCGA	CGTCGATTTC	GTGGAATGCC	ACGGGACCGG	GACGGCGCTG	GGCGACCCGA
	21661	TCGAGGTGCG	GGCGCTGAGC	GACGTGTACG	GGCAAGCCCC	CCCTGCGGAC	CGACCGCTGA
	21721	TCCTGGGAGC	CGCCAAGGCC	AACCTTGGGC	ACATGGAGCC	CGCGGCGGGC	CTGGCCGGCT
	21781	TGCTCAAGGC	GGTGCTCGCG	CTGGGGCAAG	AGCAAATACC	AGCCCAGCCG	GAGCTGGGCG
15	21841	AGCTCAACCC	GCTCTTGCCG	TGGGAGGCGC	TGCCGGTGGC	GGTGGCCCCG	GCAGCGGTGC
	21901	CGTGGCCCGC	CACGGACCGT	CCGCGCTTCG	CGGGGGTGAG	CTCGTTCGGG	ATGAGCGGAA
	21961	CGAACGCGCA	TGTGGTGCTG	GAAGAGGCGC	CGGCGGTGGA	GCTGTGGCCT	GCCGCGCCGG
	22021	AGCGCTCGGC	GGAGCTTTTG	GTGCTGTCCG	GCAAGAGCGA	GGGGGCGCTC	GACGCGCAGG
	22081	CGGCGCGGCT	GCGCGAGCAC	CTGGACATGC	ACCCGGAGCT	CGGGCTCGGG	GACGTGGCGT
20	22141	TCAGCTTGGC	GACGACGCGC	AGCGCGATGA	ACCACCGGCT	CGCGGTGGCG	GTGACGTGCG
	22201	GCGAGGGGCT	GCTGGCGGCG	CTTTCGGGCC	TGGCGCAGGG	GCAGACGCCG	CCGGGGGCGG
	22261	CGCGCTGCAT	CGCGAGCTCG	TCGCGCGGCA	AGCTGGCGTT	CCTGTTCAAC	GGACAGGGCG
	22321	TCGACGACCC	GGGCATGGGC	CGGGGGCTTT	GCGCGGCGTG	GCCAGCGTTC	CGAGAGGCGT
	22381	TCGACCGGTG	CGTGCGCTG	TTCGACCGGG	AGCTGGACCG	CCCGCTGTGC	GAGGTGATGT
25	22441	GGGCGGAGCC	GGGGAGCGCC	GAGTCGTTGT	TGCTCGACCA	GACGGCGTTC	ACCCAGCCCC
	22501	CGCTCTTCAC	GGTGGAGTAC	GCGCTGACGG	CGCTGTGGCG	GTCGTGGGGC	GTAGAGCCGG
	22561	AGCTGGTGGC	TGGGCATAGC	GCCGGGGAGC	TGGTGGCGGC	GTGCGTGGCG	GGGGTGTTC
	22621	CGCTGGAAGA	TGGGGTGAGG	CTCGTGCGCG	CGCGCGGGCG	GCTGATGCAG	GGGCTCTCGG
	22681	CGGGCGGCGC	GATGGTGTCT	CTCGGAGCGC	CGGAGGCGGA	GCTGGCCGCG	GCGGTGGCGC
30	22741	CGCACGCGGC	GTGGGTGTCT	ATCGCGGCGG	TCAATGGGCC	GGAGCAGGTG	GTGATCGCGG
	22801	GCGTGGAGCA	AGCGGTGCAG	GCGATCGCGG	CGGGGTTCGC	GGCGCGCGGC	GTGCGCACCA
	22861	AGCGGCTGCA	TGTCTCGCAC	GCATCCCACT	CGCCGCTGAT	GGAACCGATG	CTGGAGGAGT
	22921	TCGGGCGGGT	GGCGGCGTCT	GTGACGTACC	GGCGGCCAAG	CGTTTCGCTG	GTGAGCAACC
	22981	TGAGCGGGAA	GGTGGTCACG	GACGAGCTGA	GCGCGCCGGG	CTACTGGGTG	CGGCACGTGC
35	23041	GGGAGGCGGT	GCGCTTCGCG	GACGGGGTGA	AGGCGCTGCA	CGAAGCCGGC	GCGGGGACGT
	23101	TCCTCGAAGT	GGGCCCCAAG	CCGACGCTGC	TCGGCCTGTT	GCCAGCTTGC	CTGCCGGAGG
	23161	CGGAGCCGAC	GCTGCTGGCG	TCGTTGCGCG	CCGGGCGCGA	GGAGGCTGCG	GGGGTGTCTG
	23221	AGGCGCTGGG	CAGGCTGTGG	GCCGCCGGCG	GCTCGGTCAG	CTGGCCGGGC	GTCTTCCCCA
	23281	CGGCTGGGCG	GCGGGTGCCG	CTGCCGACCT	ATCCGTGGCA	GCGGCAGCGG	TACTGGCCCC
40	23341	ACATCGAGCC	TGACAGCCGT	CGCCACGCAG	CCGCGGATCC	GACCCAAGGC	TGGTTCTATC
	23401	CGGTGGACTG	GCCGGAGATA	CCTCGCAGCC	TCCAGAAATC	AGAGGAGGCG	AGCCGCGGGA
	23461	GCTGGCTGGT	ATTGGCGGAT	AAGGGTGGAG	TCGGCGAGGC	GGTCGCTGCA	GCGCTGTGCA
	23521	CACGTGGACT	TCCATGCGTC	GTGCTCCATG	CGCCGGCAGA	GACATCCGCG	ACCGCCGAGC
	23581	TGGTGACCGA	GGCTGCCGGC	GGTCGAAGCG	ATTGGCAGGT	AGTGCTCTAC	CTGTGGGGTC
45	23641	TGGACGCCGT	CGTCGGCGCG	GAGGCGTCGA	TCGATGAGAT	CGGCGACGCG	ACCGTCTGTC
	23701	CTACCGCGCC	GGTGCTCGGC	TTGGCTCGGT	TTCTGAGCAC	CGTGTCTTGT	TCGCCCCGAC
	23761	TCTGGGTCGT	GACCCGGGGG	GCATGCATCG	TTGGCGACGA	GCCTGCGATC	CCCCCTTGTC
	23821	AGGCGGCGTT	ATGGGGCATG	GGCCGGGTGG	CGGCGCTCGA	GCATCCCGGG	GCCTGGGGCG
	23881	GGCTCGTGGA	CCTGGATCCC	CGAGCGAGCC	CGCCCCAAGC	CAGCCCAGTC	GACGGCGAGA
50	23941	TGCTCGTCAC	CGAGCTATTG	TCGAGGAGGA	CCGAGGACCA	GCTCGCCTTC	CGCCATGGGC
	24001	GCCGGCACGC	GGCACGGCTG	GTGGCCGCCC	CGCCACGGGG	GGAAGCGGCA	CCGGCGTCTG
	24061	TGTCTGCGGA	GGCGAGCTAC	CTGGTGACGG	GAGGCCCTCG	TGGGCTGGGC	CTGATCGTGG
	24121	CCCAGTGGCT	GGTGGAGCTG	GGAGCGCGGC	ACTTGGTGCT	GACCAGCCGG	CGCGGGTTGC
	24181	CCGACCGGCA	GGCGTGCGCG	GAGCAGCAGC	CGCCTGAGAT	CCGCGCGCGG	ATCGCAGCGG

- 87 -

24241	TCGAGGCGCT	GGAGGCGCGG	GGTGCACGGG	TGACCGTGGC	AGCGGTGGAC	GTGGCCGACG
24301	TCGAACCGAT	GACAGCGCTG	GTTTCGTCGG	TCGAGCCCCC	GCTGCGAGGG	GTGGTGCACG
24361	CCGCTGGCGT	CAGCGTCATG	CGTCCACTGG	CGGAGACGGA	CGAGACCCTG	CTCGAGTCGG
24421	TGCTCCGTCC	CAAGGTGGCC	GGGAGCTGGC	TGCTGCACCG	GCTGCTGCAC	GGCCGGCCCTC
5 24481	TCGACCTGTT	CGTGCTGTTC	TCGTGCGGGC	CAGCGGTGTG	GGGTAGCCAT	AGCCAGGGTG
24541	CGTACGCGGC	GGCCAACGCT	TTCCTCGACG	GGCTCGCGCA	TCTTCGGCGT	TCGCAATCGC
24601	TGCCTGCGTT	GAGCGTCGCG	TGGGGTCTGT	GGGCCGAGGG	AGGCATGGCG	GACGCGGAGG
24661	CTCATGCACG	TCTGAGCGAC	ATCGGGGTTC	TGCCCATGTC	GACGTCGGCA	GCGTTGTTCG
24721	CGCTCCAGCG	CCTGGTGGAG	ACCGGCGCGG	CTCAGCGCAC	GGTGACCCGG	ATGGACTGGG
10 24781	CGCGCTTCGC	GCCGGTGTAC	ACCGCTCGAG	GGCGTCGCAA	CCTGCTTTCG	GCGCTGGTCG
24841	CAGGGCGCGA	CATCATCGCG	CCTTCCCTC	CGGCGGCAGC	AACCCGGAAC	TGGCGTGGCC
24901	TGTCCGTTGC	GGAAGCCCGC	ATGGCTCTGC	ACGAGGTCGT	CCATGGGGCC	GTCGCTCGGG
24961	TGCTGGGCTT	CCTCGACCCG	AGCGCGCTCG	ATCCTGGGAT	GGGGTTCAAT	GAGCAGGGCC
25021	TCGACTCGTT	GATGGCGGTG	GAGATCCGCA	ACCTCCTTCA	GGCTGAGCTG	GACGTGCGGC
15 25081	TTTCGACGAC	GCTGGCCTTT	GATCATCCGA	CGGTACAGCG	GCTGGTGGAG	CATCTGCTCG
25141	TCGATGTACT	GAAGCTGGAG	GATCGCAGCG	ACACCCAGCA	TGTTCCGGTCG	TTGGCGTCAG
25201	ACGAGCCCAT	CGCCATCGTG	GGAGCCGCCT	GCCGCTTCCC	GGGCGGGGTG	GAGGACCTGG
25261	AGTCTACTG	GCAGCTGTTG	GCCGAGGGCG	TGGTGGTCAG	CGCCGAGGTG	CGGCGCGACC
25321	GGTGGGATGC	GGCGGACTCG	TACGACCCTG	ATCCGGAGAT	CCCAGGCGG	ACTTACGTGA
20 25381	CCAAAGGCGC	CTTCTGCGC	GATTTGCAGA	GATTGGATGC	GACCTTCTTC	CGCATCTCGC
25441	CTCGCGAGGC	GATGACGCTC	GACCCGACGC	AGCGGTTGCT	CCTGGAGGTA	AGCTGGGAGG
25501	CGCTCGAGAG	CGCGGGTATC	GCTCCGGATA	CGCTGCGAGA	TAGCCCCACC	GGGGTGTTCG
25561	TGGGTGCGGG	GCCCAATGAG	TACTACACGC	AGCGGCTGCG	AGGCTTCACC	GACGGAGCGG
25621	CAGGGCTGTA	CGGCGGCACC	GGGAACATGC	TCAGCGTTGC	GGCTGGACGG	CTGTCTGTTT
25 25681	TCCTGGGTCT	GCACGGCCCG	ACGCTGGCCA	TGGATACGGC	GTGCTCGTCC	TCCCTGGTCG
25741	CGCTGCACCT	CGCCTGCCAG	AGCCTGCGAC	TGGGCGAGTG	CGATCAAGCG	CTGGTTGGCG
25801	GGGTCAACGT	GCTGCTCGCG	CCGGAGACCT	TCGTGCTGCT	CTACCGGATG	CGCGCGCTTT
25861	CGCCCGACGG	GCGGTGCAAG	ACGTTCTCGG	CCGACGCGGA	CGGCTACGCG	CGGGGCGAGG
25921	GGTGCGCCGT	GGTGGTGCTC	AAGCGGCTGC	GCGATGCGCA	GCGCGCCGGC	GACTCCATCC
30 25981	TGGCGCTGAT	CCGGGGAAGC	GCGGTGAACC	ACGACGGCCC	GAGCAGCGGG	CTGACCGTGC
26041	CCAACGGACC	CGCCCAGCAA	GCATTGCTGC	GCCAGGCGCT	TTGCAAGCA	GGCGTGTCTC
26101	CGGTGACGCT	TGATTTTGTG	GAGTGTACAG	GGACAGGGAC	GGCGCTGGGC	GACCCGATCG
26161	AGGTGCAGGC	GCTGAGCGAG	GTGTATGGTC	CAGGGCGCTC	CGAGGATCGA	CCGCTGGTGC
26221	TGGGGGCCGT	CAAGGCCAAC	GTCGCGCATC	TGGAGGCGGC	ATCCGGCTTG	GCCAGCCTGC
35 26281	TCAAGGCCGT	GCTTGCGCTG	CGGCACGAGC	AGATCCCGGC	CCAGCCGGAG	CTGGGGGAGC
26341	TCAACCCGCA	CTTGCCGTGG	AACACGCTGC	CGGTGGCGGT	GCCACGTAAG	CGGGTGCCGT
26401	GGGGGCGCGG	CGCACGGCCG	CGTCGGGCCG	GCGTGAGCGC	GTTCCGGTTG	AGCGGAACCA
26461	ACGTGCATGT	CGTGCTGGAG	GAGGACCCGG	AGGTGGAGCT	GGTGCCCGCG	GCGCCGGCGC
26521	GACCGGTGGA	GCTGGTTGTG	CTATCGGCCA	AGAGCGCGGC	GGCGCTGGAC	GCCGCGGCGG
40 26581	AACGGCTCTC	GGCGCACCTG	TCCGCGCACC	CGGAGCTGAG	CCTCGGCGAC	GTGGCGTTCA
26641	GCTGGCGGAC	GACGCGCAGC	CCGATGGAGC	ACCGGCTCGC	CATCGCGACG	ACCTCGCGCG
26701	AGGCCCTGCG	AGGCGCGCTG	GACGCCGCGG	CGCAGCGGCA	GACGCCGACG	GGCGCGGTGC
26761	GCGGCAAGGC	CGTGTCTCTA	CGCGGTAAGT	TGGCTTTCCT	GTTTACCGBA	CAGGGCGCGC
26821	AAATGCCGGG	CATGGGCCGT	GGGCTGTACG	AGGCGTGGCC	AGCGTTCCGG	GAGGCGTTTC
45 26881	ACCGGTGCGT	GGCGCTCTTC	GATCGGGAGC	TCGACCAGCC	TCTGCGCGAG	GTGATGTGGG
26941	CTGCGCCGGG	CCTCGCTCAG	GCGGCGCGGC	TCGATCAGAC	CGCGTACGCG	CAGCCGGCTC
27001	TCTTTGCGCT	GGAGTACGCG	CTGGCTGCCC	TGTGGCGTTC	GTGGGGCGTG	GAGCCGCACG
27061	TACTCCTCGG	TCATAGCATC	GGCGAGCTGG	TCGCCGCCTG	CGTGGCGGGC	GTGTTCTCGC
27121	TCGAAGACGC	GGTGAGTTTG	GTGGCCGCGC	GCGGGCGGCT	GATGCAGGCG	CTGCCCGCCG
50 27181	GCGGTGCCAT	GGTCGCCATC	GCAGCGTCCG	AGGCCGAGGT	GGCCGCCTCC	GTGGCACCCC
27241	ACGCCGCCAC	GGTGTCGATC	GCCGCGGTCA	ACGGTCCTGA	CGCCGTCGTG	ATCGCTGGCG
27301	CCGAGGTACA	GGTGCTCGCC	CTCGGCGCGA	CGTTCGCGGC	GCGTGGGATA	CGCACGAAGA
27361	GGCTCGCCGT	CTCCCATGCG	TTCCACTCGC	CGCTCATGGA	TCCGATGCTG	GAAGACTTCC
27421	AGCGGGTCCG	TGCGACGATC	GCGTACCGCG	CGCCAGACCG	CCCGGTGGTG	TCGAATGTCA

27481	CCGGCCACGT	CGCAGGCCCC	GAGATCGCCA	CGCCCGAGTA	TTGGGTCCGG	CATGTGCGAA
27541	GCGCCGTGCG	CTTCGGCGAT	GGGGCAAAGG	CGTTGCATGC	CGCGGGTGCC	CCACGTTCCG
27601	TCGAGATTGG	CCCGAAGCCG	GTCCTGCTCG	GGCTATTGCC	AGCGTGCCTC	GGGGAAGCGG
27661	ACGCGGTCTT	CGTGCCGTCG	CTACGCGCGG	ACCGCTCGGA	ATGCGAGGTG	GTCCTCGCGG
5 27721	CGCTCGGGAC	TTGGTATGCC	TGGGGGGGTG	CGCTCGACTG	GAAGGGCGTG	TTCCCCGATG
27781	GCGCGCGCCG	CGTGCTCTTG	CCCATGTATC	CATGGCAGCG	TGAGCGCCAT	TGGATGGACC
27841	TCACCCCGCG	AAGCGCCGCG	CCTGCAGGGA	TCGCAGGTCG	CTGGCCGCTG	GCTGGTGTCTG
27901	GGCTCTGCAT	GCCCCGCGCT	GTGTTGCACC	ACGTGCTCTC	GATCGGACCA	CGCCATCAGC
27961	CCTTCCTCGG	TGATCACCTC	GTGTTTGGCA	AGGTGGTGGT	GCCCCGCGCC	TTTCATGTCTG
10 28021	CGGTGATCCT	CAGCATCGCC	GCCGAGCGCT	GGCCCGAGCG	GGCGATCGAG	CTGACAGGCG
28081	TGGAGTTCCT	GAAGGCGATC	GCGATGAGAG	CCGACCAGGA	GGTCGAGCTC	CACGCCGTGC
28141	TCACCCCGCA	AGCCGCGGGG	GATGGCTACG	TGTTTCGAGCT	GGCGACCCTG	GCGGCGCCCG
28201	AGACCGAACG	CCGATGGACG	ACCCACGCCC	GCGGTCGGGT	GCAGCCGACA	GACGGCGCGC
28261	CCGGCGCGTT	GCCGCGCCTC	GAGGTGCTGG	AGGACCGCGC	GATCCAGCCC	CTCGACTTCG
15 28321	CCGATTTCCT	CGACAGGTTA	TCGGCGGTGC	GGATCGGCTG	GGGTCCGCTT	TGGCGATGGC
28381	TGCAGGACGG	GCGCGTCGGC	GACGAGGCCT	CGCTTGCCAC	CCTCGTGCCG	ACCTATCCGA
28441	ACGCCCCACG	CGTGGCGCCC	TTGCACCCGA	TCCTGCTGGA	CAACGGCTTT	GCGGTGAGCC
28501	TGCTGGCAAC	CCGGAGCGAG	CCGGAGGACG	ACGGGACGCC	CCCGCTGCCG	TTCCGCGTGG
28561	AACGGGTGCG	GTGGTGGCGG	GCGCCGGTTG	GAAGGTGCG	GTGTGGCGGC	GTGCCGCGGT
20 28621	CGCAGGCATT	CGGTGTCTCG	AGCTTCGTGC	TGGTCGACGA	AACTGGCGAG	GTGGTCGCTG
28681	AGGTGGAGGG	ATTTGTTTGC	CGCCGGGCGC	CGCGAGAGGT	GTTCCTGCGG	CAGGAGTCGG
28741	GCGCGTCGAC	TGCAGCCTTG	TACCGCCTCG	ACTGGCCCCG	AGCCCCCTTG	CCCGATGCGC
28801	CTGCGGAACG	GATGGAGGAG	AGCTGGGTCTG	TGGTGGCAGC	ACCTGGCTCG	GAGATGGCCG
28861	CGGCGCTCGC	AACACGGCTC	AACCGCTGCG	TACTCGCCGA	ACCCAAAGGC	CTCAGGCGCG
25 28921	CCCTCGCGGG	GGTGTCTCCC	GCAGGTGTGA	TCTGCCTCTG	GGAACCTGGA	GCCCACGAGG
28981	AAGCTCCGGC	GGCGGCGCAG	CGTGTGGCGA	CCGAGGGCCT	TTCCGTGGTG	CAGGCGCTCA
29041	GGGATCGCGC	GGTGCGCCCTG	TGGTGGGTGA	CCACGGGCGC	CGTGGCTGTC	GAGGCCGGTG
29101	AGCGGGTGCA	GGTCGCCACA	GCGCCGGTAT	GGGGCCTGGG	CCGGACAGTG	ATGCAGGAGC
29161	GCCCCGAGCT	CAGCTGCACT	CTGGTGGATT	TGGAGCCGGA	GGTCGATGCC	GCGCGTTTCA
30 29221	CTGACGTTCT	GCTGCGGGAG	CTCGGTGCGG	CTGACGACGA	GACCCAGGTG	GTTTTCCGTT
29281	CCGGAGAGCG	CCGCGTAGCG	CGGCTGGTCA	AAGCGACAAC	CCCCGAAGGG	CTCTTGGTCC
29341	CTGACGCAGA	ATCCTATCGA	CTGGAGGCTG	GGCAGAAGGG	CACATTGGAC	CAGCTCCGCC
29401	TCGCGCCGGC	ACAGCGCCGG	GCACCCGGCC	CGGGCGAGGT	CGAGATCAAG	GTAACCGCCT
29461	CGGGGCTCAA	CTTCCGGACG	GTCCTCGCTG	TGCTGGGAAT	GTATCCGGGC	GACGCTGGGC
35 29521	CGATGGGCGG	AGATTGTGCC	GGTATCGTCA	CGGCGGTGGG	CCAGGGGGTG	CACCACCTCT
29581	CGGTCCGGCG	TGCTGTCTATG	ACGCTGGGGA	CGTTGCATCG	ATTCTGTCAG	GTCGACGCGC
29641	GGCTGGTGGT	CCGGCAGCCT	GCAGGGCTGA	CTCCCGCGCA	GGCAGCTAGG	GTGCCGGTTG
29701	CGTTCTTGAC	GGCCTGGCTC	GCTCTGCACG	ACCTGGGGAA	TCTGCGGCGC	GGCGAGCGGG
29761	TGCTGATCCA	TGCTGCGGCC	GGCGGCGTGG	GCATGGCCCG	GGTGCAAATC	GCCCCATGGA
40 29821	TAGGGGCCGA	GGTGTTTCGCC	ACGGCGAGCC	CGTCCAAGTG	GGCAGCGGTT	CAGGCCATGG
29881	GCGTGCCCGG	CACGCACATC	GCCAGCTCGC	GGACGCTGGA	GTTTGCTGAG	ACGTTCCGGC
29941	AGGTCACCGG	CGGCCGGGGC	GTGGACGTGG	TGCTCAACGC	GCTGGCCGGC	GAGTTCTGTG
30001	ACGCGAGCCT	GTCCCTGCTG	ACGACGGGCG	GGCGGTTTCT	CGAGATGGGC	AAGACCGACA
30061	TACGGGATCG	AGCCGCGGTC	GCGGCGGCGC	ATCCCGGTGT	TCGCTATCGG	GTATTTCGACA
45 30121	TCCTGGAGCT	CGCTCCGGAT	CGAACTCGAG	AGATCCTCGA	GCGCGTGGTC	GAGGGCTTTG
30181	CTGCGGGACA	TCTGCGCGCA	TTGCCGGTGC	ATGCGTTTCG	GATCACCAG	GCCGAGGCAG
30241	CGTTTCGGTT	CATGGCGCAA	GCGCGGCATC	AGGGCAAGGT	CGTGCTGCTG	CCGGCGCCCT
30301	CCGCAGCGCC	CTTGCGCGCG	ACGGGCACCG	TACTGCTGAC	CGGTGGGCTG	GGAGCGTTGG
30361	GGCTCCACGT	GGCCCGCTGG	CTCGCCAGC	AGGGCGCGCC	GCACATGGTG	CTCACAGGTC
50 30421	GGCGGGGCCT	GGATACGCCG	GCGCTGCCA	AAGCCGTCGC	GGAGATCGAA	GCGCTCGGCG
30481	CTCGGGTGAC	GATCGCGGCG	TCGGATGTCG	CCGATCGGAA	CGCGCTGGAG	GCTGTGCTCC
30541	AGGCCATTCC	GGCGGAGTGG	CCGTTACAGG	GCGTGATCCA	TGCAGCCGGA	GCGCTCGATG
30601	ATGGTGTGCT	TGATGAGCAG	ACCACCGACC	GCTTCTCGCG	GGTGCTGGCA	CCGAAGGTGA
30661	CTGGCGCCTG	GAATCTGCAT	GAGCTCACGG	CGGGCAACGA	TCTCGCTTTC	TTCGTGCTGT

30721 TCTCCTCCAT GTCGGGGCTC TTGGGCTCGG CCGGGCAGTC CAACTATGCG GCGGCCAACA
30781 CCTTCCTCGA CGCGCTGGCC GCGCATCGGC GGGCCGAAGG CCTGGCGGCG GAGAGCCTCG
30841 CGTGGGGCCC ATGGTCGGAC GGAGGCATGG CAGCGGGGCT CAGCGCGGCG CTGCAGGCGC
5 30901 GGCTCGCTCG GCATGGGATG GGAGCGCTGT CGCCCGCTCA GGGCACCGCG CTGCTCGGGC
30961 AGGCGCTGGC TCGGCCGGAA ACGCAGCTCG GGGCGATGTC GCTCGAÇGTG CGTGCGGCAA
31021 GCCAAGCTTC GGGAGCGGCA GTGCCGCCTG TGTGGCGCGC GCTGGTGCGC GCGGAGGCGC
31081 GCCATGCGGC GGCTGGGGCG CAGGGGGCAT TGGCCGCGCG CCTTGGGGCG CTGCCCAGAG
31141 CGCGTCGCGC CGACGAGGTG CGCAAGGTCG TGCAGGCCGA GATCGCGCGC GTGCTTTCAT
31201 GGGGCGCCGC GAGCGCCGTG CCCGTCGATC GGCCGCTGTC GGACTTGGGC CTCGACTCGC
10 31261 TCACGGCGGT GGAGCTGCGC AACGTGCTCG GCCAGCGGGT GGGTGCGACG CTGCCGGCGA
31321 CGCTGGCATT CGATCACCCG ACGGTGACG CGCTCACGCG CTGGCTGCTC GATAAGGTCC
31381 TGGCCGTGGC CGAGCCGAGC GTATCGCCCC CAAAGTCGTC GCCGCAGGTC GCCCTCGACG
31441 AGCCCATTCG GGTGATCGGC ATCGGCTGCC GTTTCACAGG CGGCGTGACC GATCCGGAGT
31501 CGTTTTGGCG GCTGCTCGAA GAGGGCAGCG ATGCCGTCTG CGAGGTGCCG CATGAGCGAT
15 31561 GGGACATCGA CGCGTTCTAT GATCCGGATC CGGATGTGCG CGGCAAGATG ACGACACGCT
31621 TTGGCGGCTT CCTGTCCGAT ATCGACCGGT TCGAGCCGGC CTTCTTCGGC ATCTCGCCGC
31681 GCGAAGCGAC GACCATGGAT CCGCAGCAGC GGCTGCTCCT GGAGACGAGC TGGGAGGCGT
31741 TCGAGCGCGC CGGGATTTTG CCCGAGCGGC TGATGGGCAG CGATACCGGC GTGTTCTGTG
20 31801 GGCTCTTCTA CCAGGAGTAC GCTGCGCTCG CCGGCGGCAT CGAGGCGTTC GATGGCTATC
31861 TAGGCACCGG CACCACGGCC AGCGTCGCTT CCGGCAGGAT CTCTTATGTG CTCGGGCTAA
31921 AGGGGCCGAG CCTGACGGTG GACACCGCGT GCTCCTCGTC GCTGGTCGCG GTGCACCTGG
31981 CCTGCCAGGC GCTGCGGCGG GCGAGTGTT CGGTGGCGCT GCGCGGCGCT GTGGCGCTGA
32041 TGCTACGCC GCGGACGTT GTGGAGTTCA GCGGCTGCG AGGCCTGGCT CCCGACGGAC
25 32101 GGTGCAAGAG CTTCTCGGCC GCAGCCGACG CGGTGGGGTG GAGCGAAGGC TCGGCCATGC
32161 TCCTGCTCAA ACCGCTTCGC GATGCTCAGC GCGATGGGGA TCCGATCCTG GCGGTGATCC
32221 GCGGCACCGC GGTGAACCAG GATGGGCGCA GCAACGGGCT GACGGCGCCC AACGGGTCTG
32281 CGCAGCAAGA GGTGATCCGT CCGGCCCTGG AGCAGGCGGG GCTGGCTCCG GCGGACGTCA
32341 GCTACGTCGA GTGCCACGGC ACCGGCACGA CGTTGGGCGA CCCCATCGAA GTGCAGGCCC
32401 TGGGCGCCGT GCTGGCACAG GGGCGACCCT CGGACCGGCC GCTCGTGATC GGGTCGGTGA
30 32461 AGTCCAATAT CGGACATAC CAGGCTGCGG CCGGCGTGGC CGGTGTCATC AAGGTGGCGC
32521 TGGCGCTCGA GCGCGGGCTT ATCCCGAGGA GCCTGCATTT CGACGCGCCC AATCCGCACA
32581 TTCCGTGGTC GGAGCTCGCC GTGCAGGTGG CCGCCAAACC CGTCGAATGG ACAGAAACG
32641 GCGCGCCGCG ACGAGCCGGG GTGAGCTCGT TTGGCGTCAG CCGGACCAAC GCGCACGTGG
32701 TGCTGGAGGA GCGGCCAGCG GCGGCGTTCG CGCCCGCGGC GGCGCGTTCA GCGGAGCTTT
35 32761 TCGTGCTGTC GGCGAAGAGC GCCGCGGCGC TGGACGCGCA GGCGGCGCGG CTTTCGGCGC
32821 ATGTCGTTGC GCACCCGGAG CTCGGCCTCG GCGACCTGGC GTTCAGCCTG GCGACGACCC
32881 GCAGCCCGAT GACGTACCGG CTCGCGGTGG CCGCGACCTC GCGCGAGGGG CTGTCTGCGG
32941 CGCTCGACAC AGCGGCGCAG GGGCAGGCGC CGCCCGCAGC GGCTCGCGG CACGCTTCCA
33001 CAGGCAGCGC CCCAAAGGTG GTTTTCGTCT TTCTGGCCA GGGCTCCAG TGGCTGGGCA
40 33061 TGGGCCAAAA GTCCTCTCG GAGGAGCCCG TCTTCCGCGA CGCGCTCTCG CGGTGTGACC
33121 GAGCGATTCA GGCCGAAGCC GGCTGGTTCG TGCTCGCCGA GCTCGCGGCC GATGAGACCA
33181 CCTCGCAGCT CGGCCGCATC GACGTGGTGC AGCCGGCGCT GTTCGCGATC GAGGTGCGCG
33241 TGTCGGCGCT GTGGCGGTG TGGGCGGTG AGCCGGATGC AGTGGTAGGC CACAGCATGG
33301 GCGAAGTGGC GGCCGCGCAC GTCGCCGGCG CCCTGTCTGCT CGAGGATGCT GTAGCGATCA
45 33361 TCTGCCGGCG CAGCCTGCTG CTGCGGCGGA TCAGCGGCCA AGGCGAGATG GCGGTCTGTC
33421 AGCTCTCCCT GGCCGAGGCC GAGGCAGCGC TCCTGGGCTA CGAAGATCGG CTCAGCGTGG
33481 CGGTGAGCAA CAGCCCGCGA TCGACGGTGC TGGCGGGCGA GCCGGCAGCG CTCGAGAGG
33541 TGCTGGCGAT CTTGCGGCA AAGGGGGTGT TCTGCCGTCG AGTCAAGGTG GACGTGCGCA
33601 GCCACAGCCC ACAGATCGAC CCGCTGCGCG ACGAGCTATT GGCAGCATTG GCGAGCTCG
50 33661 AGCCGCGACA AGCGACCGTG TCGATGCGCT CGACGGTGAC GAGCAGGATC GTGGCGGGCC
33721 CGGAGCTCGT GGCGAGCTAC TGGGCGGACA ACGTTCGACA GCCGGTGCGC TTCGCCGAAG
33781 CGGTGCAATC GTTGATGGAA GGCGGTCATG GGCTGTTCTG GGAGATGAGC CCGCATCCGA
33841 TCCTGACGAC GTCGGTTCAG GAGATCCGAC GGGCGACGAA GCGGGAGGGA GTCGCGGTGG
33901 GCTCGTTGCG GCGTGACAG GACGAGCGCC TGTCATGTT GGAGGCGCTG GGAGCGCTCT

- 90 -

33961 GGGTACACGG CCAGGCGGTG GGCTGGGAGC GGCTGTTCTC CGCGGGCGGC GCGGGCCTCC
34021 GTCGCGTGCC GCTGCCGACC TATCCCTGGC AGCGCGAGCG GTACTGGGTC GAGCGCCGA
34081 CCGGCGGCGC GGCGAGCGGC AGCCGCTTTG CTCATGCGGG CAGTCACCCG TCCTGGGTG
34141 AAATGCAGAC CCTGTCGACC CAGAGGAGCA CGCGCGTGTG GGAGACGACG CTGGATCTCA
5 34201 AACGGCTGCC GTGGCTCGGC GATCACCGGG TGCAGGGGGC GGTCGTGTTT CCGGGCGCGG
34261 CGTACCTGGA GATGGCGCTT TCGTCTGGGG CCGAGGCCTT GGGTGACGGT CCGCTCCAGG
34321 TCAGCGATGT GGTGCTCGCC GAGGCGCTGG CCTTCGCGGA TGATACGCCG GTGGCGGTGC
34381 AGGTCATGGC GACCGAGGAG CGACCAGGCC GCCTGCAATT CCACGTTGCG AGCCGGGTGC
34441 CGGGCCACGG CCGTGCTGCC TTTCGAAGCC ATGCCCGCGG GGTGCTGCGC CAGACCGAGC
10 34501 GCGCCGAGGT CCCGGCGAGG CTGGATCTGG CCGCGCTTCG TGCCCGGCTT CAGGCCAGCG
34561 CACCCGCTGC GGCTACCTAT GCGGCGCTGG GCGAGATGGG GCTCGAGTAC GGCCAGCGT
34621 TCCAGGGGCT TGTCGAGCTG TGGCGGGGGG AGGGCGAGGC GCTGGGACGT GTGCGGCTCC
34681 CCGAGGCCGC CGGCTCCCCA GCCGCGTGCC GGCTCCACCC CGCGCTCTTG GATGCGTGCT
34741 TCCACGTGAG CAGCGCCTTC GCTGACCGCG GCGAGGCGAC GCCATGGGTA CCCGTCGAAA
15 34801 TCGGCTCGCT GCGGTGGTTC CAGCGGCCGT CCGGGGAGCT GTGGTGTCTAT GCGCGGAGCG
34861 TGAGCCACGG AAAGCCAACA CCCGATCGGC GGAGTACCGA CTTTTGGGTG GTCGACAGCA
34921 CGGGCGCGAT CGTCGCCGAG ATCTCCGGGC TCGTGGCGCA GCGGCTCGCG GGAGGTGTAC
34981 GCCGGCGCGA AGAAGACGAC TGGTTCATGG AGCCGGCTTG GGAACCGACC GCGGTCCCCG
35041 GATCCGAGGT CACGGCGGGC CCGTGGCTGC TCATCGGCTC GGGCGGCGGG CTCGGCGCTG
20 35101 CGCTCTACTC GGCGCTGACG GAAGCTGGCC ATTCCGTCGT CCACGCGACA GGGCAGCGA
35161 CGAGCGCCGC CCGGTTCGAG GCACTCCTGA CCGCGTCCTT CGACGGCCAG GCGCCGACGT
35221 CCGTGGTGCA CCTCGGCAGC CTCGATGAGC GTGGCGTGCT CGACGCGGAT CCCCCCTTCG
35281 ACGCCGATGC CCTCGAGGAG TCGCTGGTGC GCGGCTGCGA CAGCGTGCTC TGGACCGTGC
35341 AGGCCGTGGC CCGGGCGGGC TTCCGAGATC CTCCGCGGTT GTGGCTCGTG ACACGCGGCG
25 35401 CTCAGGCCAT CCGCGCCGGC GACGTCTCCG TGGCGCAAGC GCCGCTCCTG GGGCTGGGCC
35461 GCGTTATCGC CTTGGAGCAC GCCGAGCTGC GCTGCGCTCG GATCGACCTC GATCCAGCGC
35521 GGCGCGACGG AGAGGTTCGAT GAGCTGCTTG CCGAGCTGTT GGCCGACGAC GCCGAGGAGG
35581 AAGTCGCGTT TCGCGGCGGT GAGCGGCGCG TGGCCCGGCT CGTCCGAAGG CTGCCCGAGA
35641 CCGACTGCCG AGAGAAAATC GAGCCCGCGG AAGGCCGGCC GTTCCGGCTG GAGATCGATG
30 35701 GGTCCGGCGT GCTCGACGAC CTGGTGCTCC GAGCCACGGA GCGGCGCCCT CCTGGCCCGG
35761 GCGAGGTCGA GATCGCCGTC GAGGCGGCGG GGCTCAACTT TCTCGACGTG ATGAGGGCCA
35821 TGGGGATCTA CCCTGGGCCC GGGGACGGTC CCGTTGCGCT GGGCGCCGAG TGCTCCGGCC
35881 GAATTGTCGC GATGGGCGAA GGTGTCGAGA GCCTTCGTAT CCGCCAGGAC GTCGTGGCCG
35941 TCGCGCCCTT CAGTTTCGGC' ACCCACGTCA CCATCGACGC CCGGATGGTC GCACCTCGCC
35 36001 CCGCGGCGCT GACGGCCCGG CAGGCAGCCG CGCTGCCCGT CGCATTCATG ACGGCCTGGT
36061 ACGGTCTCGT CCATCTGGGG AGGCTCCGGG CCGGCGAGCG CGTGCTCATC CACTCGGCGA
36121 CGGGGGGCAC CCGGCTCGCT GCTGTGAGA TCGCCCGCCA CCTCGGCGCG GAGATATTTG
36181 CGACCGCTGG TACGCCGGAG AAGCGGGCGT GGCTGCGCGA GCAGGGGAGG GCGCACGTGA
36241 TGGACTCGCG GTGCTGGAC TTCGCCGAGC AAGTGCTGGC CGCGACGAAG GCGAGGGGG
40 36301 TCGACGTGCT GTTGAACCTG CTGTCTGGCG CCGGATCGA CGCGAGCCTT GCGACCCTCG
36361 TGCCCGACGA CCGCTTCATC GAGCTCGGCA AGACGGACAT CTATGCAGAT CGCTCGCTGG
36421 GGCTCGTCA CTTTAGGAAG AGCCTGTCTT ACAGCGCCGT CGATCTTGCG GGTTTGGCCG
36481 TGCGTCGGCC CGAGCGCGTC GCAGCGCTGC TGGCGGAGGT GGTGGACCTG CTCGCACGGG
36541 GAGCGCTGCA GCCGCTTCCG GTAGAGATCT TCCCCCTCTC GCGGGCCGCG GACGCGTTCC
45 36601 GGAAAATGGC GCAAGCGCAG CATCTCGGGA AGCTCGTGCT CGCGCTGGAG GACCCGGACG
36661 TGCGGATCCG CGTTCGGGGC GAATCCGGCG TCGCCATCCG CGCGGACGGC ACCTACCTCG
36721 TGACCGGCGG TCTGGGTGGG CTCGGTCTGA GCGTGGCTGG ATGGCTGGCC GAGCAGGGGG
36781 CTGGGCATCT GGTGCTGGTG GGCCGCTCCG GTGCGGTGAG CGCGGAGCAG CAGACGGCTG
36841 TCGCCGCGCT CGAGGCGCAC GGCGCGCGTG TCACGGTAGC GAGGGCAGAC GTCGCCGATC
50 36901 GGGCGCAGAT CGAGCGGATC CTCCGCGAGG TTACCGCGTC GGGGATGCCG CTCCGCGGGC
36961 TCGTTCATGC GGCCGGTATC CTGGACGACG GGCTGCTGAT GCAGCAAACC CCCGCGCGGT
37021 TCCGCGCGGT CATGGCGCCC AAGGTCCGAG GGGCCTTGCA CCTGCATGCG TTGACACGCG
37081 AAGCGCCGCT CTCCTTCTTC GTGCTGTACG CTTCCGGAGC AGGGCTCTTG GGCTCGCCGG
37141 GCCAGGGCAA CTACGCCGCG GCCAACACGT TCCTCGACGC TCTGGCACAC CACCGGAGGG

37201 CGCAGGGGCT GCCAGCATTG AGCATCGACT GGGGCTGTG CGCGGACGTG GGTTCGGCCG
37261 CCGGGCAGCA AAATCGCGGC GCACGGCTGG TCACCCGCGG GACGCGGAGC CTCACCCCGG
37321 ACGAAGGGCT GTGGGCGCTC GAGCGTCTGC TCGACGCGCA TCGCACCCAG GCGGGGTCA
37381 TGCCGTTTGA CGTGCGGCAG TGGGTGGAGT TCTACCCGCG GCGGCGATCT TCGCGGAGGT
5 37441 TGTCGCGGCT GGTGACGGCA CGGCGCGTGG CTTCCGGTCG GCTCGCQGGG GATCGGGACC
37501 TGCTCGAACG GCTCGCCACC GCGGAGGCGG GCGCGCGGGC AGGAATGCTG CAGGAGGTCG
37561 TGCGCGCGCA GGTCTCGCAG GTGCTGCGCC TCCCCGAAGG CAAGCTCGAC GTGGATGCGC
37621 CGCTCACGAG CCTGGGAATG GACTCGCTGA TGGGGCTAGA GCTGCGCAAC CGCATCGAGG
37681 CCGTGCTCGG CATCACCATG CCGGCGACCC TGCTGTGGAC CTACCCACG GTGGCAGCGC
10 37741 TGAGTGC GCA TCTGGCTTCT CATGTCGTCT CTACGGGGGA TGGGGAATCC GCGCGCCCGC
37801 CGGATACAGG GAACGTGGCT CCAATGACCC ACGAAGTCGC TTCGCTCGAC GAAGACGGGT
37861 TGTTGCGGTT GATTGATGAG TCACTCGCGC GTGCGGGAAA GAGGTGATTG CGTGACAGAC
37921 CGAGAAGGCC AGCTCCTGGA GCGCTTGGCT GAGGTTACTC TGGCCCTTCG CAAGACGCTG
37981 AACGAGCGCG ATACCCCTGGA GCTCGAGAAG ACCGAGCCGA TCGCCATCGT GGGGATCGGC
15 38041 TGCCGCTTCC CCGGCGGAGC GGGCACTCCG GAGGCGTTCT GGGAGCTGCT CGACGACGGG
38101 CGCGACGCGA TCCGGCCGCT CGAGGAGCGC TGGGCGCTCG TAGGTGTGCA CCCAGGCGAC
38161 GACGTACCGC GCTGGGCGGG GCTGCTCACC GAAGCCATCG ACGGCTTCGA CGCCGCGTTC
38221 TTCGGTATCG CCCCCGCGGA GGCACGGTCG CTCGACCCGC AGCATCGCTT GCTGCTGGAG
38281 GTCGCTGGG AGGGGTTCGA AGACGCCGCG ATCCCGCCTA GGTCCCTCCT CGGGAGCCCG
20 38341 ACCGGCGTGT TCGTCGGCGT CTGCGCCACG GAGTATCTCC ACGCCGCGCT CGCGCACCAG
38401 CCGCGCGAAG AGCGGGACGC GTACAGCACC ACCGGCAACA TGCTCAGCAT CGCCGCGCGA
38461 CGGCTATCGT ACACGCTGGG GCTGCAGGGA CCTTGCCTGA CCGTCGACAC GGCGTGCTCG
38521 TCATCGCTGG TGGCCATTCA CCTCGCCTGC CGCAGCCTGC GCGCTCGAGA GAGCGATCTC
38581 GCGCTGGCGG GAGGGGTCAA CATGCTTCTC TCCCCGACA CGATGCGAGC TCTGGCGCGC
25 38641 ACCCAGGCGC TGTCGCCCCA TGGCCGTTGC CAGACCTTCG ACGCGTCGGC CAACGGGTTC
38701 GTCCGTGGGG AGGGCTGCGG TCTGATCGTG CTCAAGCGAT TGAGCGACGC GCGGCGGGAT
38761 GGGGACCGGA TCTGGGCGCT GATCCGAGGA TCGGCCATCA ATCAGGACGG CCGGTCGACG
38821 GGGTTGACGG CGCCCAACGT GCTCGCCCAG GGGGCGCTCT TGCGCGAGGC GCTGCGGAAC
38881 GCCGCGCTCG AGGCCGAGGC CATCGGTTAC ATCGAGACCC ACGGGGCGGC GACCTCGCTG
30 38941 GCGGACCCA TCGAGATCGA AGCGCTGCGC ACCGTGGTGG GGCCGGCGCG AGCCGACGGA
39001 GCGCGCTGCG TGCTGGGCGC GGTGAAGACC AACCTCGGCC ACCTGGAGGG CGCTGCCGGC
39061 GTGGCGGGCC TGATCAAGGC TACACTTTCG CTACATCAG AGCGCATCCC GAGGAACCTC
39121 AACTTTCGTA CGCTCAATCC GCGGATCCGG ATCGAGGGGA CCGCGCTCGC GTTGGCGACC
39181 GAACCGGTGC CCTGGCCGCG GACGGGCCGG ACGCGCTTCG CGGGAGTGAG CTCGTTCCGG
35 39241 ATGAGCGGGA CCAACGCGCA TGTGGTGTG GAGGAGGCGC CGGCGGTGGA GCCTGAGGCC
39301 GCGGCCCCCG AGCGCGCTGC GGAGCTGTTT GTCTGTTCGG CGAAGAGCGT GCGGCGCTG
39361 GATGCGCAGG CAGCCCGGCT GCGGGACCAC CTGGAGAAGC ATGTGAGGT TGGCCTCGG
39421 GATGTGGCGT TCAGCTGGC GACGACGCGC AGCGCGATGG AGCACCGGT GCGGTGGCC
39481 GCGAGCTCGC GCGAGGCGCT GCGAGGGCGG CTTTCGGCCG CAGCGCAGG GCATACGCCG
40 39541 CCGGGAGCCG TGCGTGGGCG GGCCTCCGGC GGCAGCGCGC CGAAGGTGGT CTTGCTGTTT
39601 CCCGGCCAGG GCTCGCAGTG GGTGGGCATG GGCCGAAAGC TCATGGCCGA AGAGCCGGTC
39661 TTCCGGGCGG CGCTGGAGGG TTGCGACCGG GCCATCGAGG CGGAAGCGGG CTGGTCGCTG
39721 CTCGGGGAGC TCTCCGCCGA CGAGGCCGCC TCGCAGCTCG GGCGCATCGA CGTGGTTTCA
39781 CCGGTGCTCT TCGCCATGGA AGTAGCGCTT TCTGCGCTGT GGCGGTCTGT GGGAGTGGAG
45 39841 CCGGAAGCGG TGGTGGGCCA CAGCATGGGC GAGGTGGCGG CGGCGCACGT GGCCGGCGCG
39901 CTGTCGCTCG AGGACGCGGT GGCGATCATC TGCCGGCGCA GCCGGCTGCT GCGGCGGATC
39961 AGCGGTCAGG GCGAGATGGC GCTGGTCGAG CTGTCGCTGG AGGAGGCCGA GCGGCGGCTG
40021 CGTGGCCATG AGGGTCGGCT GAGCGTGGCG GTGAGCAACA GCGCGCGCTC GACCGTGCTC
40081 GCAGGCGAGC CGGCGGCGCT CTCGAGGTG CTGGCGGCGC TGACGGCCAA GGGGGTGTTC
50 40141 TGGCGGCAGG TGAAGTGGA CGTCGCCAGC CATAGCCCGC AGGTGACCC GCTGCGCGAA
40201 GAGCTGATCG CGGCGCTGGG GGCGATCCGG CCGCGAGCGG CTGCGGTGCC GATGCGCTCG
40261 ACGGTGACGG GCGGGGTGAT CGCGGGTCCG GAGCTCGGTG CGAGCTACTG GGCGGACAAT
40321 CTTGCGCAGC CGGTGCGCTT CGCTGCGGCG GCGCAAGCGC TGCTGGAAGG TGGCCCCACG
40381 CTGTTTCATCG AGATGAGCCC GCACCCGATC CTGGTGCCGC CCCTGGACGA GATCCAGACG

40441 GCGGTCGAGC AAGGGGGGCGC TCGGCTGGGC TCGCTGCGGC GAGGGCAGGA CGAGCGCGCG
40501 ACGCTGCTGG AGGCGCTGGG GACGCTGTGG GCGTCCGGCT ATCCGGTGAG GGGGCTCGG
40561 CTGTTCCCCG CGGGCGGCAG GCGGGTTCGG CTGCCGACCT ATCCCTGGCA GCACGAGCGG
40621 TGCTGGATCG AGGTCGAGCC TGACGCCCCG CGCCTCGCCG CAGCCGACCC CACCAAGGAC
5 40681 TGGTTCTACC GGACGGACTG GCGCGAGGTG CCCCgcgccc CCCCgAAATC GGAGACAGCT
40741 CATGGGAGCT GGCTGCTGTT GGCCGACAGG GGTGGGGTCG GCGAGGCGGT CGCTGCAGCG
40801 CTGTGACGCG GCGGACTTTC CTGCACCGTG CTTTATGCGT CGGCTGACGC CTCCACCGTC
40861 GCGGAGCAGG TATCCGAAGC TGCCAGTCGC CGAAACGACT GGCAGGGAGT CCTCTACCTG
40921 TGGGGCCTCG ACGCCGTCGT CGATGCTGGG GCATCGGCCG ACGAAGTCAG CGAGGCTACC
10 40981 CGCCGTGCCA CCGCACCCGT CCTTGGGCTG GTTCGATTCC TGAGCGCTGC GCCCCATCCT
41041 CCTCGCTTCT GGGTGGTGAC CCGCGGGGCA GCACGGTGG GCGGCGAGCC AGAGGTCTCT
41101 CTTTGCCAAG CGGCGTTGTG GGGCCTCGCG GCGCTCGTGG CGCTGGAGCA TCCCGCTGCC
41161 TGGGGTGGCC TCGTGGACCT GGATCCTCAG AAGAGCCCGA CGGAGATCGA GCCCCTGGTG
41221 GCGGAGCTGC TTTCGCCGGA CGCCGAGGAT CAACTGGCGT TCCGCGAGCG TCGCCGGCAC
15 41281 GCAGCACGCC TTGTAGCCGC CCCGCCGGAG GGCGACGTCG CACCGATATC GCTGTCCGCG
41341 GAGGGAAGCT ACCTGGTGAC GGGTGGGCTG GGTGGCCTTG GTCTGCTCGT GGCTCGGTGG
41401 CTGGTGGAGC GGGGAGCTCG ACATCTGGTG CTCACCAGCC GGCACGGGCT GCCAGAGCGA
41461 CAGGCGTCGG GCGGAGAGCA GCCGCCGGAG GCCCGCGCGC GCATCGCAGC GGTCGAGGGG
41521 CTGGAAGCGC AGGGCGCGCG GGTGACCGTG GCAGCGGTGG ATGTCGCCGA GGCCGATCCC
20 41581 ATGACGGCGC TGCTGGCCGC CATCGAGCCC CCGTTGCGCG GGGTGGTGCA CGCCGCCGGC
41641 GTCTTCCCCG TGCGTCCCTT GGCGGAGACG GACGAGGCCC TGCTGGAGTC GGTGCTCCGT
41701 CCCAAGGTGG CCGGGAGCTG GCTGCTGCAC CGGCTGCTGC GCGACCGGCC TCTCGACCTG
41761 TTCGTGCTGT TCTCGTCGGG CGCGGCGGTG TGGGGTGGCA AAGGCCAAGG CGCATACGCC
41821 GCGGCCAATG CGTTCCTCGA CGGGCTCGCG CACCATCGCC GCGCGCACTC CCTGCCGGCG
25 41881 TTGAGCCTCG CCTGGGGCCT ATGGGCCGAG GGAGGCGTGG TTGATGCAAA GGCTCATGCA
41941 CGTCTGAGCG ACATCGGAGT CCTGCCCATG GCCACGGGGC CGGCCTTGTC GGCGCTGGAG
42001 CGCCTGGTGA ACACCAGCGC TGTCACAGCT TCGGTCACAC GGATGGACTG GGCGCGCTTC
42061 GCGCCGGTCT ATGCCGCGCG AGGGCGGGCG AACTTGCTTT CGGCTCTGGT CGCGGAGGAC
42121 GAGCGCACTG CGTCTCCCCC GGTGCCGACG GCAAACCGGA TCTGGCGCGG CCTGTCCGTT
30 42181 GCGGAGAGCC GCTCAGCCCT CTACGAGCTC GTTCGCGGCA TCGTCGCCCC GGTGCTGGGC
42241 TTCTCCGACC CGGGCGCGCT CGACGTCGGC CGAGGCTTCG CCGAGCAGGG GCTCGACTCC
42301 CTGATGGCTC TGGAGATCCG TAACCGCCTT CAGCGCGAGC TGGGCGAACG GCTGTCCGGC
42361 ACTCTGGCCT TCGACCACCC GACGGTGGAG CGGCTGGTGG CGCATCTCCT CACCGACGTG
42421 CTGAAGCTGG AGGACCGGAG CGACACCCGG CACATCCGGT CGGTGGCGGC GGATGACGAC
35 42481 ATCGCCATCG TCGGTGCCGC CTGCCGGTTC CCGGGCGGGG ATGAGGGCCT GGAGACATAC
42541 TGGCGGCATC TGGCCGAGGG CATGGTGGTC AGCACCGAGG TGCCAGCCGA CCGGTGGCGC
42601 GCGGCGGACT GGTACGACCC CGATCCGGAG GTTCCGGGCC GGACCTATGT GGCCAAGGGG
42661 GCCTTCCTCC GCGATGTGCG CAGCTTGGAT GCGGCGTTCT TCTCCATCTC CCCTCGTGAG
42721 GCGATGAGCC TGGACCCGCA ACAGCGGCTG TTGCTGGAGG TGAGCTGGGA GGCGATCGAG
40 42781 CGCGTGGCC AGGACCCGAT GCGGCTGCGC GAGAGCGCCA CGGGCGTGTT GTGGGCATG
42841 ATCGGGAGCG AGCACGCCGA GCGGGTGCAG GGCCTCGACG ACGACGCGGC GTTGCTGTAC
42901 GGCACCACCG GCAACCTGCT CAGCGTCGCC GCTGGACGGC TGTCGTTCTT CCTGGGTCTG
42961 CACGGCCCGA CGATGACGGT GGACACCGCG TGCTCGTCGT CGCTGGTGGC GTTGACCTC
43021 GCCTGCCAGA GCCTGCGATT GGGCGAGTGC GACCAGGCAC TGGCCGGCGG GTCCAGCGTG
45 43081 CTTTTGTGCG CGCGGTCAAT CGTCGCGGCA TCGCGCATGC GTTTGCTTTC GCCAGATGGG
43141 CCGTGCAAGA CGTTCTCGGC CGCTGCAGAC GGCTTTGCGC GGGCCGAGGG CTGCGCCGTG
43201 GTGGTGCTCA AGCGGCTCCG TGACGCGCAG CGCGACCGCG ACCCATCCT GGCGGTGGTC
43261 CGGAGCACGG CGATCAACCA CGATGGCCCG AGCAGCGGGC TCACGGTGCC CAGCGTCTCT
43321 GCCCAGCAGG CGTTGCTAGG CCAGGCGCTG GCGCAAGCGG GCGTGGCACC GGCCGAGGTC
50 43381 GATTTCTGTT AGTGCCACGG GACGGGGACA GCGCTGGGTG ACCCGATCGA GGTGCAGGCG
43441 CTGGGCGCGG TGTATGGCCG GGGCCGCCCC GCGGAGCGGC CGCTCTGGCT GGGCGCTGTC
43501 AAGGCCAACC TCGGCCACCT GGAGGCCGCG GCGGGCTTGG CCGGCGTGCT CAAGGTGCTC
43561 TTGGCGCTGG AGCACGAGCA GATTCCGGCT CAACCGGAGC TCGACGAGCT CAACCCGCAC
43621 ATCCCGTGGG CAGAGCTGCC AGTGGCCGTT GTCCGCGCGG CGGTCCCCTG GCCGCGCGGC

	43681	GCGCGCCCCG	GTCGTGCAGG	CGTGAGCGCT	TTCGGCCTGA	GCGGGACCAA	CGCGCATGTG
	43741	GTGTTGGAGG	AGGCGCCGGC	GGTGGAGCCT	GAGGCCGCGG	CCCCGAGCG	GCTGCGGAG
	43801	CTGTTTCGTCC	TGTCGGCGAA	GAGCGTGGCG	GCGCTGGATG	CGCAGGCAGG	CCGGCTGCGG
	43861	GATCATCTGG	AGAAGCATGT	CGAGCTTGGC	CTCGGCGATG	TGGCGTTCAG	CCTGGCGACG
5	43921	ACGCGCAGCG	CGATGGAGCA	CCGGCTGGCG	GTGGCCGCGA	GCTCGCGCGA	GGCGCTGCGA
	43981	GGGGCGCTTT	CGGCCGCGAG	GCAGGGGCAT	ACGCCGCGCG	GAGCCGTGCG	TGGGCGGGCC
	44041	TCCGGCGGCA	GCGCGCCGAA	GGTGGTCTTC	GTGTTTCCCG	GCCAGGGCTC	GCAGTGGGTG
	44101	GGCATGGGCC	GAAAGCTCAT	GGCCGAAGAG	CCGGTCTTCC	GGGCGGCGCT	GGAGGGTTGC
	44161	GACCGGGCCA	TCGAGGCGGA	AGCGGGCTGG	TCGCTGCTCG	GGGAGCTCTC	CGCCGACGAG
10	44221	GCCGCCTCGC	AGCTCGGGCG	CATCGACGTG	GTTTCAGCCG	TGCTCTTCGC	CGTGGAAGTA
	44281	GCGCTTTCAG	CGCTGTGGCG	GTCGTGGGGA	GTGGAGCCGG	AAGCGGTGGT	GGGCCACAGC
	44341	ATGGGCGAGG	TTGCGGCGGC	GCACGTGGCG	GGCGCGCTGT	CGCTCGAGGA	TGCGGTGGCG
	44401	ATCATCTGCC	GGCGCAGCCG	GCTGCTGCGG	CGGATCAGCG	GTCAGGGCGA	GATGGCGCTG
	44461	GTCGAGCTGT	CGCTGGAGGA	GGCCGAGGCG	GCGCTGCGTG	GCCATGAGGG	TCCGGTGAGC
15	44521	GTGGCGGTGA	GCAACAGCCC	GCGCTCGACC	GTGCTCGCAG	GCGAGCCGGC	GGCGCTCTCG
	44581	GAGGTGCTGG	CGGCGCTGAC	GGCCAAGGGG	GTGTTCTGGC	GGCAGGTGAA	GGTGACGTC
	44641	GCCAGCCATA	GCCCCGAGGT	CGACCCGCTG	CGCGAAGAGC	TGGTCGCGGC	GCTGGGAGCG
	44701	ATCCGGCCGC	GAGCGGCTGC	GGTGCCGATG	CGCTCGACGG	TGACGGGCGG	GGTGATTGCG
	44761	GGTCCGAGC	TCCGTGCGAG	CTACTGGGCG	GACAATCTTC	GGCAGCCGGT	GCGCTTCGCT
20	44821	GCGGCGGCGC	AAGCGCTGCT	GGAAGGTGGC	CCCACGCTGT	TCATCGAGAT	GAGCCCGCAC
	44881	CCGATCCTGG	TGCCGCTCT	GGACGAGATC	CAGACGGCGG	TCGAGCAAGG	GGGCGCTGCG
	44941	GTGGGCTCGC	TGCGGCGAGG	GCAGGACGAG	CGCGCGACGC	TGCTGGAGGC	GCTGGGGACG
	45001	CTGTGGGCGT	CCGGCTATCC	GGTGAGCTGG	GCTCGGCTGT	TCCCCGCGGG	CGGACGGCGG
	45061	GTTCCGCTGC	CGACCTATCC	CTGGCAGCAC	GAGCGGTACT	GGATCGAGGA	CAGCGTGAT
25	45121	GGGTGCAAGC	CCTCGCTGCG	GCTTCGGCAG	CTTCATAACG	GCGCCACGGA	CCATCCGCTG
	45181	CTCGGGGCTC	CATTGCTCGT	CTCGGCGCGA	CCCGGAGCTC	ACTTGTGGGA	GCAAGCGCTG
	45241	AGCGACGAGA	GGCTATCCTA	TCTTTCGGAA	CATAGGGTCC	ATGGCGAAGC	CGTGTTGCCC
	45301	AGCGCGGCGT	ATGTAGAGAT	GGCGCTCGCC	GCCGGCGTAG	ATCTCTATGG	CGCGGCGACG
	45361	CTGGTGCTGG	AGCAGCTGGC	GCTCGAGCGA	GCCCTCGCCG	TGCCTTCCGA	AGGCGGACGC
30	45421	ATCGTGCAAG	TGGCCCTCAG	CGAAGAAGGG	CCCGGTGCGG	CCTCATTTCA	GGTATCGAGC
	45481	CGTGAGGAGG	CAGGTAGAAG	CTGGGTTCGG	CACGCCACGG	GGCACGTGTG	TAGCGACCAG
	45541	AGCTCAGCAG	TGGGAGCGTT	GAAGGAAGCT	CCGTGGGAGA	TTCAACAGCG	ATGTCCGAGC
	45601	GTCCTGTGCT	CGGAGGCGCT	CTATCCGCTG	CTCAACGAGC	ACGCCCTCGA	CTATGGCCCC
	45661	TGCTTCCAGG	GTGTGGAGCA	GGTGTGGCTC	GGCACGGGGG	AGGTGCTCGG	CCGGGTACGC
35	45721	TTGCCAGAAG	ACATGGCATC	CTCAAGTGGC	GCCTATCGGA	TTCATCCCCG	CTTGTTGGAT
	45781	GCATGTTTTT	AAGTGCTGAC	CGCGCTGCTC	ACCACGCCGG	AATCCATCGA	GATTCGGAGG
	45841	CGGCTGACGG	ATCTCCACGA	ACCGGATCTC	CCGCGGTCCA	GGGCTCCGGT	GAATCAAGCG
	45901	GTGAGTGACA	CCTGGCTGTG	GGACGCCCGG	CTGGACGGTG	GACGGCGCCA	GAGCGCGAGC
	45961	GTGCCCCTCG	ACCTGGTGCT	CGGCAGCTTC	ACGCGAAGT	GGGAGGTCAT	GGATCGCCTC
40	46021	GCGCAGACGT	ACATCATCCG	CACTCTCCCG	ACATGGAACG	TCTTCTGCGC	TGCTGGAGAG
	46081	CGTCACACGA	TAGACGAGTT	CCTCGTCAGG	CTCCAAATCT	CTGCTGTCTA	CAGGAAGGTC
	46141	ATCAAGCGAT	GGATGGATCA	CCTTGTCGCG	ATCGGCGTCC	TTGTAGGGGA	CGGAGAGCAT
	46201	CTTGTGAGCT	CTCAGCCGCT	GCCGGAGCAT	GATTGGGCGG	CGGTGCTCGA	GGAGGCCGCG
	46261	ACGGTGTTTC	CCGACCTCCC	AGTCCTACTT	GAGTGGTGCA	AGTTTGCCGG	GGAACGGCTC
45	46321	GCGGACGTGT	TGACCGGGAA	GACGCTGGCG	CTCGAGATCC	TCTTCCCTGG	CGGCTCGTTC
	46381	GATATGGCGG	AGCGAATCTA	TCAAGATTCT	CCCATCGCCC	GTTACTCGAA	CGGCATCGTG
	46441	CGCGGTGTCT	TCGAGTCGGC	GGCGCGGGTG	GTAGCACCCT	CGGGAACGTT	CAGCATCTTG
	46501	GAGATCGGAG	CAGGGACGGG	CGCGACCACC	GCCGCCGTCC	TCCCGGTGTT	GCTGCCTGAC
	46561	CGGACAGAAT	ACCATTTCAC	CGATGTTTCT	CCGCTCTTCC	TTGCTCGTGC	GGAGCAAAGA
50	46621	TTTCGAGATC	ATCCATTCCCT	GAAGTATGGT	ATTCTGGATA	TCGACCAGGA	GCCAGCTGGC
	46681	CAGGGATACG	CACATCAGAA	GTTTCGACGTC	ATCGTCGCGG	CCAACGTCAT	CCATGCGACC
	46741	CGCGATATAA	GAGCCACGGC	GAAGCGTCTC	CTGTCGTTGC	TCGCGCCCCG	AGGCCTTCTG
	46801	GTGCTGGTCT	AGGGCACAGG	GCATCCGATC	TGGTTCGATA	TCACCACGGG	ATTGATCGAG
	46861	GGGTGGCAGA	AGTACGAAGA	TGATCTTCGT	ACCGACCATC	CGCTCCTGCC	TGCTCGGACC

46921 TGGTGTGACG TCCTGCGCCG GGTAGGCTTT GCGGATGCCG TGAGTCTGCC AGGCGACGGA
46981 TCTCCGGCGG GGATCCTCGG ACAGCACGTG ATCCTCTCGC GCGCTCCGGG ATAGCAGGA
47041 GCCGCTTG TG ACAGCTCCGG TGAGTCGGCG ACCGAATCGC CGGCCGCGCG TCAGTACGG
47101 CAGGAATGGG CCGATGGCTC CGCTGACGGC GTCCATCGGA TGGCGTTGGA GAGAATGTAC
5 47161 TTCCACCGCC GGCCGGGCCG GCAGGTTTGG GTCCACGGTC GATTGCGTAC CGGTGGAGGC
47221 GCGTTCACGA AGGCGCTCAC TGGAGATCTG CTCCTGTTCTG AAGAGACCGG GCAGGTCGTG
47281 GCAGAGGTTT AGGGGCTCCG CCTGCCGAG CTCGAGGCTT CTGCTTTCGC GCCGCGGGAC
47341 CCGCGGGAAG AGTGGTTGTA CGCGTTGGAA TGGCAGCGCA AAGACCCTAT ACCAGAGGCT
47401 CCGGCAGCCG CGTCTTCTTC CACCGCGGGG GCTTGGCTCG TGCTGATGGA CCAGGGCGGG
10 47461 ACAGGCGCTG CGCTCGTATC GCTGCTGGAA GGGCAGGCG AGGCGTGCCT GCGCGTCGTC
47521 GCGGGTACGG CATA CGCTG CCTCGCGCGG GGGCTGTATC AAGTCGATCC GCGCGAGCCA
47581 GATGGCTTTC ATACCCTGCT CCGCGATGCA TTCGGCGAGG ACCGGATGTG CCGCGCGGTA
47641 GTGCATATGT GGAGCCTTGA TCGAAGGCA GCAGGGGAGA GGACGACAGC GGAGTCGCTT
47701 CAGGCCGATC AACTCCTGGG GAGCCTGAGC GCGCTTTCTC TGGTGCAGGC GCTGGTGC GC
15 47761 CGGAGGTGGC GCAACATGCC GCGACTTTGG CTCTTGACCC GCGCCGTGCA TCGGTTGGGC
47821 GCGGAGGACG CAGCGGCCCTC GGTGGCGCAG GCGCCGGTGT GGGGCCTCGG TCGGACGCTC
47881 GCGCTCGAGC ATCCAGAGCT GCGGTGCAGC CTCGTGGACG TGAACCCGGC GCCGTCTCCA
47941 GAGGACGCAG CTGCACTCGC GGTGGAGCTC GGGGCGAGCG ACAGAGAGGA CCAGATCGCA
48001 TTGCGCTCGA ATGGCCGCTA CGTGGCGCGC CTCGTGCGGA GCTCCTTTTC CGGCAAGCCT
20 48061 GCTACGGATT GCGGCATCCG GGCGGACGGC AGTTATGTGA TCACCGATGG CATGGGGAGA
48121 GTGGGGCTCT CGGTCGCGCA ATGGATGGTG ATGCAGGGGG CCCGCCATGT GGTGCTCGTG
48181 GATCGCGGCG GCGCTTCCGA CGCCTCCCGG GATGCCCTCC GGTCCATGGC CGAGGCTGGC
48241 GCAGAGGTGC AGATCGTGA GGGCAGCGTG CTCGGCGCG TCGATGTCGC TCGGCTTCTC
48301 TCGAAGATCG AACCGTCGAT GCCCGCGCTT CGGGGGATCG TGTACGTGGA CGGGACCTTC
25 48361 CAGGGCGACT CCTCGATGCT GGAGCTGGAT GCCCATCGCT TCAAGGAGTG GATGTATCCC
48421 AAGGTGCTCG GAGCGTGGAA CCTGCACGCG CTGACCAGGG ATAGATCGCT GGACTTCTTC
48481 GTCCTGTACT CCTCGGGCAC CTCGTTCTG GGCTTGCCCG GACAGGGGAG CCGCGCCGCC
48541 GGTGACGCTT TCTTGACGC CATCGCGCAT CACCGGTGTA GGCTGGGCCCT CACAGCGATG
48601 AGCATCAACT GGGGATTGCT CTCCGAAGCA TCATCGCCGG CGACCCCGAA CGACGGCGGC
30 48661 GCACGGCTCC AATACCGGGG GATGGAAGGT CTCACGCTGG AGCAGGGAGC GGAGGCGCTC
48721 GGGCGCTTGC TCGCACAACC CAGGGCGCAG GTAGGGGTAA TCGGGCTGAA TCTGCGCCAG
48781 TGGCTGGAGT TCTATCCCAA CGCGGCCCGA CTGGCGCTGT GGGCGGAGTT CTGAAGGAG
48841 CGTGACCGCA CCGACCGGAG CGCGTCGAAC GCATCGAACC TGCGCGAGGC GCTGCAGAGC
48901 GCCAGGCCCG AAGATCGTCA GTTGGTTCTG GAGAAGCACT TGAGCGAGCT GTTGGGGCGG
35 48961 GGGCTGCGCC TTCCGCCGGA GAGGATCGAG CGGCACGTGC CGTTCAGCAA TCTCGGCATG
49021 GACTCGTTGA TAGGCCTGGA GCTCCGCAAC CGCATCGAGG CCGCGCTCGG CATCACCGTG
49081 CCGGCGACCC TGCTATGGAC TTACCCTACC GTAGCAGCTC TGAGCGGGAA CCTGCTAGAT
49141 ATTCTGTTCC CGAATGCCGG CGCGACTCAC GCTCCGGCCA CCGAGCGGGA GAAGAGCTTC
49201 GAGAACGATG CCGCAGATCT CGAGGCTCTG CCGGGTATGA CGGACGAGCA GAAGGACGCG
40 49261 TTGCTCGCCG AAAAGCTGGC GCAGCTCGCG CAGATCGTTG GTGAGTAAGG GACTGAGGGA
49321 GTATGGCGAC CACGAATGCC GGAAGCTTG AGCATGCCCT TCTGCTCATG GACAAGCTTG
49381 CGAAAAAGAA CGCGTCTTTG GAGCAAGAGC GGACCGAGCC GATCGCCATG ATAGTATTG
49441 GCTGCCGCTT CCCC GGCGGA GCGGACACTC CGGAGGCATT CTGGGAGCTG CTCGACTCGG
49501 GCCGAGACGC GGTCCAGCCG CTCGACCGGC GCTGGGCGCT GGTGCGCGTC CATCCAGCG
45 49561 AGGAGGTGCC GCGCTGGGCC GGACTGCTCA CCGAGGCGGT GGACGGCTTC GACGCCGCGT
49621 TCTTTGGCAC CTCGCTCGG GAGGCGCGGT CGCTCGATCC TCAGCAACGC CTGCTGCTGG
49681 AGGTACCTG GGAAGGGCTC GAGGACGCCG GCATCGCACC CCAGTCCCTC GACGGCAGCC
49741 GCACCGGGGT ATTCTGGGC GCATGCAGCA GCGACTACTC GCATACCCTT GCGCAACAGC
49801 GGCGCGAGGA GCAGGACGCG TACGACATCA CCGGCAATAC GCTCAGCGTC GCCCGGGAC
50 49861 GGTTGTCTTA TACGCTAGGG CTGCAGGGAC CCTGCCTGAC CGTCGACACG GCCTGCTCGT
49921 CGTCGCTCGT GGCCATCCAC CTTGCCTGCC GCAGCCTGCG CGCTCGCGAG AGCGATCTCG
49981 CGCTGGCGGG GGGCGTCAAC ATGCTCCTTT CGTCCAAGAC GATGATAATG CTGGGGCGCA
50041 TCCAGGCGCT GTCGCCCCGAT GGCCACTGCC GGACATTCTGA CGCCTCGGCC AACGGGTTCTG
50101 TCCGTGGGGA GGGCTGCGGT ATGGTCGTGC TCAAACGGCT CTCCGACGCC CAGCGACATG

	50161	GCGATCGGAT	CTGGGCTCTG	ATCCGGGGTT	CGGCCATGAA	TCAGGATGGC	CGGTTCGACAG
	50221	GGTTGATGGC	ACCCAATGTG	CTCGCTCAGG	AGGCGCTCTT	ACGCCAGGCG	GTGAGAGCG
	50281	CTCGCGTCGA	CGCCGGGGCC	ATCGATTATG	TCGAGACCCA	CGGAACGGGG	ACCTCGCTCG
	50341	GCGACCCGAT	CGAGGTCGAT	GCGCTGCGTG	CCGTGATGGG	GCCGGCGCGG	GCCGATGGGA
5	50401	GCCGCTGCGT	GCTGGGCGCA	GTGAAGACCA	ACCTCGGCCA	CCTGGAGGGC	GCTGCAGGCG
	50461	TGGCGGGTTT	GATCAAGGCG	GCGCTGGCTC	TGCAACACGA	ATCGATCCCG	CGAAACCTCC
	50521	ATTTTCACAC	GCTCAATCCG	CGGATCCGGA	TCGAGGGGAC	CGCGCTCGCG	CTGGCGACGG
	50581	AGCCGGTGCC	GTGGCCGCGG	GCGGGCCGAC	CGCGCTTCGC	GGGGGTGAGC	GCGTTCGGCC
10	50641	TCAGCGGCAC	CAACGTCCAT	GTCGTGCTGG	AGGAGGCGCC	GGCCACGGTG	CTCGCACCGG
	50701	CGACGCCGGG	GCGCTCAGCA	GAGCTTTTGG	TGCTGTCTGG	GAAGAGCACC	GCCGCGCTGG
	50761	ACGCACAGGC	GGCGCGGCTC	TCAGCGCACA	TCGCCGCGTA	CCCGGAGCAG	GGCCTCGGAG
	50821	ACGTGCGGTT	CAGCCTGGTA	GCGACGCGGA	GCCCCGATGA	GCACCGGCTC	GCGGTGGCGG
	50881	CGACCTCGCG	CGAGGCGCTG	CGAAGCGCGC	TGGAAGCTGC	GGCGCAGGGG	CAGACCCCGG
	50941	CAGGCGCGGC	GCGCGGCAGG	GCCGCTTCCT	CGCCCGGCAA	GCTCGCCTTC	CTGTCGCCCG
15	51001	GGCAGGGCGC	GCAGGTGCCG	GGCATGGGCC	GTGGGTGTG	GGAGGCGTGG	CCGGCGTTCC
	51061	GCGAGACCTT	CGACCGGTGC	GTCACGCTCT	TCGACCGGGA	GCTCCATCAG	CCGCTCTGCG
	51121	AGGTGATGTG	GGCCGAGCCG	GGCAGCAGCA	GGTCGTCTGT	GCTGGACCAG	ACGGCATTCA
	51181	CCCAGCCGGC	GCTCTTTGCG	CTGGAGTACG	CGCTGGCCGC	GCTCTTCCGG	TCGTGGGGCG
	51241	TGGAGCCGGA	GCTCATCGCT	GGCCATAGCC	TCGGCGAGCT	GGTGGCCGCG	TGCGTGGCGG
20	51301	GTGTGTTCTC	CCTCGAGGAC	GCCGTGCGCT	TGGTGGTTCG	GCGCGGCCGG	TTGATGCAGG
	51361	CGCTGCCGGC	CGGCGGTGCG	ATGGTATCGA	TCGCGCGGCC	GGAGGCCGAG	GTGGCTGCCG
	51421	CGGTGGCGCC	GCACGCAGCG	TCGGTGTCTG	TCGCGGCAGT	CAATGGGCGG	GAGCAGGTGG
	51481	TGATCGCGGG	CGCCGAGAAA	TTCGTGCAGC	AGATCGCGGC	GGCGTTCGCG	GCGCGGGGGG
	51541	CGGAACCAA	ACCGCTGCAT	GTTTCGCACG	CGTTCCACTC	GCCGCTCATG	GATCCGATGC
25	51601	TGGAGGCGTT	CCGGCGGGTG	ACCGAGTCGG	TGACGTATCG	GCGGCCTTCG	ATGGCGCTGG
	51661	TGAGCAACCT	GAGCGGGAAG	CCCTGCACGG	ATGAGGTGTG	CGCGCCGGGT	TACTGGGTGC
	51721	GTCACGCGCG	AGAGGCGGTG	CGCTTCGCGG	ACGGCGTGAA	GGCGCTGCAC	GCGGCCGGTG
	51781	CGGGCATCTT	CGTCGAGGTG	GGCCCGAAGC	CGGCGCTGCT	CGGCCTTTTG	CCGGCCTGCC
	51841	TGCCGGATGC	CAGGCCGGTG	CTGCTCCAG	CGTCGCGCGC	CGGGCGTGAC	GAGGCTGCGA
30	51901	GCGCGCTGGA	GGCGCTGGGT	GGGTTCTGGG	TCGTGCGTGG	ATCGGTCACC	TGGTCGGGTG
	51961	TCTTCCCTTC	GGGCGGACGG	CGGGTACCGC	TGCCAACCTA	TCCCTGGCAG	CGCGAGCGTT
	52021	ACTGGATCGA	AGCGCCGGTC	GATGGTGAGG	CGGACGGCAT	CGGCCGTGCT	CAGGCGGGGG
	52081	ACCACCCCTT	TCTGGGTGAA	GCCTTTTCCG	TGTCGACCCA	TGCCGGTCTG	CGCCTGTGGG
	52141	AGACGACGCT	GGACCGAAAG	CGGCTGCCGT	GGCTCGGCGA	GCACCGGGCG	CAGGGGGAGG
35	52201	TCGTGTTTCC	TGGCGCCGGG	TACCTGGAGA	TGGCGCTGTC	GTCGGGGGCC	GAGATCTTGG
	52261	GCGATGGACC	GATCCAGGTC	ACGGATGTGG	TGCTCATCGA	GACGCTGACC	TTGCGGGGCG
	52321	ATACGGCGGT	ACCGGTCCAG	GTGGTGACGA	CCGAGGAGCG	ACCGGGACGG	CTGCGGTTCC
	52381	AGGTAGCGAG	TCGGGAGCCG	GGGGCACGTC	GCGGTCCTT	CCGGATCCAC	GCCCCGCGCG
	52441	TGCTGCGCCG	GGTCGGGCGC	GCCGAGACCC	CGGCGAGGTT	GAACCTCGCC	GCCCTGCGCG
40	52501	CCCGGCTTCA	TGCCGCCGTG	CCCGCTGCGG	CTATCTATGG	GGCGCTCGCC	GAGATGGGGC
	52561	TTCAATACGG	CCCGGCGTTG	CGGGGGCTCG	CCGAGCTGTG	GCGGGGTGAG	GGCAGGCGCG
	52621	TGGGCAGAGT	GAGACTGCCT	GAGTCCGCGG	GCTCCGCGAC	AGCCTACCAG	CTGCATCCGG
	52681	TGCTGCTGGA	CGCGTGCGTC	CAAATGATTG	TTGGCGCGTT	CGCCGATCGC	GATGAGGCGA
	52741	CGCCGTGGGC	GCCGGTGGAG	GTGGGCTCGG	TGCGGCTGTT	CCAGCGGTCT	CCTGGGGAGC
45	52801	TATGGTGCCA	TGCGCGCGTC	GTGAGCGATG	GTCAACAGGC	CCCCAGCCGG	TGGAGCGCCG
	52861	ACTTTGAGTT	GATGGACGGT	ACGGGCGCGG	TGGTCGCCGA	GATCTCCCGG	CTGGTGGTGG
	52921	AGCGGCTTGC	GAGCGGTGTA	CGCCGGCGCG	ACGCAGACGA	CTGGTCTCTG	GAGCTGGATT
	52981	GGGAGCCCGC	GGCGCTCGAG	GGGCCCCAAG	TCACAGCCGG	CCGGTGGCTG	CTGCTCGGCG
	53041	AGGGTGGTGG	GCTCGGGCGC	TCGTTGTGCT	CAGCGCTGAA	GGCCGCCGGC	CATGTCGTCTG
50	53101	TCCACGCCGC	GGGGGACGAC	ACGAGCGCTG	CAGGAATGCG	CGCGCTCCTG	GCCAACGCGT
	53161	TCGACGGCCA	GGCCCCGACG	GCCGTGGTGC	ACCTCAGCAG	CCTCGACGGG	GGCGGCCAGC
	53221	TCGACCCGGG	GCTCGGGGCG	CAGGGCGCGC	TCGACGCGCC	CCGGAGCCCA	GATGTCGATG
	53281	CCGATGCCCT	CGAGTCGGCG	CTGATGCGTG	GTTGCGACAG	CGTGCTCTCC	CTGGTGCAAG
	53341	CGCTGGTCCG	CATGGACCTC	CGAAATGCGC	CGCGGCTGTG	GCTTTTGACC	CGCGGGGCTC

53401 AGGCGGCCGC CGCCGGCGAT GTCTCCGTGG TGCAAGCGCC GCTGTTGGGG CTGGGCCGCA
53461 CCATCGCCTT GGAGCACGCC GAGCTGCGCT GTATCAGCGT CGACCTCGAT ~~CG~~AGCCCAGC
53521 CTGAAGGGGA AGCCGATGCT TTGCTGGCCG AGCTACTTGC AGATGATGCC ~~CG~~AGGAGGAGG
53581 TCGCGCTGCG CGGTGGCGAG CGGTTTGTGG CGCGGCTCGT CCACCGGCTG ~~CG~~CCGAGGCTC
5 53641 AACGCCGGGA GAAGATCGCG CCCGCCGGTG ACAGGCCGTT CCGGCTAGAG ATCGATGAAC
53701 CCGGCGTGCT GGACCAACTG GTGCTCCGGG CCACGGGGCG GCGCGCTCCT GGTCCGGGCG
53761 AGGTGAGAT CGCCGTCGAA GCGGCGGGG TCGACTCCAT CGACATCCAG CTGGCGGTGG
53821 GCGTTGCTCC CAATGACCTG CCTGGAGGAG AAATCGAGCC GTCGGTGCTC GGAAGCGAGT
53881 GCGCCGGGCG CATCGTCGCT GTGGGCGAGG GCGTGAACGG CTTGTGGTG GGCCAGCCGG
10 53941 TGATCGCCCT TGCGGCGGGA GTATTGCTA ~~CG~~CCATGTCAC CACGTCGGCC ACCTGCTGTT
54001 TGCCTCGGCC TCTGGGGCTC TCGGCGACCG ~~CG~~GGCGGCCG GATGCCCCTC GCGTATTTGA
54061 CGGCCTGGTA CGCCCTCGAC AAGGTCGCCC ~~CG~~ACCTGCAGG GGGGAGCGG GTGCTGATCC
54121 GTGCGGAGGC CGGTGGTATC GGTCTTTGCG ~~CG~~GGTGCGAT GGGCGAGCG GTGGGCGCCG
54181 AGGTGTATGC GACCGCCGAC ACGCCGAGA AACGTGCCTA CCTGGAGTCG CTGGGCGTGC
15 54241 GGTACGTGAG CGATTCCCGC TCGGGCCGGT TCGCCGAGA CGTGCATGCA TGGACGGACG
54301 GCGAGGGTGT GGACGTCGTG CTCGACTCGC TTTCCGGCGA GCACATCGAC AAGAGCCTCA
54361 TGGTCTGCG CGCCTGTGGC CGCCTTGTGA AGCTGGGCAG GCGCGACGAC TGCGCCGACA
54421 CGCAGCCTGG GCTGCCGCCG CTCCTACGGA ATTTTTCCTT CTCGCAGGTG GACTTGCGGG
20 54481 GAATGATGCT CGATCAACCG GCGAGGATCC GTGCGCTCCT CGACGAGCTG TTCGGGTTGG
54541 TCGCAGCCGG TGCCATCAGC CCACTGGGGT CGGGGTTGCG CGTTGGCGGA TCCCTCACGC
54601 CACCGCCGGT CGAGACCTTC CCGATCTCTC GCGCAGCCGA GGCATTCCGG AGGATGCGCG
54661 AAGGACAGCA TCTCGGGAAG CTCGTGCTCA GCTGGACGA CCCGAGGTG CGGATCCGCG
54721 CTCGCGCCGA ATCCAGCGTC GCCGTCCGCG CGGACGGCAC CTACCTTGTG ACCGGCGGTC
54781 TGGGTGGGCT CGGTCTGCGC GTGGCCGGAT GGCTGGCCGA GCGGGGCGCG GGGCAACTGG
25 54841 TGCTGGTGGG CCGCTCCGGT GCGGCGAGCG CAGAGCAGCG AGCCGCCGTG GCGGCGCTAG
54901 AGGCCCACGG CGCGCGCGTC ACGGTGGCGA AAGCGGATGT CGCCGATCGG TCACAGATCG
54961 AGCGGGTCCT CCGCGAGGTT ACCGCGTCGG GGATGCCGCT GCGGGGTGTC GTGCATGCGG
55021 CAGGTCTTGT GGATGACGGG CTGCTGATGC AGCAGACTCC GCGCGGGCTC CGCACGGTGA
55081 TGGGACCTAA GGTCCAGGGA GCCTTGCACT TGCACACGCT GACACGCGAA GCGCCTCTTT
30 55141 CTTTCTTCGT GCTGTACGCT TCTGCAGCTG GGCTGTTCCG CTCGCCAGGC CAGGGCAACT
55201 ATGCCGCGAG CAACGCGTTC CTCGACGCCC TTTCCGATCA CCGCAGGGCG CACGGCCTGC
55261 CGGCGCTGAG CATCGACTGG GGCATGTTCA CGGAGGTGGG GATGGCCGTT GCGCAAGAAA
55321 ACCGTGGCGC GCGGCTGATC TCTCGCGGGA TGCGGGGCAT CACCCCGCAT GAGGGTCTGT
55381 CAGCTCTGGC GCGCTTGCTC GAGGGTGATC GCGTGCAGAC GGGGGTGATA CCGATCACTC
35 55441 CGCGGCAGTG GGTGGAGTTT TACCCGGCAA CAGCGGCCTC ACGGAGGTTG TCGCGGCTGG
55501 TGACCACGCA GCGCGCGGTT GCTGATCGGA CCGCCGGGGA TCGGGACCTG CTCGAACAGC
55561 TTGCTCGGC TGAGCCGAGC GCGCGGGCGG GGCTGCTGCA GGACGTCGTG CGCGTGCAGG
55621 TCTCGCATGT GCTGCGTCTC CCTGAAGACA AGATCGAGGT GGATGCCCCG CTCTCGAGCA
55681 TGGGCATGGA CTCGCTGATG AGCCTGGAGC TCGCAACCG CATCGAGGT GCGCTGGGCG
40 55741 TCGCCGCGCC TGCAGCCTTG GGGTGGACGT ACCCAACGGT AGCAGCGATA ACGCGCTGGC
55801 TGCTCGACGA CGCCCTCGCC GTCCGGCTTG GCGGCGGGTC GGACACGGAC GAATCGACGG
55861 CAAGCGCCGG ATCGTTCGTC CACGTCTCTC GCTTTTCGTCC TGTCGTCAAG CCGCGGGCTC
55921 GTCTCTTCTG TTTTACAGGT TCTGGCGGCT CGCCGAGGG CTTCCGTTCC TGGTCGGAGA
55981 AGTCTGAGTG GAGCGATCTG GAAATCGTGG CCATGTGGCA CGATCGCAGC CTCGCTCCG
45 56041 AGGACGCGCC TGGTAAGAAG TACGTCCAAG AGGCGGCCTC GCTGATTGAG CACTATGCAG
56101 ACGCACCGTT TCGGTTAGTA GGGTTCAGCC TGGGTGTCCG GTTCGTCATG GGGACAGCCG
56161 TGGAGCTCGC TAGTCGTTCC GCGCACCGG CTCCGCTGGC CGTTTTTTCG TTGGGCGGCA
56221 GCTTGATCTC TTCTTCAGAG ATCACCCTCG AGATGGAGAC CGATATAATA GCCAAGCTCT
56281 TCTTCCGAAA TGCCGCGGGT TTCGTGCGAT CCACCCAACA AGTTCAGGCC GATGCTCGCG
50 56341 CAGACAAGGT CATCACAGAC ACCATGGTGG CTCCGGCCCC CGGGGACTCG AAGGAGCCGC
56401 CCTCGAAGAT CGCGGTCCCT ATCGTCGCCA TCGCCGGCTC GGACGATGTG ATCGTGCCTC
56461 CAAGCGACGT TCAGGATCTA CAATCTCGCA CCACGGAGCG CTTCTATATG CATCTCCTTC
56521 CCGGAGATCA CGAGTTTCTC GTCGATCGAG GCGCGGAGAT CATGCACATC GTCGACTCGC
56581 ATCTCAATCC GCTGCTCGCC GCGAGGACGA CGTCGTCAGG CCGCGGCTTC GAGGCAAAAT

5	56641	GATGGCAGCC	TCCCTCGGGC	GCGCGAGATG	GTTGGGAGCA	GCGTGGGTGC	TGGTGGCCGG
	56701	CGGCAGGCAG	CGGAGGCTCA	TGAGCCTTCC	TGGAAGTTTG	CAGCATAGGA	GATTTTATGA
	56761	CACAGGAGCA	AGCGAATCAG	AGTGAGACGA	AGCCTGCTTT	CGACTTCAAG	CCGTTTCGCGC
	56821	CTGGGTACGC	GGAGGACCCG	TTTCCCGCGA	TCGAGCGCCT	GAGAGAGGCA	ACCCCATCT
	56881	TCTACTGGGA	TGAAGGCCGC	TCCTGGGTCC	TCACCCGATA	CCACGACGTG	TCGGCGGTGT
	56941	TCCGCGACGA	ACGCTTCGCG	GTCAGTCGAG	AAGAATGGGA	ATCGAGCGCG	GAGTACTCGT
	57001	CGGCCATTCC	CGAGCTCAGC	GATATGAAGA	AGTACGGATT	GTTCGGGCTG	CCGCCGAGG
	57061	ATCACGCTCG	GGTCCGCAAG	CTCGTCAACC	CATCGTTTAC	GTCACGCGCG	ATCGACCTGC
10	57121	TGCGCGCCGA	AATACAGCGC	ACCGTCGACC	AGCTGCTCGA	TGCTCGCTCC	GGACAAGAGG
	57181	AGTTCGACGT	TGTGCGGGAT	TACGCGGAGG	GAATCCCGAT	GCGTGCATC	AGCGCTCTGT
	57241	TGAAGGTTCC	GGCCGAGTGT	GACGAGAAGT	CCGTCGCTT	CGGCTCGGCG	ACTGCGCGCG
	57301	CGCTCGGCGT	GGGTTTGGTG	CCCCGGGTCT	ATGAGGAGAC	CAAGACCCTG	GTCGCGTCCG
	57361	TCACCGAGGG	GCTCGCGCTG	CTCCATGGCG	TCTTCGATGA	GCGGCGCAGG	AACCCGCTCG
	57421	AAAATGACGT	CTTGACGATG	CTGCTTCAAG	CCGAGGCCGA	CGGCAGCAGG	CTGAGCACGA
15	57481	AGGAGCTGGT	CGCGCTCGTG	GGTGCGATTA	TCGCTGCTGG	CACCGATACC	ACGATCTACC
	57541	TTATCGCGTT	CGCTGTGCTC	AACCTGCTGC	GGTCGCCCCA	GGCGCTCGAG	CTGGTGAAGG
	57601	CCGAGCCCGG	GCTCATGAGG	AACGCGCTCG	ATGAGGTGCT	CCGCTTCGAC	AATATCCTCA
	57661	GAATAGGAAC	TGTGCGTTTC	GCCAGGCAGG	ACCTGGAGTA	CTGCGGGGCA	TCGATCAAGA
	57721	AAGGGGAGAT	GGTCTTTCTC	CTGATCCCGA	GCGCCCTGAG	AGATGGGAOT	GTATTCTCCA
20	57781	GGCCAGACGT	GTTTGATGTG	CGACGGGACA	CGAGCGCGAG	CCTCGCGTAC	GGTAGAGGCC
	57841	CCCATGTCTG	CCCCGGGGTG	TCCCTTGCTC	GCCTCGAGGC	GGAGATCGCC	GTGGGCACCA
	57901	TCTTCCGTAG	GTTCCCCGAG	ATGAAGCTGA	AAGAAACTCC	CGTGTTTGGA	TACCACCCCG
	57961	CGTTCCGGAA	CATCGAATCA	CTCAACGTCA	TCTTGAAGCC	CTCCAAAGCT	GGATAACTCG
	58021	CGGGGGCATC	GCTTCCCGAA	CCTCATTCTT	TCATGATGCA	ACTCGCGCGC	GGGTGCTGTC
25	58081	TGCCGCGGGT	GCGATTTCGAT	CCAGCGGACA	AGCCCATTGT	CAGCGCGCGA	AGATCGAATC
	58141	CACGGCCCCG	AGAAGAGCCC	GATGGCGAGC	CCGTCCGGGT	AACGTGCGAA	GAAGTGCCGG
	58201	GCGCCGCCCT	GGGAGCGCAA	AGCTCGCTCG	CTCGCGCTCA	GCGCGCCGCT	TGCCATGTCC
	58261	GGCCCTGCAC	CCGCACCGAG	GAGCCACCCG	CCCTGATGCA	CGGCCTCACC	GAGCGGCAGG
	58321	TTCTGCTCTC	GCTCGTCGCC	CTCGCGCTCG	TCTCTCTGAC	CGCGCGCGCC	TTGCGCGAGC
30	58381	TCGCGCGGCG	GCTGCGCCAG	CCCGAGGTGC	TCGGCGAGCT	CTTCGGCGGC	GTGGTGCTGG
	58441	GCCCGTCCGT	CGTCGGCGCG	CTCGCTCCTG	GGTTCCATCG	AGTCCTCTTC	CAGGATCCGG
	58501	CGGTGCGGGG	CGTGCTCTCC	GGCATCTCCT	GGATAGGCGC	GCTCGTCTCT	CTGCTCATGG
	58561	CGGGTATCGA	GGTCGATGTG	AGCATTCTAC	GCAAGGAGGC	GCGCCCCGGG	GCGCTCTCGG
	58621	CGCTCGGCGC	GATCGCGCCC	CCGCTGCGCA	CGCCGGGCCC	GCTGGTGCAG	CGCATGCAGG
35	58681	GCACGTTGAC	GTGGGATCTC	GACGTCTCGC	CGCGACGCTC	TGCGCAAGCC	TGAGCCTCGG
	58741	CGCCTGCTCG	TACACCTCGC	CGGTGCTCGC	TCCGCCCGCG	GACATCCGGG	CGCCCCCGCG
	58801	GGCCAGCTC	GAGCCGGAAT	CGCCGGATGA	CGAGGCCGAC	GAGGCGCTCG	GCCCGTTCCG
	58861	CGACGCGATC	GCCGCGTACT	CGGAGGCCGT	TCGGTGGGCG	GAGGCGCGCG	AGCGGCCGCG
	58921	GCTGGAGAGC	CTCGTGCGGC	TCGCGATCGT	GCGGCTGGGC	AAGGCGCTCG	ACAAGGCCACC
40	58981	TTCGCGCAC	ACGACGGCCG	GCGTCTCCCA	GATCGCCGGC	AGACTTCCCC	AGAAAACGAA
	59041	TTCGGTCTGG	TTCGATGTCG	CCGCCCGGTA	CGCGAGCTTC	CGCGCGGCGA	CGGAGCACGC
	59101	GCTCCGCGAC	GCGGCGTCGG	CCACGGAGGC	GCTCGCGGCC	GGCCCGTACC	GCGGATCGAG
	59161	CAGCGTGTCC	GCTGCCGTAG	GGGAGTTTCG	GGGGGAGGCG	GCGCGCCTTC	ACCCCGCGGA
	59221	CCGCGTACCC	GCGTCCGACC	AGCAGATCCT	GACCGCGCTG	CGCGCAGCCG	AGCGGGCGCT
45	59281	CATCGCGCTC	TACACCGCGT	TCGCCCCTGA	GGAGTGAGCC	TCTCTCGGGC	GCAGCCGAGC
	59341	GGCGGCGTGC	CGGTTGTTCC	CTCTTCGCAA	CCATGACCGG	AGCCGCGCCC	GGTCCGCGCA
	59401	GCGGCTAGCG	CGCGTCGAGG	CAGAGAGCGC	TGGAGCGACA	GGCGACGACC	CGCCCGAGGG
	59461	TGTCGAACGG	ATTGCCGCGC	CCCTCATTCG	GGATCCCCCT	CAGACACTCG	TTCAGCGCCT
	59521	TGGCGTTCGAT	GCCGCTGGG	CACTCGCCGA	AGGTGAGCTC	GTCGCGCCAG	TCGGATCGGA
50	59581	TCTTGTTTCGA	GCACGCATCC	TTGCTCGAAT	ACTCCCGGTC	TTGTCCGATG	TTGTTGCACC
	59641	GCGCCTCGCG	GTCGCACCGC	GCCGCCACGA	TGCTATCGAC	GGCGCTGCCG	ACTGGCACCG
	59701	GCGCCTCGCC	TTGCGCGCCA	CCCGGGGTTT	GCGCCTCCCC	GCCTGACCGC	TTTTCGCCGC
	59761	CGCACGCCGC	CGCGAGCAGG	CTCATTTCCG	ACATCGAGAT	CAGGCCACG	ACCAGTTTCC
	59821	CAGCAATCTT	TTGCATGGCT	TCCCCTCCCT	CACGACACGT	CACATCAGAG	ATTCTCCGCT

- 98 -

59881 CGGCTCGTCG GTTCGACAGC CGGCGACGGC CACGAGCAGA ACCGTCCCCG ACCAGAACAG
59941 CCGCATGCGG GTTTCTCGCA GCATGCCACG ACATCCTTGC GACTAGCGTG ~~ACTCCGCTCG~~
60001 TGCCGAGATC GGCTGTCTCTG TGCGACGGCA ATGTCTCTGCG ATCGGCCCGG ~~CAGGATCGAC~~
60061 CGACACGGGC GCCGGGCTGG AGGTGCCGCC ACGGGCTCGA AATGCGCTGT ~~GCGAGGCGCC~~
5 60121 TCCATGCCCC CTGCCGGGAA CGCAGCGCCC GGCCAGCCTC GGGGCGACGC TGCGAACGGG
60181 AGATGCTCCC GGAGAGGCGC CGGGCACAGC CGAGCGCCGT CACCACCGTG CGCACTCGTG
60241 AGCGCTAGCT CCTCGGCATA GAAGAGACCG TCACTCCCGG TCCGTGTAGG CGATCGTGCT
60301 GATCAGCGCG TCCTCCGCCT GACGCGAGTC GAGCCGGGTA TGCTGCACGA CGATGGGCAC
60361 GTCCGATTCTG ATCAGCTGG CATAGTCCGT ATCGCGCGGG ATCGGCTCGG GGTGCGTCAG
10 60421 ATCGTTGAAC CGGACGTGCC GGGTGCCTCT CGCTGGAACG GTCACCCGGT ACGGCCCGGC
60481 GGGGTCGCGG TCGCTGAAGT AGACGGTGAT ~~GGCGACCTGC~~ GCGTCCCGGT CCGACGCATT
60541 CAACAGGCAG GCCGTCTCAT GGCTCGTCAT ~~CTGCGGCTCA~~ GGTCCGTTGC TCCGGCCTGG
60601 GATGTAGCCC TCTGCGATTG CCCAGCGCGT CCGCCCGATC GGCTTGTCCA TGTGTCCTCC
60661 CTCTGGGCTC CTCTTTGGCA GCCTCCCTCT GCTGTCCAGG TGCGACGGCC TCTTCGCTCG
15 60721 ACGCGCTCGG GGCTCCATGG CTGAGAATCC TCGCCGAGCG CTCCTTGCCG ACCGGCGCGC
60781 TGAGCGCCGA CGGGCCTTGA AAGCACGCGA CCGGACACGG GATGCCGGCG CGACGAGGCC
60841 GCGCCGCGTC TGATCCCGAT CGTGGCATCA CGACGTCCGC CGACGCCTCG GCAGGCCGGC
60901 GTGAGCGCTG CGCGGTCATG GTCGTCTCTG CGTCACCGCC ACCCGCCGAT TCACATCCCA
60961 CCGCGGCACG ACGCTTGCTC AAACCGCGAC GACACGGCCG GGCGGCTGTG ~~TACCGGCCA~~
20 61021 GCGCGGACGC GAGGCCCGAG AGGGACAGTG GGTCCGCGGT GAAGCAGAGA GGCATCGAG
61081 GTGGTGAGAT GAAACACGTT GACACGGGCC GACGAGTCGG CCGCCGGATA GGGCTCACGC
61141 TCGGTCTCCT CGCGAGCATG GCGCTCGCCG GCTGCGGCGG CCCGAGCGAG AAGACCGTGC
61201 AGGGCACGCG GCTCGCGCCC GGCGCCGATG CGCACGTCAC CGCCGACGTC GACGCCGACG
61261 CCGCGACCAC GCGGCTGGCG GTGGACGTCG TTCACCTCTC GCGCCCGAG CGGATCGAGG
25 61321 CCGGCAGCGA GCGGTTCTGTC GTCTGGCAGC GTCCGAATC CGAGTCCCCG TGGCTACGGG
61381 TCGGAGTGCT CGACTACAAC GCTGCCAGCC GAAGAGGCAA GCTGGCCGAG ACGACCGTGC
61441 CGCATGCCAA CTTCGAGCTG CTCATCACCG TCGAGAAGCA GAGCAGCCCT CAGTCGCCAT
61501 CGTCTGCCGC CGTCATCGGG CCGACGTCCG TCGGGTAACA TCGCGCTATC AGCAGCGCTG
61561 AGCCCGCCAG CATGCCCCAG AGCCCTGCCT CGATCGCTTT CCCCATCATC CGTGCGCACT
30 61621 CCTCCAGCGA CGGCCGCTC AAAGCAACCG CCGTGCCGGC GCGGCTCTAC GTGCGCGACA
61681 GGAGAGCGTC CTAGCGCGGC CTGCGCATCG CTGGAAGGAT CCGCGGAGCA TGGAGAAAGA
61741 ATCGAGGATC GCGATCTACG GCGCCGTCGC CGCCAACGTG GCGATCGCGG ~~CGGTCAAGTT~~
61801 CATCGCCGCC GCCGTGACCG GCAGCTCTGC GATGCTCTCC GAGGGCGTGC ACTCCCTCGT
61861 CGATAACCGA GACGGGCTCC TCCTCCTGCT CGGCAAGCAC CGGAGCGCCC GCCCGCCGA
35 61921 CGCCGAGCAT CCGTTCGGCC ACGGCAAGGA GCTCTATTTT TGGACGCTGA TCGTCGCCAT
61981 CATGATCTTC GCCGCGGGCG GCGGCGTCTC GATCTACGAA GGGATCTTGC ACCTCTTGCA
62041 CCCGCGCTCG ATCGAGGATC CGACGTGGA CTACGTTGTC CTCGGCGCAG GCGCCGTCTT
62101 CGAGGGGACG TCGCTCGCCA TCTCGATCCA CGAGTTCAAG AAGAAAGACG GACAGGGCTA
62161 CGTCGCGGCG ATGCGGTCCA GCAAGGACCC GACGACGTTT ACGATCGTCC TGGAGGATTC
40 62221 CGCGGCGCTC GCCGGGCTCG CCATCGCCTT CCTCGGCGTC TGGCTTGGGC ACCGCTGGG
62281 AAACCCCTAC CTCGACGCGC GGGCGTCGAT CGGCATCGGC CTCGTGCTCG CCGCGGTGCG
62341 GGTCTTCTC GCCAGCCAGA GCCGTGGAAT CCTCGTAGGG GAGAGCGCGG ACAGGGAGCT
62401 CCTCGCCGCG ATCCGCGCGC TCGCCAGCGC AGATCCTGGC GTGTGCGCGG TGGGGCGGCC
62461 CCTGACGATG CACTTCGGTC CGCACGAAGT CCTGGTCGTG CTGCGCATCG AGTTCGACGC
45 62521 CGCGCTCACG GCGTCCGGGG TCGCGGAGGC GATCGAGCGA ATCGAGACAC GGATACGGAG
62581 CGAGCGACCC GACGTGAAGC ACATCTACGT CGAGGCCAGG TCGCTCCACC AGCGCGCGAG
62641 GCGGTGACGC GCCGTGGAGA GACCGCTCGC GGCCTCCGCC ATCCTCCGCG GCGCCCGGGC
62701 TCGGGTAGCC CTCGCAGCAG GCGCGCCTG GCGGGCAAAC CGTGAAGACG TCGTCTTTCG
62761 ACGCGAGGTA CGCTGGTTGC AAGTTGTAC GCCGTATCGC GAGGTCCGGC AGCGCCGGAG
50 62821 CCCGGGCGGT CCGGGCGCAC GAAGGCCCGG CGAGCGCGGG CTTCGAGGGG GCGACGTCAT
62881 GAGGAAGGGC AGGGCGCATG GGGCGATGCT CGGCGGGCGA GAGGACGGCT GGCGTCGCGG
62941 CCTCCCCGGC GCCGGCGCGC TTCGCGCCGC GCTCCAGCGC GGTCGCTCGC GCGATCTCGC
63001 CCGGCGCCGG CTCATCGCCG CCGTGTCCCT CACCGGCGGC GCCAGCATGG CGGTCTGCTC
63061 GCTGTTCCAG CTCGGGATCA TCGAGCACCT GCCCGATCCT CCGCTTCCAG GGTTCGATTC

- 99 -

	63121	GGCCAAGGTG	ACGAGCTCCG	ATATCGCGTT	CGGGCTCACG	ATGCCGGACG	CGCCGCTCGC
	63181	GCTCACCAGC	TTCGCGTCCA	ACCTGGCGCT	GGCTGGCTGG	GGAGGCGCCG	GGCGCGCCAG
	63241	GAACACCCCC	TGGATCCCCG	TCGCCGTGGC	GGCCAAGGCG	GCCGTCGAGG	CGGCCGTGTC
	63301	CGGATGGCTC	CTCGTCCAGA	TGCGACGGCG	GGAGAGGGCC	TGGTGC GCGT	ACTGCCTGGT
5	63361	CGCCATGGCG	GCCAACATGG	CCGTGTTTCG	GCTCTCGCTC	CCGGAAGGGT	GGGCGGCGCT
	63421	GAGGAAGGCG	CGAGCGCGCT	CGTGACAGGG	CCGTGCGGGC	GCCGCGGCCA	TCGGAGGCCG
	63481	GCGTGCACCC	GCTCCGTAC	GCCCCGGCCC	GCGCCGCGGT	GAGCTGCCGC	GGACAGGGCG
	63541	CGTACCGTGG	ACCCCGCACG	CGCCGCGTCG	ACGGACATCC	CCGGCGGCTC	GCGCGGCGCG
	63601	GCCGGCGCAA	CTCCGGCCCC	CGCGCGGGCA	TCGACATCTC	CCGCGAGCAA	GGGCACTCCG
10	63661	CTCCTGCCCG	CGTCCGCGAA	CGATGGCTGC	GCTGTTTCCA	CCCTGGAGCA	ACTCCGTTTA
	63721	CCGCGTGGCG	CTCGTCGGGC	TCATCGCCTC	GGCGGGCGGC	GCCATCCTCG	CGCTCATGAT
	63781	CTACGTCCGC	ACGCCGTGGA	AGCGATACCA	GTTTCGAGCC	GTCGATCAGC	CGGTGCAGTT
	63841	CGATCACCGC	CATCACGTGC	AGGACGATGG	CATCGATTGC	GTCTACTGCC	ACACCACGGT
	63901	GACCCGCTCG	CCGACGGCGG	GGATGCCCGC	GACGGCCACG	TGCATGGGGT	GCCACAGCCA
15	63961	GATCTGGAAT	CAGAGCGTCA	TGCTCGAGCC	CGTGCGGCGG	AGCTGGTTCT	CCGGCATGCC
	64021	GATCCCGTGG	AACCGGGTGA	ACTCCGTGCC	CGACTTCGTT	TATTTCAACC	ACGCGATTCA
	64081	CGTGAACAAG	GGCGTGGGCT	GCGTGAGCTG	CCACGGGCGC	GTGGACGAGA	TGGCGGCCGT
	64141	CTACAAGGTG	GCGCCGATGA	CGATGGGCTG	GTGCCTGGAG	TGCCATCGCC	TGCCGGAGCC
	64201	GCACCTGCGC	CCGCTCTCCG	CGATCACCGA	CATGCGCTGG	GACCCGGGGG	AACGGAGGGA
20	64261	CGAGCTCGGG	GCGAAGCTCG	CGAAGGAGTA	CGGGGTCCGG	CGGCTCACGC	ACTGCACAGC
	64321	GTGCCATCGA	TGAACGATGA	ACAGGGGATC	TCCGTGAAAG	ACGCAGATGA	GATGAAGGAA
	64381	TGGTGGCTAG	AAGCGCTCGG	GCCGGCGGGA	GAGCGCGCGT	CCTACAGGCT	GCTGGCGCCG
	64441	CTCATCGAGA	GCCCCGAGCT	CCGCGCGCTC	GCCGCGGGCG	AACCGCCCCG	GGGCGTGGAC
	64501	GAGCCGGCGG	GCGTCAGCCG	CCGCGCGCTG	CTCAAGCTGC	TCGGCGCGAG	CATGGCGCTC
25	64561	GCCGGCGTCG	CGGGCTGCAC	CCCGCATGAG	CCCGAGAAGA	TCCTGCCGTA	CAACGAGACC
	64621	CCGCCCGGCG	TCGTGCCGGG	TCTCTCCCAG	TCCTACGCGA	CGAGCATGGT	GCTCGACGGG
	64681	TATGCCATGG	GCCTCCTCGC	CAAGAGCTAC	GCGGGGCGGC	CCATCAAGAT	CGAGGGCAAC
	64741	CCCGCGCACC	CGGCGAGCCT	CGGCGCGACC	GGCGTCCACG	AGCAGGCCTC	GATCCTCTCG
	64801	CTGTACGACC	CGTACCGCGC	GCGCGCGCCG	ACGCGCGGCG	GCCAGGTGCG	GTCGTGGGAG
30	64861	GCGCTCTCCG	CGCGCTTCGG	CGGCGACCGC	GAGGACGGCG	GCGCTGGCCT	CCGCTTCGTC
	64921	CTCCAGCCCA	CGAGCTCGCC	CCTCATCGCC	GCGCTGATCG	AGCGCGTCCG	GCGCAGGTTT
	64981	CCCGGCGCGC	GGTTCACCTT	CTGGTCCGCG	GTCCACGCCG	AGCAAGCGCT	CGAAGGCGCG
	65041	CGGGCGGGCG	TCGGCCTCAG	GCTCTTGCC	CAGCTCGACT	TCGACCAGGC	CGAGGTGATC
	65101	CTCGCCCTGG	ACGCGGACTT	CCTCGCGGAC	ATGCCGTTCA	GCGTGCGCTA	TGCGCGCGAC
35	65161	TTCGCCGCGC	GCCGCCGACC	CGCGAGCCCG	GCGGCGGCCA	TGAACCGCCT	CTACGTGCGC
	65221	GAGGCGATGT	TCACGCCACC	GGGGACGCTC	GCCGACCACC	GGCTCCGCGT	GCGGCCCGCC
	65281	GAGGTGCGCG	GCGTCGCGGC	CGGCTGCGCG	GCGGAGCTCG	TGCACGGCCT	CGGCTGCGC
	65341	CCGCGCGGGA	TCACGGACGC	CGACGCCGCC	GCGCTGCGCG	CGCTCCGCCC	CCGCGACGGC
	65401	GAGGGGCACG	GCGCCTTCGT	CCGGGCGCTC	GCGCGCGATC	TCGCGCGCGC	GGGGGGCGCC
40	65461	GGCGTCGCGC	TCGTGCGGCA	CGGCCAGCCG	CCCATCGTCC	ACGCCCTCGG	GCACGTCATC
	65521	AACGTCGCGC	TCCGCGCCCG	GGCGGCCTGG	ATGGTCGATC	CTGTGCTGAT	CGACGCGGGC
	65581	CCCTCCACGC	AGGGCTTCTC	CGAGCTCGTC	GGCGAGCTCG	GGCGCGGCGC	GGTCGACACC
	65641	TGATCCTCCT	CGACGTGAAC	CCCGTGTACG	CCGCGCCGGC	CGACGTCGAT	TTCGCGGGCC
	65701	TCCTCGCGCG	CGTGCCACAG	AGCTTGAAGG	CCGGGCTCTA	CGACGACGAG	ACCGCCCGCG
45	65761	CTTGACAGTG	GTTTCGTGCC	ACCCGGCATT	ACCTCGAGTC	GTGGGGGGAC	GCGCGGGCGT
	65821	ACGACGGGAC	GGTCTCGTTC	GTGCAACCCC	TCGTCCGGCC	GCTGTTTCGAC	GGCCGGGCGG
	65881	TGCCCAGAGCT	GCTCGCCGTC	TTCGCGGGGG	ACGAGCGCCC	GGATCCCCCG	CTGTGCTGTC
	65941	GCGAGCACTG	GCGCGGCGCG	CGCGGAGAGG	CGGATTTCGA	GGCCTTCTGG	GGCGAGGCAT
	66001	TGAAGCGCGG	CTTCTCCTCT	GACAGCGCCC	GGCCGAGGCA	GACACCGGAT	CTCGCGCCCG
50	66061	CCGACCTCGC	CAAGGAGCTC	GCGCGGCTCG	CCGCCGCGCC	GCGGCCGGCC	GGCGGCGCGC
	66121	TCGACGTGGC	GTTCTCTCAG	TCGCCGTGCG	TCCACGACGG	CAGGTTTCGCC	AACAACCCCT
	66181	GGCTGCAAGA	GTCCTCCGCG	CCGATCACCA	GGCTCACCTG	GGGCAACGCC	GCCATGATGA
	66241	GCGCGGCGAC	CGCGGCGCGG	CTCGGCGTCG	AGCGCGGCGA	TGTCGTGCGAG	CTCGCGCTGC
	66301	GCGGCCGTAC	GATCGAGATC	CCGGCCGTCG	TCGTCCGCGG	GCACGCCGAC	GACGTGATCA

- 100 -

5	66361	GCGTCGACCT	CGGCTACGGG	CGCGACGCCG	GCGAGGAGGT	CGCGCGCGGG	GTGGGCGTGT
	66421	CGGCGTATCG	GATCCGCCCG	TCCGACGCGC	GGTGGTTCGC	GGGGGGCCCTC	TACGTGAGGA
	66481	AGACCGGCGC	CACGGCCGCG	CTCGCGCTGG	CTCAGATCGA	GCTGTCCCAG	CACGACCGTC
	66541	CCATCGCGCT	CCGAGGACG	CTGCCGAGT	ACCGTGAACA	GCCCCGTTTC	GCGGAGGAGC
	66601	ACAAGGGGCC	GGTCCGCTCG	ATCCTGCCCG	AGGTGAGTA	CACCGGCGCG	CAATGGGCGA
	66661	TGTCCATCGA	CATGTCGATC	TGCACCGGGT	GCTCCTCGTG	CGTCGTGGCC	TGTCAGGCCG
	66721	AGAACAACGT	CCTCGTCGTC	GGCAAGGAGG	AGGTGATGCA	CGGCCGCGAG	ATGCAGTGGT
	66781	TGCGGATCGA	TCAGTACTTC	GAGGGTGGAG	GCGACGAGGT	GAGCGTCGTC	AACCAGCCGA
	66841	TGCTCTGCCA	GCACTGCGAG	AAGGCGCCGT	GCGAGTACGT	CTGTCCGGTG	AACGCGACGG
10	66901	TCCACAGCCC	CGATGGCCTC	AACGAGATGA	TCTACAACCG	ATGCATCGGG	ACGCGCTTTT
	66961	GCTCCAACAA	CTGTCCGTAC	AAGATCCGGC	GTTCAATTT	CTTCGACTAC	AATGCCACG
	67021	TCCCGTACAA	CGCCGGCCTC	CGCAGGCTCC	AGCGCAACCC	GGACGTCACC	GTCCGCGCCC
	67081	GCGGCGTCAT	GGAGAAATGC	ACGTACTGCG	TGCAGCGGAT	CCGAGAGGCG	GACATCCGCG
	67141	CGCAGATCGA	GCGGCGGCCG	CTCCGGCCCG	GCGAGGTGGT	CACCGCCTGC	CAGCAGGCCT
15	67201	GTCCGACCGG	CGCGATCCAG	TTCGGGTGCG	TGGATCACGC	GGATACAAAG	ATGGTCGCGT
	67261	GGCGCAGGGA	GCCGCGCGCG	TACGCCGTGC	TCCACGACCT	CGGCACCCGG	CCGCGGACGG
	67321	AGTACCTCGC	CAAGATCGAG	AACCCGAACC	CGGGGCTCGG	GGCGGAGGGC	GCCGAGAGGC
	67381	GACCCGGAGC	CCCGAGCGTC	AAACCCGCGC	TCGGGGCGGA	GGGCGCCGAG	AGGCGACCCG
	67441	GAGCCCCGAG	CGTCAAACCG	GAGATTGAAT	GAGCCATGGC	GGGCCCCGCT	ATCCTGGACG
20	67501	CACCGACCGA	CGATCAGCTG	TCSAAGCAGC	TCCTCGAGCC	GGTATGGAAG	CCGCGCTCCC
	67561	GGCTCGGCTG	GATGCTCGCG	TTCGGGCTCG	CGCTCGGCGG	CACGGGCCCTG	CTCTTCCTCG
	67621	CGATCACCTA	CACCGTCCTC	ACCGGGATCG	GCGTGTGGGG	CAACAACATC	CCGGTCGCGT
	67681	GGGCCTTCGC	GATCACCAAC	TTCGTCTGGT	GGATCGGGAT	CGGCCACGCC	GGGACGTTCA
	67741	TCTCCGCGAT	CCTCCTCCTG	CTCGAGCAGA	AGTGGCGGAC	GAGCATCAAC	CGCTTCGCGG
25	67801	AGGCGATGAC	GCTCTTCGCG	GTCGTCCAGG	CCGGCCTCTT	TCCGGTCCTC	CACCTCGGCC
	67861	GCCCCGTGGT	CGCCTACTGG	ATCTTCCCCT	ACCCCGCGAC	GATGCAGGTG	TGGCCGCACT
	67921	TCCGGAGCGC	GCTGCCGTGG	GACGCCGCCG	CGATCGCGAC	CTACTTCACG	GTGTGCTCC
	67981	TGTTCTGGTA	CATGGGCCTC	GTCCCGGATC	TGGCGGCGCT	GCGCGACCAC	GCCCCGGGCC
	68041	GCGTCCGGCG	GGTGATCTAC	GGGCTCATGT	CGTTCGGCTG	GCACGGCGGG	GCCGACCACT
30	68101	TCCGGCATT	CCGGGTGCTG	TACGGGCTGC	TCGCGGGGCT	CGCGACGCCC	CTCGTCGTCT
	68161	CGGTGCACTC	GATCGTGAGC	AGCGATTTCG	CGATCGCCCT	GGTGCCCGGC	TGGCACTCGA
	68221	CGCTCTTTCC	GCCGTTCTTC	GTCGCGGGCG	CGATCTTCTC	CGGGTTTCGCG	ATGGTGCTCA
	68281	CGTGCTCAT	CCCGGTGCGG	CGGATCTACG	GGCTCCATAA	CGTCGTGACC	GCGCGCCACC
	68341	TCGACGATCT	CGCGAAGATG	ACGCTCGTGA	CCGGCTGGAT	CGTCATCCTC	TCGTACATCA
35	68401	TCGAGAACTT	CCTCGCCTGG	TACAGCGGCT	CGGCGTACGA	GATGCATCAG	TTTTTCCAGA
	68461	CGCGCCTGCA	CGGCCCCGAA	AGCGCCGCTT	ACTGGGCCCC	GCACGTCTGC	AACGTGCTCG
	68521	TCATCCAGCT	CCTCTGGAGC	GAGCGGATCC	GGACGAGCCC	CGTCGCGCTG	TGGCTCATCT
	68581	CCCTCCTGGT	CAACGTCGGG	ATGTGAGGCG	AGCGGTTTAC	GCTCATCTG	ATGTCGCTCG
	68641	AGCAAGAGTT	CCTCCCCTCC	AAGTGGCACG	GCTACAGCCC	GACGTGGGTG	GACTGGAGCC
40	68701	TCTTCATCGG	GTCAGGCGGC	TTCTTCATGC	TCCTGTTTCT	GAGCTTTTTG	CGCGTCTTTC
	68761	CGTTCATCCC	CGTCGCGGAG	GTCAAGGAGC	TCAACCATGA	AGAGCTGGAG	AAGGCTCGGG
	68821	GCGAGGGGGG	CCGCTGATGG	AGACCGGAAT	GCTCGGCGAG	TTCGATGACC	CGGAGGCGAT
	68881	GCTCCATGCG	ATCCGAGAGC	TCAGGCGGCG	CGGCTACCGC	CGGGTGGGAG	CGTTACGCC
	68941	CTATCCGGTG	AAGGGGCTCG	ACGAGGCGCT	CGGCCTCCCG	CGCTCGAACC	TCAACCGGAT
45	69001	GGTGCTGCCC	TTCGCGATCC	TGGGGGTCGT	GGGCGGCTAC	TTCGTCCAGT	GGTTCTGCAA
	69061	CGCTTTCCAC	TATCCGCTGA	ACGTGGGCGG	GCGCCCGCTG	AACTCGGCGC	CGGCGTTTCT
	69121	CCCGATCACG	TTCGAGATGG	GGGTGCTCTC	CACCTCGATC	TTCGGCGTGC	TCATCGGCTT
	69181	TTACCTGACG	AGGCTGCCGA	GGCTCTACCT	CCCGCTCTTC	GACGCCCCGG	GCTTCGAGCG
	69241	CGTCACGCTG	GATCGGTTTC	TGGTCGGGCT	CGACGACACG	GAACCTTCCT	TCTCGAGCGC
50	69301	CCAGGCGGAG	CGCGACCTCC	TCGCGCTCGG	CGCCCGGCGC	GTCGTGCTCG	CGAGGAGGCG
	69361	CGAGGAGCCA	TGAGGGCCGG	CGCCCCGGCT	CGCCCTCTCG	GGCGCGCGCT	CGCGCCGTTT
	69421	GCCCTCGTCC	TGCTCGCCGG	GTGCCGCGAG	AAGGTGCTGC	CCGAGCCGGA	CTTCGAGCGG
	69481	ATGATCCGCC	AGGAGAAATA	CGGACTCTGG	GAGCCGTGCG	AGCACTTCGA	CGACGGCCGC
	69541	GCGATGCAGC	ACCCGCCCGG	GGGACCGGTC	GCGCGCGGGC	GCGTCACCGG	GCCGCCCGGC

	69601	TATCTCCAGG	GCGTCCTCGA	CGGGGCGTAC	GTCACGGAGG	TGCCGCTCTT	GCTCACGGTC
	69661	GAGCTCGTGC	AGCGCGGCCG	GCAGCGCTTC	GAGACCTTCT	GCGCGCCGTG	GCACGGGATC
	69721	CTCGGCGACG	GCAGCTCGCG	CGTGGCGACG	AACATGACGC	TGCGCCCCGC	CCCGTCTGCTC
	69781	ATCGGACCCG	AGGCGCGGAG	CTTCCCCGCC	GGCAGGATCT	ACCAGGTCAT	CATCGAGGGC
5	69841	TACGGCCTGA	TGCCGCGCTA	CTCGGACGAT	CTGCCCCACA	TCGAAGAGCG	CTGGGCCGTG
	69901	GTCGCCTACG	TGAAGGCGCT	TCAGCTGAGC	CGCGGAGTGG	CCGCGGGCGC	CCTCCCGCCA
	69961	GCGCTCCGCG	GCCGGGCGAG	GCAGGAGCTG	CGATGAACAG	GGATGCCATC	GAGTACAAGG
	70021	GCGGCGCGAC	GATCGCGGCC	TCGCTCGCGA	TCGCGGCGCT	CGGCGCGGTC	GCCGCGATCG
	70081	TCGGCGGCTT	CGTCGATCTC	CGCCGGTTCT	TCTTCTCGTA	CCTCGCCGCG	TGGTCGTTCT
10	70141	CGGTGTTTCT	GTCCGTGGGC	GCGCTCGTCA	CGCTCCTCAC	CTGCAACGCC	ATGCGCGCGG
	70201	GCTGGCCAC	GGCGGTGCGC	CGCCTCTCTG	AGACGATGGT	GGCGCCGCTG	CCTCTGCTCG
	70261	CGGCGCTCTC	CGCGCCGATC	CTGGTCTGGC	TGGACACGCT	GTATCCGTGG	ATGCACCCCG
	70321	AGCGGATCGC	CGGCGAGCAC	GCGCGGCGCA	TCCTCGAGCA	CAGGGCGCCC	TACTTCAATC
	70381	CAGGCTTCTT	CGTCGTGCGC	TCGGCGATCT	ACTTCGCGAT	CTGGATCGCC	GTGCGCCTCG
15	70441	TGCTCCGCCG	GCGATCGTTC	GCGCAGGACC	GTGAGCCGAG	GGCCGACGTC	AAGGACGCGA
	70501	TGTATGGCCT	GAGCGGCGCC	ATGCTGCCGG	TCGTGGCGAT	CACGATCGTC	TTCTCGTCGT
	70561	TCGACTGGCT	CATGTCCCTC	GACGCGACCT	GGTACTCGAC	GATGTTCCCG	GTCTACGTGT
	70621	TCGCGGACGC	CTTCGTGACC	GCCGTGCGCG	CGCTCACGGT	CCTCTCGTAT	GCGCGCGAGA
	70681	CGTCCGGCTA	CCTCGCGAGG	CTGAACGACT	CGCACTATTA	CGCGCTCGGG	CCGCTGCTCC
20	70741	TCGCGTTCAC	GATATTCTGG	GCCTATGCGG	CCTATTTCCA	GTTGATGTTG	ATCTGGATCG
	70801	CGAACAAGCC	CGATGAGGTC	GCCTTCTTCC	TCGACCGCTG	GGAAGGGCCC	TGGCGGCCGA
	70861	CCTCCGTGCT	CGTCGTCTCT	ACGCGGTTCT	TCGTCCCGTT	CCTGATCCTG	ATGTCGTACG
	70921	CGATCAAGCG	GCGCCCGCGC	CAGCTCTCGT	GGATGGCGCT	CTGGGTCTGTC	GTCTCCGGCT
	70981	ACATCGACTT	TCATGGGCTC	GTGGTGCCGG	CGACAGGGCG	CCACGGGTTT	GCCTATCACT
25	71041	GGCTCGACCT	CGCGACCTTG	TGCGTCGTGG	GCGGCCTCTC	GACCGCGTTC	GCCGCGTGGC
	71101	GGCTGCGAGG	GCGGCCGGTG	GTCCCGGTCC	ACGACCCGCG	GCTCGAAGAG	GCCTTTGCGT
	71161	ACCGGAGCAT	ATGATGTTCC	GTTTCCGTCA	CAGCGAGGTT	CGCCAGGAGG	AGGACACGCT
	71221	CCCCTGGGGG	CGCGTGATCC	TCGCGTTTCG	CGTCGTGCTC	GCGATCGGCG	GCGCGCTGAC
	71281	GCTCTGGGCC	TGGTCTCGGA	TGCGGGCCCC	CGAGGCGGAT	CTGCGGCGCT	CCCTCGCGTT
30	71341	CCCCGAGAAG	GATCTCGGGC	CGCGGCGCGA	GGTCGGCATG	GTCCAGCAGT	CGCTGTTCTGA
	71401	CGAGGCGCGC	CTGGGCCAGC	AGCTCGTCGA	CGCGCAGCGC	GCGGAGCTCC	GCCGCTTCGG
	71461	CGTCGTTCGAT	CGGGAGAGGG	GCATCGTGAG	CATCCCGATC	GACGACGCGA	TCGAGCTCAT
	71521	GGTGCGGGGG	GCGCGCGGAT	GAGCCGGGCC	GTCGCCGTGG	CCCTCCTGCT	GGCAGCCGGC
	71581	CTCGTGTCGC	GCCC GGCGC	CGCGTCCGAG	CCCGAGCGCG	CGCGCCCCCG	GCTGGGCCCC
35	71641	TCCGCGGCCG	ACGCCGCGCC	GGCGAGCGAG	GGCTCCGGCG	CGGAGGAGCC	GCCCGAAGGC
	71701	GCCTTCTCTG	AGCCACGCG	CGGGGTGGAC	ATCGAGGAGC	GCCTCGGGCG	GCCGGTGGAC
	71761	CGCGAGCTCG	CCTTACCGGA	CATGGACGGG	CGGCGGGTGC	GCCTCGGGCA	CTACTTCTGCC
	71821	GACGGCAAGC	CCCTCCTCCT	CGTCTCTCGC	TACTACCGGT	GTCCCGCGCT	GTGCGGCCCTC
	71881	GTGCTGCGCG	GCGCCGTCGA	GGGGCTGAAG	CTCCTCCCGT	ACCGGCTCGG	CGAGCAGTTC
40	71941	CACGCGCTCA	CGGTCAGCTT	CGACCCGCGC	GAGCGCCCGG	CGGCGCDD	

Example 2

Construction of a *Myxococcus xanthus* Expression Vector

The DNA providing the integration and attachment function of phage Mx8 was

45 inserted into commercially available pACYC184 (New England Biolabs). An ~2360 bp MfeI-SmaI from plasmid pPLH343, described in Salmi *et al.*, Feb. 1998, J. Bact. 180(3): 614-621, was isolated and ligated to the large EcoRI-XmnI restriction fragment of

plasmid pACYC184. The circular DNA thus formed was ~6 kb in size and called plasmid pKOS35-77.

Plasmid pKOS35-77 serves as a convenient plasmid for expressing recombinant PKS genes of the invention under the control of the epothilone PKS gene promoter. In one illustrative embodiment, the entire epothilone PKS gene with its homologous promoter is inserted in one or more fragments into the plasmid to yield an expression vector of the invention.

The present invention also provides expression vectors in which the recombinant PKS genes of the invention are under the control of a *Myxococcus xanthus* promoter. To construct an illustrative vector, the promoter of the *pilA* gene of *M. xanthus* was isolated as a PCR amplification product. Plasmid pSWU357, which comprises the *pilA* gene promoter and is described in Wu and Kaiser, Dec. 1997, J. Bact. 179(24):7748-7758, was mixed with PCR primers Seq1 and Mxpil1 primers:

Seq1: 5'-AGCGGATAACAATTTACACAGGAAACAGC-3'; and

Mxpil1: 5'-TTAATTAAGAGAAGGTTGCAACGGGGGGGC-3',

and amplified using standard PCR conditions to yield an ~800 bp fragment. This fragment was cleaved with restriction enzyme KpnI and ligated to the large KpnI-EcoRV restriction fragment of commercially available plasmid pLitmus 28 (New England Biolabs). The resulting circular DNA was designated plasmid pKOS35-71B.

The promoter of the *pilA* gene from plasmid pKOS35-71B was isolated as an ~800 bp EcoRV-SnaBI restriction fragment and ligated with the large MscI restriction fragment of plasmid pKOS35-77 to yield a circular DNA ~6.8 kb in size. Because the ~800 bp fragment could be inserted in either one of two orientations, the ligation produced two plasmids of the same size, which were designated as plasmids pKOS35-82.1 and pKOS35-82.2. Restriction site and function maps of these plasmids are presented in Figure 3.

Plasmids pKOS35-82.1 and pKOS35-82.2 serve as convenient starting materials for the vectors of the invention in which a recombinant PKS gene is placed under the control of the *Myxococcus xanthus pilA* gene promoter. These plasmids comprise a single PacI restriction enzyme recognition sequence placed immediately downstream of the

transcription start site of the promoter. In one illustrative embodiment, the entire epothilone PKS gene without its homologous promoter is inserted in one or more fragments into the plasmids at the *PacI* site to yield expression vectors of the invention.

The sequence of the *pilA* promoter in these plasmids is shown below.

```

5  CGACGCAGGTGAAGCTGCTTCGTGTGCTCCAGGAGCGGAAGGTGAAGCCGGTCGGCAGCGCCGCGGAGATT
   CCCTTCCAGGCGCGTGTTCATCGCGGCAACGAACCGGCGGCTCGAAGCCGAAGTAAAGCCGGACGCTTTCG
   TGAGGACCTCTTCTACCGGCTCAACGTCATCAGTTGGAGCTGCCTCCACTGCGCGAGCGTTCCGCGGACG
   TGTCGTTGCTGGCGAACTACTTCTGTCCAGACTGTGCGAGGAGTTGGGGCGACCCGGTCTGCGTTTCTCC
10  CCCGAGACACTGGGGCTATTGGAGCGCTATCCCTTCCCAGGCAACGTGCGGCAGCTGCAGAACATGGTGGA
   GCGGGCCGCGACCCCTGTGCGATTGAGACCTCCTGGGGCCCTCCACGCTTCCACCCGAGTGCAGGGGCGATA
   CAGACCCCGCCGTGCGTCCCGTGGAGGGCAGTGAGCCAGGGCTGGTGGCGGGCTTCAACCTGGAGCGGCAT
   CTCGACGACAGCGAGCGGCGCTATCTCGTCGCGGCGATGAAGCAGGCCGGGGCGTGAAGACCCGTGCTGC
   GGAGTTGCTGGGCCTTTCGTTCCGTTTATTCCGCTACCGGTTGGCCAAGCATGGGCTGACGGATGACTTGG
15  AGCCCGGGAGCGCTTCGGATGCGTAGGCTGATCGACAGTTATCGTCAGCGTCACTGCCGAATTTGTCAGC
   CCTGGACCCATCCTCGCGGAGGGGATTGTTCCAAGCCTTGAGAATTGGGGGGCTTGGAGTGCACACCTGGG
   TTGGCATGCGTAGTGCTAATCCCATCCGCGGGCGCAGTGCCCCCGTTGCAACCTTCTCTTAATTA
  
```

To make the recombinant *Myxococcus xanthus* host cells of the invention, *M. xanthus* cells are grown in CYE media (Campos and Zusman, 1975, Regulation of development in *Myxococcus xanthus*: effect of 3': 5'-cyclic AMP, ADP, and nutrition, Proc. Natl. Acad. Sci. USA 72: 518-522) to a Klett of 100 at 30°C at 300 rpm. The remainder of the protocol is conducted at 25°C unless otherwise indicated. The cells are then pelleted by centrifugation (8000 rpm for 10 min. in an SS34 or SA600 rotor) and resuspended in deionized water. The cells are again pelleted and resuspended in 1/100th of the original volume.

DNA (one to two μ L) is electroporated into the cells in a 0.1 cm cuvette at room temperature at 400 ohm, 25 μ FD, 0.65 V with a time constant in the range of 8.8 - 9.4. The DNA should be free of salts and so should be resuspended in distilled and deionized water or dialyzed on a 0.025 μ m Type VS membrane (Millipore). For low efficiency electroporations, spot dialyze the DNA, and allow outgrowth in CYE. Immediately after electroporation, add 1 mL of CYE, and pool the cells in the cuvette with an additional 1.5 mL of CYE previously added to a 50 mL Erlenmeyer flask (total volume 2.5 ml). Allow the cells to grow for four to eight hours (or overnight) at 30 to 32°C at 300 rpm to allow for expression of the selectable marker. Then, plate the cells in CYE soft agar on plates with selection. If kanamycin is the selectable marker, then typical yields are 10^3 to 10^5

per μ g of DNA. If streptomycin is the selectable marker, then it must be included in the top agar, because it binds agar.

With this procedure, the recombinant DNA expression vectors of the invention are electroporated into *Myxococcus* host cells that express recombinant PKSs of the invention and produce the epothilone, epothilone derivatives, and other novel polyketides encoded thereby.

Example 3

Construction of a Bacterial Artificial Chromosome (BAC) for Expression of Epothilone in *Myxococcus xanthus*

To express the epothilone PKS and modification enzyme genes in a heterologous host to produce epothilones by fermentation, *Myxococcus xanthus*, which is closely related to *Sorangium cellulosum* and for which a number of cloning vectors are available, can also be employed in accordance with the methods of the invention. Because both *M. xanthus* and *S. cellulosum* are myxobacteria, it is expected that they share common elements of gene expression, translational control, and post translational modification (if any), thereby enhancing the likelihood that the epo genes from *S. cellulosum* can be expressed to produce epothilone in *M. xanthus*. Secondly, *M. xanthus* has been developed for gene cloning and expression. DNA can be introduced by electroporation, and a number of vectors and genetic markers are available for the introduction of foreign DNA, including those that permit its stable insertion into the chromosome. Finally, *M. xanthus* can be grown with relative ease in complex media in fermentors and can be subjected to manipulations to increase gene expression, if required.

To introduce the epothilone gene cluster into *Myxococcus xanthus*, one can build the epothilone cluster into the chromosome by using cosmids of the invention and homologous recombination to assemble the complete gene cluster. Alternatively, the complete epothilone gene cluster can be cloned on a bacterial artificial chromosome (BAC) and then moved into *M. xanthus* for integration into the chromosome.

To assemble the gene cluster from cosmids pKOS35-70.1A2, and pKOS35-79.85, small regions of homology from these cosmids have to be introduced into *Myxococcus*

xanthus to provide recombination sites for larger pieces of the gene cluster. As shown in Figure 4, plasmids pKOS35-154 and pKOS90-22 are created to introduce these recombination sites. The strategy for assembling the epothilone gene cluster in the *M. xanthus* chromosome is shown in Figure 5. Initially, a neutral site in the bacterial chromosome is chosen that does not disrupt any genes or transcriptional units. One such region is downstream of the *devS* gene, which has been shown not to affect the growth or development of *M. xanthus*. The first plasmid, pKOS35-154, is linearized with *DraI* and electroporated into *M. xanthus*. This plasmid contains two regions of the *dev* locus flanking two fragments of the epothilone gene cluster. Inserted in between the *epo* gene regions are the kanamycin resistance marker and the *galK* gene. Kanamycin resistance arises in colonies if the DNA recombines into the *dev* region by a double recombination using the *dev* sequence as regions of homology. This strain, K35-159, contains small regions of the epothilone gene cluster that will allow for recombination of pKOS35-79.85. Because the resistance markers on pKOS35-79.85 are the same as that for K35-159, a tetracycline transposon was transposed into the cosmid, and cosmids that contain the transposon inserted into the kanamycin marker were selected. This cosmid, pKOS90-23, was electroporated into K35-159, and oxytetracycline resistant colonies were selected to create strain K35-174. To remove the unwanted regions from the cosmid and leave only the epothilone genes, cells were plated on CYE plates containing 1% galactose. The presence of the *galK* gene makes the cells sensitive to 1% galactose. Galactose resistant colonies of K35-174 represent cells that have lost the *galK* marker by recombination or by a mutation in the *galK* gene. If the recombination event occurs, then the galactose resistant strain is sensitive to kanamycin and oxytetracycline. Strains sensitive to both antibiotics are verified by Southern blot analysis. The correct strain is identified and designated K35-175 and contains the epothilone gene cluster from module 7 through two open reading frames past the *epoL* gene.


To introduce modules 1 through module 7, the above process is repeated once more. The plasmid pKOS90-22 is linearized with *DraI* and electroporated into K35-175 to create K35-180. This strain is electroporated with the tetracycline resistant version of pKOS35-70.1A2, pKOS90-38, and colonies resistant to oxytetracycline are selected. This

- 106 -

creates strain K35-185. Recombinants that now have the whole epothilone gene cluster are selected by resistance to 1% galactose. This results in strain K35-188. This strain contains all the epothilone genes as well as all potential promoters. This strain is fermented and tested for the production of epothilones A and B.

- 5 To clone the whole gene cluster as one fragment, a bacterial artificial chromosome (BAC) library is constructed. First, SMP44 cells are embedded in agarose and lysed according to the BIO-RAD genomic DNA plug kit. DNA plugs are partially digested with restriction enzyme, such as Sau3AI or HindIII, and electrophoresed on a FIGE or CHEF gel. DNA fragments are isolated by electroeluting the DNA from the
- 10 agarose or using gelase to degrade the agarose. The method of choice to isolate the fragments is electroelution, as described in Strong *et al.*, 1997, Nucleic Acids Res. 19: 3959-3961, incorporated herein by reference. The DNA is ligated into the BAC (pBeloBACII) cleaved with the appropriate enzyme. A map of pBeloBACII is shown below.

- 107 -



The DNA is electroporated into DH10B cells by the method of Sheng *et al.*, 1995, Nucleic Acids Res. 23: 1990-1996, incorporated herein by reference, to create an *S. cellulorum* genomic library. Colonies are screened using a probe from the NRPS region of the epothilone cluster. Positive clones are picked and DNA is isolated for restriction analysis to confirm the presence of the complete gene cluster. This positive clone is designated pKOS35-178.

To create a strain that can be used to introduce pKOS35-178, a plasmid, pKOS35-164, is constructed that contains regions of homology that are upstream and downstream of the epothilone gene cluster flanked by the dev locus and containing the kanamycin resistance galK cassette, analogous to plasmids pKOS90-22 and pKOS35-154. This plasmid is linearized with DraI and electroporated into *M. xanthus*, in accordance with the method of Kafeshi *et al.*, 1995, Mol. Microbiol. 15: 483-494, to create K35-183. The plasmid pKOS35-178 can be introduced into K35-183 by electroporation or by

transduction with bacteriophage P1 and chloramphenicol resistant colonies are selected. Alternatively, a version of pKOS35-178 that contains the origin of conjugative transfer from pRP4 can be constructed for transfer of DNA from *E. coli* to K35-183. This plasmid is made by first constructing a transposon containing the oriT region from RP4 and the tetracycline resistance maker from pACYC184 and then transposing the transposon *in vitro* or *in vivo* onto pKOS35-178. This plasmid is transformed into S17-1 and conjugated into *M. xanthus*. This strain, K35-190, is grown in the presence of 1% galactose to select for the second recombination event. This strain contains all the epothilone genes as well as all potential promoters. This strain will be fermented and tested for the production of epothilones A and B.

Besides integrating pKOS35-178 into the dev locus, it can also be integrated into a phage attachment site using integration functions from myxophages Mx8 or Mx9. A transposon is constructed that contains the integration genes and att site from either Mx8 or Mx9 along with the tetracycline gene from pACYC184. Alternative versions of this transposon may have only the attachment site. In this version, the integration genes are then supplied in trans by coelectroporation of a plasmid containing the integrase gene or having the integrase protein expressed in the electroporated strain from any constitutive promoter, such as the mgl promoter (see Magrini *et al.*, Jul. 1999, J. Bact. 181(13): 4062-4070, incorporated herein by reference). Once the transposon is constructed, it is transposed onto pKOS35-178 to create pKOS35-191. This plasmid is introduced into *Myxococcus xanthus* as described above. This strain contains all the epothilone genes as well as all potential promoters. This strain is fermented and tested for the production of epothilones A and B.

Once the epothilone genes have been established in a strain of *Myxococcus xanthus*, manipulation of any part of the gene cluster, such as changing promoters or swapping modules, can be performed using the kanamycin resistance and galK cassette.


Cultures of *Myxococcus xanthus* containing the epo genes are grown in a number of media and examined for production of epothilones. If the levels of production of epothilones (in particular B or D) are too low to permit large scale fermentation, the

M. xanthus-producing clones are subjected to media development and strain improvement, as described below for enhancing production in *Streptomyces*.

Example 4

Construction of a *Streptomyces* Expression Vector


The present invention provides recombinant expression vectors for the heterologous expression of modular polyketide synthase genes in *Streptomyces* hosts. These vectors include expression vectors that employ the actI promoter that is regulated by the gene actII ORF4 to allow regulated expression at high levels when growing cells enter stationary phase. Among the vectors available are plasmids pRM1 and pRM5, and derivatives thereof such as pCK7, which are stable, low copy plasmids that carry the marker for thiostrepton resistance in actinomycetes. Such plasmids can accommodate large inserts of cloned DNA and have been used for the expression of the DEBS PKS in *S. coelicolor* and *S. lividans*, the picromycin PKS genes in *S. lividans*, and the oleandomycin PKS genes in *S. lividans*. See U.S. Patent No. 5,712,146. Those of skill in the art recognize that *S. lividans* does not make the tRNA that recognizes the TTA codon for leucine until late-stage growth and that if production of a protein is desired earlier, then appropriate codon modifications can be made.



Plasmid pCK7

- 110 -

Another vector is a derivative of plasmid pSET152 and comprises the actII ORF4-PactI expression system but carries the selectable marker for apramycin resistance. These vectors contain the attP site and integrase gene of the actinophage phiC31 and do not replicate autonomously in *Streptomyces* hosts but integrate by site specific recombination into the chromosome at the attachment site for phiC31 after introduction into the cell.
Derivatives of pCK7 and pSET152 have been used together for the heterologous production of a polyketide, with different PKS genes expressed from each plasmid. See U.S. patent application Serial No. 60/129,731, filed 16 Apr. 1999, incorporated herein by reference.



Plasmid pKOS010-153, a pSET152 Derivative

The need to develop expression vectors for the epothilone PKS that function in *Streptomyces* is significant. The epothilone compounds are currently produced in the slow growing, genetically intractable host *Sorangium cellulosum* or are made synthetically. The streptomycetes, bacteria that produce more than 70% of all known antibiotics and important complex polyketides, are excellent hosts for production of epothilones and epothilone derivatives. *S. lividans* and *S. coelicolor* have been developed for the expression of heterologous PKS systems. These organisms can stably maintain cloned heterologous PKS genes, express them at high levels under controlled conditions, and modify the corresponding PKS proteins (e.g. phosphopantetheinylation) so that they

are capable of production of the polyketide they encode. Furthermore, these hosts contain the necessary pathways to produce the substrates required for polyketide synthesis, e.g. malonyl CoA and methylmalonyl CoA. A wide variety of cloning and expression vectors are available for these hosts, as are methods for the introduction and stable maintenance of large segments of foreign DNA. Relative to the slow growing *Sorangium* host, *S. lividans* and *S. coelicolor* grow well on a number of media and have been adapted for high level production of polyketides in fermentors. A number of approaches are available for yield improvements, including rational approaches to increase expression rates, increase precursor supply, etc. Empirical methods to increase the titers of the polyketides, long since proven effective for numerous other polyketides produced in streptomycetes, can also be employed for the epothilone and epothilone derivative producing host cells of the invention.

To produce epothilones by fermentation in a heterologous *Streptomyces* host, the epothilone PKS (including the NRPS module) genes are cloned in two segments in derivatives of pCK7 (loading domain through module 6) and pKOS010-153 (modules 7 through 9). The two plasmids are introduced into *S. lividans* employing selection for thiostrepton and apramycin resistance. In this arrangement, the pCK7 derivative replicates autonomously whereas the pKOS010-153 derivative is integrated in the chromosome. In both vectors, expression of the epothilone genes is from the actI promoter resident within the plasmid.

To facilitate the cloning, the two epothilone PKS encoding segments (one for the loading domain through module six and one for modules seven through nine) were cloned as translational fusions with the N-terminal segment of the KS domain of module 5 of the ery PKS. High level expression has been demonstrated from this promoter employing KS5 as the first translated sequence, see Jacobsen *et al.*, 1998, Biochemistry 37: 4928-4934, incorporated herein by reference. A convenient BsaBI site is contained within the DNA segment encoding the amino acid sequence EPIAV that is highly conserved in many KS domains including the KS-encoding regions of *epoA* and of module 7 in *epoE*.

The expression vector for the loading domain and modules one through six of the epothilone PKS was designated pKOS039-124, and the expression vector for modules seven through nine was designated pKOS039-126. Those of skill in the art will recognize that other vectors and vector components can be used to make equivalent vectors.

5 Because preferred expression vectors of the invention, described below and derived from pKOS039-124 and pKOS039-126, have been deposited under the terms of the Budapest Treaty, only a summary of the construction of plasmids pKOS039-124 and pKOS039-126 is provided below.

The eryKS5 linker coding sequences were cloned as an ~0.4 kb PacI-BglII
10 restriction fragment from plasmid pKOS10-153 into pKOS039-98 to construct plasmid pKOS039-117. The coding sequences for the eryKS5 linker were linked to those for the epothilone loading domain by inserting the ~8.7 kb EcoRI-XbaI restriction fragment from cosmid pKOS35-70.1A2 into EcoRI-XbaI digested plasmid pLitmus28. The ~3.4 kb of BsaBI-NotI and ~3.7 kb NotI-HindIII restriction fragments from the resulting plasmid
15 were inserted into BsaBI-HindIII digested plasmid pKOS039-117 to construct plasmid pKOS039-120. The ~7 kb PacI-XbaI restriction fragment of plasmid pKOS039-120 was inserted into plasmid pKAO18' to construct plasmid pKOS039-123. The final pKOS039-124 expression vector was constructed by ligating the ~34 kb XbaI-AvrII restriction fragment of cosmid pKOS35-70.1A2 with the ~21.1 kb AvrII-XbaI restriction fragment
20 of pKOS039-123.

The plasmid pKOS039-126 expression vector was constructed as follows. First the coding sequences for module 7 were linked from cosmids pKOS35-70.4 and pKOS35-79.85 by cloning the ~6.9 kb BglII-NotI restriction fragment of pKOS35-70.4 and the ~5.9 kb NotI-HindIII restriction fragment of pKOS35-79.85 into BglII-HindIII
25 digested plasmid pLitmus28 to construct plasmid pKOS039-119. The ~12 kb NdeI-NheI restriction fragment of cosmid pKOS35-79.85 was cloned into NdeI-XbaI digested plasmid pKOS039-119 to construct plasmid pKOS039-122.

To fuse the eryKS5 linker coding sequences with the coding sequences for module 7, the ~1 kb BsaBI-BglII restriction fragment derived from cosmid pKOS35-70.4
30 was cloned into BsaBI-BclII digested plasmid pKOS039-117 to construct plasmid

- 113 -

pKOS039-121. The ~21.5 kb AvrII restriction fragment from plasmid pKOS039-122 was cloned into AvrII-XbaI digested plasmid pKOS039-121 to construct plasmid pKOS039-125. The ~21.8 kb PacI-EcoRI restriction fragment of plasmid pKOS039-125 was ligated with the ~9 kb PacI-EcoRI restriction fragment of plasmid pKOS039-44 to construct
5 pKOS039-126.

Plasmids pKOS039-124 and pKOS126 were introduced into *S. lividans* K4-114 sequentially employing selection for the corresponding drug resistance marker. Because plasmid pKOS039-126 does not replicate autonomously in streptomycetes, the selection is for cells in which the plasmid has integrated in the chromosome by site-specific
10 recombination at the attB site of phiC31. Because the plasmid stably integrates, continued selection for apramycin resistance is not required. Selection can be maintained if desired. The presence of thiostrepton in the medium is maintained to ensure continued selection for plasmid pKOS039-124. Plasmids pKOS039-124 and pKOS039-126 were transformed into *Streptomyces lividans* K4-114, and transformants containing the plasmids were
15 cultured and tested for production of epothilones. Initial tests did not indicate the presence of an epothilone.

To improve production of epothilones from these vectors, the eryKS5 linker sequences were replaced by epothilone PKS gene coding sequences, and the vectors were introduced into *Streptomyces coelicolor* CH999. To amplify by PCR coding sequences
20 from the *epoA* gene coding sequence, two oligonucleotides primers were used: N39-73, 5'-GCTTAATTAAGGAGGACACATATGCCCGTCGTGGCGGATCGTCC-3'; and N39-74, 5'-GCGGATCCTCGAATCACCGCCAATATC-3'.

The template DNA was derived from cosmid pKOS35-70.8A3. The ~0.8 kb PCR product was digested with restriction enzymes PacI and BamHI and then ligated with the ~2.4 kb
25 BamHI-NotI and the ~6.4 kb PacI-NotI restriction fragments of plasmid pKOS039-120 to construct plasmid pKOS039-136. To make the expression vector for the *epoA*, *epoB*, *epoC*, and *epoD* genes, the ~5 kb PacI-AvrII restriction fragment of plasmid pKOS039-136 was ligated with the ~50 kb PacI-AvrII restriction fragment of plasmid pKOS039-124 to construct the expression plasmid pKOS039-124R. Plasmid pKOS039-124R has

been deposited with the ATCC under the terms of the Budapest Treaty and is available under accession number _____.

To amplify by PCR sequences from the *epoE* gene coding sequence, two oligonucleotide primers were used:

- 5 N39-67A, 5'-GCTTAATTAAGGAGGACACATATGACCGACCGAGAAGGCCAGCTC-CTGGA-3', and N39-68, 5'-GGACCTAGGCGGGATGCCGGCGTCT-3'.

The template DNA was derived from cosmid pKOS35-70.1A2. The ~0.4 kb amplification product was digested with restriction enzymes *PacI* and *AvrII* and ligated with either the ~29.5 kb *PacI*-*AvrII* restriction fragment of plasmid pKOS039-126 or the
10 ~23.8 kb *PacI*-*AvrII* restriction fragment of plasmid pKOS039-125 to construct plasmid pKOS039-126R or plasmid pKOS039-125R, respectively. Plasmid pKOS039-126R was deposited with the ATCC under the terms of the Budapest Treaty and is available under accession number _____.

The plasmid pair pKOS039-124R and pKOS039-126R (as well as the plasmid
15 pair pKOS039-124 and pKOS039-126) contain the full complement of *epoA*, *epoB*, *epoC*, *epoD*, *epoE*, *epoF*, *epoK*, and *epoL* genes. The latter two genes are present on plasmid pKOS039-126R (as well as plasmid pKOS039-126); however, to ensure that these genes were expressed at high levels, another expression vector of the invention, plasmid pKOS039-141 (Figure 8), was constructed in which the *epoK* and *epoL* genes
20 were placed under the control of the *ermE** promoter.

The *epoK* gene sequences were amplified by PCR using the oligonucleotide primers:

- N39-69, 5'-AGGCATGCATATGACCCAGGAGCAAGCGAATCAGAGTG-3'; and
N39-70, 5'-CCAAGCTTTATCCAGCTTTGGAGGGCTTCAAG-3'.

25 The *epoL* gene sequences were amplified by PCR using the oligonucleotide primers:

- N39-71A, 5'-GTAAGCTTAGGAGGACACATATGATGCAACTCGCGCGGGTG-3'; and
N39-72, 5'-GCCTGCAGGCTCAGGCTTGCGCAGAGCGT-3'.

The template DNA for the amplifications was derived from cosmid pKOS35-
30 79.85. The PCR products were subcloned into PCR-script for sequence analysis. Then,

- 115 -

the *epoK* and *epoL* genes were isolated from the clones as NdeI-HindIII and HindIII-EcoRI restriction fragments, respectively, and ligated with the ~6 kb NdeI-EcoRI restriction fragment of plasmid pKOS039-134B, which contains the *ermE** promoter, to construct plasmid pKOS039-140. The ~2.4 kb NheI-PstI restriction fragment of plasmid pKOS039-140 was cloned into XbaI-PstI digested plasmid pSAM-Hyg, a plasmid pSAM2 derivative containing a hygromycin resistance conferring gene, to construct plasmid pKOS039-141.

Another variant of plasmid pKOS039-126R was constructed to provide the *epoE* and *epoF* genes on an expression vector without the *epoK* and *epoL* genes. This plasmid, pKOS045-12 (Figure 9), was constructed as follows. Plasmid pXH106 (described in J. Bact., 1991, 173: 5573-5577, incorporated herein by reference) was digested with restriction enzymes StuI and BamHI, and the ~2.8 kb restriction fragment containing the *xylE* and hygromycin resistance conferring genes was isolated and cloned into EcoRV-BglII digested plasmid pLitmus28. The ~2.8 kb NcoI-AvrII restriction fragment of the resulting plasmid was ligated to the ~18 kb PacI-BspHI restriction fragment of plasmid pKOS039-125R and the ~9 kb SpeI-PacI restriction fragment of plasmid pKOS039-42 to construct plasmid pKOS045-12.

To construct an expression vector that comprised only the *epoL* gene, plasmid pKOS039-141 was partially digested with restriction enzyme NdeI, the ~9 kb NdeI restriction fragment was isolated, and the fragment then circularized by ligation to yield plasmid pKOS039-150.

The various expression vectors described above were then transformed into *Streptomyces coelicolor* CH999 and *S. lividans* K4-114 in a variety of combinations, the transformed host cells fermented on plates and in liquid culture (R5 medium, which is identical to R2YE medium without agar). Typical fermentation conditions follow. First, a seed culture of about 5 mL containing 50 µg/L thiostrepton was inoculated and grown at 30°C for two days. Then, about 1 to 2 mL of the seed culture was used to inoculate a production culture of about 50 mL containing 50 µg/L thiostrepton and 1 mM cysteine, and the production culture was grown at 30°C for 5 days. Also, the seed culture was used

to prepare plates of cells (the plates contained the same media as the production culture with 10 mM propionate), which were grown at 30°C for nine days.

Certain of the *Streptomyces coelicolor* cultures and culture broths were analyzed for production of epothilones. The liquid cultures were extracted with three times with
5 equal volumes of ethyl acetate, the organic extracts combined and evaporated, and the residue dissolved in acetonitrile for LC/MS analysis. The agar plate media was chopped and extracted twice with equal volumes of acetone, and the acetone extracts were combined and evaporated to an aqueous slurry, which was extracted three times with equal volumes of ethyl acetate. The organic extracts were combined and evaporated, and
10 the residue dissolved in acetonitrile for LC/MS analysis.

Production of epothilones was assessed using LC-mass spectrometry. The output flow from the UV detector of an analytical HPLC was split equally between a Perkin-Elmer/Sciex API100LC mass spectrometer and an Alltech 500 evaporative light scattering detector. Samples were injected onto a 4.6 x 150 mm reversed phase HPLC
15 column (MetaChem 5 m ODS-3 Inertsil) equilibrated in water with a flow rate of 1.0 mL/min. UV detection was set at 250 nm. Sample components were separated using H₂O for 1 minute, then a linear gradient from 0 to 100% acetonitrile over 10 minutes. Under these conditions, epothilone A elutes at 10.2 minutes and epothilone B elutes at 10.5 minutes. The identity of these compounds was confirmed by the mass spectra obtained
20 using an atmospheric chemical ionization source with orifice and ring voltages set at 75 V and 300 V, respectively, and a mass resolution of 0.1 amu. Under these conditions, epothilone A shows [M+H] at 494.4 amu, with observed fragments at 476.4, 318.3, and 306.4 amu. Epothilone B shows [M+H] at 508.4 amu, with observed fragments at 490.4, 320.3, and 302.4 amu.

25 Transformants containing the vector pairs pKOS039-124R and pKOS039-126R or pKOS039-124 and pKOS039-126R produced detectable amounts of epothilones A and B. Transformants containing these plasmid pairs and the additional plasmid pKOS039-141 produced similar amounts of epothilones A and B, indicating that the additional copies of the *epoK* and *epoL* genes were not required for production under the test conditions
30 employed. Thus, these transformants produced epothilones A and B when recombinant

epoA, *epoB*, *epoC*, *epoD*, *epoE*, *epoF*, *epoK*, and *epoL* genes were present. In some cultures, it was observed that the absence of propionate increased the proportion of epothilone B to epothilone A.

Transformants containing the plasmid pair pKOS039-124R and pKOS045-12
5 produced epothilones C and D, as did transformants containing this plasmid pair and the additional plasmid pKOS039-150. These results showed that the *epoL* gene was not required under the test conditions employed to form the C-12-C-13 double bond. These results indicate that either the epothilone PKS gene alone is able to form the double bond or that *Streptomyces coelicolor* expresses a gene product able to convert epothilones G
10 and H to epothilones C and D. Thus, these transformants produced epothilones C and D when recombinant *epoA*, *epoB*, *epoC*, *epoD*, *epoE*, and *epoF* genes were present.

The heterologous expression of the epothilone PKS described herein is believed to represent the recombinant expression of the largest proteins and active enzyme complex that have ever been expressed in a recombinant host cell. The epothilone
15 producing *Streptomyces coelicolor* transformants exhibited growth characteristics indicating that either the epothilone PKS genes, or their products, or the epothilones inhibited cell growth or were somewhat toxic to the cells. Any such inhibition or toxicity could be due to accumulation of the epothilones in the cell, and it is believed that the native *Sorangium* producer cells may contain transporter proteins that in effect pump
20 epothilones out of the cell. Such transporter genes are believed to be included among the ORFs located downstream of the *epoK* gene and described above. Thus, the present invention provides *Streptomyces* and other host cells that include recombinant genes that encode the products of one or more, including all, of the ORFs in this region.

For example, each ORF can be cloned behind the *ermE** promoter, see Stassi *et*
25 *al.*, 1998, Appl. Microbiol. Biotechnol. 49: 725-731, incorporated herein by reference, in a pSAM2-based plasmid that can integrate into the chromosome of *Streptomyces coelicolor* and *S. lividans* at a site distinct from *attB* of phage ϕ C31, see Smokvina *et al.*, 1990, Gene 94: 53-59, incorporated herein by reference. A pSAM2-based vector carrying the gene for hygromycin resistance is modified to carry the *ermE** promoter

- 118 -

along with additional cloning sites. Each ORF downstream is PCR cloned into the vector which is then introduced into the host cell (also containing pKOS039-124R and pKOS039-126R or other expression vectors of the invention) employing hygromycin selection. Clones carrying each individual gene downstream from *epoK* are analyzed for
5 increased production of epothilones.

Additional fermentation and strain improvement efforts can be conducted as illustrated by the following. The levels of expression of the PKS genes in the various constructs can be measured by assaying the levels of the corresponding mRNAs (by quantitative RT PCR) relative to the levels of another heterologous PKS mRNA (e.g.
10 picromycin) produced from genes cloned in similar expression vectors in the same host. If one of the epothilone transcripts is underproduced, experiments to enhance its production by cloning the corresponding DNA segment in a different expression vector are conducted. for example, multiple copies of any one or more of the epothilone PKS genes can be introduced into a cell if one or more gene products are rate limiting for
15 biosynthesis. If the basis for low level production is not related to low level PKS gene expression (at the RNA level), an empirical mutagenesis and screening approach that is the backbone of yield improvement of every commercially important fermentation product is undertaken. Spores are subjected to UV, X-ray or chemical mutagens, and individual survivors are plated and picked and tested for the level of compound produced
20 in small scale fermentations. Although this process can be automated, one can examine several thousand isolates for quantifiable epothilone production using the susceptible fungus *Mucor hiemalis* as a test organism.

Another method to increase the yield of epothilones produced is to change the KS^Y domain of the loading domain of the epothilone PKS to a KS^Q domain. Such altered
25 loading domains can be constructed in any of a variety of ways, but one illustrative method follows. Plasmid pKOS39-124R of the invention can be conveniently used as a starting material. To amplify DNA fragments useful in the construction, four oligonucleotide primers are employed:

N39-83: 5'-CCGGTATCCACCGCGACACACGGC-3',
30 N39-84: 5'-GCCAGTCGTCCTCGCTCGTGGCCGTTC-3',

and N39-73 and N39-74, which have been described above. The PCR fragment generated with N37-73 and N39-83 and the PCR fragment generated with N39-74 and N39-84 are treated with restriction enzymes PacI and BamHI, respectively, and ligated with the ~3.1 kb PacI-BamHI fragment of plasmid pKOS39-120 to construct plasmid pKOS039-148.

- 5 The ~0.8 kb PacI-BamHI restriction fragment of plasmid pKOS039-148 (comprising the two PCR amplification products) is ligated with the ~2.4 kb BamHI-NotI restriction fragment and the ~6.4 kb PacI-NotI restriction fragment of plasmid pKOS39-120 to construct pKOS39-136Q. The ~5 kb PacI-AvrII restriction fragment of plasmid pKOS039-136Q is ligated to the ~50 kb PacI-AvrII restriction fragment of plasmid
10 pKOS039-124 to construct plasmid pKOS39-124Q. Plasmids pKOS039-124Q and pKOS039-126R are then transformed into *Streptomyces coelicolor* CH999 for epothilone production.

- The *epoA* through *epoF*, optionally with *epoK* or with *epoK* plus *epoL*, genes cloned and expressed are sufficient for the synthesis of epothilone compounds, and the
15 distribution of the C-12 H to C-12 methyl congeners appears to be similar to that seen in the natural host (A:B::2:1). This ratio reflects that the AT domain of module 4 more closely resembles that of the malonyl rather than methylmalonyl specifying AT consensus domains. Thus, epothilones D and B are produced at lower quantities than their C-12 unmethylated counterparts C and A. The invention provides PKS genes that
20 produce epothilone D and/or B exclusively. Specifically, methylmalonyl CoA specifying AT domains from a number of sources (e.g. the narbonolide PKS, the rapamycin PKS, and others listed above) can be used to replace the naturally occurring at domain in module 4. The exchange is performed by direct cloning of the incoming DNA into the appropriate site in the epothilone PKS encoding DNA segment or by gene replacement
25 through homologous recombination.

- For gene replacement through homologous recombination, the donor sequence to be exchanged is placed in a delivery vector between segments of at least 1 kb in length that flank the AT domain of *epo* module 4 encoding DNA. Crossovers in the homologous regions result in the exchange of the *epo* AT4 domain with that on the delivery vector.
30 Because pKOS039-124 and pKOS039-124R contain AT4 coding sequences, they can be

- 120 -

used as the host DNA for replacement. The adjacent DNA segments are cloned in one of a number of *E. coli* plasmids that are temperature sensitive for replication. The heterologous AT domains can be cloned in these plasmids in the correct orientation between the homologous regions as cassettes enabling the ability to perform several AT exchanges simultaneously. The reconstructed plasmid (pKOS039-124* or pKOS039-124R*) is tested for ability to direct the synthesis of epothilone B and/or by introducing it along with pKOS039-126 or pKOS039-126R in *Streptomyces coelicolor* and/or *S. lividans*.

Because the titers of the polyketide can vary from strain to strain carrying the different gene replacements, the invention provides a number of heterologous methylmalonyl CoA specifying AT domains to ensure that production of epothilone D at titers equivalent to that of the C and D mixture produced in the *Streptomyces coelicolor* host described above. In addition, larger segments of the donor genes can be used for the replacements, including, in addition to the AT domain, adjacent upstream and downstream sequences that correspond to an entire module. If an entire module is used for the replacement, the KS, methylmalonyl AT, DH, KR, ACP – encoding DNA segment can be obtained from for example and without limitation the DNA encoding the tenth module of the rapamycin PKS, or the first or fifth modules of the FK-520 PKS.

Example 5

Heterologous Expression of EpoK and Conversion of Epothilone D to Epothilone B

This Example describes the construction of *E. coli* expression vectors for *epoK*. The *epoK* gene product was expressed in *E. coli* as a fusion protein with a polyhistidine tag (his tag). The fusion protein was purified and used to convert epothilone D to epothilone B.

Plasmids were constructed to encode fusion proteins composed of six histidine residues fused to either the amino or carboxy terminus of EpoK. The following oligos were used to construct the plasmids:

55-101.a-1:

5' -AAAAACATATGCACCACCACCACCACATGACACAGGAGCAAGCGAAT-CAGAGTGAG-3',

- 121 -

55-101.b:

5'-AAAAAGGATCCTTAATCCAGCTTTGGAGGGCTT-3',

55-101.c:

5'-AAAAACATATGACACAGGAGCAAGCGAAT-3', and

5 55-101.d:

5'-AAAAAGGATCCTTAGTGGTGGTGGTGGTGGTGTCCAGCTTTGGAGGGCTTC-AAGATGAC-3'.

The plasmid encoding the amino terminal his tag fusion protein, pKOS55-121, was constructed using primers 55-101.a and 55-101.b, and the one encoding the carboxy terminal his tag, pKOS55-129, was constructed using primers 55-101.c and 55-101.d in
10 PCR reactions containing pKOS35-83.5 as the template DNA. Plasmid pKOS35-83.5 contains the ~5 kb NotI fragment comprising the *epoK* gene ligated into pBluescriptSKII+ (Stratagene). The PCR products were cleaved with restriction enzymes BamHI and NdeI and ligated into the BamHI and NdeI sites of pET22b (Invitrogen). Both plasmids were sequenced to verify that no mutations were introduced during the
15 PCR amplification. Protein gels were run as known in the art.

Purification of EpoK was performed as follows. Plasmids pKOS55-121 and pKOS55-129 were transformed into BL21(DE3) containing the groELS expressing plasmid pREP4-groELS (Caspers *et al.*, 1994, Cellular and Molecular Biology 40(5): 635-644). The strains were inoculated into 250 mL of M9 medium supplemented with 2
20 mM MgSO₄, 1% glucose, 20 mg thiamin, 5 mg FeCl₂, 4 mg CaCl₂ and 50 mg levulinic acid. The cultures were grown to an OD₆₀₀ between 0.4 and 0.6, at which point IPTG was added to 1 mM, and the cultures were allowed to grow for an additional two hours. The cells were harvested and frozen at -80°C. The frozen cells were resuspended in 10 ml of buffer 1 (5 mM imidazole, 500 mM NaCl, and 45 mM Tris pH 7.6) and were lysed by
25 sonicating three times for 15 seconds each on setting 8. The cellular debris was pelleted by spinning in an SS-34 rotor at 16,000 rpm for 30 minutes. The supernatant was removed and spun again at 16,000 rpm for 30 minutes. The supernatant was loaded onto a 5 mL nickel column (Novagen), after which the column was washed with 50 mL of buffer 1 (Novagen). EpoK was eluted with a gradient from 5 mM to 1M imidazole.
30 Fractions containing EpoK were pooled and dialyzed twice against 1 L of dialysis buffer (45 mM Tris pH7.6, 0.2 mM DTT, 0.1 mM EDTA, and 20% glycerol). Aliquots were

frozen in liquid nitrogen and stored at -80°C. The protein preparations were greater than 90% pure.

The EpoK assay was performed as follows (See Betlach *et al.*, *Biochem* (1998) 37:14937, incorporated herein by reference). Briefly, reactions consisted of 50 mM Tris (pH7.5), 21 μ M spinach ferredoxin, 0.132 units of spinach ferredoxin: NADP⁺ oxidoreductase, 0.8 units of glucose-6-phosphate dehydrogenase, 1.4 mM NADP, and 7.1 mM glucose-6-phosphate, 100 μ M or 200 μ M epothilone D (a generous gift of S. Danishefsky), and 1.7 μ M amino terminal his tagged EpoK or 1.6 μ M carboxy terminal his tagged EpoK in a 100 μ L volume. The reactions were incubated at 30°C for 67 minutes and stopped by heating at 90°C for 2 minutes. The insoluble material was removed by centrifugation, and 50 μ L of the supernatant were analyzed by LC/MS. HPLC conditions: Metachem 5 μ ODS-3 Inertsil (4.6 X 150 mm); 80% H₂O for 1 min, then to 100% MeCN over 10 min at 1 mL/min, with UV (λ_{max} =250 nm), ELSD, and MS detection. Under these conditions, epothilone D eluted at 11.6 min and epothilone B at 9.3 min. the LC/MS spectra were obtained using an atmosphere pressure chemical ionization source with orifice and ring voltages set at 20 V and 250 V, respectively, at a mass resolution of 1 amu. Under these conditions, epothilone E shows an [M+H] at m/z 493, with observed fragments at 405 and 304. Epothilone B shows an [M+H] at m/z 509, with observed fragments at 491 and 320.


The reactions containing EpoK and epothilone D contained a compound absent in the control that displayed the same retention time, molecular weight, and mass fragmentation pattern as pure epothilone B. With an epothilone D concentration of 100 μ M, the amino and the carboxy terminal his tagged EpoK was able to convert 82% and 58% to epothilone B, respectively. In the presence of 200 μ M, conversion was 44% and 21%, respectively. These results demonstrate that EpoK can convert epothilone D to epothilone B.

- 123 -

Example 6

Modified Epothilones from Chemobiosynthesis


This Example describes a series of thioesters provided by the invention for production of epothilone derivatives via chemobiosynthesis. The DNA sequence of the biosynthetic gene cluster for epothilone from *Sorangium cellulosum* indicates that priming of the PKS involves a mixture of polyketide and amino acid components. Priming involves loading of the PKS-like portion of the loading domain with malonyl CoA followed by decarboxylation and loading of the module one NRPS with cysteine, then condensation to form enzyme-bound N-acetylcysteine. Cyclization to form a thiazoline is followed by oxidation to form enzyme bound 2-methylthiazole-4-carboxylate, the product of the loading domain and NRPS. Subsequent condensation with methylmalonyl CoA by the ketosynthase of module 2 provides the substrate for module, as shown in the following diagram.



The present invention provides methods and reagents for chemobiosynthesis to produce epothilone derivatives in a manner similar to that described to make 6-dEB and


erythromycin analogs in PCT Pat. Pub. Nos. 99/03986 and 97/02358. Two types of feeding substrates are provided: analogs of the NRPS product, and analogs of the module 3 substrate. The module 2 substrates are used with PKS enzymes with a mutated NRPS-like domain, and the module 3 substrates are used with PKS enzymes with a mutated KS domain in module 2.

The following illustrate module 2 substrates (as N-acetyl cysteamine thioesters) for use as substrates for epothilone PKS with modified inactivated NRPS:



The module 2 substrates are prepared by activation of the corresponding carboxylic acid and treatment with N-acetylcysteamine. Activation methods include formation of the acid chloride, formation of a mixed anhydride, or reaction with a condensing reagent such as a carbodiimide.

Exemplary module 3 substrates, also as NAc thioesters for use as substrates for epothilone PKS with KS2 knockout are:



These compounds are prepared in a three-step process. First, the appropriate aldehyde is treated with a Wittig reagent or equivalent to form the substituted acrylic ester. The ester is saponified to the acid, which is then activated and treated with N-acetylcysteamine.

Illustrative reaction schemes for making module 2 and module 3 substrates follow. Additional compounds suitable for making starting materials for polyketide synthesis by the epothilone PKS are shown in Figure 2 as carboxylic acids (or aldehydes that can be converted to carboxylic acids) that are converted to the N-acetylcysteamides for supplying to the host cells of the invention.

A. Thiophene-3-carboxylate N-acetylcysteamine thioester

A solution of thiophene-3-carboxylic acid (128 mg) in 2 mL of dry tetrahydrofuran under inert atmosphere was treated with triethylamine (0.25 mL) and diphenylphosphoryl azide (0.50 mL). After 1 hour, N-acetylcysteamine (0.25 mL) was added, and the reaction was allowed to proceed for 12 hours. The mixture was poured into water and extracted three times with equal volumes of ethyl acetate. The organic extracts were combined, washed sequentially with water, 1 N HCl, sat. CuSO₄, and brine, then dried over MgSO₄, filtered, and concentrated under vacuum. Chromatography on SiO₂ using ether followed by ethyl acetate provided pure product, which crystallized upon standing.

B. Furan-3-carboxylate N-acetylcysteamine thioester

A solution of furan-3-carboxylic acid (112 mg) in 2 mL of dry tetrahydrofuran under inert atmosphere was treated with triethylamine (0.25 mL) and diphenylphosphoryl azide (0.50 mL). After 1 hour, N-acetylcysteamine (0.25 mL) was added and the reaction was allowed to proceed for 12 hours. The mixture was poured into water and extracted three times with equal volumes of ethyl acetate. The organic extracts were combined, washed sequentially with water, 1 N HCl, sat. CuSO₄, and brine, then dried over MgSO₄, filtered, and concentrated under vacuum. Chromatography on SiO₂ using ether followed by ethyl acetate provided pure product, which crystallized upon standing.

C. Pyrrole-2-carboxylate N-acetylcysteamine thioester

A solution of pyrrole-2-carboxylic acid (112 mg) in 2 mL of dry tetrahydrofuran under inert atmosphere was treated with triethylamine (0.25 mL) and diphenylphosphoryl azide (0.50 mL). After 1 hour, N-acetylcysteamine (0.25 mL) was added and the reaction was allowed to proceed for 12 hours. The mixture was poured into water and extracted three times with equal volumes of ethyl acetate. The organic extracts were combined, washed sequentially with water, 1 N HCl, sat. CuSO₄, and brine, then dried over MgSO₄, filtered, and concentrated under vacuum. Chromatography on SiO₂ using ether followed by ethyl acetate provided pure product, which crystallized upon standing.

D. 2-Methyl-3-(3-thienyl)acrylate N-acetylcysteamine thioester

(1) Ethyl 2-methyl-3-(3-thienyl)acrylate: A mixture of thiophene-3-carboxaldehyde (1.12 g) and (carbethoxyethylidene)triphenylphosphorane (4.3 g) in dry tetrahydrofuran (20 mL) was heated at reflux for 16 hours. The mixture was cooled to ambient temperature and concentrated to dryness under vacuum. The solid residue was suspended in 1:1 ether/hexane and filtered to remove triphenylphosphine oxide. The filtrate was filtered through a pad of SiO₂ using 1:1 ether/hexane to provide the product (1.78 g, 91%) as a pale yellow oil.

(2) 2-Methyl-3-(3-thienyl)acrylic acid: The ester from (1) was dissolved in a mixture of methanol (5 mL) and 8 N KOH (5 mL) and heated at reflux for 30 minutes. The mixture was cooled to ambient temperature, diluted with water, and washed twice with ether. The aqueous phase was acidified using 1N HCl then extracted 3 times with equal volumes of ether. The organic extracts were combined, dried with MgSO₄, filtered, and concentrated to dryness under vacuum. Crystallization from 2:1 hexane/ether provided the product as colorless needles.

(3) 2-Methyl-3-(3-thienyl)acrylate N-acetylcysteamine thioester: A solution of 2-Methyl-3-(3-thienyl)acrylic acid (168 mg) in 2 mL of dry tetrahydrofuran under inert atmosphere was treated with triethylamine (0.56 mL) and diphenylphosphoryl azide (0.45 mL). After 15 minutes, N-acetylcysteamine (0.15 mL) is added and the reaction is allowed to proceed for 4 hours. The mixture is poured into water and extracted three times with equal volumes of ethyl acetate. The organic extracts are combined, washed sequentially with water, 1 N HCl, sat. CuSO₄, and brine, then dried over MgSO₄, filtered, and concentrated under vacuum. Chromatography on SiO₂ using ethyl acetate provided pure product, which crystallized upon standing.

The above compounds are supplied to cultures of host cells containing a recombinant epothilone PKS of the invention in which either the NRPS or the KS domain of module 2 as appropriate has been inactivated by mutation to prepare the corresponding epothilone derivative of the invention.

Example 7

Producing Epothilones and Epothilone Derivatives in *Sorangium cellulosum* SMP44

The present invention provides a variety of recombinant *Sorangium cellulosum* host cells that produce less complex mixtures of epothilones than the naturally occurring epothilone producers as well as host cells that produce epothilone derivatives. This Example illustrates the construction of such strains by describing how to make a strain that produce only epothilones C and D without epothilones A and B. To construct this strain, an inactivating mutation is made in *epoK*. Using plasmid pKOS35-83.5, which contains a NotI fragment harboring the *epoK* gene, the kanamycin and bleomycin resistance markers from Tn5 are ligated into the ScaI site of the *epoK* gene to construct pKOS90-55. The orientation of the resistance markers is such that transcription initiated at the kanamycin promoter drives expression of genes immediately downstream of *epoK*. In other words, the mutation should be nonpolar. Next, the origin of conjugative transfer, oriT, from RP4 is ligated into pKOS90-55 to create pKOS90-63. This plasmid can be introduced into S17-1 and conjugated into SMP44. The transconjugants are selected on phleomycin plates as previously described. Alternatively, electroporation of the plasmid can be achieved using conditions described above for *Myxococcus xanthus*.

Because there are three generalized transducing phages for *Myxococcus xanthus*, one can transfer DNA from *M. xanthus* to SMP44. First, the *epoK* mutation is constructed in *M. xanthus* by linearizing plasmid pKOS90-55 and electroporating into *M. xanthus*. Kanamycin resistant colonies are selected and have a gene replacement of *epoK*. This strain is infected with Mx9, Mx8, Mx4 ts18 hft hrm phages to make phage lysates. These lysates are then individually infected into SMP44 and phleomycin resistant colonies are selected. Once the strain is constructed, standard fermentation procedures, as described below, are employed to produce epothilones C and D.

Prepare a fresh plate of *Sorangium* host cells (dispersed) on S42 medium. S42 medium contains tryptone, 0.5 g/L; MgSO₄, 1.5 g/L; HEPES, 12 g/L; agar, 12 g/L, with deionized water. The pH of S42 medium is set to 7.4 with KOH. To prepare S42 medium, after autoclaving at 121°C for at least 30 minutes, add the following ingredients (per liter): CaCl₂, 1 g; K₂HPO₄, 0.06 g; Fe Citrate, 0.008 g; Glucose, 3.5 g; Ammonium

sulfate, 0.5 g; Spent liquid medium, 35 mL; and 200 micrograms/mL of kanamycin is added to prevent contamination. Incubate the culture at 32°C for 4-7 days, or until orange sorangia appear on the surface.

To prepare a seed culture for inoculating agar plates/bioreactor, the following protocol is followed. Scrape off a patch of orange *Sorangium* cells from the agar (about 5 mm²) and transfer to a 250 ml baffle flask with 38 mm silicone foam closures containing 50 ml of Soymeal Medium containing potato starch, 8 g; defatted soybean meal, 2 g; yeast extract, 2 g; Iron (III) sodium salt EDTA, 0.008 g; MgSO₄·7H₂O, 1 g; CaCl₂·2H₂O, 1 g; glucose, 2 g; HEPES buffer, 11.5 g. Use deionized water, and adjust pH to 7.4 with 10% KOH. Add 2-3 drops of antifoam B to prevent foaming. Incubate in a coffin shaker for 4-5 days at 30°C and 250 RPM. The culture should appear an orange color. This seed culture can be subcultured repeatedly for scale-up to inoculate in the desired volume of production medium.

The same preparation can be used with Medium 1 containing (per liter) CaCl₂·2H₂O, 1 g; yeast extract, 2 g; Soytone, 2 g; FeEDTA, 0.008 g; Mg SO₄·7H₂O, 1 g; HEPES, 11.5 g. Adjust pH to 7.4 with 10% KOH, and autoclave at 121°C for 30 minutes. Add 8 ml of 40% glucose after sterilization. Instead of a baffle flask, use a 250 ml coiled spring flask with a foil cover. Include 2-3 drops of antifoam B, and incubate in a coffin shaker for 7 days at 37°C and 250 RPM. Subculture the entire 50 mL into 500 mL of fresh medium in a baffled narrow necked Fernbach flask with a 38 mm silicone foam closure. Include 0.5 ml of antifoam to the culture. Incubate under the same conditions for 2-3 days. Use at least a 10% inoculum for a bioreactor fermentation.

To culture on solid media, the following protocol is used. Prepare agar plates containing (per liter of CNS medium) KNO₃, 0.5 g; Na₂HPO₄, 0.25 g; MgSO₄·7H₂O, 1 g; FeCl₂, 0.01 g; HEPES, 2.4 g; Agar, 15 g; and sterile Whatman filter paper. While the agar is not completely solidified, place a sterile disk of filter paper on the surface. When the plate is dry, add just enough of the seed culture to coat the surface evenly (about 1 mL). Spread evenly with a sterile loop or an applicator, and place in a 32°C incubator for 7 days. Harvest plates.

For production in a 5 L bioreactor, the following protocol is used. The fermentation can be conducted in a B. Braun Biostat MD-1 5L bioreactor. Prepare 4 L of production medium (same as the soymeal medium for the seed culture without HEPES buffer). Add 2% (volume to volume) XAD-16 absorption resin, unwashed and untreated, e.g. add 1 mL of XAD per 50 mL of production medium. Use 2.5 N H₂SO₄ for the acid bottle, 10% KOH for the base bottle, and 50% antifoam B for the antifoam bottle. For the sample port, be sure that the tubing that will come into contact with the culture broth has a small opening to allow the XAD to pass through into the vial for collecting daily samples. Stir the mixture completely before autoclaving to evenly distribute the components. Calibrate the pH probe and test dissolved oxygen probe to ensure proper functioning. Use a small antifoam probe, ~3 inches in length. For the bottles, use tubing that can be sterile welded, but use silicone tubing for the sample port. Make sure all fittings are secure and the tubings are clamped off, not too tightly, with C-clamps. Do not clamp the tubing to the exhaust condenser. Attach 0.2 µm filter disks to any open tubing that is in contact with the air. Use larger ACRO 50 filter disks for larger tubing, such as the exhaust condenser and the air inlet tubing. Prepare a sterile empty bottle for the inoculum. Autoclave at 121°C with a sterilization time of 90 minutes. Once the reactor has been taken out of the autoclave, connect the tubing to the acid, base, and antifoam bottles through their respective pump heads. Release the clamps to these bottles, making sure the tubing has not been welded shut. Attach the temperature probe to the control unit. Allow the reactor to cool, while sparging with air through the air inlet at a low air flow rate.

After ensuring the pumps are working and there is no problem with flow rate or clogging, connect the hoses from the water bath to the water jacket and to the exhaust condenser. Make sure the water jacket is nearly full. Set the temperature to 32°C. Connect pH, D.O., and antifoam probes to the main control unit. Test the antifoam probe for proper functioning. Adjust the set point of the culture to 7.4. Set the agitation to 400 RPM. Calibrate the D.O. probe using air and nitrogen gas. Adjust the airflow using the rate at which the fermentation will operate, e.g. 1 LPM (liter per minute). To control the dissolved oxygen level, adjust the parameters under the cascade setting so that agitation

- 131 -

will compensate for lower levels of air to maintain a D.O. value of 50%. Set the minimum and maximum agitation to 400 and 1000 RPM respectively, based on the settings of the control unit. Adjust the settings, if necessary.

Check the seed culture for any contamination before inoculating the fermenter.

- 5 The *Sorangium cellulosum* cells are rod shaped like a pill, with 2 large distinct circular vacuoles at opposite ends of the cell. Length is approximately 5 times that of the width of the cell. Use a 10% inoculum (minimum) volume, e.g. 400 mL into 4 L of production medium. Take an initial sample from the vessel and check against the bench pH. If the difference between the fermenter pH and the bench pH is off by ≥ 0.1 units, do a 1 point
- 10 recalibration. Adjust the deadband to 0.1. Take daily 25 mL samples noting fermenter pH, bench pH, temperature, D.O., airflow, agitation, acid, base, and antifoam levels. Adjust pH if necessary. Allow the fermenter to run for seven days before harvesting.


- Extraction and analysis of compounds is performed substantially as described above in Example 4. In brief, fermentation culture is extracted twice with ethyl acetate,
- 15 and the ethyl acetate extract is concentrated to dryness and dissolved/suspended in ~500 μ L of MeCN-H₂O (1:1). The sample is loaded onto a 0.5 mL Bakerbond ODS SPE cartridge pre-equilibrated with MeCN-H₂O (1:1). The cartridge is washed with 1 mL of the same solvent, followed by 2 mL of MeCN. The MeCN eluent is concentrated to dryness, and the residue is dissolved in 200 μ L of MeCN. Samples (50 μ L) are analyzed
- 20 by HPLC/MS on a system comprised of a Beckman System Gold HPLC and PE Sciex API100LC single quadrapole MS-based detector equipped with an atmospheric pressure chemical ionization source. Ring and orifice voltages are set to 75V and 300V, respectively, and a dual range mass scan from m/z 290-330 and 450-550 is used. HPLC conditions: Metachem 5 μ ODS-3 Inertsil (4.6 X 150 mm); 100% H₂O for 1 min, then to
- 25 100% MeCN over 10 min at 1 mL/min. Epothilone A elutes at 0.2 min under these conditions and gives characteristic ions at m/z 494 (M+H), 476 (M+H-H₂O), 318, and 306.

Example 8

Epothilone Derivatives as Anti-Cancer Agents

The novel epothilone derivatives shown below by Formula (1) set forth above are potent anti-cancer agents and can be used for the treatment of patients with various forms of cancer, including but not limited to breast, ovarian, and lung cancers.

The epothilone structure-activity relationships based on tubulin binding assay are (see Nicolaou *et al.*, 1997, Angew. Chem. Int. Ed. Engl. 36: 2097-2103, incorporated herein by reference) are illustrated by the diagram below.



- 10 A) (3S) configuration important; B) 4,4-ethano group not tolerated; C) (6R, 7S) configuration crucial; D) (8S) configuration important, 8,8-dimethyl group not tolerated; E) epoxide not essential for tubulin polymerization activity, but may be important for cytotoxicity; epoxide configuration may be important; R group important; both olefin geometries tolerated; F) (15S) configuration important; G) bulkier group reduces activity; 15 H) oxygen substitution tolerated; I) substitution important; J) heterocycle important.

Thus, this SAR indicates that modification of the C1-C8 segment of the molecule can have strong effects on activity, whereas the remainder of the molecule is relatively tolerant to change. Variation of substituent stereochemistry with the C1-C8 segment, or removal of the functionality, can lead to significant loss of activity. Epothilone derivative 20 compounds A-H differ from epothilone by modifications in the less sensitive portion of

the molecule and so possess good biological activity and offer better pharmacokinetic characteristics, having improved lipophilic and steric profiles.

These novel derivatives can be prepared by altering the genes involved in the biosynthesis of epothilone optionally followed by chemical modification. The 9-hydroxy-
5 epothilone derivatives prepared by genetic engineering can be used to generate the carbonate derivatives (compound D) by treatment with triphosgene or 1,1' carbonyldiimidazole in the presence of a base. In a similar manner, the 9,11-dihydroxy-epothilone derivative, upon proper protection of the C-7 hydroxyl group if it is present, yields the carbonate derivatives (compound F). Selective oximation of the 9 oxo-
10 epothilone derivatives with hydroxylamine followed by reduction (Raney nickel in the presence of hydrogen or sodium cyanoborohydride) yield the 9-amino analogs. Reacting these 9-amino derivatives with p-nitrophenyl chloroformate in the presence of base and subsequently reacting with sodium hydride will produce the carbamate derivatives (compound E). Similarly, the carbamate compound G, upon proper protection of the C7
15 hydroxyl group if it is present, can be prepared from the 9-amino-11 hydroxy-epothilone derivatives.

Illustrative syntheses are provided below.

Part A. Epothilone D -7, 9-cyclic carbonate

To a round bottom flask, a solution of 254 mg epothilone D in 5 mL of methylene
20 chloride is added. It is cooled by an ice bath, and 0.3 mL of triethyl amine is then added. To this solution, 104 mg of triphosgene is added. The ice bath is removed, and the mixture is stirred under nitrogen for 5 hours. The solution is diluted with 20 mL of methylene chloride and washed with dilute sodium bicarbonate solution. The organic solution is dried over magnesium sulfate and filtered. Upon evaporation to dryness, the
25 epothilone D-7, 9 -cyclic carbonate is isolated.

Part B. Epothilone D-7,9-cyclic carbamate

(i) 9-amino-epothilone D

To a rounded bottom flask, a solution of 252 mg 9-oxo-epothilone D in 5 mL of
30 methanol is added. Upon the addition of 0.5 mL 50% hydroxylamine in water and 0.1 mL

acetic acid, the mixture is stirred at room temperature overnight. The solvent is then removed under reduced pressure to yield the 9-oxime-epothilone D. To a solution of this 9 oxime compound in 5 mL of tetrahydrofuran (THF) at ice bath is added 0.25 mL 1M solution of cyanoborohydride in THF. After the mixture is allowed to react for 1 hour, the ice bath is removed, and the solution is allowed to warm slowly to room temperature. One mL of acetic acid is added, and the solvent is then removed under reduced pressure. The residue is dissolved in 30 mL of methylene chloride and washed with saturated sodium chloride solution. The organic layer is separated and dried over magnesium sulfate and filtered. Upon evaporation of the solvent yields the 9-amino-epothilone D.

10 (ii) Epothilone D-7,9-cyclic carbamate

To a solution of 250 mg of 9-amino-epothilone D in 5 mL of methylene is added 110 mg of 4-nitrophenyl chloroformate followed by the addition of 1 mL of triethylamine. The solution is stirred at room temperature for 16 hours. It is diluted with 25 mL of methylene chloride. The solution is washed with saturated sodium chloride and the organic layer is separated and dried over magnesium sulfate. After filtration, the solution is evaporated to dryness at reduced pressure. The residue is dissolved in 10 mL of dry THF. Sodium hydride, 40 mg (60% dispersion in mineral oil), is added to the solution in an ice bath. The ice bath is removed, and the mixture is stirred for 16 hours. One-half mL of acetic acid is added, and the solution is evaporated to dryness under reduced pressure. The residue is re-dissolved in 50 mL methylene chloride and washed with saturated sodium chloride solution. The organic layer is dried over magnesium sulfate and the solution is filtered and the organic solvent is evaporated to dryness under reduced pressure. Upon purification on silica gel column, the epothilone D-7,9-carbamate is isolated.

25

The invention having now been described by way of written description and examples, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments and that the foregoing description and examples are for purposes of illustration and not limitation of the following claims.

- 135 -

Claims

1. An isolated recombinant nucleic acid compound that comprises a
nucleotide sequence encoding at least a domain of an epothilone polyketide synthase
5 (PKS) protein and/or encoding a functional region of an epothilone modification enzyme.

2. The nucleic acid of claim 1, wherein said domain is selected from the
group consisting of a loading domain, a thioesterase domain, an NRPS, an AT domain, a
KS domain, an ACP domain, a KR domain, a DH domain, and an ER domain, a methyl
10 transferase domain and a functional oxidase domain.

3. The nucleic acid of claim 1 or 2 that comprises the coding sequence of an
epoA gene, and/or
the coding sequence of an *epoB* gene, and/or
15 the coding sequence of an *epoC* gene, and/or
the coding sequence of an *epoD* gene, and/or
the coding sequence of an *epoE* gene, and/or
the coding sequence of an *epoF* gene, and/or
the coding sequence of an *epoK* gene, and/or
20 the coding sequence of an *epoL* gene.

4. The nucleic acid of any of claims 1-3 that further comprises a promoter
positioned to transcribe said encoding nucleotide sequence in host cells in which said
promoter is operable.

25

5. The nucleic acid of claim 4, wherein said promoter is a promoter from a
Sorangium gene, or
from a *Myxococcus* gene, or
from a *Streptomyces* gene, or
30 from an epothilone PKS gene, or

- 136 -

from a *pilA* gene, or
from an actinorhodin PKS gene.

6. The nucleic acid of any of claims 1-5 that is a recombinant DNA
5 expression vector.

7. Host cells which contain the nucleic acid of any of claims 4-6.

8. The cells of claim 7 which are *Sorangium* cells, or
10 *Myxococcus* cells, or
Pseudomonas cells, or
Streptomyces cells.

9. A method to produce a polyketide which method comprises culturing the
15 cells of claim 7 or 8 under conditions wherein the encoding nucleotide sequence is
expressed to obtain a functional PKS.

10. A recombinant *Sorangium cellulosum* host cell that contains a mutated
gene for an epothilone PKS protein or epothilone modification enzyme, wherein said
20 mutated gene was inserted in whole or in part into genomic DNA of said cell by
homologous recombination with a recombinant vector comprising all or a part of an
epothilone PKS gene or epothilone modification gene.

11. The recombinant host cell of claim 10 that
25 makes epothilone C or D but not A or B due to a mutation inactivating or deleting
an *epoK* gene, or
makes epothilone A or C but not B or D due to a mutation in *epoD* altering
module 4 AT domain specificity, or
makes epothilone B or D but not A or C due to a mutation in *epoD* altering
30 module 4 AT domain specificity, or

- 137 -

makes epothilone C but not epothilone A, B or D due to a mutation in *epoD*
altering module 4 AT domain specificity and a mutation in *epoK*, or

makes epothilone D but not epothilone A, B or C due to a mutation in *epoD*
altering module 4 AT domain specificity and a mutation in *epoK*.

5

12. Recombinant *Streptomyces* or *Myxococcus* host cells that express an
epothilone PKS gene or an epothilone modification enzyme gene, optionally comprising
one or more of said epothilone PKS or modification enzyme genes integrated into their
chromosomal DNA and/or one or more of said epothilone PKS or modification enzyme
10 genes on an extrachromosomal expression vector.

13. The host cells of claim 12 or 13 that are *S. coelicolor* CH999.

14. A method to produce an epothilone or epothilone derivative which
15 comprises culturing the cells of claims 12 or 13.

15. A modified functional epothilone PKS wherein said modification
comprises at least one of:

20 replacement of at least one AT domain with an AT domain of different
specificity;
inactivation of the NRPS-like module 1 or of the KS2 catalytic domain;
inactivation of at least one activity in at least one β -carbonyl modification
domain;
addition of at least one of KR, DH and ER activity in at least one β -carbonyl
25 modification domain; and
replacement of the NRPS module 1 with an NRPS of different specificity.

16. The modified PKS of claim 15 contained in a cell or contained in a cell-
free system, wherein said cell or system contains additional enzymes for modification of
30 the product of said epothilone PKS.

- 138 -

17. The modified PKS of claim 16 wherein said modifying enzymes comprise at least one of a methyltransferase, an oxidase or a glycosylation enzyme.

5 18. A method to prepare an epothilone derivative which method comprises providing substrates including extender units to the modified PKS of any of claims 15-17.

19. A modified functional epothilone PKS wherein said modification comprises inactivation of the NRPS of module 1 or the KS2 of module 2 thereof.

10

20. A method to make an epothilone derivative which method comprises contacting the modified PKS of claim 19 with a module 2 substrate or a module 3 substrate and extender units.

15

21. Recombinant host cells which comprise the modified PKS of any of claims 15-17 or 19.

20

22. The cells of claim 21 that produce an epothilone derivative selected from the group consisting of 16-desmethyl epothilones, 14-methyl epothilones, 11-hydroxyl epothilones, 10-methyl epothilones, 8,9-anhydro epothilones, 9-hydroxyl epothilones, 9-keto epothilones, 8-desmethyl epothilones, and 6-desmethyl epothilones.

25

23. A compound selected from the group consisting of 16-desmethyl epothilones, 14-methyl epothilones, 11-hydroxyl epothilones, 10-methyl epothilones, 8,9-anhydro epothilones, 9-hydroxyl epothilones, 9-keto epothilones, 8-desmethyl epothilones, and 6-desmethyl epothilones.

- 139 -


24. A recombinant PKS enzyme that comprises one or more domains, modules, or proteins of a non-epothilone PKS and one or more domains, modules, or proteins of an epothilone PKS, and/or contains a loading domain that comprises a KS^Q domain.

5

25. The PKS enzyme of claim 24, wherein said PKS comprises a DEBS loading domain and 5 modules of DEBS and an NRPS of the epothilone PKS, wherein said PKS comprises all of a non-epothilone PKS with an MT domain of the epothilone PKS

10

26. A compound of the formula:



15 including the glycosylated forms thereof and stereoisomeric forms where the stereochemistry is not shown,

wherein A is a substituted or unsubstituted straight, branched chain or cyclic alkyl, alkenyl or alkynyl residue optionally containing 1-3 heteroatoms selected from O, S and N; or wherein A comprises a substituted or unsubstituted aromatic residue;

20

R² represents H,H, or H,lower alkyl, or lower alkyl,lower alkyl;

X⁵ represents =O or a derivative thereof, or H,OH or H,NR₂ wherein R is H, alkyl or acyl, or H,OCOR₂, H,OCONR₂ wherein R is H or alkyl, or is H,H;

R⁶ represents H or lower alkyl, and the remaining substituent on the corresponding carbon is H;

- 140 -

X^7 represents OR, or NR_2 , wherein R is H, alkyl or acyl or is OCOR, or $OCONR_2$ wherein R is H or alkyl or X^7 taken together with X^9 forms a carbonate or carbamate cycle, and wherein the remaining substituent on the corresponding carbon is H;

R^8 represents H or lower alkyl and the remaining substituent on the carbon is H;

5 X^9 represents =O or a derivative thereof, or H,OR or H, NR_2 wherein R is H, alkyl or acyl, or is H,OCOR or H, $OCONR_2$, wherein R is H or alkyl, or represents H,H or wherein X^9 together with X^7 or with X^{11} can form a cyclic carbonate or carbamate;

R^{10} is H,H or H,lower alkyl, or lower alkyl,lower alkyl;

10 X^{11} is =O or a derivative thereof, or H,OR, or H, NR_2 wherein R is H, alkyl or acyl or H,OCOR or H, $OCONR_2$ wherein R is H or alkyl, or is H,H or wherein X^{11} in combination with X^9 may form a cyclic carbonate or carbamate;

R^{12} is H,H, or H,lower alkyl, or lower alkyl,lower alkyl;

X^{13} is =O or a derivative thereof, or H,OR or H, NR_2 wherein R is H, alkyl or acyl or is H,OCOR or H, $OCONR_2$ wherein R is H or alkyl;


15 R^{14} is H,H, or H,lower alkyl, or lower alkyl,lower alkyl;

R^{16} is H or lower alkyl; and


wherein optionally H or another substituent may be removed from positions 12 and 13 and/or 8 and 9 to form a double bond, wherein said double bond may optionally be converted to an epoxide.

20


27. A compound of the formula




- 141 -



1(b),




1(c),



1(d),

and

- 142 -



1(e)

wherein both Z are O or one Z is N and the other Z is O and the remaining substituents are defined as in claim 26.

5

28. A recombinant vector selected from the group consisting of pKOS35-70.8A3, pKOS35-70.1A2, pKOS35-70.4, pKOS35-79.85, pKOS039-124R, and pKOS039-126R.

- 143 -

Abstract

Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells for the
5 production of epothilones, epothilone derivatives, and polyketides that are useful as cancer chemotherapeutics, fungicides, and immunosuppressants.






Figure 2


Alternative Primers for Biosynthetic Epothilone Analogs




R =





X = CH₂, O, S
Y = CH₂, O, S




X = H, Me, Et, CH₂OH, Br
Y = O, S




X = H, Me, Et, Br, OH
Y = NH, O, S




X = NO₂, CN, Me, O-alkyl, halo, etc.
Y = CH, N




X = NO₂, CN, alkyl, aryl, halo, O-alkyl, etc.
Y = CH, N




X = NO₂, CN, alkyl, aryl, halo, O-alkyl, etc.
Y = CH, N



X = CH, N
Y = CH, N





X = CH₂, O, S, NH, N-alkyl, N-aryl
Y = CH₂, O, S, NH, N-alkyl, N-aryl



X = CH₂, O, S, NH, N-alkyl, N-aryl
Y = CH₂, O, S, NH, N-alkyl, N-aryl

Figure 3







Figure 4






Figure 5

Figure 6






Figure 7





Figure 8



pKos045-12
30.40 Kb

Figure 9

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR UTILITY PATENT APPLICATION**

AS A BELOW-NAMED INVENTOR, WE HEREBY DECLARE THAT:

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: **RECOMBINANT METHODS AND MATERIALS FOR PRODUCING EPOTHILONE AND EPOTHILONE DERIVATIVES**, the specification of which is attached hereto unless the following box is checked:

☒ was filed on November 19, 1999 as United States Application Serial No. _____ and was amended on _____ (if applicable).

WE HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
			<input type="checkbox"/> Yes <input type="checkbox"/> No

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
60/109,401	20 November 1998
60/119,386	10 February 1999
60/122,620	3 March 1999
60/130,560	22 April 1999

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, we acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

We hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Sanjay Bagade (Reg No. 42,280)
Richard R. Batt (Reg No. 43,485)
Kimberly A. Bolin (Reg No. P-44,546)
Barry E. Bretschneider (Reg No. 28,055)
Jingming Cai (Reg No. P-44,579)
Mark R. Carter (Reg No. 39,131)
Thomas Chuang (Reg No. P-44,616)
Steven X. Cui (Reg No. P-44,637)
Raj S. Davé (Reg No. 42,465)
Carolyn A. Favorito (Reg No. 39,183)
Franklin Y. Han (Reg No. 41,055)
Charles D. Holland (Reg No. 35,196)
Madeline I. Johnston (Reg No. 36,174)
Ararat Kapouytian (Reg No. 40,044)
Kawai Lau (Reg No. 44,461)
Richard H. Lilley (Reg No. 42,803)
Wen Liu (Reg No. 32,822)
Harry J. Macey (Reg No. 32,818)
Thomas D. Mays (Reg No. 34,524)
Kate H. Murashige (Reg No. 29,959)
William C. Revelos (Reg No. 42,101)
Robert Saltzberg (Reg No. 36,910)
Kevin R. Spivak (Reg No. 43,148)
E. Thomas Wheelock (Reg No. 28,825)
Karen K. Wong (Reg No. 44,409)
Kevin R. Kaster (Reg No. 32,704)

Erwin J. Basinski (Reg No. 34,773)
Frank P. Becking (Reg No. 42,309)
Sean Brennan (Reg No. 39,917)
Nicholas Buffinger (Reg No. 39,124)
Alan W. Cannon (Reg No. 34,977)
Robert K. Cerpa (Reg No. 39,933)
Thomas E. Ciotti (Reg No. 21,013)
Matthew M. D'Amore (Reg No. 42,457)
Stephen C. Durant (Reg No. 31,506)
Hector Gallegos (Reg No. 40,614)
Douglas Hodder (Reg No. 41,840)
Peter Hsieh (Reg No. P-44,780)
Richard D. Jordan (Reg No. 33,519)
Phanesh B. Koneru (Reg No. 40,053)
Susan K. Lehnhardt (Reg No. 33,943)
David C. Liu (Reg No. P-43,755)
David C. Lundmark (Reg No. 42,815)
Michael J. Mauriel (Reg No. 44,226)
Gladys H. Monroy (Reg No. 32,430)
Catherine M. Polizzi (Reg No. 40,130)
Paul J. Riley (Reg No. 38,596)
Debra A. Shetka (Reg No. 33,309)
Suzannah K. Sundby (Reg No. 43,172)
Thomas G. Wiseman (Reg No. 35,046)
Frank Wu (Reg No. 41,386)

Please direct all communications to:

Kate H. Murashige
Morrison & Foerster LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1888

Please direct all telephone calls to Kate H. Murashige at (202) 887-1533.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

11/29/99
Date

Bryan Julien
Name: Bryan JULIEN
Residence: Oakland, CA 94619
Citizenship: United States of America
Post Office Address: 4514 Fleming Avenue, Oakland, California 94619

11-29-99
Date

Leonard Katz
Name: Leonard KATZ
Residence: ~~Hayward, CA 94611~~
Citizenship: United States of America
Post Office Address: 22294 City Center Drive, Apt. 5104, Hayward, California 94541
6389 LONGCROFT DR., OAKLAND, CA 94611

Date

Chaitan Khosla
Name: Chaitan KHOSLA
Residence: Palo Alto, California 94306
Citizenship: India
Post Office Address: 740 La Para Avenue, Palo Alto, California 94306

11-29-99
Date

Tang Li
Name: Li TANG
Residence: Foster City, CA 94404
Citizenship: People's Republic of China
Post Office Address: 1167-3 Foster City Blvd., Foster City, California 94404

12/8/99
Date

Rainer Ziermann
Name: Rainer ZIERMANN
Residence: San Mateo, CA 94403
Citizenship: ~~Germany~~ United States of America
Post Office Address: 3908 Leona Street, San Mateo, California 94403